Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol  
Hutchison MediPharma  Page 2 of 113 
CONFIDENTIAL  STATEMENT OF COMPLIA NCE  
The study will be conducted in compliance with this clinical study protocol, Good Clinical 
Practices (GCP) as outlined by ICH E6(R2), and all applicable local and national regulatory 
requirements.  Enrollment at any clinical study site may not begin prior to that site receiving 
approval from the ethics committee of record for the protocol and all materials provided to 
potential participants.  
Any amendments to the protocol or changes to the consent document will be approved before 
implementation of that amendment.  Reconsent of previously enrolled participants may be 
necessary depending on the nature of the amendment. 
The Principal Investigator will ensure that changes to the study plan as defined by this protocol 
will not be made without prior agreement from the Sponsor and documented approval from the 
ethics committee  of record, unless such a change is necessary to eliminate an immediate hazard to 
the study participants.  
All personnel involved in the conduct of this study have completed Human Patients  Protection and 
GCP Training as outlined by their governing institution. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol  
Hutchison MediPharma  Page 4 of 113 
CONFIDENTIAL  INVESTIGATOR’S AGREE MENT  
I have read the protocol, appendices, and accessory materials related to Study 2019-013- GLOB1  
and agree to the following: 
•To conduct this study as described by the protocol and any accessory materials
•To protect the rights, safety, and welfare of the participants under my care
•To provide oversight of all personnel to whom study activities have been delegated
•To control all investigational products provided by the sponsor and maintain records
of the disposition of those products
•To conduct the study in accordance with all applicable local and national regulations,the requirements of the ethics committee of record for my clinical site, and GoodClinical Practices as outlined by ICH E6(R2).
•To obtain approval for the protocol and all written materials provided to participantsprior to initiating the study at my site
•To obtain informed consent – and updated consent in the event of new information or
amendments – from all participants enrolled at my study site prior to initiating any
study-specific procedures or administering investigational products to thoseparticipants
•To maintain records of each patient ’s participation and all data required by the
protocol
Name  [Last name, first name]  Title  [Title at institution]  Institution [Address]  
Signature  Date  [DD Month  YYYY] 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol  
Hutchison MediPharma  Page 5 of 113 
CONFIDENTIAL  TABLE OF CONTENTS  
A GLOBAL, MULTICENTER, RANDOMIZED, PLACEBO -CONTR OLLED PHASE 3 
TRIAL TO COMPARE THE  EFFICACY AND SAFETY OF FRUQUINTINIB 
PLUS BEST SUPPORTIVE CARE TO PLACEBO PLUS BEST SUPPORTIVE 
CARE IN PATIENTS WITH REFRACTORY METASTATIC COLON CANCER 
(FRESCO -2) ............................................................................................................... 1  
STATEMENT OF COMPLIA NCE  ............................................................................................... 2  
SPONSOR’S APPROVAL  ............................................................................................................ 3  
INVESTIGATOR’S AGREE MENT  ............................................................................................. 4  
TABLE OF CONTENTS  ............................................................................................................... 5  
LIST OF TABLES  ....................................................................................................................... 10  
LIST OF FIGURES  ..................................................................................................................... 11  
LIST OF APPENDICES .............................................................................................................. 11  
LIST OF ABBREVIATIONS ...................................................................................................... 12  
1. SYNOPSIS  ............................................................................................................... 15  
Study Schemat ic ....................................................................................................... 20  
Schedule of Events ................................................................................................... 20  
Footnotes for Schedule of Events Table 1 ................................................................ 22  
Footnotes for the Schedule of Events Tables 2 and 3 ............................................... 26  
2. INTRODUCTION  .................................................................................................... 27
Background ............................................................................................................... 27  
Administration Regimen  ........................................................................................... 28  
Justification for Dosing Strategy  .............................................................................. 28  
Supportive Nonclinical Data  ..................................................................................... 29  
Pharmacology ........................................................................................................... 29  
Metabolism and Pharmacokinetic Drug Interaction  ................................................. 29  
Toxicology ................................................................................................................ 30  
Supportive Clinical Data  ........................................................................................... 30  
Clinical Pharmacokinetics  ........................................................................................ 30  
Clinical Safety  .......................................................................................................... 31  
Benefit/Risk Assessment  .......................................................................................... 33  
Risk Assessment  ....................................................................................................... 33  
Benefit Assessment  ................................................................................................... 33  
Overall Benefit/Risk Conclusion  .............................................................................. 34  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol  
Hutchison MediPharma  Page 6 of 113 
CONFIDENTIAL  
Study Rationale ......................................................................................................... 34  
3. OBJECTIVES AND ENDPOINTS  .......................................................................... 35  
Primary Objective  ..................................................................................................... 35  
Secondary Objectives  ............................................................................................... 35  
Exploratory Objectives  ............................................................................................. 35  
4. STUDY PLAN  .......................................................................................................... 37  
Study Design ............................................................................................................. 37  
Enrollment in Study .................................................................................................. 37  
Rationale for the Electrocardiogram Collection and Pharmacokinetic Sampling 
Schedule .................................................................................................................... 38  
5. POPULATION  ......................................................................................................... 39
Recruitment  ............................................................................................................... 39  
Definitions  ................................................................................................................ 39  
Inclusion Criteria  ...................................................................................................... 39  
Exclusion Criteria  ..................................................................................................... 40  
6. STUDY CONDUCT  ................................................................................................. 43  
Study Procedures ...................................................................................................... 43  
Study Assessments  .................................................................................................... 43  
Informed Consent  ..................................................................................................... 43  
Medical History  ........................................................................................................ 43  
Tumor Diagnosis and Treatment History ................................................................. 43  
Demographics ........................................................................................................... 43  
Concomitant Medication and Procedures  ................................................................. 44  
Comprehensive Physical Examination ..................................................................... 44  
Limited Physical Examination .................................................................................. 44  
Eastern Cooperative Oncology Group (ECOG) Performance Status ....................... 44  
Vital Signs  ................................................................................................................ 44  
Hematology ............................................................................................................... 44  
Blood Chemistry ....................................................................................................... 44  
Coagulation ............................................................................................................... 45  
Thyroid Function ...................................................................................................... 45  
Urinalysis  .................................................................................................................. 45  
Pregnancy Test  .......................................................................................................... 45  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol  
Hutchison MediPharma  Page 7 of 113 
CONFIDENTIAL  
Electrocardiograms Monitoring  ................................................................................ 45  
Echocardiogram ........................................................................................................ 46  
Tumor Evaluation/Imaging  ....................................................................................... 46  
Tumor Marker s ......................................................................................................... 47  
Circulating Tumor DNA  ........................................................................................... 47  
Subject Randomization  ............................................................................................. 47  
Quality of Life Assessment  ...................................................................................... 47  
Pharmacokinet ics Evaluations  .................................................................................. 47  
Sample Collection and Handling .............................................................................. 47  
Analytical Procedures ............................................................................................... 48  
End of Treatment Visit ............................................................................................. 48  
Safety Follow -Up Visit  ............................................................................................. 48  
Efficacy Follow- Up .................................................................................................. 48  
Survival Follow- Up .................................................................................................. 48  
Long- term Extension  ................................................................................................ 48  
Discontinuation or Withdr awal  ................................................................................. 48  
Permanent Discontinuation of Treatment ................................................................. 48  
Withdrawal from Study  ............................................................................................ 49  
Replacement of Subjects  ........................................................................................... 49  
Subjects Lost to Fo llow-up ....................................................................................... 49  
Study Termination .................................................................................................... 50  
End of Study ............................................................................................................. 50  
7. STUDY DRUGS  ...................................................................................................... 51  
Study Drug Administration ....................................................................................... 51  
Description of Products  ............................................................................................ 51  
Formulation, Storage, Preparation and Handling ..................................................... 51  
Drug Accountability ................................................................................................. 51  
Assignment/Disposal (Study Site) ............................................................................ 51  
Drug Return (Subject)  ............................................................................................... 52  
Treatment Assignment and Bias Minimization  ........................................................ 52  
Treatment Allocation  ................................................................................................ 52  
Extent and Maintenance of Blinding ........................................................................ 52  
Unblinding Procedures  ............................................................................................. 53  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol  
Hutchison MediPharma  Page 8 of 113 
CONFIDENTIAL  
Emergency Unblinding ............................................................................................. 53  
Assessment and Verification of Compliance  ............................................................ 53  
Prior and Concomitant Therapies ............................................................................. 53  
Prohibited Therapies ................................................................................................. 53  
Permitted Therapies  .................................................................................................. 53  
Drug -Drug Interactions  ............................................................................................. 54  
Rescue Therapies  ...................................................................................................... 54  
General Dose Adjustment Note ................................................................................ 55  
Dose Modification Guidance .................................................................................... 55  
Dose Modification Sequence by Starting Dose and for General Hematologic and 
Non-Hematologic Toxicity ....................................................................................... 55  
Dose Modification for Important Identified Risks  ................................................... 56  
8. SAFETY MONITORING ........................................................................................ 60  
Definitions  ................................................................................................................ 60  
Adverse Event ........................................................................................................... 60  
Serious Adverse Event  .............................................................................................. 60  
Adverse Event Reporting .......................................................................................... 60  
Adverse Event Reporting Period .............................................................................. 60  
Expedited Reporting ................................................................................................. 60  
Eliciting Adverse Events  .......................................................................................... 61  
Assessment of Severity  ............................................................................................. 61  
Causality assessment  ................................................................................................ 62  
Documenting Adverse Events .................................................................................. 62  
Diagnosis versus Symptoms and Signs .................................................................... 63  
Adverse Event Occurring Secondary to Other Events ............................................. 63  
Persistent or Recurrent Adverse Events  ................................................................... 63  
Abnormal Laboratory Values or Abnormal Vital Signs ........................................... 63  
Preexisting Medical Condition  ................................................................................. 64  
Pregnancy ................................................................................................................. 64  
Worsening of Solid Tumor ....................................................................................... 64  
Death  ......................................................................................................................... 65  
Duration of Follow-up for Adverse Events .............................................................. 65  
9. STATISTICAL ANALYSIS .................................................................................... 66  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol  
Hutchison MediPharma  Page 9 of 113 
CONFIDENTIAL  
Statistics and Analysis Method  ................................................................................. 66  
Statistical Hypothesis  ................................................................................................ 66  
Sample Size Rationale  .............................................................................................. 66  
Analysis Sets ............................................................................................................. 67  
Primary and Secondary Endpoints ............................................................................ 67  
Primary Endpoint ...................................................................................................... 67  
Secondary Efficacy Endpoints .................................................................................. 67  
Progression-free Survival ......................................................................................... 67  
Objective Response Rate .......................................................................................... 67  
Disease Control  Rate ................................................................................................ 68  
Duration of Response ............................................................................................... 68  
Secondary Safety Endpoints ..................................................................................... 68  
Other Endpoints ........................................................................................................ 68  
Patient Reported Outcomes  ...................................................................................... 68  
Assessment of Resource Utilization  ......................................................................... 68  
Statistical Methods  .................................................................................................... 68  
Analysis of Efficacy Endpoints ................................................................................ 68  
Analysis of Safety Endpoints .................................................................................... 69  
Analysis of Other Endpoints ..................................................................................... 69  
Pharmacokinetic and Pharmacodynamic Analyses .................................................. 70  
Population PK and Exposure- Response Analyses .................................................... 70  
Pharmacodynamic (ECG) Analysis  .......................................................................... 70  
QTc Intervals  ............................................................................................................ 70  
Heart Rate, QRS, and PR intervals  ........................................................................... 71  
T-wave and U -wave Morphology ............................................................................. 71  
QTc-PK Analysis  ...................................................................................................... 71  
Interim Analysis  ........................................................................................................ 72  
10. ETHICAL CONSIDERATIONS  .............................................................................. 73  
Quality Control and Quality Assurance  .................................................................... 73  
Ethics Review  ........................................................................................................... 73  
Ethical Conduct of the Study .................................................................................... 73  
Informed Consent  ..................................................................................................... 73  
Data Privacy  .............................................................................................................. 73  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol  
Hutchison MediPharma  Page 10 of 113 
CONFIDENTIAL  
Disclosure  ................................................................................................................. 74  
Biological Specimens and Data ................................................................................ 74  
11. OVERSIGHT  ............................................................................................................ 75
Independent Monitoring ........................................................................................... 75  
Independent Data Monitoring Committee ................................................................ 75  
Quality Control and Assurance ................................................................................. 75  
Monitoring ................................................................................................................ 75  
Audits ........................................................................................................................ 76  
Protocol Deviations .................................................................................................. 76  
Records ..................................................................................................................... 76  
Data Capture and Management  ................................................................................ 76  
Source Documentation .............................................................................................. 77  
Study Files ................................................................................................................ 77  
Records Retention  ..................................................................................................... 77  
Study Termination or Study Site Closure ................................................................. 78  
12. PUBLICATION POLICY ........................................................................................ 79  
13. FINANCING AND INSURANCE  ........................................................................... 80  
14. REFERENCES ......................................................................................................... 81  
15. APPENDICES .......................................................................................................... 82
LIST OF TABLES  
Table  1 ............ Schedule of Events ............................................................................................... 21  
Table  2 ............ Schedule of Events for Pharmacokinetic and Electrocardiogram Evaluations for 
the First Approximately 120 Patients  .................................................................. 25  
Table  3 ............ Schedule of Events for Pharmacokinetic and Electrocardiogram Evaluations for 
Patients Enrolled After the First Approximately 120 Patients  ............................. 26  
Table  4 ............ Objectives and Corresponding Endpoints ............................................................ 35  
Table  5 ............ Information on Investigational Products .............................................................. 51  
Table  6 ............ Dose Modification Sequence by Starting Dose ................................................... 55  
Table  7 ............ Dose Modification Recommendations for Hematologic and Non-Hematologic 
Toxicity  ................................................................................................................ 56  
Table  8 ............ Dose Modification for Palmar-Plantar Erythrodysethesia ................................... 56  
Table  9 ............ Dose Modification for Proteinuriaa ...................................................................... 57  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol  
Hutchison MediPharma  Page 11 of 113 
CONFIDENTIAL  Table  10 .......... Dose Modification for Hypertension ................................................................... 57  
Table  11 .......... Dose Adjustment for Decreased Platelet Count  ................................................... 58  
Table  12 .......... Dose Adjustment for Hemorrhage at any Site ..................................................... 58  
Table  13 .......... Dose Adjustment for Abnormal Liver Function .................................................. 58  
Table 14 .......... Time Point Response: Patients with Target Lesions (with or without Non -Target 
Lesions)  ................................................................................................................ 90  
Table  15 .......... Time Point Response: Patients with Non -Target Lesions Only  .......................... 91  
Table  16 .......... Best Overall Response When Confirmation of Complete Response and Partial 
Response is Requir ed ........................................................................................... 92  
Table  17 .......... Typical Strong Inhibitors of CYP3A4 ................................................................. 96  
Table  18 .......... Typical Strong Inducers of CYP3A4 ................................................................... 97  
Table  19 .......... Sensi tive Substrates of P -gp or BCRP  ................................................................. 98  
Table  20 .......... Summary of Clinical Trial Program of Fruquintinib in China and the US .......... 99  
LIST OF FIGURES  
Figure 1  ........... Study Design Schema  .......................................................................................... 20  
Figure 2  ........... Severe or Serious Hemorrhagic Events Management Flow Chart  .................... 108  
Figure 3  ........... Schema from American Heart Association/ American College of Cardiology for 
Controlling Hypertension in Adults ................................................................... 110  
LIST OF APPENDICES  
Appendix 1  ..... ECOG Performance Status  .................................................................................. 83  
Appendix 2  ..... Response Evaluation Criteria in Solid Tumors (RECIST v1.1) .......................... 84  
Appendix 3  ..... Prohibited Medication  .......................................................................................... 95  
Appendix 4  ..... Study Plan ............................................................................................................ 99  
Appendix 5  ..... Clinical Evaluation of Possible Drug-Induced Liver Injury (DILI) .................. 104  
Appendix 6  ..... Clinical Management of Severe or Serious Hemorrhagic Events  ..................... 106  
Appendix 7  ..... Management of Hypertension in Patients Receiving Fruquintinib .................... 109  
Appendix 8  ..... Conversion Table for Urinalysis Results ........................................................... 113  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol  
Hutchison MediPharma  Page 12 of 113 
CONFIDENTIAL  LIST OF ABBREVIATION S 
Abbreviation  Definition  
AE Adverse Event 
ALP  Alkaline phosphatase 
ALT  Alanine aminotransferase/glutamic -pyruvic transaminase  
ANC Absolute neutrophil count 
APTT  Activated partial thromboplastin time  
AST  Aspartate aminotransferase/glutamic- oxalacetic transaminase  
AUC 0-24 hr Area under the concentration -time curve from 0 to 24 hours after drug 
administration  
BCRP  Breast cancer resistance protein  
BSC  Best supportive care 
CDK  Cyclin -dependent kinase 
CEA  Carcino -embryonic antigen  
CHL  Chinese Hamster Lung  
c-MET Mesenchymal epithelial cells transforming factor 
CR Complete response 
CRC  Colorectal cancer  
CRO  Contract research organization  
CT Computed tomography  
CTCAE Common Terminology Criteria for Adverse Event 
DCR  Disease control rate  
dMMR  D eficient mismatch repair  
DoR  Duration of response  
IDMC Independent Data Monitoring Committee 
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group 
eCRF  Electronic case report form  
EDC  Electronic data capture  
EGFR Epidermal growth factor receptor  
EORTC  European Organization for Research and Treatment of Cancer  
EOT  End of treatment  
EC Ethics Committee  
EOT  End of Treatment 
FDA  Food and Drug Administration 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol  
Hutchison MediPharma  Page 13 of 113 
CONFIDENTIAL  Abbrev
iation  Definition  
FDG -PET Fluorodeoxyglucose positron emission tomography  
IB Investigator’s brochure 
IC50  Half maximal inhibitory concentration  
ICF Informed consent form 
ICH International Conference on Harmonization 
IDMC Independent data monitoring committee 
INR International normalized ratio  
ITT Intent- to-treat 
IWRS  Interactive web response s ystem  
LDH  Lactic dehydrogenase  
LVEF  Left ventricular ejection fraction  
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram  
MID  Minimally important difference  
mL Milliliter  
MRI  Magnetic r esonance imaging 
MSI-H High levels of microsatellite instability  
MTD  Maximum t olerated dose  
NCCN  National Comprehensive Cancer Network  
NCI National Cancer Institute  
NCI CTCAE  The National Cancer Institute Common Terminology Criteria for Adverse 
Event 
NE Not evaluable 
NOAEL  No observed adverse effect level  
NSCLC  Non-small -cell lung cancer  
ORR  Objective Response Rate  
OS Overall Survival 
PD Progressive disease  
PDGFR  Platelet -derived growth factor receptor 
PFS Progression- free survival 
PK Pharmacokinetic 
PO Per os (oral administration) 
PPE Palmar -plantar erythrodysesthesia  
PR Partial response  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 14 of 113 
 CONFIDENTIAL   
 Abbreviation  Definition  
PS  Performance status  
PT Preferred term  
PTT Prothrombin time  
QD Quaque die  (once daily) 
RECIST  Response Evaluation Criteria In Solid Tumors 
RP2D  Recommended phase 2 dose 
SAE  Serious adverse event 
SD Stable d isease 
SOC  System organ class  
TSH  Thyroid stimulating hormone 
TTD  Time to deterioration  
TTP Time to progression  
ULN  Upper limit of normal  
VEGF  Vascular endothelial growth factor  
VEGFR  Vascular endothelial growth factor receptor  
WHO  World Health Organization  
 
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol  
Hutchison MediPharma  Page 15 of 113 
CONFIDENTIAL  1. SYNOPSIS
Title  A Global, Multicenter, Randomized, Placebo -Controlled Phase 3 Trial to 
Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to 
Placebo Plus Best Supportive Care in Patients with Refractory Metastatic Colon 
Cancer (FRESCO -2) 
Short Title  A global,  randomized, placebo -controlled phase 3 study of fruquintinib in 
patients with refractory metastatic colorectal cancer  
Acronym FRESCO -2 
Phase  3 
Study Design This is a global , randomized, double -blind, placebo -controlled, multicenter 
phase  3 clinical trial to compare the efficacy and safety of fruquintinib plus  best 
supportive care ( BSC) versus  placebo plus BSC in subjects with refractory 
metastatic colorectal cancer  (mCRC) .  Approximately 522 subjects will be 
randomized in a 2:1 ratio to either the fruquintinib plus BSC treatment group or 
the placebo plus BSC treatment group . 
Randomization will be stratified by the following factors:  
•Prior therapy with trifluridine/tipiracil ( TAS -102) versus  regorafenib
versus  both trifluridine/tipiracil (TAS -102) and regorafenib
•RAS  status (wild type versus  mutant)
•Duration of metastatic disease (< 18 months versus  ≥18 months)
Subjects will receive study treatment with each 4-week cycle consisting of 
3 weeks of daily oral (PO) study medication and 1 week of study drug 
interruption (3 weeks on/1 week off) .  Tumor evaluation will be performed by 
imaging (computed tomography [ CT] or magnetic resonance imaging [ MRI ] 
scan) every 8 weeks until there is progression of disease (PD) , death, new anti -
cancer treatment, or study completion, whichever comes first .  Safety parameters 
will include adverse events (AE), and results from laboratory tests, vital signs, 
ECG, and echocardiogram.   Post -discontinuation a nti-tumor treatment and 
survival follow up after PD will also be recorded.  
Rationale Colorectal cancer (CRC) is the second  most common malignancy in both men 
and women and the third most common cause of cancer- related  death in the US, 
with an estimated 145,600 new cases and 51,020 deaths in 2019 .  Similarly, CRC 
is a major global health issue, with an estimated 1.8 million new cases and 880,000 deaths in 2018 worldwide (Bray 2018).  
There is no standard of care for patients who have progressed on approved 
standard -of-treatments, including chemotherapy, relevant biologics and TAS-
102 and/ or regorafenib.  Patients who are well enough to receive additional 
therapy following all standard therapies  either are considered for treatment on a 
clinical trial when available or are re -challenged with agents such as 5 -FU or 
bevacizumab.   
Consequently, there is an unmet medical need for new 
medications that are safe and effective in patients with refractory mCRC who have progressed on, or had intolerable toxicity from, available standard systemic therapies, and for whom no effective therapy or standard of care exists.   
Fruquintinib is a novel, potent, and highly selective small molecule tyrosine 
kinase inhib itor of vascular endothelial growth factor receptors (VEGFR )-1, -2, 
and -3.  In the FRESCO trial conducted in China, fruquintinib improved the 
median overall survival in patients with mCRC in a third- line or later setting 
when compared to placebo (median o verall survival 9.3  months  versus  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol  
Hutchison MediPharma  Page 16 of 113 
CONFIDENTIAL  6.6 months; hazard ratio for death 0.65 (95% CI: 0.51 -0.83; p < 0.001) (Li 2018 ). 
The results from this pivotal trial led to fruquintinib’s approval in China . 
The safety profile of fruquintinib from an ongoing phase 1 /1b study in the US is 
consistent with that of clinical studies performed in China, as well as published 
data for other small molecule VEGF  inhibitors.  The pharmacokinetic ( PK) 
profile of fruquinti nib in the US phase 1 /1b study is also  comparable to the PK 
profile in patients treated with fruquintinib in China at the same dose and dosing 
regimen ( 5 mg PO, QD , 3 weeks on, 1 week off, for each 4 -week cycle).   
These data showing favorable efficacy and  acceptable safety indicates 
fruquintinib is a promising candidate for development as a new treatment for 
patients with refractory mCRC and may address  an unmet medical need  globally . 
This global , multicenter,  randomized, double -blind, placebo -controlled c linical 
trial will compare the efficacy and safety of fruquintinib in combination with 
BSC, to placebo in combination with BSC , in patients with  refractory metastatic 
colorectal cancer who have progressed on, or were intolerant to , TAS- 102 and/ or 
regorafenib.  Patients must have also received prior standard therapies, including 
two lines of chemotherapy (fluoropyrimidine -, oxaliplatin -, and irinotecan -
based), a biological VEGF inhibitor, and, if RAS wild type,  an EGFR inhibitor.  
Patients with M SI-H/MMR  deficient  tumors must have also received an immune 
checkpoint inhibitor  if approved and available and if deemed appropriate. 
Target Population The study population will consist of subjects  ≥18 years of age with histologically 
and/or cytologically  documented metastatic colorectal adenocarcinoma who 
progressed on , or were intolerant to , all standard chemotherapies and relevant 
biologics and TAS- 102 and/or regorafenib . 
Inclusion/Exclusion Criteria  Inclusion Criteria  
Subjects may be enrolled in this study only if they satisfy all the following 
criteria: 
1.Provide written informed consent;
2.Age ≥18 years;
3.Histologically and/or cytologically documented  metast atic colorectal
adenocarcinoma;
4.Subjects must have progressed on or been intolerant to treatment  with
either trifluridine/tipiracil (TAS -102) or regorafenib if approved and
available in the subject’s country.  Subjects are considered intolerant to
TAS- 102 or regorafenib if they have received at lea st one dose of either
agent and were discontinued from  therapy for reasons other than disease
progression.  Subjects who have been treated with both TAS -102 and
regorafenib a re permitted.  Subjects must also have been previously
treated with standard approved therapies: fluoropyrimidine- ,
oxaliplatin -, and irinotecan -based chemotherapy, an anti -VEGF
biological therapy, and, if RAS wild -type, an anti -EGFR therapy.
5.Subjects with  microsatellite -high ( MSI- H) or mismatch repair deficient
(dMMR)  tumors must have been treated with immune checkpoint
inhibitors if approved and available in the subject’s country and if
deemed appropriate;
6.Subjects  who received oxaliplatin in the adjuvant setting must have
progressed within 6 months of compl eting adjuvant therapy;
7.Body weight ≥40kg;
8.Eastern Cooperative Oncology Grou p (ECOG) performance status of 0
to 1;
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol  
Hutchison MediPharma  Page 17 of 113 
CONFIDENTIAL  9.Have measurable disease according to RECIST Version 1.1
(RECIST  v1.1) , assessed locally .  Tumors that were treated with
radiotherapy are not measurable per RECIST  v1.1, unless there has been 
documented progression of those lesions.
10.Expected survival >12 weeks.
11.For female subjects of childbearing potential and male subjects with
partners of childbearing potential, agreement to use a highly effective
form(s) of contraception, that results in a low failure rate (<1% pe r year)
when used consistently and correctly, starting during the screening
period, continuing throughout the entire study period, and for 90 days
after taking the last dose of study drug.  Such methods include: oral
hormonal contraception (combined estrog en/ progestogen, or
progestogen -only) associated with inhibition of ovulation together with
a barrier method (eg, diaphragm, always containing a spermicide),intrauterine device (IUD), intrauterine hormone -releasing system (IUS), 
bilateral tubal ligation, vasectomized partner, or sexual abstinence.  Oral
contraception should always be combined with an additional
contraceptive method ( ie, barrier method) because of a potential
interaction with the study drug.  The same criteria are applicable to male
subject s involved in this clinical trial if they have a partner of childbirth
potential, and male subjects must always use a condom.
Exclusion Criteria : 
Subjects are not eligible for enrollment into this study if they have any of the  
following criteria: 
1. Absolute neutrophil count (ANC) <1.5×109/L, platelet count
<100×109/L, or hemoglobin <9.0 g/dL.  Blood transfusion within 1
week prior to enrollment for the purpose of increasing the likelihood ofeligibility is not allowed;
2.Serum total bilirubin >1.5 × the upper l imit of normal (ULN).  Subject s
with Gilbert syndrome, bilirubin <2 X ULN, and normal aspartateaminotransferase  (AST )/alanine aminotransferase ( ALT ) are eligible;
3.ALT or  AST > 2.5 × ULN in subjects without hepatic  metastases;
ALT or AST >5  × ULN in subject s with hepatic metastases;
4.Serum electrolytes, potassium, calcium, or magnesium levels outside of
the normal laboratory reference range, and clinically significant in theinvestigator’s judgment;
5.Serum creatinine >1.5 × ULN or creatinine clearance  <60 mL/min.
Creatinine clearance can either be measured in a 24 -
hour urine
collection or estimated by the Cockcroft -Gault equation.
6.Urine dipstick protein ≥2+ or 24-hour urine protein ≥ 1.0 g/24-h.
Subjects with greater than 1+ proteinuria on urinalysis m ust unde rgo a
24-hour urine collection .  For conversion between qualitative and
quantitative results, pl ease see Appendix 8 ;
7.Uncontrolled hypertension, defined as: systolic blood pressure
≥140  mm Hg and/or diastolic blood press ure ≥90 mm Hg despite
optimal medical management;
8.International Normalized Ratio (INR) >1.5 x ULN or activated partialthromboplastin time (aPTT) >1.5 × ULN, unless the subject  is currently
receiving or intended to receive anticoagulants for prophylactic
purposes;
9.History  of, or active gast ric/duodenal ulcer or ulcerative colitis, active
hemorrhage of an unresected gastrointestinal tumor, history of
perforation or fistulas; or any other condition that could, in the
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol  
Hutchison MediPharma  Page 18 of 113 
CONFIDENTIAL  investigator’s judgment, result in gastrointestinal hemorrhage or 
perforation; within the 6 months prior to screening;  
10.History or presence of hemorrhage from any other site (eg, hemoptysis
or hematemesis) within 2 months prior to screening;
11.History of a thromboembolic event, including deep vein thrombosis
(DVT), pulmonary embolism (PE), or arterial embolism within
6 months prior t o screening.
12.Stroke and/or transient ischemic attack within 12  months prior to
screening;
13.Clinically significant cardiovascular disease, including but not limited
to acute myocardial infarction or coronary artery bypass surgery within
6 months prior to e nrollment, severe or unstable angina pectoris, New
York Heart Association Class III/IV congestive heart failure, ventricular 
arrhythmias requiring treatment, or left ventricular ejection fraction(LVEF) <50% by echocardiogram;
14.Mean corrected QT interval u
sing the Fridericia method (QTcF)
>480 msec or any factors that increase the risk of QTc prolongation or
risk of arrhythmic events such as hypokalemia, congenital long QT
syndrome, family history of long QT syndrome, or unexplained sudden
death under 40 years of age in a first -degree relative.
15.Concomitant medications with a known risk of causing QT prolongation and/or torsades de pointes (See list in  Appendix 3  
source list is
continuously updated online at www. crediblemeds .org).
16.Systemic anti -neoplastic therapies (except for those described in
Exclusion Criterion  18) or any investigational therapy within 4 weeks
prior to the first dose of study drug, including chemotherapy, radicalradiotherapy, hormonotherapy, biotherapy and immunotherapy;
17.
Systemic small molecule targeted therapies (eg, tyrosine kinase
inhibitors) within 5 half -lives or 4 weeks (whichever is shorter) prior to
the first dose of study drug;
18.Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior
to the initiation of study drug;
19.Brachytherapy (ie, implantation of radioactive seeds) within 60 days
prior to the  first dose of study drug.
20.Use of strong inducers or inhibitors of CYP3A4 within 2 weeks before
the first dose of study drug; (see Appendix  3 for a list of applicable
drugs);
21.Surgery or invasive procedure (ie, a procedure that includes a biopsy;central venous catheter placement is allowed) within 60 days prior to
the first dose of study drug or unhealed surgical incision;
22.Any unresolved toxicities from a  previous antitumor treatment greater
than National Cancer Institute (NCI) Common Terminology Criteria for
Adverse Event ( CTCAE ) v5.0 grade 
1 (except for alopecia or
neurotoxicity grade ≤2).
23.Known human immunodeficiency virus (HIV) infection;
24.Known history of active viral hepatitis.  For subject s with evidence of
chronic hepatitis B virus (HBV) infection, the HBV viral load must beundetectable on suppressive therapy, if indicated.  Subject s with HCV
infection who are currently on treatment are eligible if they have an
undetectable HCV viral load.
25.Clinically uncontrolled active infection requiring IV antibiotics;
26.Tumor invasion of a large vascular structure (eg, pulmonary artery,
superior or inferior vena cava );
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 19 of 113 
 CONFIDENTIAL   
 27. Women who are pregnant or lac tating;  
28. Brain metastases and/or spinal cord compression untreated with surgery 
and/or radiotherapy, and without clinical imaging evidence of stable 
disease for 14 days or longer; subject s requiring steroids within 4 weeks 
prior to start of study treatment  are excluded;  
29. No other malignancy, except for non -melanoma skin cancer, in situ  
cervical ca or bladder ca (Tis and T1) that have been adequately treated 
during the 5 years prior to screening;  
30. Inability to take medication orally, dysphagia or an active ga stric ulcer 
resulting from previous surgery (eg, gastric bypass) or a severe 
gastrointestinal disease, or any other condition that investigators believe may affect absorption of the investigational product;  
31. Other disease, metabolic disorder, physical exam
ination anomaly, 
abnormal laboratory result, or any other condition (eg, current alcohol 
or drug abuse) that investigators suspect may prohibit use of the 
investigational product, affect interpretation of study results, or put the subject  at undue risk of harm based on the investigator’s assessment;  
32. Known hypersensitivity to fruquintinib or any of its inactive ingredients.  
Number of Subject s Approximately 522 subjects  will be randomized 2:1 (fruquintinib plus BSC: 
placebo plus BSC) . 
Length of Participation  Subjects  may continue to receive treatment until they meet a criterion for 
discontinuation.   
Intervention  Investigational Drug:   Fruquintinib (HMPL -013) capsule 5 mg will be 
administered PO, QD , 3 weeks on, 1 week off (4 -week cycles).  Doses may be 
given either in the fasting state or after meals.  If dose adjustment is required, 
1 mg fruquintinib capsules will be used.  
Reference Drug:   Placebo capsules matching fruquintinib 5 mg will be 
administered PO, QD , 3 weeks on, 1 week off (4 -week cycles).  Doses may be 
given either in the fasting state or after meals.  If dose adjustment is required, 
1 mg matching placebo capsules will be used . 
Primary Objective  To evaluate the overall survival of fruquintinib plus BS C compared to placebo 
plus BSC in subjects  with refractory mCRC. 
Secondary Objective(s)  • To evaluate progression -free survival (PFS)  of fruquintinib plus BSC 
compared to placebo plus BSC  
• To evaluate the objective response rate (ORR),  disease control rate 
(DCR), and duration of response (DoR)  
• To assess the safety and tolerability of fruquintinib plus BSC compared to placebo plus BSC  
• To characterize the PK  exposure of fruquintinib  and metabolite M11  in 
subjects with refractory mCRC  
• To e valuate the effect of fruquintinib on cardiac repolarization, as 
detected by changes in electrocardiogram (ECG) QT c intervals , and the  
potential relationship with fruquintinib and M11 plasma concentrations  
• To evaluate the relationship between fruquintinib 
exposure and 
endpoints for efficacy and safety  
• To evaluate quality of life (QoL) as assessed by using QLQ- C30: 
cancer -specific; and EQ -5D-5L questionnaires  
• To assess resource utilization  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 20 of 113 
 CONFIDENTIAL   
 Exploratory 
Objective(s)  To assess potential predictive biomarkers  of response to fruquintinib  
Number of Sites  This study will be conducted at approximately 100 sites globally.  
Study Duration  Recruitment period is estimated to take approximately 1 3 months.  Estimated 
duration for the entire study from time  the study is open  to enrollment until 
completion of data analyses is approximately 2 0 months .   
Independent Data Safety Monitoring Committee  The IDMC will be comprised of at least 4 independent  oncologists from 
representative geographies and at least 1 independent statistician.  
 
 Study Schematic  
The study schematic is presented in Figure 1. 
Figure 1 Study Design  Schema  
 
 
 Schedule of Events  
The schedules of events (SOE) are presented in Table  1, Table  2, and Table  3. 
 

Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 23 of 113 
 CONFIDENTIAL   
 
 Procedural details for medical history are available in Section  6.1.1.2.  Tumor diagnosis, tumor treatment history, and 
evaluation of RAS status is described in Section  6.1.1.3. 
 Procedural details for patient demographics, including baseline characteristics are available in Section  6.1.1.4. 
 Procedural details for concomitant medications/treatments are available in Section  6.1.1.5. 
 Procedural details for comprehensive physical examination are available i n Section  6.1.1.6. 
 Procedural details for limited physical examination are available in Section  6.1.1.7. 
 Procedural details for ECOG performance status are available in Section  6.1.1.8. 
 Procedural details for vital signs are available in Section  6.1.1.9. 
 Procedural details for h ematology are available in Section  6.1.1.10. 
 Procedural details for blood chemistry are available in Section  6.1.1.11. 
 Coagulation tests include prothrombin time (PT T), international normalized ratio (INR), and activated partial thromboplastin 
time (APTT).  Additional procedural details are available in Secti on 6.1.1.12. 
 Thyroid function tests include serum free triiodothyronine (fT3), serum free thyroxine (fT4) and thyroid stimulating hormone 
(TSH) .  Addi tional procedural details are available in Section  6.1.1.13. 
 Twenty -four-hour urine for quantitative protein should be collected from all patients with ≥ 2+ proteinuria during s creening .  
If urine protein ≥ 2+ during the period of study treatment, a 24-hour urine protein should be collected within 1 week.  Additional procedural details for urinalysis are available in Section  6.1.1.14. 
 All female patients of childbearing potential must complete a blood pregnancy test at screening and at the Safety Follow up Visit.  Serum pregnancy test should be repeated for patients with suspected pregnancy.  This is not applicable for postmenopausal female patients, but the date of menopause should be recorded instead.  Additional procedural details are 
available in Section  6.1.1.15. 
 All female patients of childbearing potential must complete a urine pregnancy test at each day 1- visit starting at cycle 2. 
 See Table  2 and Table  3 for specific ECG parameters and time points.   Electrocardiogram  is to be performed before PK and 
echocardiogram assessments at each relevant visit.  Other procedural details for Holter Monitor and 12 -lead ECG are available 
in Section  6.1.1.16. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 24 of 113 
 CONFIDENTIAL   
 
 An echocardiogram should be done at Screening, C2D1, and on the first day, every 3 cycles thereafter.  Additional procedural 
details for echocardiogram are available in Section  6.1.1.17.  MUGA scans are acceptable if an echocardiogram cannot be 
performed. 
 Baseline tumor assessment should be completed within 28 days prior to enrollment.  Post- baseline tumor evaluations shall be 
performed on C3D1, C5D1, and day 1 of every other cycle thereafter until progression of disease (PD).  Each tumor 
assessment should document measurable lesions at the scheduled visit ± 7 days.  Additional procedural details are available in 
Section  6.1.1.18. 
 Serum carcino -embryonic antigen ( CEA) level is collected at screening and at day 1 of every cycle (±1 week)  starting at cycle 
2 until disease progression.  Additional procedural details are available in Section  6.1.1.19. 
 Collection of circulating tumor DNA (ctDNA).  Additional procedural details are available in Section  6.1.1.20. 
 See Table  2 and Table  3 for specific PK time  points.  Sampling for  PK assessments is  described in Section  6.1.2.1, and 
evaluation procedures are described in Section  6.1.2.2 
 Patient randomization occurs on day -2 to day 1.  Additional procedural details on patient randomization are available in Section  6.1.1.21.  
 For the method of drug dispensation and return, see Section 7.2.2. 
 Study drug is taken daily on a 3 weeks on, 1 week off schedule for each 28- day cycle.  On days with PK collection, treatment 
should be administered at the site by a delegated study staff member. 
 After informed consent, but prior to initiation of study drug, all SAEs regardless of at tribution will be collected.  After 
initiation of study drug, all SAEs and AEs regardless of attribution will be collected until 30 days after the last dose of study drug or a new treatment of anti-tumor therapy, whichever is earlier.  After this period, investigators should report only SAEs 
that are considered to be related to the study drug. 
 Survival follow -up (by telephone) should be performed every 12 weeks (±2 weeks) after the end of treatment ( EOT ) visit.  All 
subsequent anti -tumor therapy and information about study drug- related SAEs shall be collected.  For the patients that 
discontinue the study without PD, all available tumor assessment results during survival follow up shall be recorded in the eCRF 
until confirmation of PD.  The date and cause of death should be recorded, if applicable.  Patients who withdraw consent are 
encouraged to be followed for survival.  If the patient has clearly expressed his/her refusal to be followed after withdrawal of 
consent, he/she will terminate the study and no follow up for survival will be performed. 
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 25 of 113 
 CONFIDENTIAL   
 Table  2 Schedule of Events  for Pharmacokinetic  and Electrocardiogram  Evaluations 
for the First Approximately 120 Patients 
Study day  Time Relative 
to Dosing  Study Drug 
Intake 1 Pharmacokinetic 
Samples 2 Triplicate ECG for 
QTc Evaluation 
(Holter Monitor) Safety ECG  
(Standard 
Equipment)  
C1D1 Pre-dose 3  X X - 
0 h X - - - 
1 h  X X - 
2 h  X X - 
3 h  X X - 
4 h  X X - 
C1D21 Pre-dose 3  X X - 
0 h X - - - 
1 h  X X - 
2 h  X X - 
3 h  X X - 
4 h  X X - 
C2D1 Pre-dose 3  X - - 
0 h X - - - 
C2D21 Pre-dose 3  X - - 
0 h X - - - 
2 h  X - X 
C3D1 Pre-dose 3  X - - 
0 h X - - - 
C3D21 Pre-dose 3  X - - 
0 h X - - - 
2 h  X - X 
C5D1 and every 
other cycle 
thereafter Pre-dose 3  X - - 
0 h X - - - 
C1D1= cycle 1, day 1; C1D21 = cycle  1, day 21; C2D1 = cycle 2, day  1; C2D21 = cycle 2, day  21; C3D1 = cycle  3, day 1; C3D21 = cycle 3, 
day 21; C5D1 = cycle 1, day 1; ECG = Electrocardiogram  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 26 of 113 
 CONFIDENTIAL   
 Table  3 Schedule of Events for Pharmacokinetic and Electrocardiogram Evaluations 
for Patients Enrolled After the First Approximately 120 Patients  
Study day  Time  Relative to 
Dosing  Study Drug Intake 1 Pharmacokinetic 
Samples 2 Safety ECG 
(Standard 
Equipment)  
C1D1  Pre-dose 3  X X 
0 h X - - 
2 h  X X 
C1D21  Pre-dose 3  X - 
0 h X - - 
2 h  X X 
C2D1  Pre-dose 3  X - 
0 h X - - 
C2D21  Pre-dose 3  X - 
0 h X - - 
2 h  X X 
C3D1  Pre-dose 3  X - 
0 h X - - 
C3D21  Pre-dose 3  X - 
0 h X - - 
2 h  X X 
C5D1 and every other 
cycle thereafter  Pre-dose 3  X - 
0 h X - - 
C1D1= cycle  1, day 1; C1D21 = cycle 1, day 21; C2D1 = cycle  2, day 1; C2D21 = cycle  2, day 21; C3D1 = cycle  3, day 1; C3D21 = cycle  3, 
day 21; C5D1 = cycle 1, day 1; ECG = Electrocardiogram  
 Footnotes for the Schedule of Events Tables 2 and 3  
 On PK sampling day, study drug must be taken at the investigative site under the supervision 
of the investigator or designee and should not be taken at home on the morning of the visits.  
The date and time of the dose administered on the day of PK collection and one day before PK collection m ust be recorded in the e CRF.  
 The actual date and time of the PK samples must be recorded on the eCRF.  
 Pre-dose PK and ECG should be performed within 30 minutes BEFORE study drug 
administration. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 27 of 113 
 CONFIDENTIAL   
 2. INTRODUCTION  
During tumor igenesis, malignancies release growth factors to induce angiogenesis, which provides 
nutrients and oxygen for rapid tumor growth.  The immature arrangement of endothelial cells on 
the rapidly growing blood vessels can result in exudation of tumor cells into the circulatory system, 
through which the tumor cells may spread to other tissues, leading to tumor metastasis.  Vascular 
endothelial growth factor receptor  (VEGF ) is one of the key factors known to induce tumor 
angiogenesis , and agents that target  VEGF and the VEGFR are important therapies for malignant 
solid tumors, including colorectal cancer ( Duda 2016, Jayson 2016). 
Fruquintinib (HMPL -013) is a small molecul e anti-tumor drug with a novel  chemical structure that 
belongs to the quinazoline class  and is  a potent and highly selective tyrosine kinase inhibitor of 
vascular endothelial growth factor receptors ( VEGFR) .  In vitro  studies demonstrated that 
fruquintinib is highly selective for  VEGFR -1, -2, and -3, which are related to tumor angiogenesis, 
and possess weak or no measurable activity against other kinases ( Sun 2014).  Fruquintinib was 
discovered  by Hutchison MediPharma Limited (hereafter referred to as the sponsor ) through in 
vitro  and in vivo biological screening of a large number of synthetic compounds. 
Results  from preclinical and clinical studies conducted in China and in the US have provided 
evidence that fruquintinib has anti -cancer activity in solid tumors.  The clinical development 
program in China has been ongoing since 2009.  In the phase 3 clinical trial , FRESCO ,  that led to 
the drug’s approval in China, fruquintinib improved median overall survival in patients with metastatic colorectal cancer (mCRC) in a third -line or later setting when compared to placebo from 
6.6 to 9.3 months ( hazard ratio for death 0.65 ; 95% confidence interval [CI]  0.51- 0.83; P < 
0.001).( Li 2018)  The cumulative safety data from the clinical trial program has shown that 
fruquintinib has an acceptable level of toxicity that is consistent with other antiangiogenic drugs, 
particularly small molecule VEGFR inhibitors .  These data provide a strong justif ication for the 
investigation of fruquintinib in patients with refractory mCRC  globally. 
 Background 
Colorectal cancer (CRC) is a major global health issue, with an estimated 1.8 million new cases 
and 880,000 deaths in 2018 worldwide  (Bray 2018 ).  The established initial and second -line 
systemic therapy for mCRC  consists of fluoropyrimidin e-, oxaliplatin, and irinotecan -based 
cytotoxic chemotherapy (eg, FOLFOX: [5- Fluorouracil, leucovorin, and oxaliplatin] and FOLFIRI 
[5-fluoroura cil, leucovorin, and irinotecan ]).  In addition, a biologic anti -VEGF therapy is typically 
given with chemotherapy (eg, bevacizumab), and if the tumor is RAS  wild type, an anti -EGFR 
therapy (eg, cetuximab) is administered.  In the small proportion of patie nts that are deficient 
mismatch repair (dMMR )/ high levels of microsatellite instability  (MSI-H) in the metastatic setting 
(Koopman 2009) , immunotherapy with nivolumab or pem brolizumab may be used ( NCCN 201 9). 
When there is disease progression after the first two lines of chemotherapy, the established options are either:  
• Trifluridine/tipiracil (L ONSURF
®, TAS -102), an oral combination of trifluridine, a 
nucleoside metabolic inhibitor, and tipiracil,  a thymidine phosphorylase inhibitor; 
(LONSURF® USPI ) or 
• Regorafenib (S TIVARGA®), a multikinase inhibitor with numerous in vitro  targets that 
include VEGFR ( STIVARGA® USPI ). 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 28 of 113 
 CONFIDENTIAL   
 There is an unmet medical need for new medications that are safe and effective in patients with 
refractory mCRC who have progressed on, or had intolerable toxicity from, available standard systemic therapies, and for whom no effective therapy or standard of care exists.  A recent 
estimation of the median overall survival (OS) for patients with mCRC, based on data from phase 3 clinical trials, observation studies, and registries, is 30 months  (Grothey 2013, Mayer 2015 ).  
During this time, patients may receive several lines of th erapy, with one or more “breaks.”  Both 
TAS -102 and regorafenib are approved in the third -line or greater (3+ line) of therapy after 
progression on chemotherapy, and there are  no approved treatments following progression on these 
agents.  In this setting , the current options for patients with good performance status are to enter a 
clinical trial or to be re -challenged with prior chemotherapy ( eg, 5-FU).  Pa tients with poor 
performance status generally enter hospice care.   
The purpose of this global, phase 3 clinical trial is to evaluate the efficacy and safety of fruquintinib in patients with refractory mCRC  who have progressed on standard  approved therapies, including 
TAS -102 and/or regorafenib.  
 Administration Regimen  
Fruquintinib (HMPL -013) capsule 5 mg will be administered orally ( PO) once daily (QD) , 3 weeks 
on, 1 week off (4 -week cycles).  Doses may be given either in the fasting state or after meals.  If 
dose adjustment is required, 1 mg capsules will be used.  
 Justification for Dosing Strategy  
The optimal fruquintinib dose and dosing regimen were determined in two Chinese phase 1 studies, 
2009-013- 00CH1 and 2012-013- 00CH3 , as well as one US phase 1/1b study, 2015-013-00US1.  
During dose escalation, study 2009-013- 00CH1 investigated continuous daily doses of 1 mg, 
2 mg, 4 mg, 5 mg, and 6 mg; in addition, 5 mg QD and 6 mg QD were studied on a regimen of 3 
weeks on , 1 week off (4- week ) cycles.  The maximum- tolerated dose ( MTD )/ recommended 
phase 2 dose ( RP2D) was 4 mg QD (continuous) or 5 mg  QD (3 weeks on , 1 week off).  
In study 2012-013- 00CH3, the safety and tolerability of these two dosing regimens ( 4 mg QD 
continuously versus  5 mg QD, 3 weeks on, 1 week off) were  compared in patients with mCRC.  
The safety profile was better in the 5 mg QD (3 weeks on, 1 week off) group than the 4 mg QD 
(continuous) group.  In addition, there was accumulation of drug over time in the 4 mg QD 
(continuous) group.  Thus, the 5 mg PO, QD, 3 weeks on, 1 week off , dose and regimen was 
selected as the RP2D and the dosing regimen to be used in subsequent clinical development  in 
China.  
The RP2D and dosing regimen were tested in the phase 2 ( 2012-013- 00CH1 ) and phase 3 (2013-
013-00CH1 [FRESCO])  studies, which  confirmed that the dose and dosing regimen were  safe and 
effective in patients with refractory mCRC .  The 5 mg PO , QD, 3  weeks on, 1 week off  is the 
standard dose and dosing regimen in all other completed, ongoing, and planned studies in patients 
with advanced cancer. 
In the US p hase 1 /1b study (2015-013-00US1) , there were 2 dose cohorts  in the dose escalation  
phase, 3 mg PO, QD (n=7) and 5 mg PO, QD (n=7).  Fruquintinib was well tolerated in both dose 
cohorts.  T herefore, 5 mg PO, QD, 3 weeks on, 1 week off was confirmed as the RP2D for global 
studies, as well.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 31 of 113 
 CONFIDENTIAL   
 5 mg QD and 6 mg QD  at the 3 week on/ 1 week off schedule, plasma fruquintinib concentrations 
declined during the off week, as expected.  Preliminary PK results from the US patient population 
(ongoing Study 2015- 013-00US1)  that received fruquintinib at 3 mg  and 5 mg QD 3 weeks 
on/1 week off suggested that there were no meaningful differences in fruquintinib exposure 
between Chinese and US patients.  Following fruquintinib 5 mg QD 3 weeks on/ 1 week off, mean 
fruquintinib C max and AUC tau values on day 21 were 326 ng/mL and 5969 ng*h/mL in Chinese 
patients ( Study 2012- 013-00CH3 ), respectively , compared with 385 ng/L and 7530 ng*h/mL in 
US patients, respectively.  
The effect of a high fat high calorie meal on the PK of fruquintinib 4 mg (4 x 1 mg  capsules) wa s 
studied in healthy Chinese males (Study 2012-013- 00CH2).  Food delayed T max of fruquintinib by 
2.6 hours.  A slight decrease in fruquintinib C max by 17% was seen, though there was  no observed 
effect on the AUC 0-∞.  These results were  sufficient to recomm end dosing of fruquintinib without 
regard to food. 
The results from the mass balance study conducted in healthy Chinese subjects (Study 2015-013-
00CH2) indicated that 60.31% of total radioactivity was recovered in urine and 29.80% in feces.  
A total of 22 metabolites were identified in the plasma, urine , and feces samples.  The M11 (N -
desmethylation product) and M9 (carboxylic acid product) were the main metabolites, where M11 accounted for 17.31% and M9 accounted for 4.46% of the plasma exposure of total radioactivity.  
Only a small amount of unchanged fruquintinib was detected in urine, which accounted for 0.50% 
of the dose administered.  The amount of fruquintinib in feces accounted for 5.34% of the dose 
administered.  
M11 is a pharmacologically active metabolite  found to inhibit  VEGFR2  kinase activity and VEGF -
induced VEGFR2 phosphorylation, with a potency approximately 2 to 10 times lower  than that of 
fruquintinib.  After multiple  doses of fruquintinib 5 mg QD to patients for 21 days (Study 2015 -
013-00US1, preliminary data), M11 reached T
max after 1 hour.  The mean ( standard d eviation) 
Cmax and AUC 0-24 values were 144 (56.2) ng/mL and 3080 (1250) h*ng/mL, respectively.  M11 
accumulated by 31.5- fold after multiple dosing.  The mean (standard deviation ) metabolite -to-
parent ratio of M11 was 0.409 (0.135) at steady  state.  Overall, M11 is not expected to have 
clinically meaningful contribution to the total pharmacological activity of fruquintinib at therapeutic exposure.  
 Clinical Safety  
As of the data cut -off date ( 03 Sep 2019), 7 clinical trials in patients with cancer were completed.  
In order to conduct a comprehensive and robust safety assessment across the fruquintinib clinical 
studies, a pooled dataset has been generated and analyzed, which consists of data from 739 patients 
in 4 completed double -blind studies (2012-013- 00CH1, 2013 -013- 00CH1, 2014-013- 00CH1, and 
2015-013- 00CH1) (Table  20 ) who received fruquintinib monotherapy.  In addition, the safety data 
from 2 comp leted early phase open -label studies ( phase 1 2009-013-00CH1, phase 1b 2012-013-
00CH3) and 1 completed phase 1b/2 study (2014-013-00CH3) has also been analyzed.  
As of the data cut -off date, 5 clinical studies in patients with cancer were ongoing.  The safety 
profile of fruquintinib from a US phase 1 /1b open -label, multi -center study (2015- 013-00US1), 
from a China phase 2 open- label study of fruquintinib in combination with gefitinib  (2016-013-
00CH1), and from a China  phase 1b/2 open- label study of fruquintinib in combination with 
sintilimab (2018-013- 00CH3) are also presented in this section.  N o formal analysis is available  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 32 of 113 
 CONFIDENTIAL   
 for the safety profile of fruquintinib in the other 2 ongoing studies ; the China randomized phase 3 
study of paclitaxel with or  without fruquintinib in metastatic gastric cancer (2017- 013-00CH1 ) 
remains blinded , and no patients have been enrolled into the  China open label single arm study 
evaluating fruquintinib in elderly patients with NSCLC (2017-013- 00CH2 ). 
Adverse Events in Co mpleted Studies : 
A total of 739 patients received at least 1  dose of fruquintinib in the 4 completed double -blind , 
placebo -controlled, monotherapy  studies, among whom 729 (98.6 %) patients reported treatment -
emergent adverse events ( TEAEs ).  The incidence of the most commonly reported TEAEs (≥10% 
of patients) are provided in the current investigator’s brochure (IB).  
In the pooled data of all-causality TEAEs reported, the most commonly reported TEAEs of grade 
≥3 (≥5% of patients) included Hypertension (19.9%) and P almar -plantar erythrodysaesthesia 
syndrome (10.7% ). 
Serious Adverse Events in Completed Studies : 
A total of 1 or more serious adverse events ( SAE s) have been reported by 169 (22.9%)  patients 
out of the 739 patients who received fruquintinib .  The most common SAEs (≥1.0%) by MedDRA 
preferred term ( PT) included I nfectious pneumonia in 24 (3.2%) patients, intestinal obstruction in 
17 (2.3%) patients, pleural effusion in 9 (1.2%) patients, death in 10 (1.4%) patients, hepatic 
function abnormal in 8 (1.1%) patients, and gastrointestinal haemorrhage in 8 (1.1%) patients.  The 
SAEs in more than 1 patient in the pooled data are summarized in  the current IB . 
2.1.4.2.1. Clinical Efficacy  
Monotherapy Efficacy:  
As of the data cut -off date ( 03 September  2019), the available fruquintinib efficacy data from the 
completed open- label and double -blind studies showed strong antitumor activity, including 
improved overall survival (OS) and progress ion-free survival (PFS), durable partial response (PR) 
and durabl e stable disease (SD), and improved overall response rate (ORR) in heavily pre- treated 
patients with advanced cancer.  
Two (2) proof -of-concept studies have been conducted in patients with CRC who were previously 
treated with two or more lines of standard chemotherapeutic regimens (Study 2012-013-00CH1) 
and in patients with NSCLC who have failed two lines of standard chemotherapies (Study 2014-
013-00CH1).  The studies both met  their primary efficacy endpoint of PFS  and demonstrated a 
significant improvement in PFS in the fruquintinib arm compared to the placebo arm.  
In addition, the phase 3 pivotal trial (FRESCO) was completed in patients with CRC who were 
previously treated with 2 or more lines of standard chemotherapeutic regimens (Study 2013-013-00CH1) .  In this study, fruquintinib significantly prolonged the OS compared  to placebo with a 
hazard ratio of 0.65 (95% CI: 0.51-0.83; 2-sided p <0.001).  Statistically significant benefits were also seen with fruquintinib in all secondary endpoints, including as PFS, ORR , and disease control 
rate (DCR).  
One phase 3 study of fruquintinib was completed in patients with NSCLC who had failed second-
line standard chemotherapy (2015- 013-00CH1): there was no significant difference between the 
fruquintinib group and the placebo group in the primary efficacy endpoint (OS).  However, 
fruquintinib significantly prolonged the PFS comparing to placebo with a HR of 0.34 (95% CI: 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 33 of 113 
 CONFIDENTIAL   
 0.279, 0.425) with p < 0.001 (stratified log- rank test).  Statistically significant benefits were al so 
shown with fruquintinib in ORR and DCR. 
The efficacy data in the  ongoing study of fruquintinib in patients with advanced solid tumors 
(2015-013- 00US1) are not available as of the data cut -off date (03 Sep 2019). 
Combination Therapy Efficacy  
A phase 1b/2 study had been conducted to investigate the treatment of fruquintinib, in combination 
with paclitaxel , as second -line therapy in patients with gastric cancer (GC) (2014 -013-00CH3).  
The results showed that the ORR and DCR were 27.3% (9/33) and 63.6% (21/33), respectively.  
The median PFS and median OS at the RP2D (fruquintinib 4 mg + paclitaxel) were 4.0 months 
and 8.5 months, respectively.  
The efficacy data in 1 ongoing study of fruquintinib in combination with gef itinib in patients with 
NSCLC (2016-013- 00CH1) and in 1 ongoing study of fruquintinib in combination sintilimab  
patients with  advanced solid tumor are not available as of the data cut -off date (03 Sep 2019). 
 Benefit/Risk Assessment  
There are robust cumulative efficacy and safety data f or fruquintinib from the entire clinical 
program in China, as well as the ongoing US phase 1/1b study.  As of the data cut -off date 
(03 Sep tember  2019) a total of 1600 patients and 87 healthy volunteers had received at least one 
dose of fruquintinib or placebo through development programs.  Among them, 955 patients and 
87 healthy volunteers had received at least one dose of fruquintinib, 284 patients had received at 
least one dose of blinded treatment (fruquintinib versu s placebo), and 361 patients had received at 
least one dose of placebo . 
 Risk Assessment  
A total of 739 patients received at least 1 dose of fruquintinib in the 4 completed double -blind 
studies, among whom 739 (98.6 %) patients reported TEAEs.  
In the pooled data of all- causality  TEAEs rep orted in the 3 completed double-blind, monotherapy 
studies, the most commonly reported TEAEs of grade ≥3 (≥5% of patients) included hypertension 
(19.9 %) and palmar -plantar erythrodysaesthesia syndrome (10.7 %).  
The incidence of the most commonly reported TEAEs ( ≥10% of patients) is provided in the current 
IB.  
The safety analysis that resulted in the identified risks w as performed on the pooled data set from 
4 completed double -blind studies (N=  739 fruquintinib; N=  361 placebo), in which the incidence 
of adverse events (AEs) in fruquintinib- treated patients was compared with those in the placebo -
treated control patients.  The identified risks presented by Standardized M edical Dictionary for 
Regulatory Activities  (MedDRA) Query (SMQ) are presented in Table 54 of the current IB .  
 Benefit Assessment  
The efficacy data in the phase 1 study conducted in China (Study 2009-013- 00CH1) showed 
encouraging clinical activity for fruquintinib.  A response was observed in the majority of heavily 
pre-treated patients with advanced cancers (see the current IB).  The results of two phase 2 proof-
of-concept (POC) studies provided evidence of clinical efficacy in patients with metastatic CRC 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 34 of 113 
 CONFIDENTIAL   
 (Study 2012 -013-00CH1, third or later lines therapy ) and NSCLC (Study 2014-013- 00CH1, third-
line therapy) as compared with placebo.  The PFS results established POC in both studies by 
meeting their respective primary efficacy endpoints.  Clinical efficacy was also provided by the 
phase 3, double-blind, pla cebo -controlled trial, 2013-013- 00CH1  (FRESCO) . 
 Overall Benefit/Risk Conclusion  
The safety profile of fruquintinib is consistent with those of other anti -angiogenic therapies, 
particularly the small molecule tyrosine kinase inhibitors (ie, sorafenib, regorafenib, axitinib, and 
sunitinib), as demonstrated by the identified risks for fruquintinib (Section  2.1.5.1) .  In addition, 
safety data from the completed and ongoing studies showed that  fruquintinib was well tolerated , 
with most of the AEs reported as grade  1 to 2 (see c urrent IB).  There have been no new or 
unexpected safety findings from the ongoing clinical trials to date.  
 Study Rationale  
Colorectal cancer (CRC) is a major global health issue, with an estimated 1.8 million new cases and 880,000 deaths in 2018 worldwide ( Bray 2018 ).  There is an unmet medical need for new 
medications tha t are safe and effective in patients with refractory mCRC who have progressed 
after treatment with, or had intolerable toxicity from, available standard systemic therapies . 
There is no standard of care after patients progress on-chemotherapy, relevant biologics and TAS -
102 or regorafenib.  In clinical studies performed in China, fruquintinib has demonstrated robust 
anti-tumor activity and was well tolerated .  Fruquintinib is approved in China for the treatment of 
patients with refractory mCRC.  The safety p rofile of fruquintinib from an ongoing phase 1 /1b 
study in the US is consistent with those from clinical studies performed in China.  This global phase 3 trial is being conducted to confirm the results of the FRESCO trial conducted in China in 
patients with refractory mCRC.  
This is a randomized, double -blind, placebo -controlled, clinical trial to compare the efficacy and 
safety of fruquintinib in combination with the best supportive care ( BSC) versus placebo in 
combination with BSC in patients with refra ctory mCRC who have progressed on, or were 
intolerant to TAS -102 and/or regorafenib. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 35 of 113 
 CONFIDENTIAL   
 3. OBJECTIVES AND ENDPO INTS  
 Primary Objective  
To evaluate the overall survival (OS) of fruquintinib plus BSC compared to placebo plus BSC in 
subject s with refractory mCRC  
 Secondary Objectives 
• To PFS of fruquintinib plus BSC compared to placebo plus BSC 
• To evaluate the objective response rate (ORR), disease control rate (DCR) , and duration 
of response (DoR)  
• To assess the safety and tolerability of fruquintinib plus BSC compared to placebo plus 
BSC  
• To characterize the PK  exposure of fruquintinib and metabolite M11  in subjects with 
refractory mCRC  
• To evaluate the effect of fruquintinib on cardiac repolarization, as detected by changes in 
electrocardiogram (ECG) QT c intervals , and the  potential relationship with fruquintinib 
and M11 plasma concentrations 
• To explore the relationship between fruquintinib exposure and endpoints for efficacy and safety  
• To evaluate quality of life (QoL) as assessed by using QLQ -C30: cancer- specific;  and 
EQ-5D-5L questionnaires 
• To assess resource utilization (for example, hospitalizations, concomitant medications) 
 Exploratory Objectives 
• To assess potential predictive biomarkers of response to fruquintinib  
The objectives and corresponding endpoints are summarized in Table  4. 
Table  4 Objectives and Corresponding Endpoints  
Tier Objectives  Endpoints  
Primary  To evaluate the overall survival (OS) of 
fruquintinib plus BSC compared to placebo 
plus BSC in subject s with refractory mCRC  OS 
Secondary  
 To evaluate progression -free survival (PFS) 
of fruquintinib plus  BSC compared to 
placebo plus BSC  PFS 
To evaluate  the objective response rate 
(ORR), disease control rate (DCR) , and 
duration of response (DoR)  • ORR  
• DCR 
• DoR  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 36 of 113 
 CONFIDENTIAL   
 Table  4 Objectives and Corresponding Endpoints  
Tier Objectives  Endpoints  
To assess the safety and tolerability of 
fruquintinib plus BSC compared to placebo 
plus BSC  Safety including TEAEs, SAEs, deaths, ECG’s, 
and clinical laboratory abnormalities  
To characterize the pharmacokinetic (PK) profile of fruquintinib in subjects with 
refractory mCRC Observed plasma concentrations , estimated 
population PK and e xposure parameters of 
fruquintinib and M11 
To evaluate the effect of fruquintinib on 
cardiac repolarization, as detected by 
changes in electrocardiogram (ECG) QTc intervals, and the potential relationship with 
fruquintinib and M11 plasma concentrations  QTc interval and plasma concentrations of fruquintinib and M11 at specified time  points  
To evaluate  the relationsh ip between 
fruquintinib exposure and endpoints for 
efficacy and safety  Parameters describing exposure- response with 
efficacy (eg, OS) and safety (eg, AEs) endpoints  
 To evaluate quality of life (QoL) as 
assessed by using QLQ -C30: cancer -
specific; and EQ -5D-5L questionnaires  Changes in health status (QLQ -C30: cancer -
specific; and EQ -5D-5L) 
 To assess resource utilization (for example, hospitalizations, medications)  Resource utilization including all co ncomitant 
medications, days in hospital  
Exploratory  To assess potential predictive biomarkers of 
response to fruquintinib  • Change from baseline in ctDNA  
• Change from baseline in tumor markers 
(CEA) 
• Pharmacogenomics  
 
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 37 of 113 
 CONFIDENTIAL   
 4. STUDY PLAN 
Detailed information on the fruquintinib clinical trial program in China and in the US  can be found 
in Appendix 4 of this protocol and also in the fruquintinib  IB. 
 Study Design 
This is a global, randomized, double -blind, placebo- controlled, multicenter phase 3  clinical trial 
to compare the efficacy and safety of fruquintinib in combination with BSC versus placebo in 
combination with BSC in advanced colorectal cancer patients who have progressed on or were 
intolerant to chemotherapy, biologics and TAS-102 or regorafenib. 
Metastatic colorectal cancer cannot be cured by surgery.  Therefore , treatment principals are 
primarily aimed at controlling disease progression and prolonging survival.  Standard first - and 
second -line therapy includes cytotoxic drugs such as 5- fluorouracil, oxaliplatin, and irinotecan; 
anti-VEGF therapy; and , if RAS wild type , anti-EGFR therapy.  After the first two lines of 
chemotherapy, standard third -line treatment is either TAS -102 or regorafenib.  There are currently 
no effective treatments for patients who have progressed  on standard, approved therapies, and 
treatment options include reuse of prior therapies, clinical trials , or BSC.  Consequently, there is 
an unmet medical need for additional safe and effective treatment.  
 Enrollment in Study  
After checking the eligibility criteria, subjects will be randomized into either fruquintinib in 
combination with BSC group (treatment group) or placebo in combination with BSC group 
(control group) in  a 2:1  ratio (Figure 1). 
• Treatment group: Fruquintinib 5 mg PO, QD, plus BSC, 3 w eeks on/ 1 w eek off , every 4-
week cycle).  
• Control group: Matching  placebo 5  mg PO, QD plus BSC, 3 w eeks on/ 1 w eek off , every 
4-week cycle.  
A treatment cycle is 4 weeks.  Patient s’ safety assessment and drug accountability will be 
performed at each treatment cycle.  Continuous drug safety monitoring and assessment will be 
performed through the whole study period (including a 30- day observation period after the end of 
treatment).  
As described in Section  2, in the phase 3 FRESCO trial  that led to the drug’s approval in China, 
fruquintinib improved the median overall survival in patients with metastatic colorectal cancer 
(mCRC) in a third line or later setting when compared to placebo ( median OS 9.3 ver sus 6.6 
months); hazard ratio for death was 0.65 (95% CI, 0.51- 0.83; P < 0.001)  (Li 2018) .  The results of 
the FRESCO study indicate that fruquintinib is a candidate therapy for patients with refractory mCRC globally, and provides the strongest rationale for the current clinical trial.  
Since the current standard of care f or patients with mCRC in the US, EU , and Japan is different 
than it was in China during the conduct of the FRESCO trial, the curren t study is necessary to  
evaluate fruquintinib in a patient population that is representative of global treatment practices .  In 
FRESCO, prior therapy included the standard first two lines of cytotoxic chemotherapy (fluoropyrimidine- , oxaliplatin - and irinotecan -based), but only about 30% of patients had received 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 38 of 113 
 CONFIDENTIAL   
 prior therapy with a VEGF inhibitor (bevacizumab), and patients with prior exposure to VEGFR 
inhibitors such as regorafenib were excluded. 
 Rationale for the Electrocardiogram Collection and Pharmacokinetic Sampling Schedule  
In accordance with ICH E14 guideline, QT evaluation is e xpected to be routine in oncology drug 
development, and a t horough QT (TQT) study should be conducted, if possible.  In the case of 
fruquintinib , in view of nonclinical (hERG and CV safety study) and clinical data suggest ing no 
apparent relationship between fruquintinib and QT prolongation, an alternative design to the TQT 
study has been chosen. 
In this study, changes in QT c interval following drug administration will be evaluated relative to 
the baseline measurement.  Electrocardiogram time points have been selected to match the 
expected PK profile of fruquintinib and metabolite M11.  The ECG time points have also been 
selected to expl ore a potential relationship between exposure and effect on QTc. 
In order to assess the QTc interval prior to exposure to fruquintinib, baseline triplicate ECG assessments will be performed prior to first study drug administration on cycle 1 day 1 (within 30 minutes before dosing).  A baseline PK sample will also be collected at pre- dose, immediately 
after the EC Gs have been collected and prior to the first d ose of fruquintinib or placebo.  
Subsequently, the purpose of all other ECGs is to assess for potential prolongation of the QTc interval and other ECG changes as a result of fruquintinib administration, with ECG collection coinciding with PK measurements to establish correlations between ECG changes and drug exposure.  Triplicate ECGs, followed by blood samples for PK assessment, will be collected at multiple time  points post -dose around T
max of fruquintinib and M11 after the first dose and  at 
steady -state as described in Table  2. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 39 of 113 
 CONFIDENTIAL   
 5. POPULATION  
 Recruitment  
To randomize 522 patients,  approximately 100 sites will be opened globally for patient 
recruitment.   
 Definitions  
Subjects officially enter the Screening Period after providing  informed consent , either directly or 
via a legally authorized representative.  
Subjects who withdraw from the study after signing the ICF and before the randomization will be 
considered screen failure s.  Subjects who failed the original screening may be screened again using  
their original subject number as assigned by interactive web response system ( IWRS ).  A subject 
may only be re- screened once. 
A randomized subject is one who has been deemed eligible and has been assigned to a treatment 
group by IRT/IWRS .  
 Inclusion Criteria  
Subjects may  be enrolled in this study only if they satisfy all the following criteria:  
1. Provide written informed consent;  
2. Age ≥18 years;  
3. Histologically and/or cytologically documented metastatic colorectal adenocarcinoma;  
4. Subjects must have progressed on or been intolerant treatment with either 
trifluridine/tipiracil (TAS -102) or regorafenib if approved and available in the subject’s 
country.  Subjects are considered intolerant to TAS -102 or regorafenib if they have 
received at least 1 dose of either agents and were discontinued from therapy for reasons 
other than disease progression.    Subjects who have been treated with both TAS -102 and 
regorafenib are permitted.  Subjects must also have been previously treated with stand ard 
approved therapies: fluoropyrimidine -, oxaliplatin- , and irinotecan -based chemotherapy, 
an anti-VEGF biological therapy, and, if RAS wild- type, an anti -EGFR therapy.  
5. Subjects with microsatellite -high ( MSI- H) or mismatch repair deficient (dMMR)  tumors 
must have been treated with immune checkpoint inhibitors if approved and available in the 
subject’s country  and if deemed appropriate; 
6. Subject s who received oxaliplatin in the adjuvant setting must have progressed within 6 
months of completion of adjuvant therapy;  
7. Body weight ≥40kg;  
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1;   
9. Have measurable disease according to RECIST Version 1.1 (RECIST v1.1) , assessed 
locally .  Tumors that were treated with radiotherapy are not measurable per RECIST v1.1, 
unless there has been documented progression of those lesions.  
10. Expected survival >12 weeks. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 40 of 113 
 CONFIDENTIAL   
 11. For female subjects of childbearing potential and male subjects with partners of 
childbearing potential, agreement to use a highly effective form(s) of contraception, that 
results in a low failure rate (<1% per year) when used consistently and correctly, starting during the screening period, continuing throughout the entire study period, and for 90 days after taking the last dose of study drug.  Such methods include: oral hormonal contraception 
(combined estrogen/ progestogen, or progestogen- only) associated with inhibition of 
ovulation together with a barrier method ( eg, diaphragm, always containing a spermicide), 
intrauterine device (IUD), intrauterine hormone -releasing system (IUS), bilateral tubal 
ligation, vasectomized partner, or sexual abstinence.  Oral contraception should always be 
combined with an additional contraceptive method ( ie, barrier method) because of a 
potential interaction with the study drug.  The same criteria are applicable to male subjects  
involved in this clinical trial if they have a partner of childbirth potential, and male subjects must always use a condom.  
 Exclusion Criteria  
Subjects are not eligible for enrollment into this study if they have any of the following criteria: 
1. Absolute neutrophil count (ANC) <1.5×109/L, platelet count <100 × 109/L, or hemoglobin 
<9.0 g/dL.  Blood transfusion within 1 week prior  to enrollment for the purpose of 
increasing the likelihood of eligibility is not allowed; 
2. Serum total bilirubin >1.5 × the upper limit of normal (ULN).  Subject s with Gilbert 
syndrome, bilirubin <2 X ULN, and normal aspartate aminotransferase ( AST )/ alanine 
aminotransferase ( ALT ) are eligible;  
3. ALT or AST > 2.5 × ULN in subject s without hepatic metastases; ALT or AST >5  × ULN 
in subject s with hepatic metastases;  
4. Serum electrolytes, potassium, calcium, or magnesium levels out side of the normal 
laboratory reference range, and clinically significant in the investigator’s judgment;  
5. Serum creatinine >1.5 × ULN or creatinine clearance <60 mL/min. Creatinine clearance 
can either be measured in a 24 -hour urine collection or estimated by  the Cockc roft-Gault 
equation. 
6. Urine dipstick protein ≥2+ or 24- hour urine protein ≥ 1.0 g/24-h.  Subjects with greater 
than 1+ proteinuria on urinalysis must undergo a 24- hour urine collection .  For conversions 
between quantitative and qualitative results,  please see Appendix 8;  
7. Uncontrolled hypertension, defined as: systolic blood pressure ≥ 140 mmHg and/or 
diastolic blood pressure ≥ 90 mm Hg despite optim al medical management;  
8. International Normalized Ratio (INR) >1.5 x ULN  or activated partial thromboplastin time 
(aPTT) >1.5 × ULN, unless the subject is currently receiving or intended to receive 
anticoagulants for prophylactic purposes; 
9. History  of, or ac tive gastric/duodenal ulcer or ulcerative colitis, active hemorrhage of an 
unresected gastrointestinal tumor, history of perforation or fistulas; or any other condition that could, in the investigator’s judgment, result in gastrointestinal hemorrhage or perforation; within the 6 months prior to screening; 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 41 of 113 
 CONFIDENTIAL   
 10. History or presence of hemorrhage from any other site (eg, hemoptysis or hematemesis) 
within 2 months prior to screening;  
11. History of a thromboembolic event, including deep vein thrombosis (DVT), pulmonary 
embolism (PE), or arterial embolism within 6 months prior to screening.  
12. Stroke and/or transient ischemic attack within 12 months prior to screening;  
13. Clinically significant cardiovascular disease, including but not limited to acute myocardial 
infarction or coronary artery bypass surgery within 6 months prior to enrollment, severe or unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, ventricular arrhythmias requiring treatment, or left ventricular ejection fraction (LVEF) <50% by echocardiogram;  
14. Mean corrected QT interval using the Fridericia method (QTcF) >480 msec or any factors that increase the risk of QTc prolongation or risk of a rrhythmic events such as 
hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in a first- degree relative.  
15. Concomitant medications with a known risk of causing QT prolongation and/or Torsades de Pointes (See list in Appendix 3; source list is continuously updated online at 
www. crediblemeds.org). 
16. Systemic anti -neoplastic therapies ( except for those described in Exclusion Criterion  18) 
or any investigational therapy within 4 weeks prior to the first dose of study drug, including chemotherapy, radical radiotherapy, hormonotherapy, biotherapy and immunotherapy;  
17. Systemic small molecule targeted therapies (eg, tyrosine kinase inhibitors) within 5 half -
lives or 4 weeks (whichever is shorter) prior to the first dose of study drug;  
18. Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior to the initiation of study drug;  
19. Brac hytherapy ( ie, implantation of radioactive seeds) within 60 days prior to the first dose 
of study drug. 
20. Use of strong inducers or inhibitors of CYP3A4 within 2 weeks before the first dose of study drug (see Appendix 3 for a list of applicable drugs); 
21. Surgery or invasive procedure ( ie, a procedure that includes a biopsy; central venous 
catheter placement is allowed) within 60 days prior to the first dose of study drug or unhealed surgical incision;  
22. Any unresolved toxicities from a previous antitumor treatment greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE ) v5.0 
grade 1 (except for alopecia or neurotoxicity grade ≤2). 
23. Known human immunodeficiency virus (HIV) infection;  
24. Known history of active viral hepatitis.  For subject s with evidence of chronic hepatitis B 
virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.  Subject s with HCV infection who are currently on treatment are eligible if they 
have an undetectable HCV viral load. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 42 of 113 
 CONFIDENTIAL   
 25. Clinically uncontrolled active infection requiring IV antibiotics;   
26. Tumor invasion of a large vascular structure ( eg, pulmonary artery, superior or inferior 
vena cava );   
27. Women who are pregnant or lactating;  
28. Brain metastases and/or spinal cord compression untreated with surgery and/or 
radiotherapy, and without clinical imaging evidence of stable disease for 14 days or longer; subject s req uiring steroids within 4 weeks prior to start of study treatment are excluded;  
29. No other malignancy, except for non- melanoma skin cancer, in situ  cervical ca or bladder 
ca (Tis and T1) that have been adequately treated during the 5 years prior to screening;  
30. Inability to take medication orally, dysphagia or an active gastric ulcer resulting from 
previous surgery (eg, gastric bypass) or a severe gastrointestinal disease, or any other 
condition that investigators believe may affect absorption of the investigational product;  
31. Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other condition ( eg, current alcohol or drug abuse) that investigators suspect 
may prohibit use of the investigational product, affect interpretation of study results, or put the subject  at undue risk of harm based on the investigator’s assessment;  
32. Known hypersensitivity to fruquintinib or any of its inactive ingredients. 
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 43 of 113 
 CONFIDENTIAL   
 6. STUDY CONDUCT  
 Study Procedures  
 Study Assessments  
The following procedures will be performed according to the schedule in Table  1.  All assessments  
must occur within ±  3 days (±1 day during cycle 1) from the scheduled date, unless otherwise 
noted.  
 Informed Consent  
All subjects must sign the informed consent form ( ICF) prior to any study- related examinations 
or protocol procedures.  Tumor assessments completed as standard of care prior to signing the 
informed consent, but within 28 days of first dose of study treatment, may be used as baseline scans. 
All subjects who sign ICF  are to be entered into the IWRS system.  The system will generate a 
subject identification  number, which will be assigned to the subject. 
 Medical History  
A complete medical history, including the subject ’s medical history, disease history and prior 
therapies for disease prior to signing of the ICF, should be recorded at screening.  Comorbidities 
that began prior to signing the ICF should be recorded and followed as medical history. 
 Tumor Diagnosis and Treatment History  
Tumor diagnosis should include the  date of primary diagnosis of CRC and its type , disease stage, 
the date of first metastasis, type of  previous treatment, start  and end date /s, best overall response, 
date of PD , adverse reaction with severity ≥ grade 3.  Prior use (yes/no) of trifluridine/tipiracil 
(Lonsurf®, TAS -102) , regorafenib (Stivarga®), or both of these drugs , prior use of 
fluoropyrimidine- , oxaliplatin, and irinotecan -based chemotherapy.  P rior use of a biological anti -
VEGF therapy (yes versus no), prior RAS gene status (mutant versus wild type). 
If the RAS gene test was not performed previously, it should be performed  during s creening .  In 
subjects who are RAS wild type, anti -EGFR therapy  must be offered unless medically 
contraindicated . 
The subject ’s history of r adiation therapy, including  the start and end date /s and the site of radiation 
must be recorded.  Surgical history, including operations and less -invasive diagnostic or 
therapeutic procedures (such as GI endoscopy, biopsy, etc.) , the start and end date /s, name of each 
procedure and operation site must also be recorded at screening and in the appropriate eCRF.  
 Demogr aphics  
Demographic characteristics, including date of birth, sex, ethnic group/race, and any relevant 
lifestyle habits should be recorded at screening and in the applicable eCRF (as permitted by local 
regulations).  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 44 of 113 
 CONFIDENTIAL   
 
 Concomitant Medication and Procedures  
Concomitant therapy includes any prescription medications or over -the-counter preparations used 
by a subject .  All concomitant m edications within 28 days before randomization must be recorded 
in the eCRF, including the generic name of the drug and daily dose , the reason /s for using th e 
medication , as well as the start and stop date /s of the medication.   Concomitant medications should 
be reviewed during the study according to the schedule in Table  1. 
 Comprehensive Physical Examination  
A comprehensive physical examination includes subject height, weight and general condition, as 
well as an examination of the head, heart, chest (including the lungs), abdomen, extremities, skin, 
lymph nodes, nervous system and additional areas/systems as clinically indicated. 
 Limited Physical Examination  
Limited physical examination includes vital signs and any change from baseline, any new abnormalities, examination of weight, thorax, abdomen, and additional areas/systems as clinically 
indicated.  In order to assess changes from baseline and to evaluate for new abnormalities, the 
limited physical examination should assess for new or changed skin lesions, enlarged lymph nodes, palpable masses, and appropriate examination to address any subject-reported symptoms. 
 Eastern Cooperative Oncology Group (ECOG) Performance Status 
Subject performance status will be graded according to the Eastern Cooperative Oncology Group 
(ECOG) performance  status scale at study visits as detailed in Table  1.  It is recommended that 
ECOG performance status scores be evaluated by the same investigator throug hout the study.  
Details on the ECOG assessment and grading scale are available in Appendix 1. 
 Vital Signs  
Vital signs include blood pressure, heart rate, respiration rate and temperature.  For subject s with 
a baseline history of hypertension or hypertension that develops on study, blood pressure should be monitored per institutional standard practice.  
 Hematology  
Hematology assessments include red blood cell count, hemoglobin, hematocrit, platelet count, 
white blood count with differential (absolute counts).   
Note:  If neutrophil count  ≤1.0×109/L or platelet count≤  25 ×109/L, hematology assessments 
should be conducted per institutional standard practice.  
 Blood Chemistry  
The blood chemistry panel includes sodium, potassium, chloride, bicarbonate, blood urea nitrogen, 
creatinine, glucose, calcium, magnesium, phosphorus, total bilirubin, ALT, AST, ALP , lactate 
dehydrogenase, non- fasting total cholesterol, triglycerides, uric acid, total protein and albumin. 
Blood chemistry tests for subjects with ALT or AST increase by >3x ULN, or increase  by >2x 
baseline value should performed per institutional standard practice.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 45 of 113 
 CONFIDENTIAL   
 Creatinine clearance (C rCl) rate (units, mL/min) should be calculated using the baseline serum 
creatinine (Scr) value according to the Cockroft -Gault formula: for males: Ccr = [(1 40 - age) × 
weight (kg)] / [72 × Scr (mg/dL) x ideal body weight (IBW)].  For females, the same formula 
should be calculated and multiplied by  0.85. 
 Coagulation 
Coagulation tests include prothrombin time  (PTT) , international normalized ratio (INR), and 
activated partial thromboplastin time (APTT).  
 Thyroid Function  
Thyroid function tests include serum free triiodothyronine (fT3), serum free thyroxine (fT4) and thyroid stimulating hormone (TSH). 
 Urinalysis  
Urinalysis parameters include urine pH, protein, g lucose, and blood; microscopic for white blood 
cell and red blood cell count.  A 24-hour urine for quantitative protein must  be collected from all 
subject s with ≥ 2+ proteinuria.  For conversions between quantitative and qualitative results, 
please see Appendix 8. 
 Pregnancy Test  
All female subject s of childbearing potential must complete a blood pregnancy test at screening 
and within 30 days at the Safety  Follow Up Visit, and a urine pregnancy test on day 1 of every 
cycle starting at cycle 2.  Serum pregnancy test should be repeated for women  with suspected 
pregnancy.  This is not applicable for postmenopausal female subject s (ie, no menses for 12 months 
without an alternative medical cause), and the  date of menopause should be recorded instead.  
Pregnancy testing and contraception are not required for women with documented permanent sterilization (eg , hysterectomy, bilateral salpingectomy and bilateral oophorectomy, or tubal 
ligation ). 
 Electrocardiograms Monitoring  
Single 12- lead electrocardiograms (ECG) will be collected in all subject s using standardized 
equipment, as described in Table  1, Table  2, and Table  3 during c ycles 1 to 3.  ECGs from standard 
equipment will be evaluated for safety by the p rincipal investigator.  In addition, continuous 12-
lead Holter monitor will be used for QTc evaluation during cycle 1 in a subset of subject s and will 
be sent for central reading (see below in Continuous 12- Lead Holter Monitor for QTc Evaluation 
for details).  From cycle 4 onward, ECG will only be performed as clinically indicated.  Vital signs 
will be measured, a sympt om-directed physical exam will be conducted, and safety related blood 
samples will be collected as per the time  points in Table  1.  These assessments sh ould be completed 
before the start of any ECG recordings. 
Continuous 12 -Lead Holt er Monitor for QTc Evaluation  
Continuous ECG recordings using 12- lead Holter monitoring will be collected from the first 
approximately 120 patients (80 fruquintinib, 40 placebo) enrolled in the study to evaluate the 
effects of fruquintinib  on ventricular repolarization .  The assessments will be conducted at pre -
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 46 of 113 
 CONFIDENTIAL   
 dose and post -dose on cycle 1 day  1 and cycle 1 day 21 at specific time  points summarized in 
Table  2. 
Subject s should reside in a quiet setting without distractions (eg, television, cell phones and staff 
talking) at each scheduled time point for ECG measurements.  Su bject s should rest in a supine 
position for at least 10  minutes before and 5 minutes after the scheduled time point and should 
refrain from talking or moving arms or legs.  Skin preparation should be optimal to obtain high 
quality ECGs; if deemed appropriate, the chest should be shaved and prepared  with light abrasion.  
Continuous digital 12- lead Holter ECGs will be recorded as described in the ECG/Holter manual. 
Good quality 12- lead ECG selection and extraction will occur during a 10 -minute timeframe 
starti ng 5 minutes before and ending 5 minutes after the scheduled ECG time  point.  All Holter 
recorder devices (as supplied by the central ECG laboratory) will be of the same brand and model 
with the same software, and would have been recently serviced and cali brated.  Documentation 
describing the brand, type, software and service/calibration history of Holter recorders will be 
provided by the central ECG laboratory and archived at the site as well as in the sponsor’s study 
file.  Transfer of the Holter recordin gs and extraction of the ECG tracings will be performed as 
described in the ECG/Holter manual.  
Ten-second digital ECG tracings will be extracted from the Holter device in triplicate by the 
central ECG laboratory according to the following principles: 
• The a ctual time of dosing will be communicated to the central ECG laboratory on the 
Holter acquisition form completed by the site.  
• Using visual inspection or automated tools as appropriate, the central ECG laboratory 
will identify a period of stable HR on the c ontinuous Holter tracing within ±5 minutes 
of the nominal ECG time  point (determined relative to the actual dosing time for an 
individual subject).  Three 10- second ECGs will be extracted in close succession 
from this identified segment.  
• The scheduled time points for triplicate ECG extraction are summarized in Table  2. 
Unless warranted by a specific safety endpoint of the study, the Holter tracings will not be routinely analyzed for rhythm and conduction abnormalities.  These analyses will only be performed on 
individual subject ’s Holter if warranted by TEAEs (eg, syncope).  
 Echocardiogram 
An echocardiogram  should be done at Screening, cycle 2 day  1, and on day  1, every 3 cycles 
thereafter.  Assessment parameters include left ventricular ejection f raction and general assessment 
of cardiac function.  MUGAs are permitted if echocardiograms cannot be performed. 
 Tumor Evaluation/Imaging  
Tumor assessments will be performed at study visits specified in Table  1. 
All measurable an d evaluable lesions should be assessed and documented using image -based 
evaluation.  All subject s are to be evaluated utilizing contrast -enhanced computed tomography 
(CT) scan of the chest, abdomen, and pelvis , or other acceptable cross -sectional imaging per 
RECIST v1.1.  Evaluations should include other areas of the body, as clinically indicated.  Disease 
status will be assessed by the investigator or designated site staff using RECIST v1.1.  The same 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 47 of 113 
 CONFIDENTIAL   
 imaging procedure used to define measurable lesions at baseline must be used throughout the study 
for each subject , unless medically contra -indicated.  At the investigator’s discretion, other methods 
of assessment of measurable disease as per RECIST v1.1 may be used.   
Tumor assessments completed as standard of care prior to signing the informed consent, but within 
28 days of first dose of study treatment, may be used as baseline scans.  
Imaging for all subject s will also be collected for central storage.  Please refer to the study -specific 
central imaging manual for collection and shipping instructions. 
 Tumor M arkers  
Assessment of serum carcino -embryonic antigen ( CEA) level s will be performed according to the 
schedule in Table  1.  The dates of blood sampling must be recorded in the eCRF. 
 Circulating Tumor DNA  
Collection of circulating tumor DNA (ctDNA) will be collected according to the schedule in Table  1.  For collection and shipping instructions please refer to study specific laboratory manual. 
The dates of blood sampling must be recorded in the eCRF. 
 Subject Randomization  
On day  -2 to day  1, after verifying the subject’s eligibility, the site will log into the IWRS and the 
subject will be randomized by the system .  The system will generate a serial number matching a 
bottle of investigational product in the site’s inventory.  The s ite will take investigational product 
with the serial number assigned by IWRS from inventory and dispense it to the subject.  The first 
dose should be administered on c ycle 1 day  1. 
 Quality of Life Assessment  
A quality of life assessment, using QLQ -C30: cancer -specific; and EQ -5D- 5L: general, must be 
performed during the screening visit as well as day  1 of each cycle until treatment is discontinued.  
 Pharmacokinetic s Evaluations 
 Sample Collection and Handling  
Samples for PK analysis will be collected in all subjects according to the schedule in Table  2 and 
Table  3.  The actual  dates and times of PK sampling should be recorded in appropriate e CRF .  In 
addition, the dates and times of the dose administered on the day of PK collection and one day before PK collection must be recorded in the e CRF.  
Instructions for the collection, handling, storage, and shipment of samples are found in the laboratory manual that will be provided to the sites.  Collection, handling, storage, and shipment 
of samples must be under the specified, and where applicable, controlled temperature conditions 
as indicated in the laboratory manual. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 48 of 113 
 CONFIDENTIAL   
 
 Analytical Procedures  
Plasma samples will be analyzed to determine concentrations of fruquintinib and its active 
metabolite M11 using a validated, specific, and sensitive Liquid Chromatography- Tandem Mass 
Spectrometry (LC MS/MS) method.  
If required, then plasma samples may be analyzed to document the presence of circulating metabolites using a qualified research method. 
 End of Treatment Visit  
Subject s who have completed the study or have discontinued study treatment will be asked to 
return to the investigational site to receive safety examinations and assessments within 7 (±3) days 
after the last dose of study drug. 
 Safety Follow- Up Visit 
All subjects who have completed an End of  Treatment Visit  will have a Safety Follow -Up Visit .  
The Safety Follow- Up Visit will be conducted at 30 (±7) days from the EOT Visit.  
 Efficacy Follow -Up 
Any subject who discontinues study treatment for any reason other than disease progression should be followed until progression is document ed or until a new anti -cancer treatment  is initiated  for 
PFS assessment and until death for OS assessment . 
 Survival Follow-Up 
Every 12 (±2) weeks after  the End of Treatment Visit the investigator or their designee shoul d 
call the subject  to collect  information related  to survival status and their use of other anti -
cancer  treatments, including drug name, dosage , treatment start and end dates, and efficacy.  
Information related to radiotherapy received after disease progression is also needed, including 
radiotherapy location, radiation dose, start date, and end date. 
 Long -term Extension  
Subject s who are still on study treatment at the time of study completion may continue to receive 
study treatment if they are experiencing clinical benefit and no undue risks. 
Continued access will apply to this study only if at least 1subject  is still on study treatment when 
study completion occurs.  The sponsor will notify investigators when the continued access period 
begins. 
 Discontinuation or Withdrawal  
 Permanent Discontinuation of Treatment  
The investigator has the right to discontinue a subject from the study for any medical condition 
that the investigator determines is in the best intere st of the subject , reasons of non- compliance 
(eg, missed doses, visits), or pregnancy.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 49 of 113 
 CONFIDENTIAL   
 Any subject who discontinues treatment should be encouraged to return to the study site for an 
End of Treatment Visit and continue with the remaining study visits outlined in Table  1.  The 
primary reason for discontinuation must be recorded on the appropriate e CRF.  
Subjects may  be discontinued from treatment for any of the following reasons : 
 Disease progression (according to RECIST 1.1), unless there is reasonable evidence of 
clinical benefit to justify continuation on the study treatment.  The continuation decision 
should be made by the investigators in consultation with the sponsor.  The disease 
progression date is the date when radiological disease progression is first reported acco rding 
to RECIST 1.1 criteria . 
 Withdrawal of consent;  
 Intolerable toxicity;  
 Poor subject compli ance;  
 Use of other antitumor treatment during the study;  
 Pregnancy;  
 Subject is lost to follow -up; 
 The investigator or sponsor determines it is in the best interest of the subject;  
 Study is terminated by the sponsor ;  
 Death ; 
 End of this study. 
 Withdrawal  from Study  
All study participants have the right to withdraw from the study at any time.  During the treatment 
period and follow -up period, a subject  who withdraws consent to continue participation in the 
study will not be followed for any reason after consent has been withdrawn.  Every effort should be made to obtain information on subject s who discontinue study treatment but who do not 
withdraw consent to continue participation in the study.  If a participant withdraws consent for 
disclosure of future information, the sponsor may retain and continue to use any data collected before such a withdrawal of consent. 
If a participant withdraws from the stud y, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records. 
 Replacement of Subjects  
Subjects will not be replaced in this study. 
 Subjects Lost to Follow -up 
A participant will be  considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site. Before a participant is deemed lost to follow up, the investigator or designee must make every 
effort to regain cont act with the participant (where possible, 3 telephone calls and, if necessary, a 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 50 of 113 
 CONFIDENTIAL   
 certified letter to the participant’s last known mailing address or local equivalent methods).  These 
contact attempts should be documented in the participant’s medical record. 
Should the participant continue to be unreachable, he/she will be considered to be withdrawn from 
the study.  
 Study Termination  
The sponsor has the right to terminate the study prematurely.  Reasons may include efficacy, 
safety, or futility, among others.  Should the s ponsor decide to terminate the study, the 
investigator(s) will be notified in writing.  
 End of Study  
The end of the study defined as the last visit of the last subject in the study .  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 51 of 113 
 CONFIDENTIAL   
 7. STUDY DRUGS  
 Study Drug Administration  
Fruquintinib (at a dose of 5 mg) or matching placebo will be administered PO , QD, on a 3 weeks 
on, 1 week off schedule .  One treatment cycle is 4 weeks.  The administration time should be 
recorded accurately.   Study drug may be given either in the fasting state or after meals.  If dose 
adjustment is required, 1 mg fruquintinib or matching placebo capsules will be used.  
On days  with PK collection , treatment should be administered at the site by a delegated study staff 
member.  
 Description of Products 
Fruquint inib will be provided as 1  mg or 5 mg capsules for oral administration .  Matching placebo 
capsules for each strength will also be provided.   
 Formulation, Storage, Preparation and Handling  
The investigational drug s are formulated  as capsules , which are packaged  in labeled bottles .  The 
drug information is provided in  Table  5.  Additional information is available in the pharmacy 
manual. 
Table  5 Information on Investigational Products 
Name  Dosage  
 Specification  Administration Method  
Fruquintinib  Capsule  5 mg Oral 
Fruquintinib  Capsule  1 mg Oral 
Matching  placebo*  Capsule 5 mg Oral 
Matching  placebo *  Capsule  1 mg Oral 
* The appearance of the matching placebo is identical to that of the study drug.  
All the investigational drugs should be sealed and stored in a secure, limited access area under 
appropriate conditions.  The storage temperature should be between 10℃  to 30℃ .  Investigational 
drugs should not be used beyond expiration date provided by the manufacturer. 
The temperature -monitoring log should be recorded and filed in the study binder. 
 Drug Accountability  
 Assignment/Disposal (Study Site)  
All study drug required for  this study will be provided by Hutchison MediPharma  Limited .  The 
recipient will acknowledge receipt of the drug by returning the appropriate documentation form 
indicating shipment content and condition.  Damaged supplies will be replaced.  
Accurate record s of all study drug received at, dispensed from, returned to and disposed of by the 
study site should be recorded by using the Drug Inventory Log. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 52 of 113 
 CONFIDENTIAL   
 Study drug will be disposed of at the study site according to the study site’s institutional standard 
operati ng procedure or returned to Hutchison MediPharma Limited  or a Hutchison identified entity 
with appropriate documentation, as determined by the study site.  If the study site chooses to 
destroy study drug, the method of destruction must be documented. 
 Drug Return (Subject)  
On day -2 to day 1, only subject randomization and drug assignment will be performed.  The first dose of study drug should be administered on C1D1.  Subjects will be provided with a pill diary 
at randomization and be instructed on how to account for each day’s dose  appropriately.  Subjects 
should return all unused study drug and containers from the previous cycle on day  1 (date of 
scheduled visits) of each subsequent cycle, and new study drug will be dispensed on the same day.  
Site study staff should review  subjects pill diary and provide a new diary if necessary at the day 1 
visit of each cycle.  
If a dose adjustment is required (eg, decrease from 5  mg QD to 4 mg QD), the subject  must return 
to the investigational site and return all unused study drug.  The s ite must  log into the IWRS, adjust 
the dose, reassign the drug serial number, and dispense new study drug dose (in 1 mg capsules) to 
the subject .  If the dose is adjusted a second time, ie, from 4 mg QD to 3 mg QD, the site must  log 
into the IWRS and record the second dose adjustment.  On this occasion, it is not necessary to reassign a new drug serial number.  If tumor evaluation shows PD during the previous cycle and new drug has been dispensed, the subject  must return all unused study drug on the 30 -day safety 
visit after EOT.  
 Treatment Assignment and Bias Minimization  
 Treatment Allocation  
Treatment will be allocated using IWRS randomization s trategy and procedure (refer to the IWRS 
manual).  After screening, subjects who meet t he eligibility criteria will be randomized into the 
fruquintinib  or placebo group in  a 2:1 ratio .  Randomization will be stratified by:  
• Prior therapy with trifluridine/tipiracil (TAS -102) versus regorafenib versus  both 
trifluridine/tipiracil (TAS -102) and regorafenib ;  
• RAS status (wild type versus mutant) ; and  
• Duration of metastatic disease ( ≤ 18 months versus > 18 months).  
 Extent and Maintenance of Blinding  
The s tudy subject , investigators, and study site personnel will remain blinded to all randomization 
assignments throughout the study except for the specific circumstances described in Section  7.3.3.  
The sponsor’s study director, study monitor, and any other sponsor and contract research 
organization (CRO) personnel who are in regular contact with the study site will remain blinded 
to all subject randomization assignme nts, except sponsor pharmacovigilance personnel for the 
purpose of IND safety reports. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 53 of 113 
 CONFIDENTIAL   
 
 Unblinding Procedures  
 Emergency Unblinding  
Unblinding can occur in emergency  cases.  If unblinding is required for treatment of a subject for 
an SAE , the investigator must first contact the sponsor’ s medical monitor before unblinding, and 
then unblind the subject  using the IWRS.  Once unblinded, the subject should discontinue the 
treatment but will continue to be followed for safety and efficacy.  The investigator should record 
the event in the source document. 
 Assessment and Verification of Compliance  
The investigator is responsible for ensuring the subject’s treatment compliance.  The sponsor will 
provide supervision through on- site monitoring visits  made by its representatives.  The 
investigators should maintain complete and accurate records of drug use.  The dosing regimen and 
subject ’s actual dosing should be recorded in the original treatment records as well as eCRF.  At 
each treatment visit, the investigators or study staff should comprehensively assess the subject 's 
treatment compliance according to the drug dispensing and return status at each visit and the actual dosing conditions, such as missed doses and overdosing reported by the subject .  The subject s must 
return all drug bottles and remaining capsules at the end of the study.  The investigational sites 
must return all remaining supplies and drugs to the sponsor or provide evidence of destruction at the conclusion of the study.  
 Prior and Concomitant Therapies  
 Prohibited Therapies  
Any therapy intended for the treatment of cancer (with the exceptions as noted in Section  7.5.2, 
whether currently marketed or experimental, is prohibited.  This includes, but is not limited to, the 
following: chemotherapy, hormonal therapy, biologic therapy, radiotherapy, or herbal therapy. 
Concomitant use of medications that have a known risk of causing QT prolongation and/or 
torsades de pointes (see “combined” list at http://www. crediblemeds.org, with attention to those 
drugs listed as KR (“known risk”).  
 Permitted Therapies 
Concomitant therapy includes any prescription medications or over -the-counter preparations used 
by a subject .  All concomitant therapy  within  28 days prior to randomization and the Safety Follow 
Up visit .  All concomitant medications should be reported to the investigator and recorded on the 
appropriate e CRF.  
Subject s who use oral contraceptives, hormone -replacement therapy, or other allowed 
maintenance therapy may continue their use if indicated.  
Prophylact ic use of anticoagulation for the maintenance of patency of permanent indwelling 
central venous access devices or for subject s at high risk of venous thromboembolism is permitted 
during study treatment.  If subject s are receiving anti -coagulation, they should be very closely 
monitored for potential hemorrhage, and: 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 54 of 113 
 CONFIDENTIAL   
 The investigator should closely monitor subject s receiving anti- platelet and/or anti-thrombotic 
drugs during study drug treatment and make a timely decision on whether to continue or stop such 
drugs in subject s that report grade ≥2 hemorrhagic events at any site, based on an individual 
assessment of the risk -benefit balance (See Appendix 6 for ad ditional information on the clinical 
management of severe or serious hemorrhagic AEs).  
Subject s that develop arterial thromboembolic events should discontinue the study drug.  If a 
subject suffers a venous thromboembolic event while still receiving study drug, it may still be 
possible for him or her to remain on study treatment under close monitoring and dose modification of study drug. 
Prophylactic antiemetic, granulocyte colony stimulating factors, granulocyte macrophage colony -
stimulating factors, platelet simulating factors or erythropoietin are permitted as clinically 
indicated. 
Palliative radiation for symptom control is allowed provided it does not compromise tumor 
assessments of target lesions.  However, fruquintinib treatment should be suspended dur ing the 
radiation period and not resumed until at least 7 days after radiation only after meeting the 
following criteria:  
• Radiation related toxicities resolves to grade ≤ 2; 
• No disease progression observed.  
All supportive measures consistent with optimal su bject  care will be given throughout the study. 
 Drug -Drug Interactions 
In vitro  metabolism data indicate that CYP3A plays an important role in the metabolism of 
fruquintinib.  The potential effects of medications that can affect the PK of fruquintinib via the 
CYP3A pathway have not been tested in the clinic.  Therefore, medications that are strong inhibitor 
or strong inducer of CYP3A should not be administered concomitantly with  fruquintinib.  
Examples of the se med ications  to avoid are listed in Appendix 3.  
In vitro , fruquintinib is shown to have the potential to inhibit P -gp and BCRP (see Section  2.1.3.2).  
Avoid concomitant use with medications that are sensitive substrates of P -gp or BCRP where 
possible.  If used together, monitor subject s more frequently for adverse reactions, and consider 
dose reduction of the P -gp or BCRP substrate medication.  Examples of the medications that are 
sensitive substrates of P -gp and BCRP are listed in Appendix 3. 
Fruquintinib shows pH -dependent solubility (ie , solubility at pH 6.0–6.5 < solubility at pH 1–2) 
and is less well absorbed as gastrointestinal pH increases.  Subject s should avoid using proton 
pump inhibitors (eg, esomeprazole, lansoprazole, pantoprazole) during the study.  If concomitant 
use of an acid -reducing agent is unavoidable, H 2-antagonist ( eg famotidine, ranitidine, nizatidine) 
may be used but should be administered approximately 10 hours before or 2 hours after 
fruquintinib  dosing.  Antacid may be used, but the antacid dose should be administered at least 2 
hours before or 2 hours after fruquintinib dosing. 
 Rescue Therapies  
Not applicable. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 55 of 113 
 CONFIDENTIAL   
 
 General Dose Adjustment Note  
The severity of AEs will be graded according to the NCI CTCAE v5.0.  Reasons for dose 
modifications or delays, the supportive measures taken, and the outcome should be documented 
in the subject’s chart and recorded in the e CRF.  
• For any concomitant conditions already apparent at baseline, the dose modifications 
will apply according to the corresponding shift in toxicity grade, if the investigator feels 
it is appropriate.  For example, if a subject  has grade 1 asthenia at baseline that increases 
to grade 2 during treatment, this will be considered a shift of one grade and treated as 
grade 1 toxicity for dose-modification purposes. 
• For toxicities that are considered by the investigator to be unlikely to develop into serious or life -threatening events, treatment can be continued at the same dose.  
• To recover from acute toxicity, unless otherwise indicated, the treatment can be  delayed  
for up to 14 days.  If a treatment delay longer than 14 days is required, treatment  should 
be disconti nued.  Continuation/resumption of fruquintinib treatment after an 
interruption of more than 14 days must be discussed with the medical monitor or his or 
her designee.  
• Where several toxicities with different grades or severity occur at the same time, the dose modifications should be according to the highest grade observed. 
 Dose Modification Guidance  
 Dose Modification Sequence by Starting Dose and for General Hematologic and 
Non-Hematologic Toxicity 
The d ose reduction sequence by starting dose is shown in Table  6.  Subjects are allowed to have 
no more than 2 dose reductions: one reduction from 5 mg QD to 4 mg QD, and if not tolerated, 
then a second reduction from 4 mg QD to 3 mg QD (see Table  6).  Once a dose has been 
reduced, it cannot be re- escalated.  
Table  6 Dose Modification Sequence by Starting Dos e  
Dose Level 0 * 
(Original dose)  5 mg QD 3 weeks on, 1 week off  Fruquintinib of 5  mg, 1 capsule, or 
1 capsule of the matching  placebo  
Dose Level -1* 
(the 1st dose reduction)  4 mg QD 3 weeks on, 1 week off  Fruquintinib of 1  mg, 4 capsules, or 
4 capsules of the  matching  placebo  
Dose Level -2* 
(the 2nd dose reduction)  3 mg QD 3 weeks on, 1 week off  Fruquintinib of 1  mg, 3 capsules, or 
3 capsules of the matching  placebo  
* Doses are daily, on days 1-21 each 28 -day cycle  (3 weeks on, 1 week off)  
 
Dose reduction guidelines for haematologic and non- haematologic toxicities, other than P almar -
plantar erythrodysesthesia (PPE), P roteinuria , Hypertension, D ecreased platelet count, 
Hemorrhage , and liver function impairment, are shown in are shown in Table  7.  Treatment should 
be held until AE/toxicity resolves or improves to ≤ grade 1.  If a subject has a grade 3 toxicity that 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 56 of 113 
 CONFIDENTIAL   
 is expected to be manageable and reversible with a dose reduction, treatment should be held until 
toxicity resolves to ≤grade 1.  Subjects with grade  3 non- haematologic toxicity not described 
below that does not resolve to ≤grade 1 within 14 days should permanently discontinue the study 
drug unless approval to continue is obtained in writing from the sponsor . 
Table  7 Dose Modification Recommendations for Hematologic and Non-
Hematologic Toxicity  
NCI CTCAE v 5.0 Toxicity 
Grading  Action  
Grade 1 or 2a None  
Grade 3b Interrupt the dose until the toxicity resolved to ≤ grade  1 or baseline 
level within 14 days , then reduce the dose to lower a dose level  
Grade 4  Discontinue treatment permanently  
a Should any arterial thrombosis occur the treatment should be terminated.  
b Including grade 3 diarrhea and stomatitis, etc. that are ineffectively treated by drug therapies, but excluding 
grade 3 menstrual cycle extension.  
 Dose Modification for Important Identifi ed Risks  
The dose modification and treatment suggestions for specific identified risks are provided in Table  8(PPE ), Table  9 (proteinuria), Table  10 (hypertension), Table 11 (dec reased platelet 
count), Table  12 (hemorrhage at any site), and Table  13 (abnormal liver function).  
Table  8 Dose Modification for Palmar- Plantar Erythrodysethesia
 
AE Grading Standard  Dose Adjustment  Treatment Suggestions  
Grade 1 : numb, paresthesia, 
dysesthesia, erythema, painless 
edema, desquamation, thicken 
skin and hand and foot discomfort 
which does not affect the normal 
activities; without any pain  None.  Active supportive treatment can be 
adopted to relieve the symptoms; for example, moisturizing skin cream, 
lotion, or hydrophilic urea ointment 
can be used.  
Grade 2 : erythema with pain 
accompanied by hand and foot swelling and /or discomfort, which affect s normal activities  Hold treatment .  Resume at 
the same dose if the AE 
recovers to g rade 1 or 
baseline level within 14 
days.  Active supportive treatment can be 
adopted to relieve the symptoms; for example, moisturizing skin cream, lotion, or hydrophilic ur ea ointment 
can be used.  
Grade 3 : wet desquamation, 
ulcer, blister or severe hand and foot pain or severe discomfort , 
which affects work or normal activities .   Hold treatment .  Dose 
reduce and resume treatment at the next  lowe st 
dose level if the AE recovers to g rade 1 or 
baseline level within 14 
days.  Active supportive treatment can be 
adopted to relieve the symptoms; Should the same AE occur for 3 
times or still occurs after 2 times of 
dose reduction, the drug should be terminated.  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 57 of 113 
 CONFIDENTIAL   
 Table  9 Dose Modification for Proteinuriaa 
AE Grading Standard  Dose Adjustment  Treatment Suggestions  
Grade 1 : Proteinuria 1+ by 
urinalysis;  
24-hour urine  protein  
quantitation  <1.0 g  None  Follow up at scheduled study visits.  
Grade 2 : Proteinuria 2+ by the 
urinalysis; 
24-hour urine  protein  
quantitation  is between 1.0 to 
<2.0 g  None  Provide supportive treatment and 
increase the frequency of urine monitor to once a week; consult nephrologist if 
necessary.  
Grade 2 : Proteinuria 2+ or 
above by urinalysis;  
24-hour urine  protein  
quantitation  is between 2.0 to 
<3.5 g (excluding 3.5 g)  Hold treatment.  Dose reduce 
and resume treatment at the 
next lowe st dose level if the 
AE recovers to grade 1 or 
baseline level within 14 days.  Provide supportive treatment and 
increase the frequency of urine monitor to once a week; consult nephrologist if necessary.  
Grade 3 : 24-hour urine  protein  
quantitation  ≥3.5 g  Hold treatment.  Dose reduce 
and resume treatment at the next lowe st dose level if the 
AE recovers to grade 1 or 
baseline level within 14 days.  Provide supportive t reatment and 
increase the frequency of urine monitor to once or twice a week; consult 
nephrologist if necessary.  Should the 
same AE occur for 3  times or still 
occurs after 2 times of dose reduction, 
the drug should be terminated.  
a: If protein ≥ 2+ on urinalysis  during  the study, a 24 -hour urine test should be conducted within 1 week , 
and dose modification will be done by the result of 24 -hour urine protein quantitation.  
 
Table  10 Dose Modification for Hypertension  
AE Gradi ng Dose adjustment  Treatment Suggestions  
Grade 1 : prehypertension  
(systolic BP 120 -139 mmHg or 
diastolic BP 80 -89 mmHg)  None.  Follow up as planned schedule  
Grade 2 : SBP 140 -159 mmHg 
or DBP of 90 -99 mmHg; or DBP 
symptomatic increase >20 
mmHg  None.  Treatment objective: lower the 
blood pressure to <140/90  mm Hg 
(or <130/80  mm Hg in subject s 
with chronic renal disease and/or diabetes).  
 
Refer to Appendix  7.   
Grade 3 : SBP ≥ 160 mmHg  or 
DBP ≥100mmHg; or more than 
one drug or more intensive therapy are used  If BP >160/100mmHg lasts for > 7 days 
after initiation of anti -hypertensive 
treatment or modification of current anti -
hypertensive treatment, treatment should be held .  If hypertension resolves to 
grade 1 or baseline level within 14 days, 
treatment should be resumed at the next 
lowest dose level.  Treatment objective: lower the 
blood pressure to <140/90  mmHg 
(or <130/80  mm Hg in subject 
with chronic renal disease and/or 
diabetes).  
 Refer to Appendix 7 . 
Grade 4 : Life threatening (eg, 
malignant hypertension, temporary or permanent neurological deficits and 
hypertensive crisis)  Permanently d iscontinue study 
treatment . Emergent medical treatme nt. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 58 of 113 
 CONFIDENTIAL   
  
Table  11 Dose Adjustment for Decreased Platelet Count  
AE Grading  Dose Adjustment  Treatment Suggestions  
Grade 1 :  
Platelet count <LLN - 
75,000/ mm3;  
<LLN - 75.0 ×109/L           None.  Perform follow up visit as scheduled.  
Grade 2 :  
Platelet count <75,000 -
50,000/mm3;  
<75.0 - 50.0 ×109/L Hold treatment .  Resume at the 
same  dose if the AE recovers to 
grade  1 or baseline level within 7 
days.  Hematology test should be monitored every 
2-3 days; active treatment for platelet 
elevation  is recommended.  
Hold treatment .  Dose reduce and 
resume treatment at the next  lowe st 
dose level if the AE recovers to 
grade 1 or baseline level within 7-
14 days.  Hematology test should be monitored every 
2-3 days; active treatment for platelet 
elevation  is recommended.  
Grade 3:  
Platelet count <50,000 - 
25,000/mm3;  
<50.0 - 25.0 × 109/L  Hold treatment .  Dose reduce and 
resume treatment at the next  lowe st 
dose level if the AE recovers to 
grade 1 or baseline level within  14 
days.  Hematology test should be monitored every 
2-3 days; active treatment (platelet 
transfusion) to elevate the platelet count is recommended.  
Hematology examination should be 
performed once every week in the follow up 
visit.  
Grade 4:  
Platelet count <25,000/mm
3;  
<25.0 × 109/L Permanently discontinue study 
treatment . Hematology test should be performed once 
daily until the AE recovers to grade  2 or a 
lower grade; platelet transfusion or other 
active treatment should be provided  
 
Table  12 Dose Adjustment for Hemorrhage at any Site  
AE Grading  Dose Adjustment  Treatment Suggestions  
Grade 1  None  Perform follow up visit as 
scheduled.  
Grade 2  The drug can be interrupted and then reduced to the lower dose 
level should the AE recovered to grade  1 or baseline level 
within 14 days.  Provide active treatmentb 
Grade 3 or 
abovea Permanently discontinue study treatment . Emergent medical 
interven tionb 
a Refer to  Appendix  6 for clinical management of severe or serious hemorrhage.  
b The investigator should closely monitor subject s receiving anti -platelet and/or anti -thrombotic drugs during 
study drug treatment and make a timely decision on whether to continue or stop such drugs in subject s that 
report grade  ≥2 hemorrhagic events at any site, based on an individual assessment of the risk -benefit balance 
(See Section  7.5.2 ). 
 
Table  13 Dose Adjustment for Abnormal Liver Function  
AE Gradinga Dose Adjustment  Treatment Suggestions  
Grade 1  None . Follow up per planned 
schedule.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 59 of 113 
 CONFIDENTIAL   
 Table  13 Dose Adjustment for Abnormal Liver Function  
AE Gradinga Dose Adjustment  Treatment Suggestions  
Grade 2  or 3 (Liver 
function is abnormal but 
the biochemical criteria for 
Hy’s Lawb are not met)  1. Drug interruption can be considered ; 
2. The dose should be reduced to the lower 
dose level if the AE recovers to grade  1 or 
baseline within 14  days.  Provide supportive care and 
increase the frequency of liver 
function monitoring to 1- 2 
times a week.  
Grade 2 or 3  (Liver 
function is abnormal and 
the biochemical criteria for  
Hy’s Lawb are met)  The study drug should be terminated 
immediately.  Provide supportive care and increase the frequency of liver 
function monitoring to 2- 3 
times a week.  Urgent medical intervention indicated.  
Grade 4  The study drug should be terminated.  Urgent medical intervention 
indicated.  
a Including increasing of ALT, AST, and total bilirubin, whether or not the biochemical criteria for Hy’s Law 
have been met.  
b Hy’s Law  is an increase in serum AST or ALT ≥3 × ULN together with total bilirubin ≥2 × ULN, and no other 
reaso n can be found to explain the biochemical changes, for example, new or worsening hepatobiliary 
metastases, elevated serum alkaline phosphatase indicating  cholestasis, viral hepatitis, another suspect drug, or 
any other specific cause of severe hepatocellular injury.  The elevation in transaminases must precede or be 
coincident with (ie, on the same day as) the elevation in total bilirubin, but there is no specified timeframe 
within which the elevations in transaminases and total bilirubin must occur.  See Section  8.2.2 for special 
reporting requirements and Appendix 5  for additional information regarding Hy’s Law.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 60 of 113 
 CONFIDENTIAL   
 8. SAFETY MONITORING  
 Definitions  
 Adverse Event  
An AE  is any unfavorable and unintended sign, symptom, or disease temporally associated with 
the use of an investigational medicinal product or other protocol- imposed intervention, whether 
or not considered related to the medicinal product.  Adverse events will be assessed according to 
the NCI CTCAE v 5.0. 
 Serious Adverse Event  
An AE is considered “serious” if, in the view of either the i nvestigator or sponsor , it results in 
any of the following outcomes:  
• Death  
• A life-threatening AE .  An event is considered “life-threatening ” if, in the view of the 
investigator , its occurrence places the subject at imm ediate risk of death.  It does not 
include an AE or suspected adverse reaction (AR) that, had it occurred in a more severe form, might have caused death. 
• Inpatient hospitalization or prolongation of existing hospitalization 
• A persistent or significant incapacity or substantial disruption of the ability to c onduct 
normal life functions  
• A congenital anomaly/birth defect 
• Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardi ze the subject  or patient and may require medical or surgical  
intervention to prevent one of the outcomes listed in this definition.  Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient 
hospitalization, or the development of drug dependency or drug abuse. 
 Adverse Event  Reporting  
 Adverse Event Reporting Period  
After informed consent, but prior to initiation of study drug, all serious adverse events ( SAEs ) 
regardless of attribution will be collected.   After initiation of study drug, all  SAEs and AEs 
regardless of attribution will be collected until 30  days after the last dose of study drug or a new 
treatment of anti -tumor th erapy, whichever is earlier.   After this period , investigators should report 
only SAEs that are considered to be related to the study drug. 
 Expedited Reporting  
Certain events require immediate reporting to allow the sponsor to take appropriate measures to 
address potential new risks in a clinical trial.  The investigator must report such events (both initial 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 61 of 113 
 CONFIDENTIAL   
 and follow -up) to the sponsor immediately; under no circumstances should reporting take place 
more than 24 hours after the investigator learns of the event.  The following is a list of events that 
the investigator must report to the s ponsor within 24 hours after first learning of the event, 
regardless of relat ionship to study drug: 
• SAEs  (from informed consent to 30 days following the last dose of study drug or a new 
treatment of anti -tumor therapy), 
• Abnormal hepatic function is defined as serum AST or ALT ≥3 × ULN together with total 
bilirubin ≥2 × ULN, regardl ess of seriousness.  
o For management for hepatic function abnormal event , refer to Table  13 ( Dose 
Adjustment for Abnormal Liver Function).  Hy ’s Law is an  increase in serum AST 
or ALT ≥3 × ULN together with total bilirubin ≥2 × ULN, and no other reason can 
be found to explain the biochemical changes, for example, new or worsening 
hepatobiliary metastases, elevated serum alkaline phosphatase ( ALP ) indicating 
cholestasis, viral hepatitis, another suspect drug, or any other specific cause of severe hepatocellular injury.  The elevation in transaminases must precede or be 
coincident with (ie, on the same day as) the elevation in total bilirubin, but t here is 
no specified timeframe within which the elevations in transaminases and total bilirubin must occur.  See Appendix 5 (Clinical Evaluation of Possible Drug -
Induced Liver Injury (DILI) for additional information regarding Hy’ s Law.  
• CTCAE grade ≥3 hemorrhagic event, 
o When there is a grade ≥3 hemorrhagic event per NCI CTCAE (Version 5.0).  The 
management of severe or serious hemorrhagic events will be c onducted according 
to Appendix 6 (Clinical Management of Severe or Serious Hemorrhagic Events).   
• Pregnancy, 
 Eliciting Adverse Events 
A consistent method ology of non-directive questioning for eliciting AEs at all subject evaluation 
time points should be adopted.  Examples of non- directive questions include:  
• “How have you felt since your last clinic visit?” 
• “Have you had any new or changed health problems since you were last here?”  
 Assessment of Severity  
Investigators will seek information on AEs and SAEs at each subject contact.  All AEs and 
SAEs, whet her reported by the subject or noted by authorized study personnel, will be recorded 
in the subject’s medi cal record and on the appropriate AE/SAE form. 
For each AE and SAE recorded on the applicable e CRF, the investigator will make an assessment 
of severity through clinical description by referring to the five -grade determination standard in the 
NCI CTCAE v5. 0.  Please use the guideline below for the assessment of severity when the 
observed or reported AE is not listed in the NCI CTCAE v5.0: 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 62 of 113 
 CONFIDENTIAL   
 • Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
• Grad e 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental activities of daily living (ADL)*.  
• Grade 3: Severe or medically significant but not immediately life  threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self -care 
ADL**.  
• Grade 4: Life -threatening consequences; urgent intervention indicated. 
• Grade 5: D eath related to AE.  
Note:  
*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, 
etc. 
**Self -care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not 
bedridden.  
 Causality assessment  
Investigators should use their knowledge of the subject , the circumstances surrounding the AE, 
and an evaluation of any potential alternative causes to determine whether or  not an AE is 
considered to be related to the study drug.  To ensure consistency of  causality assessments, 
investigators should apply the general guidelines in provided as below:  
 
• Related: There is a reasonable possibility that the event may have been caused by the  
product under investigation.  Factors that point toward this assessment include but are not 
limited to: a positive re -challenge, a reasonable temporal sequence between  administration 
of the drug and the event, a known response pattern of the suspected drug, improvement 
following discontinuation or dose reduction, a biologically  plausible relationship between 
the drug and the AE, or a lack of an  alternative explanation for the AE. 
 
• Not Related: There is not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between the study intervention and event onset, or an alter nate etiology has been established.  
Ambiguous cases should be considered as being a “reasonable possibility ” of a causal 
relationship unless further evidence becomes available to refute this.  Causal relationship in cases 
where the disease under study has deteriorated due to lack of effect should be classified as no 
reasonable possibility.  
 Documenting Adverse Events 
When an AE or SAE is recorded, the preferred medical terminology or concept should be used.  
Abbreviations and colloquialisms (eg, jargon or slang) should be avoided. 
All AEs (including SAEs) should be recorded on the AE eCRF, and the check box for “Serious” 
should be ticked for entries that fit the criteria for SAEs.  The investigator should also complete 
an SAE report and submit this to the sponsor or its designee within 24 hours of knowledge of the 
event.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 63 of 113 
 CONFIDENTIAL   
 Only one medical concept should be recorded in the event field on the e CRF.  
 Diagnosis versus Symptoms and Signs  
If known, a diagnosis should be recorded on the eCRF rather than individual signs and symptoms 
(eg, hepatic failure should be recorded instead of jaundice, asterixis, and elevated transaminases) .  
However, if a constellation of signs and/or symptoms cannot be medically characterized as a single 
diagnosis or syndrome at the time of reporting, each individual event should be recorded as an AE 
or SAE on the e CRF.  If a diagnosis is subsequently established, it should be reported as follow -
up information. 
 Adverse Event Occurring Secondary to Other Events 
In general, AEs occurring secondary to other events ( eg, cascade events or clinical sequelae) 
should be identified by their primary cause with the exception of severe or serious secondary events.  For example, if severe diarrhea is known to have resulted in dehydration, it is sufficient to 
record only diarrhea as an AE or SAE on the eCRF if the dehydration is mild. 
However, medically significant AEs occurring secondary to an initiating event that are separated 
in time should be recorded as independent events on the eCRF.  For example, if a severe 
gastrointestinal hemorrhage leads to renal failure, both events should be recorded separately on 
the e CRF.  
 Persistent or Recurrent Adverse Events  
A persistent AE is one that extends continuously, without resolution betw een subject evaluation 
time points.  Such events should only be recorded once in the eCRF.  The event’s initial severity 
should be recorded and updated when it increases so as to record to highest severity. 
A recurrent AE is one that occurs and resolves between subject evaluation time points and 
subsequently recurs.  All recurrent AEs should be recorded on the e CRF respectively.  
 Abnormal Laboratory Values or Abnormal Vital Signs  
Not every laboratory abnormality/abnormal vital sign  qualifies as an AE.  A laboratory test 
result /abnormal vital sign  must be reported as an AE if it is a change from baseline and meets any 
of the following criteria:  
• Accompanied by clinical symptoms,  
• Results in a change in study treatment ( eg, dosage modification, treatment interruption, or 
treatment discontinuation),  
• Results in a medical intervention ( eg, potassium supplementation for hypokalemia) or a 
change in concomitant therapy,  
• Clinically significant in the investigator’s judgment.  
Investigators are responsible for revi ewing  all laboratory findings  and abnormal vital signs  and 
determining whether or not each abnormality should be reported as an AE. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 64 of 113 
 CONFIDENTIAL   
 If the clinically significant laboratory abnormality is a sign of a disease or syndrome (eg , ALP and 
bilirubin 5 × ULN associated with cholecystitis), only the diagnosis ( eg, cholecystitis) needs to be 
recorded on the eCRF.  
If the clinically significant laboratory abnormality is not a sign of a disease or syndrome, the 
abnormality itself should be recorded as an AE or SAE on the eCRF .  If the laboratory abnormality 
can be characterized by a precise clinical term, the clinical term should be recorded as the AE or SAE.  For example, an elevated serum potassium level of 7.0 mmol/L should be recorded as 
“hyperkalemia.” 
Observations of the same clinically significant laboratory abnormality from visit to visit should 
not be repeatedly recorded as AEs or SAEs on the e CRF, unless their severity, seriousness, or 
etiology changes. 
 Preexisting Medical Condition  
A preexisting medical condition is one that is present at screening .  Such conditions should be 
recorded on the eCRF as medical history.  A preexisting medical condition should be recorded as 
an AE or SAE only if the frequency, severity, or character of the condition worsens during the 
study (excluding deterioration of the study disease conditions).  When such events are recorded on 
the e CRF, it is important to convey the concept that the preexisting condition has changed by 
including applicable descriptors ( eg, “more frequent headaches”).  
 Pregnancy  
A female subject  must be instructed to stop taking the study drug and immediately inform the 
investigator if she becomes pregnant during the study.  The investigator should report all 
pregnancies within 24 hours of awareness to the sponsor (the reporting period for pregnancy 
continues up to 30 days after completion of the study drug).  The investigator should counsel the 
subject and discuss the risks of continuing with the pregnancy and the possible effects on the fetus.  
Moni toring of the subject  should continue until outcome of the pregnancy.  Pregnancies occurring 
up to 30 days after the completion of the study drug must also be reported to the investigator. 
Male subject s must also be instructed to inform the investigator immediately if their partner 
becomes pregnant during the study or within 90 days after the last dose of study drug.  If such an 
event occurs, it should be reported as described above. 
Pregnancy loss of any kind should always be classified as serious AE (as t he sponsor considers 
these medically significant), recorded on the eCRF, and expeditiously reported to sponsor. Any congenital anomaly/birth defect in a child born to a female subject or female partner of a male 
subject exposed to the investigational product should be recorded and reported as an SAE. 
 Worsening of Solid T umor  
Worsening and/or progression of the subject ’s solid tumor should not be recorded as an AE or 
SAE.  These data will be captured as efficacy assessment data only.  If there is any uncertainty 
about an AE being related only to the disease under study, it should be reported as an AE or SAE. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 65 of 113 
 CONFIDENTIAL   
 
 Death  
All deaths that occur during the protocol -specified AE reporting period must have the underlying 
cause reported to the sponsor as an SAE with death listed as the outcome.  Deaths due solely to 
the progression of disease must also be reported to the sponsor as an SAE .  Death events that occur 
after 30 days following last dose of study drug must be reported to the sponsor as an SAE  only if 
it is confirmed as related to study drug.  If the primary cause of death is unknown and cannot be 
ascertained at the time of reporting , please record “Unknown cause death” on the e CRF, and the 
“unexplained/unknown death” should be  reported expedi tiously as an SAE .  The SAE should be 
reported before the specific cause of death  has been determined . 
 Duration of Follow- up for Adverse Events 
The investigator will follow all unresolved AEs and SAEs until the events are resolved or 
stabilized, the subjec t is lost to follow -up, subject  death, or end of study.  Resolution of AEs and 
SAEs (with dates) should be documented on the appropriate e CRF and in the subject ’s medical 
record to facilitate source data verification (SDV).  For SAEs, if, after follow -up, return to baseline 
status or stabilization cannot be established, an explanation should be recorded in the additional case details section of the e CRF.  
For some SAEs, additional case details deemed necessary to appropriately evaluate the SAE report (eg, hospital discharge summary, consultant report, or autopsy report) may be followed- up by 
telephone, fax, email, and/or a monitoring visit. 
All pregnancies that occur during the study should be followed until pregnancy outcome.  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 66 of 113 
 CONFIDENTIAL   
 9. STATISTICAL  ANALYSIS 
 Statistics and Analysis Method  
A separate statistical analysis plan (SAP) will provide specific details on analytical methods.   
 Statistical Hypothesis  
This study is designed to demonstrate superiority of fruquintinib plus BSC  (treatment arm ) over 
placebo plus BSC  (placebo arm ) in prolonging OS for subject s with refractory mCRC .  The study 
is designed to test the null hypothesis H0: λ=1.0 versus the alternative hypothesis H a: λ < 1.0, 
where λ is the hazard ratio ( treatment arm /placebo arm ). 
 Sample Size Rationale 
The total sample size and num ber of OS events  required for efficacy assessment  in the ITT 
population is calculated based on the following assumptions:  
• A one- sided significance level of 0.025;  
• Assuming an OS HR (treatment arm/placebo arm) of 0.73, t his sample size yields 
approximately 80% statistical power to detect superiority of the fruquintinib arm over 
placebo arm.  If the true median OS for the placebo arm is 5 months, then the HR of 0.73 
corresponds to median OS of 6.8 months in the fruquintinib  arm (median OS improvement 
of 1.8 months).   
• An enrollment rate of 30 subjects per month during the first 3 months and 50 subjects per month thereafter;  
• Yearly dropout rate of 10%; 
• Randomization ratio = 2:1; 
• Data maturity = 70%;  
• One interim futility analysis when 1/3 of the total number of OS events  (ie, 121 OS events) have occurred   
Under the premise of these assumptions, approximately 522 subjects will be randomized to this 
study over approximately 13 months in this study.  OS will be analyzed  when 364 OS events are 
observed, which is expected to occur in approximately 7 months after the end of enrollment. 
In clinical practic e, TAS -102 is used more commonly than regorafenib.  To ensure that the subject  
population is representative of clinical practi ce, post-regorafenib subjects will be capped at 
262 subjects if there is an unanticipated enrichment of that population.  This will ensure that at 
least 50% of the subjects will be post-TAS.  Subjects are considered in post -TAS-102 or post -
regorafenib populations if they have received at least one dose of either agent , respectively, prior 
to entering the study.  Based on the similar mechanisms of action between regorafenib and 
fruquintinib , it will be of clinical interest to ev aluate the magnitude of benefit in each of the 
populations when compared to the ITT population. 
    
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 67 of 113 
 CONFIDENTIAL   
 
 Analysis Sets  
Intent- to-Treat (ITT) Population  
All randomized subjects will be included in the ITT population.  Subjects will be analyzed by 
treatment arm as randomized.  The ITT population will be the primary population for evaluating 
all efficacy endpoints and patient characteristics.   
Safety Analysis Population 
All randomized subjects who received at least one dose of study treatment will be included in the 
safety analysis population .  Subjects in this population will be  analyzed according to the treatment 
they actually received.  This population will be used for all safety analyses. 
 Primary and Secondary Endpoints  
 Primary E ndpoint  
The primary endpoint of the study is overall survival, defined as the time (months) from date of 
randomization to death from any cause.  Subjects without report of death at the time of analysis 
will be censored at the date last known alive.  
 Secondary Efficacy Endpoints  
Secondary efficacy end points include PFS, ORR, DCR, and DoR.  
 Progression -free Survival  
PFS is defined as the time (months) from randomization until the first radiographic documentation 
of objective progression as assessed by i nvestigator using RECIST  v1.1, or death from any cause.  
Subjects who did not die or progress will be censored at the date of last radiographic assessment.   
If no baseline or post -baseline radiologic assessment was available, the subject will be censored a t 
the date of randomization.  The use of new anticancer therapy prior to progression will result in 
censoring at the date of last radiographic assessment prior to initiation of new therapy.  If death/PD 
occurred after two or more consecutive missed radiographic visits, subjects will be censored at the date of last radiographic assessment prior to missed visits.  
 Objective Response Rate 
Objective response rate is defined as  the proportion of subject s achieving a best overall response 
of confirmed c omplete response (CR) or partial response (PR) , per RECIST v1.1, as determined 
by the investigator.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 68 of 113 
 CONFIDENTIAL   
 
 Disease Control Rate  
Disease control rate is defined as proportion of subject s achieving a best overall response of 
confirmed CR, PR , or SD, per RECIST v1.1 , as determined by the investigator .  To be qualified 
for SD, the duration of SD should last for at least 6 weeks.  
 Duration of Response  
Duration of response is defined as the time ( months ) from the first occurrence of PR or CR, 
whichever comes first, until the date of radiographic PD or death .  The duration of response will 
be determined for subjects with best overall response of confirmed CR or PR. 
 Secondary Safety Endpoints  
Safety endpoints include AE, laboratory tests, vital signs and weight, ECG, 
echocar diogram /MUGA (especially LVEF) and ECOG PS.  
All AEs, whether related to the drug or not, will be recorded in the e CRF including the start/end 
date, measures taken, treatment a ffected (yes v ersus  no) and the outcome.  For all the events, the 
causality with  the treatment and the severity will be determined by the investigator.  
 Other Endpoints  
 Patient Reported Outcomes  
Quality of life will be assessed using EORTC QLQ-C30 and EQ-5D- 5L questionnaires.  Quality 
of life score, change from baseline, subject s achieving minimally important difference (MID) 
cut-off, and time to deterioration (TTD) will be assessed.  
 Assessment of Resource Utilization  
Health care resource utilization assessments such as physician visits, emergency room visits, hospital care (eg , inpatient and outpatient), drug prescriptions etc. will be assessed.  
 Statistical Methods  
 Analysis of Efficacy Endpoints  
Efficacy analyses will be based on ITT population.  All secondary endpoints based on radiological 
assessments of tumor burden will be derived from investigator assessment  using RECIST v1.1.  
Additional sensitivity analyses may be performed and will be outlined in the SAP. 
9.2.5.1.1. Primary Endpoint - Overall Survival 
A 1-sided s tratified log -rank test will be used for the comparison of OS of the fruquintinib with 
placebo group at a significance level of 0.025.  The same factors used for randomization will be 
used for stratification: prior therapy with TAS  versus regorafenib versus both trifluridine/tipiracil 
(TAS -102) and regorafenib; RAS status ( wild type versus mutant) ; and duration of metastatic 
disease (<18 months versus ≥18 months) .  Kaplan -Meier methodology will be used to estimate the 
median OS and its 2- sided 95% Confidence Interval (CI) for each treatment arm.  Plots will be 
produced by tr eatment arm.  The Hazard Ratio (HR)  will be esti mated by stratified COX model 
including a 2-sided 95% Confidential Interval (CI).   
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 69 of 113 
 CONFIDENTIAL   
 9.2.5.1.2. Secondary Effic acy Endpoints (PFS, ORR, DCR, DoR)  
First secondary endpoint is to evaluate PFS in subject s with refractory mCRC  treated with 
fruquintinib plus BSC versus placebo plus BSC.  The Fixed -Sequence Method will be used to 
adjust for multiple comparisons of OS between the fruquintinib plus BSC arm and the placebo 
plus BSC arm (primary endpoint) and PFS (first secondary  endpoint).  If the primary endpoint 
analysis is significant at the 0.05 (two- sided) level, a superiority test of PFS in the first secondary 
endpoint will be done at the 0.05 (two- sided) significant level.  Kaplan -Meier methodology will 
be used to estimate the median PFS and its 2-sided 95% confidence i nterval (CI) for each treatment 
arm.  Plots will be produced by treatment arm.  
The hazard ratio (HR) will be estimated by stratified COX model including a 2 -sided 95% CI.   
The estimates of DCR and ORR in each treatment group and their 2-sided 95% CI s will be 
presented .  Comparison of DCR and ORR between treatment groups will be performed using 
stratified Cochran- Mantel -Haensze l test.  The CI  of difference in DCR and ORR between 
treatment groups will be calculated using the approximate normal distribution method of binomial 
distribution. 
Duration of response (DoR) will only be determined for subjects who responded ( confirmed best 
overall response of CR or PR) .  Statistical  test will not be conducted, as subject s with response are 
not randomized.  Descriptive analysis will be adopted for DoR.  For each treatment group, results 
will be presented by Kaplan- Meier estimates and distribution curve.  
9.2.5.1.3. Subgroup Analyses  
Subset analyses may be conducted, for example, by age, performance status, prior lines of therapy, prior use of TAS-102, prior use of regorafenib, region, and others as deemed appropriate. 
 Analysis of Safety Endpoints  
All safety parameters will  be summarized and listed  by using the safety population.  
TEAEs will be summarized by MedDRA system organ class (SOC) and PT .  The incidence and 
percentage of subject s with at least 1 occurrence of a preferred term will be included according to 
the most severe NCI -CTCAE version  5.0.  Relationship to study therapy (causality) will be 
summarized separately.  If more than one AE was recorded for a subject within a PT, the subject  
will be counted once in the most severe grade.   
Laboratory data will be summarized by visit.  All TEAEs and abnormal laboratory variables shall 
be evaluated by the NCI CTC AE Version 5.0 Classification System.  Other  safety data including 
vital signs, ECG, ECOG PS will be summarized using descriptive statistics.  
 Analysis of Other Endpoints  
9.2.5.3.1. Subject Reported Outcomes  
Subject reported outcomes will be assessed using EORTC QLQ -C30 and EQ -5D-5L 
questionnaires .  The number and percentage of subject s who completed the questionnaires will be 
summarized for each treatment arm by visit.  Reasons for non -compl etion will be presented.  
Quality of life scores and change from baseline scores will be compared between treatment arms 
using mixed model repeated measures approach adjusting for covariates.  For each scale, 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 70 of 113 
 CONFIDENTIAL   
 appropriate minimally important difference (MID ) cut -off will be determined and number and 
percent of subjects achieving the MID will be presented.  In addition, time to deterioration (TTD) 
will be summarized using Kaplan -Meier methodology.  
9.2.5.3.2. Resource Utilization  
Health care resource utilization  data including number and percent of subject s hospitalized, 
reasons for hospitalizations, emergency room visits, drug prescriptions will be summarized. 
 Pharmacokinetic and Pharmacodynamic Analyses 
 Population PK and Exposure -Response Analyses  
Descriptive statistics (including but not limited to arithmetic mean, standard deviation, coefficient 
of variation, median, minimum, maximum and geometric mean ) will be provided for the observed 
concentrations for fruquintinib and metabolite M11. 
Population PK analysis of plasma concentration -time data of fruquintinib and metabolite M11 will 
be performed using nonlinear mixed- effects modeling.  The population PK modeling will include 
all subjects with sufficient and interpretable PK assessments.  The data from the population PK 
samples may be combined together with the data from other studies for the population PK analysis .  
If relevant and sufficient data are available, the relationship of exposure to fruquintinib and M11 
to measures of efficacy and AEs may  also be analyzed.  Details of the population PK and/or 
exposure- response analysis will be given in a population PK/ pharmacodynamic analysis plan .  The 
results of the population PK/pharmacodynamic analysis will be presented in a separate report.  
 Pharmacody namic (ECG ) Analysis 
Subjects who 1) receive at least 1 dose of study drug, and 2) have baseline and at least 1 post-dose 
ECG measurement will be evaluable for pharmacodynamic (ECG) evaluation.  Subjects who had 
reduced dosage, prolonged dose interruption of >2  days in cycle  1, or who had any dose 
interruption within 7 days before cycle  1 day 21, or were discontinued from the study prior to the 
completion of ECG data collection ( cycle  1 day 21) will be excluded.  For each of the ECG 
parameters, the average values from the 3 readings of a triplicate ECG set will be used in the 
analysis.  
For all ECG parameters, the baseline will be defined as the mean values of the triplicate ECG 
measurements taken at pre-dose on cycle 1 day 1. 
 QTc Intervals  
The terminology QTc is used in this section as a general notation for corrected QT intervals using 
any of the specified methods. 
The QT interval data will be corrected for heart rate using 2 correction methods ( Fridericia – QTcF  
and Bazett – QTcB).  For each QTc correction method, the relationship between QTc and RR at 
baseline will be evaluated graphically by plotting the logarithm of baseline QTc values against the 
logarithm of corresponding RR intervals.  Fridericia will be us ed as the primary correction method 
for statistical analysis.  If the correlation between QTc and RR intervals remains significant using 
the Fridericia correction method, an alternative correction method may be considered for statistical analysis in additi on to QTcF. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 71 of 113 
 CONFIDENTIAL   
 For the statistical analysis based on the primary correction method ( QTcF ), the mean changes from 
baseline (ΔQTc ) at each time point will be summarized (mean, standard deviation, median and 
range , 2-sided 90% confidence interval ).  T he difference in ΔQTc between fruquintinib and 
placebo ( ΔΔQTc) for each individual will also be calculated at each time point ( individual ΔQTc 
for fruquintinib – mean ΔQTc for  placebo at the same time point).  Mean values for the difference 
and 2- sided 90%  CI for mean difference will be calculated at each time point . 
The primary analysis will focus on the maximum m ean change from baseline in QTc (ΔQTc) on 
cycle 1 day 21, which wi ll be estimated by the mean QTc change at around T max, the time when 
the maximu m plasma concentration is reached (ie, steady state) .  The same analysis will be 
performed for ΔQT  data using other correction methods if data warrant .  The m ean change from 
baseline in QTc (± standard deviation ) over time will be plotted.  
In addition, QTc will be categorized based on ICH E14 guidelines.  Tables will present the number 
and percentage of subjects meeting or exceeding the following categories:  
• QTc interval prolongation: 
− Absolute values > 450 to ≤ 480 msec  
− Absolute values > 480 to ≤ 500 msec  
− Absolute values > 500 msec 
• QTc interval change from baseline:  
− Increase from baseline > 30 to ≤ 60 msec  
− Increase from baseline > 60 msec  
 Heart Rate , QRS , and PR intervals 
For each treatment and time point of measurement, heart rate ( HR), QRS interval and  PR interval, 
as well as the change from baseline in HR, QRS and PR (∆HR, ∆QRS, ∆PR), will be summarized 
using descriptive statistics (mean, standard deviation, median, range, and 90% CI).  The number 
and percentage of subjects with HR >100 bpm  will be tabulated for each time  point.  The number 
and percentage of subjects with QRS >110 msec will be tabulated for each time point.  The number 
and percentage of subjects with PR >200 msec will be tabulated for each time point. 
 T-wave and U-wave M orphology 
The number and percentage of subjects having T -wave  morphology changes from baseline and/or 
the occurrence of abnormal U -waves that represent the appearance or worsening of the 
morphological abnormality will be summarized.  Subjects with abnormal ECG  findings will be 
listed.  Additional analyses will be performed if deemed necessary.  
 QTc -PK Analysis  
The potential relationship between QTc and PK will be evaluated using data from all subjects who 
have data from baseline and at least 1 post-dose ECG measurement following the first dose.  QTc  
change from baseline before and after correction for placebo ( ΔQTc  and ΔΔQTc)  using the primary 
correction method (see Section  9.3.2.1) at each time  point of measurement  will be plotted against 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 72 of 113 
 CONFIDENTIAL   
 the corresponding plasma concentrations of fruquintinib and M11 separately.  Additional plots will 
be produced, if deemed necessary . 
A linear mixed effects model wil l be fitted to the ∆ QTc and ΔΔQTc  data from cycle 1 day 1 and 
cycle 1 d ay 21 with either parent or metabolite concentration as a predictor and subject as a random 
effect; if the intercept term is not significant, the model will be re -fitted with a zero intercept term.  
Based upon these relationships , the predicted population average ΔQTc and ΔΔQTc  as well as 
their corresponding upper 90% 2-sided confidence interval bound will be computed at the mean 
maximum plasma concentrations (ie, C max) of fruquintinib and M11, or other concentrations of 
interest. 
 Interim Analysis 
An independent data monitoring committee ( IDMC) will be convened to review  accumulating 
safety data.  During the study, safety interim analyses will be performed approximately every 
6 months.  The frequency of safety interim analysis may be modified upon I DMC 
recommendat ion.   
One interim futility analysis will be performed when approximately 1/3 of the total number of OS 
events (ie, 121 OS events) had occurred.  This interim analysis is for futility only.  The IDMC will be instructed to recommend stopping the study for futility if the 1- sided p -value from a stratified 
log-rank test is at least 0.622 (corresponding to an observed HR of 1.062).  Otherwise, the st udy 
will continue with full enrollment.  There is a 37.8% chance of terminating the study for futility at 
the interim analysis if the true median OS in fruquintinib arm is 5 months, ie, fruquintinib is 
ineffective.  There is a 2.6% chance of stopping for f utility, declaring fruquintinib ineffective at 
the interim if the true median OS in fruquintinib arm is 6. 8 months, ie, fruquintinib is effective in 
our study population.   
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 73 of 113 
 CONFIDENTIAL   
 10. ETHICAL CONSIDERATIONS  
 Quality Control and Quality Assurance  
The clinical study will be executed and reported following GCPs, all applicable regulatory 
requirements and applicable SOPs, including quality control of documents.  Deviations will be 
documented.  To ensure compliance, the sponsor may conduct one or several quality assurance 
audit(s).  
 Ethics Review  
The Independent Ethics Committee (IEC) / Institutional Review Board (IRB) must review the 
protocol and amendments, investigator’s brochure, informed consent form, study- relevant 
materials (such as advertisement s for subject  recruitment) and any other essential documents.  
IEC/IRB approval is to be obtained prior to the study.  
All amendments are to be reviewed and approved by the IEC/IRB , applicable regulatory 
authorities (as required)  and documented.  All unexpe cted SAEs should be reported to the sponsor, 
IEC/IRB and applicable regulatory authorities as required.  During the study, protocol deviations 
that may increase a subject ’s risk should be reported to the IEC/IRB in a timely manner.  
 Ethical Conduct of the S tudy  
The study will be conducted in accordance with the protocol, International Conference on 
Harmonization (ICH) guidelines, applicable regulations and guidelines governing clinical study 
conduct and the ethical principles that have their origin in the D eclaration of Helsinki.  
 Informed Consent  
Investigators or designees must obtain the signed informed consent form from subject s prior to 
conducting any study- related procedures.  The nature, objectives, and potential risks and benefits 
of participating in the study must be explained to subject s.  Subject s must be informed that they 
may withdraw consent to participate in the study without any limitations.  If the subject cannot 
sign the informed consent form, a legally acceptable representative of the subject must sign the 
informed consent form.  If the subject  and the legally acceptable representative are not able to read 
and write, an impartial witness should be present throughout the whole process of providing informed consent.  Once the subject and the legally acceptable representative give their oral 
consent, the informed consent form should be signed by the impartial witness to confirm that the 
subject and the legally acceptable representative fully understand the study and their right to 
withdraw informe d consent without any limitations.  Informed consent should be recorded in the 
CRF.  If the risk and benefit assessment changes after the safety analysis, the informed consent 
form needs to be reviewed and updated and all updated information should be provided to subject s 
(including subjects who have already received the study drug). 
 Data Privacy 
All information about fruquintinib (such as patent application, formulation, manufacturing process 
and basic study information) is considered confidential as long as it is unpublished. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 74 of 113 
 CONFIDENTIAL   
 All information obtained in the study is considered co nfidential.  Hutchison  MediPharma Limited 
will open the information to investigational personnel, the NMPA (National Medical Products 
Administration ), and any other regulatory authority when necessary.  To ensure the completeness 
of the study analysis data, investigational personnel are accountable for providing all results and data to the sponsor. 
Investigators must guarantee the privacy of subject s by not disclosing subject -related information 
to third parties without authorization.  e CRFs and other documents submitted to the sponsor should 
not contain the subject ’s name.  Subject s are identified only by Patient Code.  Investigators may 
retain the identification forms, which  include subject  numbers, names , and addresses.  Informed 
consent forms and other documents should be documented properly, and should not be given to 
the sponsor. 
 Disclosure  
Final study results will be published on a public clinical trial website according  to applicable local 
guidelines and regulations. 
 Biological Specimens and Data  
Subjects who agree to participate in  a future biomedical research sub -study will be required to 
consent to this optional sub- study before samples are collected  for long- term sto rage.   No 
additional sample s will be collected for future biomedical research .  Samples will be single/double-
coded as defined by ICH guideline E15. 
The unused samples for study -related research, as well as unused PK samples, will be stored for 
up to 15 years after the final date of the database lock.   The unused samples may be utilized  for 
future biomedical research.   After  15 years, any residual samples will be destroyed.  The results of 
these future biomedical research analyses will not be shared with subjects and will not be presented 
in the CSR.  
If there are specific site or country requirements involving the pharmacogenomic analyses that  the 
sponsor is unable to comply with, samples will not be collected at those sites. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 75 of 113 
 CONFIDENTIAL   
 11. OVERSIGHT  
 Independent Monitoring  
 Independent Data Monitoring Committee  
An IDMC will be established in this study.  T he IDMC will consist of at least 4 independent 
clinical oncology physicians and 1 independent  statistician with no conflicts of interest with the 
sponsor.  The ID MC will evaluate the safety data regularly , and the patient s’ safety will be 
determined by the evaluation of the risk/benefit at a regular review meeting .  The responsibilities 
of the IDMC will include: 
• Regular (approximately every 6 months)  blinded review of the study data to provide 
suggestions such as “continue as planned, suspend, protocol amendment, terminate study” 
so as to prevent patient s from being exposed to unsafe dose and treatment regimes.  
• Review of interim analysis data to provide suggestions such as “continue as planned, 
suspend, protocol amendment, terminate study.” 
Upon completion of the data review, the IDMC will provide suggestions on whether or not to continue the study, if modification of the protocol is recommended or if study termination is required.  The final decision shall be made by Hutchison MediPharma Limited.  The IDMC 
membership and governance is outlined in a separate I DMC charter.  
 Quality Control and Assurance  
In accordance with ICH, the sponsor is responsible for quality assurance to ensure that the study 
is conducted, and the data are generated, recorded, and reported in compliance with the protocol, 
GCP, and any applicable regulatory requirement(s).  The investigator is responsible for supervising any individual or party to whom the investigator delegates trial -related duties and functions 
conducted at the trial site.  The sponsor and investigator ensure that any individual or party who performs trial- related duties or functions on behalf of the sponsor/investigator is qualified to 
perform the trial-related duties or functions. 
The overall procedures for quality assurance of clinical study data are described in the sponsor or 
designee ’s standard operational pro cedures.  The planned quality assurance and quality control 
procedures for the study are described in the following section s. 
 Monitoring  
Monitors designated by the sponsor will contact and visit investigators at regular intervals  to verify 
that data record ed in the CRF by authorized site personnel are accurate, complete, and verifiable 
from source documents, that the safety and rights of  subjects are being protected, and that the study 
is being conducted in accordance with the current approved protocol version and any other study agreements, GCP, and all applicable regulatory requirements.  During regular visits, the monitors 
may verify CRFs for protocol compliance, data completeness, consistency , and accuracy .  
Monitors may also obtain laboratory test results and other records for verifying CRF accuracy.  
Investigators (or their designee) should cooperate with monitors to resolve questions raised during 
monitoring.  
The investigator must allow study-related monitoring. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 76 of 113 
 CONFIDENTIAL   
 
 Audits  
Authorized representatives of Hut chison MediPharma Limited, a regulatory/competent authority, 
and/or an IRB/IEC representative may visit the site to perform audits or inspections, including 
source data verification.  The purpose of an audit or inspection is to examine all study -related 
activities and documents systematically and independently to determine whether these activities 
were conducted, and data were recorded, analyzed, and accurately reported according to the 
protocol, GCP guidelines, and any applicable regulatory requirements.  The investigator should 
notify the sponsor ( eg, CRA) listed within the protocol or other contacts provided immediately if 
contacted by a regulatory agency about an inspection. 
 Protocol Deviations 
This protocol is monitored at several levels, as described e lsewhere in this section.  The study 
principal investigator is responsible for monitoring the conduct and progress of the clinical trial, including the ongoing review of accrual, subject -specific clinical and laboratory data, and routine 
and SAE s; reportin g of expedited AE s; and accumulation of reported AE s from other trials testing 
the same drug(s).  The sponsor and statistician have access to the data at all times.  
All study investigators at participating sites who register/enroll subjects on a given protocol are 
responsible for timely submission of data via the mechanism described elsewhere in this section.  
All studies are also reviewed in accordance with the enrolling institution’s data safety monitoring plan. 
 Records 
 Data Capture and Management 
The term cas e report form (CRF) or electronic case report form (eCRF) should be understood to 
refer to electronic data capture (EDC) system.  The EDC system is the database where pertinent 
study data are collected.  For all subjects, including screen failures, data will be collected on source 
documents first.   The  principal investigator is responsible for assuring that the data  entered into  
eCRFs is complete, accurate, and that entry and updates are performed in a timely manner .  Blood 
and tumor samples for PK  and biomarkers assessments will be collected by  study sites and sent to 
the designated central laboratory for processing.  Data from  ECG will be collected at the study 
sites,  and the data will be transmitted to a designated CRO for centralized analysis, as well as  
for further processing and data reconciliation .  Imaging data will be collected at the  study sites,  
and a designated CRO will perform  further processing, data reconciliation , and holding. 
At all times, the principal investigator has final responsibility for the accuracy and authenticity of 
all clinical and laboratory data entered in the EDC.  Subject source documents are the 
investigator's /physician's subject records maintained at the study site.  In cases where the source 
documents are the hospital or the physician's chart, the information collected in the EDC must 
match those charts.  All final data recorded in EDC system will be copied onto CDs and kept by 
the sponsor .  A copy of these CDs will also be kept at the clinical site.   All data recorded on source 
documents will be kept at the clinical site.  
The completed pages of the EDC system are the sole property of the sponsor and should not be 
made available in any form to third parties without written permission from the sponsor, except for authorized representatives of the sponsor or appropriate regulatory authorities.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 77 of 113 
 CONFIDENTIAL   
 
 Source Documentation  
The investigator/institution should maintain adequate and accurate source documents and study 
records that include all pertinent observations on each of the site’s study subjects.  Source data should be attributable, legible, contemporaneous, original, accurate, and complete.  Changes to 
source data should be traceable  and not obscure the original entry.  Any changes  should be 
explained if necessary (eg, via an audit trail).  
 Study Files  
For studies using eCRFs, Hutchison MediPharma Limited personnel (or designated CRO ) will 
review the data entered by investigational staff for completeness and accuracy .  Electronic data 
queries stating the nature of the problem and requesting clarification will be created for 
discrepancies and missing values and sent to the investigational site via the EDC system.  
Designated investigator site staff is  required to respond promptly to queries and to make any 
necessary changes to the data.  Concomitant treatments and prior medications entered into the 
database will be coded using the World Health Organization ( WHO ) Drug Reference List, which 
employs the Anatomical Therapeutic  Chemical classification system.  Medical history/current 
medical conditions and AEs will be coded using the MedDRA terminology.  Samples collected 
for all third party  data such as ECG, PK and biomarker will be processed centrally and the results 
will be sent electronically to  HMP  (or a designated CRO).  At the conclusion of the study, the 
occurrence of any protocol deviations will be determined.  After these actions have been completed 
and the data has been verified to be complete and accurate, the database will be declared locked.  
Authorization is required prior to making any database changes to locked data, by joint written agreement between the Head of Biostatistics and Data Management and  the Head  of Clinical 
Development.  For EDC studies, after database lock, the investigator will receive a CD -ROM or 
paper copies of the subject data for archiving at the investigational site. 
 Records Retention  
The study should be recorded accurately by investigators so that study data can be verified.  The 
study documents can be divided into two types:  investigator documents and subject  source data.  
Investigator documents include protocol and amendments, the e CRF and data clarification forms, 
approvals and correspondence with the IEC and regulatory authorities, ICF, study drug records, study personnel curriculum vitae  and authorization forms, and any other essential documents.
 
Subject source data documents (recording primary efficacy/safety data) include clinic/hospital 
medical history, scheduled visit dates, original la boratory test results, ECG, electroencephalogram, 
radiological imaging, pathological and specific assessment reports, signed ICF, medical records , 
and subject  screening forms.  The documents mentioned above should be properly stored by the 
investigator for 5 years after the study is completed.  If investigators need to transfer the documents 
to another party or place, the sponsor must be notified in advance. 
If the documents cannot be stored properly at the investigational site, the documents can be 
transferred by the investigator and sponsor to an approved storage facility.  The documents must 
be sealed for storage and easily found for review in the case of a  regulatory authority audit.  If the 
documents are still in use, they can be copied and stored elsewhere.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 78 of 113 
 CONFIDENTIAL   
 
 Study Termination or Study Site Closure  
The sponsor and the investigator have the right to close out a site prematurely.  
Investigator’s Decision   
The investigator must notify the sponsor of a desire to close  out a site in writing, providing at least 
30 days’ notice.  The final decision should be made through mutual agreement with the 
sponsor.  Both parties will arrange the close  out procedures after review and consultation 
Sponsor’s Decision  
The sponsor will notify the investigator(s) of a decision to close  out a study site in writing .  Reasons 
may include the following, among others:   
• The investigator has received all items and information necessary to perform the study, but has not enrolled any subject within a reasonable period of time   
• The investigator has violated any fundamental obligation in the study agreement, 
including but not limited to, breach of this protocol (and any applicable amendments), 
breach of the applicable laws and regulations, or breach of any applicable ICH guidelines   
• The total number of subjects required for the study are enrolled earlier than expected   
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the investigator s, the ECs/IRBs, the regulatory authorities, and any CROs used in the study of the 
reason for termination or suspension, as specified by the applicable regulato ry requirements.  The 
investigator shall promptly inform the subject and should assure appropriate subject therapy and/or follow-up.  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 79 of 113 
 CONFIDENTIAL   
 12. PUBLICATION POLICY 
The study results may be published in scientific journals.  The names of investigators who make 
an imp ortant contribution to the study implementation and management, and personnel who make 
an important contribution to the study design, analysis,  and interpretation (such as staff or 
consultants from Hutchison MediPharma Limited ) will be listed in the public ation.  Hutchison 
MediPharma Limited agrees to provide the article to investigators for review prior to publishing any study results.  Investigators must obtain approval from the sponsor before contributing to any 
related articles or abstracts.  
The property of confidential information belongs to Hutchison MediPharma Limited.  Without 
permission from Hutchison MediPharma Limited, the information cannot be used for any purpose 
other than this study. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 80 of 113 
 CONFIDENTIAL   
 13. FINANCING AND INSURA NCE  
Financing and insurance information will be addressed in a separate agreement.  
  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 81 of 113 
 CONFIDENTIAL   
 14. REFERENCES  
American Cancer Society, Key Statistics for Colorectal Cancer, 2019. URL:   www.cancer.org/ 
cancer/ colon -rectal -cancer/about/key -statistics.html; accessed February 12, 2019. 
Bray  F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: 
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.  
CA Cancer J Clin .  2018 Nov;68(6):394-424  
Duda DG, Batchelor TT, Willett CG, Jain RK.  VEGF -targeted cancer therapy strategies: current 
progress, hurdles and future prospects.  Trends Mol Med . 2007 Jun;13(6):223-30. 
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, GoldbergRM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.  Lancet  2013 Jan 26;381(9863):303- 12. 
Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP. Management of hypertension in angiogenesis inhibitor- treated patients.  Ann Oncol . 2009 
May;20(5):807-15. 
Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status 
and future directions.  Lancet .  2016 Jul 30;388 (10043):518- 29. 
Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, Punt CJ, van Kr ieken JH.  Deficient mismatch repair system in patients with sporadic advanced 
colorectal cancer.  Br J Cancer.  2009 Jan 27;100(2):266-73. 
Li J, Qin S, Xu R, et al. Effect of fruquintinib vs placebo on overall survival in patients with 
previously treated metastatic colorectal cancer.  JAMA . 2018;319(24):2486-96. 
LONSURF
® (trifluridine and tipiracil) Prescribing Information.  Taiho Pharmaceutical Co, Taiho 
Oncology, Inc. Princeton NJ, USA.  Revised Feb 2019 
Mayer R, Van Cutsem E, Falcone A, et al. Randomized Trial of TAS -102 for Refractory 
Metastatic Colorectal Cancer  (RECOURSE ). N Engl J Med 2015; 372: 1909-19. 
National Comprehensive Cancer Netwo rk (NCCN), Version 2019.  
STIVARGA® (regorafenib) Prescribing Information.  Bayer HealthCare Pharmaceuticals, Inc, 
Whippany NJ, USA.  Revised Apr 2017. Sun Q, Zhou J, Zhang Z, Guo M et al., Discovery of fruquintinib, a potent and highly selective 
small mol ecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol 
Ther . 2014;15 (12):1635-45. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 82 of 113 
 CONFIDENTIAL   
 15. APPENDICES  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 83 of 113 
 CONFIDENTIAL   
 APPENDIX 1 ECOG PERFORMANCE STATUS  
Grade  Activity Level  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature, eg , light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work 
activities. Up and about more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of 
waking hours 
4 Completely disabled, cannot carry on any self-care, totally confined to bed or 
chair  
5 Death  
  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 84 of 113 
 CONFIDENTIAL   
 APPENDIX 2 RESPONSE EVALUATION CRITERIA IN SOLID TUMORS 
(RECIST V1.1) 
Selected sections from the Response Evaluation Criteria in Solid Tumors (RECIST), Version  1.1, 
are presented below.  
1. Measurability of Tumor at Baseline  
1.1 Definitions  
At baseline, tumor lesions/lymph nodes will be categorized as measurable or non -measurable as 
described below. 
1.1.1 Measurable Tumor Lesions 
Tumor lesions must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size as follows:  
• 10  mm by CT or magnetic resonance imaging (MRI) scan (CT/MRI scan slice 
thickness/interval no greater than 5 mm)  
• 10-mm caliper measurement by clinical examination (lesions that cannot be accur ately 
measured with calipers should be recorded as non- measurable)  
• 20 mm by chest X- ray 
• Malignant lymph nodes: To be considered pathologically enlarged and measurable, a 
lymph node must be ≥ 15 mm in the short axis when assessed by CT scan (CT scan slice 
thickness recommended to be no greater than 5 mm).  At baseline and follow-up, only the 
short axis will be measured and followed.  
1.1.2 Non- Measurable Tumor Lesions 
Non-measurable tumor lesions encompass small lesions (longest diameter < 10 mm or pathological 
lymph nodes with short axis ≥  10 but <  15 mm) as well as truly non- measurable lesions. Lesions 
considered truly non- measurable include leptomeningeal disease, ascites, pleural or pericardial  
effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, peritoneal 
spread, and abdominal mass/abdominal organomegaly identified by physical examination that is not measurable by reproducible imaging techniques. 
1.1.3 Special Consi derations Regarding Lesion Measurability  
Bone lesions, cystic lesions, and lesions previously treated with local therapy require particular 
comment, as outlined below. 
Bone Lesions:  
• Bone scan, positron emission tomography (PET) scan, or plain films are not  considered 
adequate imaging techniques for measuring bone lesions.  However, these techniques can 
be used to confirm the presence or disappearance of bone lesions. 
• Lytic bone lesions or mixed lytic –blastic lesions, with identifiable soft tissue components , 
that can be evaluated by cross- sectional imaging techniques such as CT or MRI can be 
considered as measurable lesions if the soft tissue component meets the definition of 
measurability described above.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 85 of 113 
 CONFIDENTIAL   
 • Blastic bone lesions are non -measurable.  
Cystic Lesi ons: 
• Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non- measurable) since they are, 
by definition, simple cysts. 
• Cystic lesions thought to represent cystic meta stases can be considered as measurable 
lesions, if they meet the definition of measurability described above.  However, if non-cystic lesions are present in the same patient, these are preferred for selection as target 
lesions.  
Lesions with Prior Local Treatment:  
• Tumor lesions situated in a previously irradiated area, or in an area subjected  to other 
loco- regional therapy, are usually not considered measurable unless there has been 
demonstrated progression in the lesion.  Study protocols should detail the conditions under which such lesions would be considered measurable. 
1.2 Specifications by Methods of Measurements 
1.2.1 Measurement of Lesions  
All measurements should be recorded in metric notation, using calipers if clinically assessed. All 
baseline evaluations should be performed as close as possible to the treatment start and never more 
than 4 weeks before the beginning of the treatment. 
1.2.2 Method of Assessment  
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during the study.  Imaging- based evaluation should 
always be the preferred option.  
Clinical Lesions.  Clinical lesions will only be considered measurable when they are superficial 
and ≥ 10 mm in diameter as assessed using calipers ( eg, skin nodules).  For the case of skin lesions, 
documentation by color photography including a ruler to estimate the size of the lesion is 
suggested. 
Chest X -Ray.  Chest CT is preferred over chest X -ray, particularly when progression is an 
important endpoint, since CT is more sensitive than X -ray, particularly in identifying new lesions.  
However, lesions on chest X -ray may be considered measurable if they are clearly defined and 
surrounded by aerated lung. 
CT, MRI.  CT is the best currently available and reproducible method to measure lesions selected 
for response assessment.  This guideline has defined measurability of lesions on CT scan based on 
the assumption that CT slice thickness is 5 mm or less.  When CT scans have slice thickness greater 
than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.  MRI is 
also acceptable.  
If prior to enrollment it is known that a patient is unable to undergo CT scans with intravenous 
(IV) contrast be cause of allergy or renal insufficiency, the decision as to whether a non -contrast 
CT or MRI (without IV contrast) will be used to evaluate the patient at baseline and during the 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 86 of 113 
 CONFIDENTIAL   
 study should be guided by the tumor type under investigation and the anatomic  location of the 
disease.  For patients who develop contraindications to contrast after baseline contrast CT is done, 
the decision as to whether non- contrast CT or MRI (enhanced or non- enhanced) will be performed 
should also be based on the tumor type and the anatomic location of the disease, and should be 
optimized to allow for comparison with the prior studies if possible. Each case should be discussed 
with the radiologist to determine if substitution of these other approaches is possible and, if not, 
the patient should be considered not evaluable from that point forward. Care must be taken in 
measurement of target lesions on a different modality and interpretation of non- target disease or 
new lesions, since the same lesion may appear to have a different s ize using a new modality. 
Ultrasound.  Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement. 
Endoscopy, Laparoscopy, Tumor Markers, Cytology, Histology.  The utilization of these 
techniques for objective tumor evaluation cannot generally be advised. 
2. Tumor Response Evaluation 
2.1 Assessment of Overall Tumor Burden and Measurable Disease  
To assess objective response or future progression, it is necessary to estimate the overall tumor 
burden at baseline and use this as a comparator for subsequent measurements.  Measurable disease 
is defined by the presence of at least one measurable lesion, as detailed above.  
2.2 Baseline Documentation of Target and Non- Target Lesions  
When more than one measurable lesion is present at baseline, all lesions up to a maximum of five lesions total (and a maximum of two lesions per organ) representative of all involved organs should 
be identified as target lesions and will be recorded and measured at baseline.  This means that, for  
instances in which patients have only one or two organ sites involved, a maximum of two lesions 
(one site) and four lesions (two sites), respectively, will be recorded.  Other lesions (albeit 
measurable) in those organs will be recorded as non -measurable lesions (even if the size is > 10 mm 
by CT scan). 
Target lesions should be selected on the basis of their size (lesions with the longest diameter) and 
be representative of all involved organs, but in addition should lend themselves to reproducible 
repeated measurements.  It may be the case that, on occasion, the largest lesion does not lend itself 
to reproducible measurement, in which circumstance the next largest lesion that can be measured 
reproducibly should be selected. 
Lymph nodes merit special mention since they are normal anatomical structures that may be visible 
by imaging even if not involved by tumor.  As noted above, pathological nodes that are defined as 
measurable and may be identified as target lesions must meet the criterion of a short axis of ≥15 mm by CT scan.  Only the short axis of these nodes will contribute to the baseline sum.  The 
short axis of the node is the diameter normally used by radiologists to judge if a node is involved 
by solid tumor.  Nodal size is normally reported as two dimensions in the plane in which the image 
is obtained (for CT this is almost always the axial plane; for MRI the plane of acquisition may be 
axial, sagittal, or coronal).  The smaller of these measures is the short axis.  For example, an 
abdominal node that is reported as being 20 mm ×  30 mm has a short axis of 20 mm and qualifies 
as a malignant, measurable node.  In this example, 20 mm should be recorded as the node 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 87 of 113 
 CONFIDENTIAL   
 measurement.  All other pathological nodes (those with short axis ≥ 10 mm but < 15 mm) should 
be considered non- target lesions.  Nodes that have a short axis of < 10 mm are considered non -
pathological and should not be recorded or followed. 
A sum of the diameters (longest for non- nodal lesions, short axis for nodal lesions) for all target  
lesions will be calculated and reported as the baseline sum of diameters.  If lymph nodes are to be 
included in the sum, then, as noted above, only the short axis is added into the sum.  The baseline 
sum of diameters will be used as a reference to charact erize further any objective tumor regression 
in the measurable dimension of the disease.  
All other lesions (or sites of disease), including pathological lymph nodes, should be identified as non-target lesions and should also be recorded at baseline.  Measu rements are not required and 
these lesions should be followed as “present,” “absent,” or in rare cases “unequivocal progression.” 
In addition, it is possible to record multiple non -target lesions involving the same organ as a single 
item on the Case Report  Form ( eCRF) (eg, “multiple enlarged pelvic lymph nodes” or “multiple 
liver metastases”).  
2.3 Response Criteria  
2.3.1 Evaluation of Target Lesions 
This section provides the definitions of the criteria used to determine objective tumor response 
for target lesions. 
• Complete response (CR): Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non- target) must have reduction in short axis to <  10 mm. 
• Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking 
as reference the baseline sum of diameters  
• Progressive disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the 
relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. 
The appearance of one or more new lesions is also considered progression. 
• Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study  
2.3.2 Special Notes on the Assessment of Target Lesions  
Lymph Nodes.   Lymph nodes identified as target lesions should always have the actual short axis 
measurement recorded (measured in the same anatomical plane as the baseline examination), even 
if the nodes regress to < 10 mm on study.  This means that when lymph nodes are included as 
target lesions, the sum of lesions may not be zero even if complete response criteria are met, since a normal lymph node is defined as having a short axis of <  10 mm.  
Target Lesions That Become Too Small to Measure.   During the study, all lesions (nodal and 
non-nodal) recorded at baseline should have their actual measurements recorded at each 
subsequent evaluation, e ven when very small (eg, 2 mm).  However, sometimes lesions or lymph 
nodes that are recorded as target lesions at baseline become so faint on CT scan that the radiologist 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 88 of 113 
 CONFIDENTIAL   
 may not feel comfortable assigning an exact measure and may report them as being too small to 
measure.  When this occurs, it is important that a value be recorded on the e CRF, as follows:  
• If it is the opinion of the radiologist that the lesion has likely disappeared, the measurement should be recorded as 0 mm. If the lesion is believed to be present and is faintly seen but too small to measure, a default value of 5 mm should be assigned and 
BML (below measurable limit) should be ticked. (BML is equivalent to a “less than” 
sign.) (Note: It is less likely that this rule will be used for lymph  nodes since they usually 
have a definable size when normal and are frequently surrounded by fat such as in the 
retroperitoneum; however, if a lymph node is believed to be present and is faintly seen 
but too small to measure, a default value of 5 mm should be assigned in this circumstance as well and BML should also be ticked).  
To reiterate, however, if the radiologist is able to provide an actual measure, that should be 
recorded, even if it is below 5 mm, and in that case BML should not be ticked. 
Lesions That Split or Coalesce on Treatment.   When non- nodal lesions fragment, the longest 
diameters of the fragmented portions should be added together to calculate the target lesion sum. Similarly, as lesions coalesce, a plane between them may be maintained that  would aid in obtaining 
maximal diameter measurements of each individual lesion.  If the lesions have truly coalesced 
such that they are no longer separable, the vector of the longest diameter in this instance should be the maximum longest diameter for the coalesced lesion.  
2.3.3 Evaluation of Non- Target Lesions  
This section provides the definitions of the criteria used to determine the tumor response for the group of non- target lesions.  While some non -target lesions may actually be measurable, they need 
not be measured and instead should be assessed only qualitatively at the time point s specified in 
the protocol. 
• Complete response (CR): Disappearance of all non -target lesions and (if applicable) 
normalization of tumor marker level.  All lymph nodes must be non- pathological in size 
(< 10 mm short axis).  
• Non-CR/Non -PD: Persistence of one or more non- target lesions and/or (if applicable) 
maintenance of tumor marker level above the normal limits 
• Progressive disease (PD): Unequivocal progression of existing non- target lesions. The 
appearance of one or more new lesions is also considered progression.  
2.3.4 Special Notes on Assessment of Progression of Non- Target Disease 
When the Patient Also Has Measurable Disease.   In this setting, to achieve unequivocal 
progress ion on the basis of the non- target disease, there must be an  overall level of substantial 
worsening in non- target disease in a magnitude that, even in the presence of SD or PR in target 
disease, the overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest increase in the size of one or more non- target lesions is usually not sufficient to qualify for 
unequivocal progression status.  The designation of overall progression solely on the basis of 
change in non- target disease in the face of SD or PR of target disease will therefore be extremely 
rare. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 89 of 113 
 CONFIDENTIAL   
 When the Patient Has Only Non -Measurable Disease.   This circumstance arises in some phase 3 
trials when it is not a criterion of study entry to have measurable disease.  The same general 
concepts apply here as noted above; however, in this instance there is no measurable disease 
assessment to factor into the interpretation of an increase in non -measurable disease burden.  
Because worsening in non- target disease cannot be easily quantified (by  definition: if all lesions 
are truly non -measurable), a useful test that can be applied when assessing patients for unequivocal 
progression is to consider if the  increase in overall disease burden based on the change in non -
measurable disease i s comparable in magnitude to the increase that would be required to declare 
PD for measurable disease, that is, an increase in tumor burden representing an additional 73% increase in volume (which is equivalent to a 20% increase in diameter in a measurable lesion). Examples include an increase in a pleural effusion from “trace” to “large” or an increase in 
lymphangitic disease from localized to widespread, or may be described in protocols as “sufficient 
to require a change in therapy.”  If unequivocal progression is seen, the patient should be 
considered to have had overall PD at that point.  While it would be ideal to have objective criteria 
to apply to non- measurable disease, the very nature of that disease makes it impossible to do so; 
therefore, the incr ease must be substantial.  
2.3.5 New Lesions 
The appearance of new malignant lesions denotes disease progression; therefore, some comments 
on detection of new lesions are important.  There are no specific criteria for the identification of 
new radiographic lesions; however, the finding of a new lesion should be unequivocal, that is, not 
attributable to differences in scanning technique, change in imaging modality, or findings thought 
to represent something other than tumor (for example, some “new” bone lesions may be simply healing or flare of preexisting lesions).  This is particularly important when the patient’s baseline 
lesions show partial or complete response.  For example, necrosis of a liver lesion may be reported 
on a CT scan report as a “new” cystic lesion, which it is not. 
A lesion identified during the study in an anatomical location that was not scanned at baseline is 
considered a new lesion and will indicate disease progression.  
If a new lesion is equivocal, for example because of its small size, continued therapy and follow -
up evaluation will clarify if it represents truly new disease.  If repeat scans confirm there is 
definitely a new lesion, then progression should be declared using the date of the initial scan.  
(18) F-Fluorodeoxyglucose Positron Emission Tomography (FDG- PET)  
While FDG -PET response assessments need additional study, it is sometimes reasonable to 
incorporate the use of FDG -PET scanning to complement CT scanning i n assessment of 
progression (particularly, possible “new” disease).  New lesions on the basis of FDG -PET imaging 
can be identiﬁed according to the following algorithm:  
A negative FDG -PET scan at baseline with a positive FDG -PET scan during the study is a sign of 
PD based on a new lesion.  
In the case of no FDG- PET scan at baseline and a positive FDG -PET scan during the study: 
• If the positive FDG -PET scan during the study corresponds to a new site of disease 
conﬁrmed by CT, this will be considered PD. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 90 of 113 
 CONFIDENTIAL   
 • If the positive FDG -PET scan during the study is not conﬁrmed as a new site of disease on 
CT, additional follow -up CT scans are needed to determine whether there is truly 
progression occurring at that site (if so, the date of PD will be the date of the initial 
abnormal FDG- PET scan).  
• If the positive FDG -PET scan during the study corresponds to a preexisting site of disease 
on CT that is not progressing on the basis of the anatomic images, this will not be considered PD.  
2.4 Evaluation of Response 
2.4.1 Time  Point Response (Overall Response)  
It is assumed that at each protocol -specified time  point, a response assessment occurs.  Table  14 
provides a summary of the overall response status calculation at each time point for patients who 
have measurable disease at baseline.  
When patients have non- measurable (therefore non -target) disease only, Table  15 is to be used. 
Table  14 Time  Point Response: Patients with Target Lesions (with or without Non -
Target Lesions)  
Target Lesions  Non-Target Lesions  New Lesions  Overall Response  
CR CR No CR 
CR Non-CR/non -PD No PR 
CR Not evaluated  No PR 
PR Non-PD or not all evaluated  No PR 
SD Non-PD or not all evaluated  No SD 
Not all evaluated  Non-PD No NE 
PD Any Yes or no  PD 
Any PD Yes or no  PD 
Any Any Yes PD 
CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable 
disease.  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 91 of 113 
 CONFIDENTIAL   
 Table  15 Time Point Response: Patients with Non -Target Lesions Only  
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non -PD No Non-CR/non -PD a 
Not all evaluated  No NE 
Unequivocal PD  Yes or no  PD 
Any Yes PD 
CR = complete response; NE = not evaluable; PD = progressive disease.  
a “Non -CR/non -PD” is preferred over “stable disease” for non -target disease since stable disease is increasingly 
used as an endpoint for assessment of efficacy in some trials; thus, assigning “stable disease” when no lesions can 
be measured is not advised.  
 
2.4.2 Missing Assessments and Not -Evaluable Designation  
When no imaging/measurement is done at all at a particular time  point, the patient is not evaluable 
at that time  point.  If only a subset of lesion measurements are made at an assessment, usually the 
case is also considered not evaluable at that time point, unless a convincing argument can be m ade 
that the contribution of the individual missing lesion(s) would not change the assigned time  point 
response.  This would be most likely to happen in the case of PD.  For example, if a patient had a 
baseline sum of 50 mm with 3 measured lesions and , during the study, only 2 lesions were 
assessed, but those gave a sum of 80 mm, the patient will have achieved PD status, regardless of 
the contribution of the missing lesion. 
If one or more target lesions were not assessed either because the scan was not done or the scan 
could not be assessed because of poor image quality or obstructed view, the response for target lesions should be “unable to assess” since the patient is not evaluable.  Similarly, if one or more 
non-target lesions are not assessed, the response for non- target lesions should be “unable to assess” 
except where there is clear progression.  Overall response would be “unable to assess” if either the 
target response or the non- target response is “unable to assess” except where this is clear evid ence 
of progression, as this equates with the case being not evaluable at that time point. 
2.4.3 Best Overall Response: All Time Points 
The best overall response is determined once all the data for the patient is known.  Best response 
determination in trials where confirmation of complete or partial response IS NOT required: Best 
response in these trials is defined as the best response across all time points (for example, a patient 
who has SD at first assessment, PR at second assessment, and PD on last assessment has a best 
overall response of PR).  When SD is believed to be best response, it must also meet the protocol 
specified minimum time from baseline.  If the minimum time is not met when SD is otherwise the 
best time point response, the patient’s best response depends on the subsequent assessments.  For 
example, a patient who has SD at first assessment, PD at second and does not meet minimum duration for SD, will have a best response of PD.  The same patient lost to follow -up after the first 
SD assessment would be considered inevaluable. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 92 of 113 
 CONFIDENTIAL   
 Best response determination in trials where confirmation of complete or partial response IS 
required: Complete or partial responses may be claimed only if the criteria for each are met at a 
subsequent time point as speci fied in the protocol (generally 4 weeks later).  In this circumstance, 
the best overall response can be interpreted as in Table  16. 
Table  16 Best O verall R esponse When C onfirmation of Complete Response and 
Partial R esponse is R equired  
Overall response  
First time point  Overall response  
Subsequent time point  BEST overall response  
CR CR CR 
CR PR SD，PD or PRa 
CR SD SD provided minimum criteria for SD duration met, 
otherwise, PD  
CR PD SD provided minimum criteria for SD duration met, 
otherwise, PD  
CR NE SD provided minimum criteria for SD duration met, 
otherwise NE  
PR CR PR 
PR PR PR 
PR SD SD 
PR PD SD provided minimum criteria for SD duration met, 
otherwise, PD  
PR NE SD provided minimum criteria for SD duration met, 
otherwise NE  
NE NE NE 
 
CR = complete response, PR = partial response, SD = stable disease, PD =progressive disease, and NE = inevaluable.  
a: If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR 
criteria relative to baseline, makes the disease PD at that point (since disease must have reappeared after CR). Best 
response would depend on whether minimum duration for SD was met. However, sometimes ‘CR’ may be claimed 
when subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not CR at the first time point. Under these circumstances, the original CR should be changed to PR and the best response is PR.
 
 
Special Notes on Response Assessment  
When nodal disease is included in the sum of target lesions and the nodes decrease to “normal” 
size (< 0 mm), they may still have a measurement reported on scans.  This measurement should be 
recorded even though the nodes are normal in order not to overstate progression should it be based on increase in size of the nodes.  As noted earlier, this means that patients with CR may not have 
a total sum of “zero” on the eC RF. 
Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as “symptomatic 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 93 of 113 
 CONFIDENTIAL   
 deterioration.”   Every effort should be made to document objective progression even after 
discontinuation of treatment.  Symptomatic deterioration is not a descriptor of an objective 
response; it is a reason for stopping study therapy.  The objective response status of such patients 
is to be determined by evaluation of target and non- target disease as shown in Table  14 and 
Table  15. 
For equivocal findings of progression ( eg, very small and uncertain new lesions; cystic changes or 
necrosis in existing lesions), treatment may continue until the next scheduled assessment. If at the 
next scheduled assessment, progression is confirmed, the date of progression should be the earlier 
date when progression was suspected.  
In studies for which patients with advanced disease are eligible ( ie, primary disease still or partially 
present), the primary tumor should also be captured as a target or non- target lesion, as appropriate. 
This is to avoid an incorrect assessment of complete response if the primary tumor is still present 
but not evaluated as a target or non- target lesion.  
2.5 Frequency of T umo r Re-evaluation 
Frequency of tumo r re-evaluation while on treatment should be protocol specific and adapted to 
the type and schedule of treatment.  However, in the context of phase 2 studies where the beneficial 
effect of therapy is not known, follow -up every 6–8 weeks (timed to coincide with the end of a 
cycle) is reasonable.  Smaller or greater time intervals than these could be justified in specific 
regimens or circumstances.  The protocol should specify which organ sites are to be evaluated at 
baseline (usually those most likely to be involved with metastatic disease for the tumo r type under 
study) and how often evaluations are repeated.  Normally, all target and non- target sites are 
evaluated at each assessment.  In selected circumstances certain non -target organs may be 
evaluated less frequently.  For example, bone scans may need to be repeated only when complete 
response is identified in target disease or when progression in bone is suspected.  
After the end of the treatment, the need for repetitive tumo r evaluations depends on whether  the 
trial has as a goal the response rate or the time to an event (progression/death).  If ‘time to an event’ 
(eg, time to progression, disease -free survival, progression -free survival) is the main endpoint of 
the study, then routine scheduled re -evaluati on of protocol specified sites of disease is warranted.  
In randomiz ed comparative trials in particular, the scheduled assessments should be performed as 
identified on a calendar schedule (for example: every 6–8 weeks on treatment or every 3–4 months after treatment) and should not be affected by delays in therapy, drug holidays or any other events 
that might lead to imbalance in a treatment arm in the timing of disease assessment.  
2.6 Confirmatory measurement/duration of response 
2.6.1. Confirmation 
In non- randomiz ed trials where response is the primary endpoint, confirmation of PR and CR is 
required to ensure responses identified are not the result of measurement error.  This will also 
permit appropriate interpretation of results in the context of historic al data where response has 
traditionally required confirmation in such trials (see the paper by Bogaerts et al. in this Special 
Issue10).  However, in all other circumstances, for example  in randomiz ed trials (phase 2 or 3) or 
in studies where stable disease or progression are the primary endpoints, confirmation of response 
is not required since it will not add value to the interpretation of trial results.  However, elimination 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 94 of 113 
 CONFIDENTIAL   
 of the requirement for response confirmation may increase the importance of cent ral review to 
protect against bias, in particular in studies that are not blinded. 
In the case of SD, measurements must have met the SD criteria at least once after study entry at a 
minimum interval (in general not less than 6 –8 weeks) that is defined in t he study protocol. 
2.6.2. Duration of overall response 
The duration of overall response is measured from the time measurement criteria are first met for 
CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease is objec tively documented (taking as reference for progressive disease the smallest measurements 
recorded on study).  
The duration of overall complete response is measured from the time measurement criteria are first met for CR until the first date that recurrent d isease is objectively documented.  
2.6.3. Duration of stable disease 
Stable disease is measured from the start of the treatment (in randomiz ed trials, from date of 
randomiz ation) until the criteria for progression are met, taking as reference the smallest sum on 
study (if the baseline sum is the smallest, this is the reference for calculation of PD).  
The clinical relevance of the duration of stable disease varies in different studies and diseases.  If 
the proportion of patients achieving stable disease for a  minimum period of time is an endpoint of 
importance in a particular trial, the protocol should specify the minimal time interval required 
between two measurements for determination of stable disease.  
Note: The duration of response and stable disease as well as the progression -free survival are 
influenced by the frequency of follow -up after baseline evaluation.  It is not in the scope of this 
guideline to define a standard follow -up frequency.  The frequency should take into account many 
parameters includin g disease types and stages, treatment periodicity and standard practice.  
However, these limitations of the precision of the measured endpoint should be taken into account if comparisons between trials are to be made.  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 95 of 113 
 CONFIDENTIAL   
 APPENDIX 3 PROHIBITED MEDICATION  
A series of strong inducers and strong inhibitors of CYP3A are listed in Table  17 and Table  18 
below.  Examples of sensitive substrates of P -gp and BCRP are listed in Table  19. 
Patients who received a CYP3A strong inducer or strong inhibitor within 2 weeks ( 3 weeks for 
hyperforin perforatum/St. John’s Wort  treatment) prior to the first dose of the study drug will not 
be allowed to participate in the study.  During the study, co -administration of strong inducers and 
inhibitors of CYP3A with fruquintinib should be avoided unless investigators consider it 
necessary.  In this case, fruquintinib efficacy reduction or  toxicity increases resulting from the 
interaction should be closely monitored. 
Not all the medications are listed in the following tables.  Other drugs known possibly to affect 
CYP3A activity and to be substrates of P -gp and BCRP should be used with caution.  When 
combining fruquintinib with other drugs the prescription information of all concomitant 
medications should be reviewed. 
  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 96 of 113 
 CONFIDENTIAL   
 Table 17 Typical Strong Inhibitors of CYP3A4  
Strong Inhibitors of CYP3A4  
Boceprevir  
Clarithromycin  
Conivaptan  
Elvitegravir/Ritonavir  
Fluconazole  
Grapefruit juicea,b 
Indinavir  
Itraconazole  
Ketoconazole  
Lopinavir/Ritonavir  
Mibefradil  
Nelfinavir  
Posaconazole  
Ritonavir  
Saquinavir  
Telaprevir  
Telithromycin  
Tipranavir/Ritonavir  
Troleandomycin  
Voriconazole  
a Super -concentrated g rapefruit juice  
b During the study, patients should not consume large amounts of grapefruit or lime (or products that include 
these f ruits, such as grapefruit juice, Seville oranges, and orange jam). No more than one cup (120 mL) of grapefruit 
juice, half a grapefruit or a spoon full (15 g) of orange  jam should be consumed each day.  
  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 97 of 113 
 CONFIDENTIAL   
 Table  18 Typical Strong Inducers of CYP3A4  
Strong Inducers of CYP3A4  
Apalutamide  
Avasimibe  
Carbamazepine 
Enzalutamide  
Mitotane  
Phenobarbital  
Phenytoin  
Rifabutin  
Rifampin (or r ifampicin ) 
St. John’s wort  
  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 98 of 113 
 CONFIDENTIAL   
 Table  19 Sensitive Substrates of P -gp or BCRP  
Substrates of P -gp Substrates of BCRP  
Aliskiren  
Ambrisentan  
Colchicine  
Dabigatran etexilate  
Digoxin  
Everolimus  
Fexofenadine  
Imatinib  
Lapatinib  
Maraviroc  
Nilotinib  
Posaconazole  
Ranolazine  
Saxagliptin  
Sirolimus  
Sitagliptin  
Talinolol  
Tolvaptan  
Topotecan  Methotrexate  
Mitoxantrone  
Imatinib  
Irrinotecan  
Lapatinib  
Rosuvastatin  
Sulfasalazine  
Topotecan  
 
  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 100 of 113 
 CONFIDENTIAL   
 Table  20 Summary of Clinical Trial Program of Fruquintinib in China and the US  
Study 
Number  
(Name)  
NCT# and 
Indication  Study Title  Study 
Objectives  and 
Phase  Study Subjects  
 Study  Design  Current * 
Status  
2012 -013-
00CH3  
[STUDY_ID_REMOVED] 
3rd or above 
line mCRC  A Phase Ib, 
Randomized, Open -
Label Study for Comparing Two 
Different Dosing 
Regimens  of 
Fruquintinib as Third -
Line or up Therapy for Advanced Colorectal 
Cancer in Patients Who 
Had Failed with Standard Therapy  Compare two 
dosing regimens of fruquintinib. (Safety, 
tolerability, PK, 
preliminary efficacy)  
Phase 1b  Fruquintinib  
N=62 Randomized, 
two-stage, open -
label, multicenter study.  
Stage 1: two arms, two dose 
regimens, 
randomized  
Stage 2: selected 
dose regimen 
expansion  Completed  
2012 -013-
00CH1  
[STUDY_ID_REMOVED] 
3rd line 
mCRC  A Randomized, 
Double -blind, Placebo -
controlled, Multi -center 
Phase II Clinical Trial to Evaluate the 
Efficacy and Safety of 
Fruquintinib  Plus Best Supportive Care in 
advanced colorectal 
cancer patients who have progressed after 
second -line 
chemotherapy  PFS 
(Fruquintinib versus  PBO), 
OS, ORR, safety 
Phase 2  Fruquintinib: 
N=47; Placebo: 
N=24 (Tot. 71)  Randomized, 
double -blind, 
placebo -
controlled, multicenter study  Completed  
2014 -013-
00CH1  
[STUDY_ID_REMOVED] 
3rd line 
NSCLC  A Randomized, 
Double -blind, Placebo -
controlled, Multi -center 
Phase II Clinical Trial 
to Evaluate the 
Efficacy and Safety of Fruquintinib Plus Best 
Supportive Care in 
Patients With Advanced Non-
squamous Non -small 
Cell Lung Cancer  (Fruquintinib 
versus  PBO), 
OS, ORR, safety 
Phase 2  Fruquintinib 
N=61. Placebo: 
N=30  
(Tot. 91) Randomized, 
double -blind, 
placebo -
controlled, multicenter study  Completed  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 101 of 113 
 CONFIDENTIAL   
 Table  20 Summary of Clinical Trial Program of Fruquintinib in China and the US  
Study 
Number  
(Name)  
NCT# and 
Indication  Study Title  Study 
Objectives  and 
Phase  Study Subjects  
 Study  Design  Current * 
Status  
2015 -013-
00CH1  
[STUDY_ID_REMOVED] 
(FALUCA)  
3rd line 
NSCLC  A Randomized, 
Double -blind, Placebo -
controlled, Multi -center 
Phase III Clinical Trial 
in Patients With 
Advanced Non-
squamous Non -small 
Cell Lung Cancer Treated With Fruquintinib  Confirmatory 
efficacy and safety NSCLC. Phase 3  Fruquintinib 
N=352 
Placebo N= 171 
(Total N=523) Randomized, 
double -blind, 
placebo -
controlled, 
multicenter study  Ongoing 
(Enrollment completed)  
2017 -013-
00CH1  
[STUDY_ID_REMOVED] 
2nd line 
gastric cancer  A Phase III Study to 
Evaluate the Efficacy and Safety of 
Fruquintinib in 
Combination With Paclitaxel Versus 
Paclitaxel Alone in 
Second Line Gastric Cancer  Phase 3  Planned:  544 
Current:  N=120 Randomized, 
double -blind, 
placebo -
controlled, multicenter study  Ongoing  
2014 -013-
00CH3  
[STUDY_ID_REMOVED] 
2nd line 
gastric cancer  
 A Phase Ib/2 Clinical 
Study to Evaluate the Safety, Pharmacokinetic 
Characteristics and 
Preliminary Efficacy of 
Fruquintinib Combined 
With Paclitaxel in 
Patients With 
Advanced Gastric 
Cancer  (Fruquintinib + 
paclitaxel combo), safety, tolerability, PK, 
preliminary 
efficacy Phase 1b/2 Fruquintinib 
N=34 Two-stage, open -
label, multicenter study. Stage 1: dose escalation. 
Stage 2: selected 
dose re gimen 
expansion  
(combo + paclitaxel)  Completed  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 103 of 113 
 CONFIDENTIAL   
 Table  20 Summary of Clinical Trial Program of Fruquintinib in China and the US  
Study 
Number  
(Name)  
NCT# and 
Indication  Study Title  Study 
Objectives  and 
Phase  Study Subjects  
 Study  Design  Current * 
Status  
2013 -013-
00CH2  A Single Center, Open -
label, Randomized, Two-period Crossover 
Study to Evaluate the 
Pharmacokinetics and Bioequivalence in 
Healthy Male Chinese 
Volunteers Following Single Doses of 
Fruquintinib Capsules 
Produced by Two Different Manufacturers  Primary: to 
determine the bioequivalence of fruquintinib 
produced at two 
manufacturing 
sites.  
Secondary: to 
assess the safety 
and tolerability  
Phase 1  Healthy males  
N=28 Randomized, 
open -label, two -
period crossover, 
two-stage, single 
center study.  
Stage 1: 
Exploring 
preliminary study. Stage 2: 
Bioequivalence 
study  Completed  
2014 -013-
00CH5  
 A Single Center, Open -
label, Randomized, Two-period Crossover 
Study to Evaluate the Pharmacokinetics and Bioequivalence in 
Healthy Male Chinese 
Volunteers Following Single Doses of 
Fruquintinib Capsules 
Produced by Two Different Manufacturers  Primary: to 
assess the bioequivalence 
of fruquintinib 
produced at two manufacturers; 
Secondary: 
safety, explore metabolism and excretion  
Phase 1  Healthy Males 
(N=24)  Randomized, 
open -label, two -
period crossover, 
two-stage, single 
center study.  
 Completed  
2015 -013-
00CH2  
[STUDY_ID_REMOVED] 
 Absorption, 
Metabolism and 
Excretion of [14C] 
Fruquintinib in Healthy 
Male Volunteers after a 
Single Oral 
Administration of 5mg/100 μCi/Subject of [
14C] Fruquintinib  Evaluate mass 
balance in 
healthy male 
volunteers following a 
single oral 
administration of 5 mg/100 
μCi/Subject of 
[
14C] 
fruquintinib Phase 1  Healthy Males 
(N=6)  To investigate the 
absorption, drug 
biotransformation 
and mass balance and to evaluated 
the PK and safety 
of fruquintinib. To identify the 
compound's 
major metabolites  Completed  
*Fruquintinib Investigator’s Brochure, v11.0  
  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 104 of 113 
 CONFIDENTIAL   
 APPENDIX 5 CLINICAL EVALUATION OF POSSIBLE DRUG -INDUCED LIVER 
INJURY (DILI)  
If ALT or AST is elevated to higher than 3 x ULN and  bilirubin is elevated to higher than 2 X 
ULN, fruquintinib treatment should be discontinued immediately, and supportive treatment should 
be given. This combination of lab abnormalities meets the biochemical criteria for Hy’s law, which 
is associated with a markedly increased possibility of severe drug -induced liver injury (DILI), and 
may progress to liver transplantation or death (FDA Guidance for Industry - Drug -Induced Liver 
Injury: Premarketing Clinical Evaluation. FDA, 2009). 
If the biochemical criteria for Hy’s law are met, fruquintinib should be immediately discontinued, 
and patients need to be very closely monitored (bilirubin, ALP, AST, and ALT measured 2- 3 times 
weekly until the results return to baseline or normal), and other causes of liver injury evaluated 
(eg, new or worsening hepatobiliary metastases; non- malignant biliary obstruction; viral hepatitis 
A, B, or C; alcoholic or autoimmune hepatitis; preexisting or acute liver disease; ischemic liver 
injury; right -sided congestive heart failure; new or worsening liver metastases; or concomitant 
medication that could cause the observed injury). Consultation with a gastroenterologist or hepatoligist should be considered. 
If the biochemical criteria for Hy’s Law have been met, expedited reporting is required (see 
Section 8.1.1 ), before waiting for the evaluation of other causes to be completed.  
Recommended Data Collection for Suspected DILI 
The investigator is recommended to obtain the following information, so as to further evaluate and 
follow up and complete the clinical data.  Data should be recorded on e CRFs where possible, and 
supplemented by investigator reporting as text in the clinical database: 
• Medical history of the patient 
o Detailed history of current symptoms, diagnosis of complications and medical history 
o Previous medical history (viral hepatitis, alcoholic hepatitis, autoimmune disease, 
biliary tract disease and cardiovascular disease, etc.)  
o History of concomitant medication (including OTC and prescription drugs, herbal medicine and dietary supplements), alcohol consumption, recreational drugs and special diet  
o History of exposure to potentially hepatotoxic chemicals 
• Complete the following laboratory tests:  
o Hematology 
o Clinical biochemistry: ALT, AST, bilirubin (including total bilirubin and direct bilirubin), ALP, albumin, PTT or INR, amylase, fasting blood glucose, cholesterol and triglycerides 
o Other Serum Tests: Hepatitis A (Anti- IgM and Anti -IgG), hepatitis B (HbsAg, Anti-
HBs and HBV DNA), hepatitis C (Anti -HCV, and HCV RNA test is required for any 
patient with positive test result), hepatitis D (Anti -IgM and Anti - IgG), hepatitis E 
(Anti- HEV and Anti -HEV IgM).  
• Complete appropriate auxiliary examination: 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 105 of 113 
 CONFIDENTIAL   
 o Patients with confirmed elevation of ALT/AST combined with TBili are required to 
receive abdominal ultrasonography or other clinically applicable imaging examination within 48 hours (to exclude biliary tract, pancreatic, or intrahepatic causes, such as  new 
or worsening hepatobiliary metastases or biliary calculi) and obtain the liver imaging result as soon as possible.  If an alternative cause (such as biliary tract, pancreatic, or 
intrahepatic causes) of abnormal hepatic results cannot be confirmed by imaging, paracentesis is recommended for pathological examination after obtaining consent of the patient;  
o If suspected cardiovascular causes exist, cardiac ultrasonography is recommended to exclude cardiovascular dysfunction ( ie, right heart failure);  
Long- term follow -up: Perform close monitoring on the patient through repetitive tests of ALT, 
AST and bilirubin (including total bilirubin and direct bilirubin) two to three times weekly until 
the laboratory ALT and/or AST abnormality becomes stable or rec overs, and then proceed 
according to the protocol. 
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 106 of 113 
 CONFIDENTIAL   
 APPENDIX 6 CLINICAL MANAGEMENT OF SEVERE OR SERIOU S 
HEMORRHAGIC EVENTS  
If hemorrhagic events are evaluated as severe (CTCAE grade ≥3) or SAE s, fruquintinib treatment 
should be discontinued or interrupted immediately, and appropriate treatment measures initiated 
to control bleeding ( eg transfusion, radiologic, endoscopic, or elective operative intervention as 
indicated).  When the patient is not well enough to tolerate an invasiv e procedure or operation, 
best supportive care is given (see Section  7.5.6.2 ).  Patients need to be very closely monitored, 
both clinically (continuo usly), and by relevant laboratory testing (INR, aPTT, platelet count, 
hemoglobin) every 2 -3 days until the results return to baseline or normal).  During the initial 
assessment, a focused history and physical examination, with collection of vital signs and  
laboratory evaluation and imaging evaluation should be obtained, aimed at determining the time of onset, location, severity of bleeding, and whether bleeding is ongoing.  Clinicians should be mindful of comorbidities and concomitant treatments (eg. anti -platelet therapy and/or 
thrombocytopenia, or liver disease)  that could also contribute to bleeding and manage them as 
appropriate.  Consultation with other department clinicians should be considered when necessary. 
The investigator should closely monitor pa tients receiving anti -platelet and/or anti-thrombotic 
drugs during study drug treatment and make a timely decision on whether to continue or stop such 
drugs in patients that report grade  ≥2 hemorrhagic events at any site, based on an individual 
assessment of the risk -benefit balance.  
If a hemorrhagic event is evaluated as a severe (CTCAE grade ≥3) or SAE  after taking fruquintinib, 
the investigator is required to report the event in an expedited fashion (within 24 hours of first awareness) to sponsor (see Section  8.2.2).  
See Figure 2  below for guidance on the management of severe or serious hemorrhage at any site.  
Recommended Data Collection for Severe or Serious Hemorrhagic Events:  
The investigator is recommended to obtain the following information, so as to further evaluate and follow up and complete the clinical data.  Data should be recorded on SAE/AES I report form 
where possible, and supplemented by Bleeding Event F ollow -Up Questionnaire: 
• Medical history of the patient 
o Detailed history of current symptoms, diagnosis of complications and medical history  
o Previous medical history  
o History of concomitant medication ( 
 Vitamin K antagonists ( eg warfarin)  
 NSAIDs ( eg aspirin) 
 Anti-platelet drugs (eg, clopidogrel/glycoprotein GPIIb/IIIa 
inhibitors/dipyridamole) 
 Other anticoagulants (eg  heparin/thrombolytics/SSRIs) 
 Food and herbal supplements with anticoagulant property 
 Immunosuppressants 
 Alcohol consumption 
 Recreational drugs and special diet  
o Family history of bleeding events 
• Complete the following laboratory tests:  
o Hematology: hemoglobin, platelet, hematocrit, reticulocyte count 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 107 of 113 
 CONFIDENTIAL   
 o Clinical biochemistry: bleeding  time, PTT, aPTT, INR  
• Complete appropriate auxiliary examination:  
o Patients with confirmed bleeding are required to receive upper or lower GI endoscopy, 
bronchoscopy or other clinically applicable procedure or radiologic imaging within 48 hours, to confirm the site of bleeding.  
o If suspected cardiovascular causes exist, cardiac ultrasonography is recommended to exclude cardiovascular dysfunction (ie, right heart failure). 
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 108 of 113 
 CONFIDENTIAL   
 Figure 2 Severe or Serious Hemorrhagic Events Management F low Chart 
•Closely monitor  
•Interrupt study drug  
•Initiate appropriate measures 
to control bleeding if necessary  
•Closely monitor patients receiving anti -platelet and/or 
anti-thrombotic drugs during 
study drug treatment, and make a timely decision on whether to continue or stop such drugs in patients that report Grade ≥2 hemorrhagic 
events at any site  
•Fill in SAE/AESI form and expedited reporting of this hemorrhagic event to sponsor  
•Complete the bleeding event follow up questionnaire when received from sponsor  
•Continue monitoring  
•Expedited reportin g to 
sponsor if upgraded to severe or serious 
hemorrhagic event  
Hemorrhagic event meeting any of the criteria below:  
•CTCAE grade ≥ 3 (severe AE) 
•Serious adverse event  
•CTCAE grade ≥ 2 and receiving anti-platelet and/or anti -thrombotic drugs during study drug treatment  
 
Hemorrhage is severe (CTCAE grade ≥3) (regardless 
of whether or not it meets “serious” criteria)  
Hemorrhage is non-severe (CTCAE grade ≤ 2)  
Does the hemorrhagic event meet SAE criteria?  
•Discontinue study drug immediately  
•Initiate appropriate measures to control 
bleeding  
•Closely monitor laboratory tests (INR, 
aPTT, platelet count, hemoglobin and blood pressure) every 2 -3 days  
•A focused history and physical examination, with collection of vital signs, and laboratory evaluation as appropriate 
•Closely monitor patients receiving anti-
platelet and/or anti-thrombotic drugs during 
study drug treatment, and make a timely decision on whether to continue or stop such drugs in patients that report Grade ≥ 2 
hemorrhagic events at any site  
Grade=2  
 Grade=1  
Yes 
 No 
•Closely monitor  
•Initiate appropriate measures to control bleeding if necessary  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 109 of 113 
 CONFIDENTIAL   
 APPENDIX 7 MANAGEMENT OF HYPERTENSION IN PATIENTS RECEIVING 
FRUQUINTINIB  
Hypertension is a common AE that has been reported in patients taking angiogenesis inhibitors 
(Izzedine 2009), including fruquintinib.  Grade 3 AEs have been reported in 16% of patients treated 
with fruquintinib; no Grade 4 events have been reported to date.  It appears  that hypertension is a 
class -effect of VEGFR inhibitors (either antibodies or small molecules).  
There is no standard therapy for angiogenesis inhibitor -induced hypertension because there have 
not been any published controlled clinical trials with specific  agents.  Therefore, one can take an 
approach based on the clinical characteristics of particular patients.  Calcium channel blockers and angiotensin converting enzyme inhibitors (ACEI) are a reasonable first choice in most cases.  For 
patients with proteinuria, chronic renal disease or metabolic disease, an ACE inhibitor or 
angiotensin II receptor blockers (ARB) may be preferred; for elderly patients, dihydropyridine calcium channel blockers may be preferred.  In this appendix is a summary of the most rece nt 
American Heart Association (AHA)/American College of Cardiology (ACC) hypertension treatment guidelines.  A cardiologist may be consulted if appropriate. 
The objective of antihypertensive therapy in general is to control the blood pressure to a target 
level <140/90 mmHg.  For high -risk populations, such as patients with chronic renal disease and/or 
diabetes, it may be appropriate to aim for a target blood pressure < 130/80 mmHg.  On the following two pages  (Figure 3) , please see a summary of the most recent AHA/ACC hypertension 
treatment guidelines.  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 110 of 113 
 CONFIDENTIAL   
 Figure 3 Schema from American Heart Association/ American College of Cardiology  
for Controlling Hypertension in Adults  
 

Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 112 of 113 
 CONFIDENTIAL   
 Hypertension Guidelines From: Go A, Bauman M, Coleman King S, et al. An Effective Approach to High Blood 
Pressure Control. A Science Advisory from the American Heart Association, the American College of Cardiolo gy, and 
the Centers for Disease Control and Prevention . J Am Coll Cardiol  2014; 63:1230-8. 
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Version 1.0 / Original Protocol    
Hutchison MediPharma   Page 113 of 113 
 CONFIDENTIAL   
 APPENDIX 8 CONVERSION TABLE FOR URINALYSIS RESULTS  
Blood  Leucocytes  
Negative  0 0 cells/ μL Negative  0 <10 mg/dL  
Trace  1+ 1-24 cells/ μL Trace  1+ 11-99 mg/dL  
Small  2+ 25-79 cells/ μL Small  2+ 99-299 mg/dL  
Medium  3+ 80-199 cells/ μL Medium  3+ 300-999 mg/dL  
Large 4+ ≥ 200 cells/ μL large  4+ >1000  mg/dL  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 1 
 CONFIDENTIAL   
   
Clinical Study Protocol  
A GLOBAL, MULTICENTE R, RANDOMIZED, PLACE BO-
CONTROLLED PHASE 3 T RIAL TO COMPARE THE EFFICACY AND 
SAFETY OF FRUQUINTIN IB PLUS BEST SUPPORT IVE CARE TO 
PLACEBO PLUS BEST SU PPORTIVE CARE IN PAT IENTS WITH 
REFRACTORY METASTATI C COLORECTAL CANCER (FRESCO -2) 
Short  Title : A global, randomized, placebo -controlled phase 3 study of 
fruquintinib in patients with refractory metastatic 
colorectal cancer  
Acronym : FRESCO -2  
Investigational Product(s)  Fruquintinib  
Protocol Number : 2019 -013-GLOB1  
Clinical Phase:  3 
Date  of Issue:  24 June 2021  
Amendment : 4 
Version Number:  1 (for sponsor’s use only)  
Sponsor  Hutchison MediPharma Limited  
Building 4, 720 Cailun Road,  
Zhangjiang Hi-Tech Park, Shanghai, China  
Post Code: 201203  
Regulatory Agency Identifier 
Number(s)  IND: 131038  
EudraCT 2020 -000158 -88 
Confidentiality Statement  
The information contained in this protocol and all other information relevant to fruquintinib 
are the confidential and proprietary information of Hutchison MediPharma Limited, and 
except as may be required by federal, state, or local laws or regulation, may not be disclosed 
to others without prior written permission of Hutchison MediPharma Limited  
 

Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 2 
 CONFIDENTIAL   
 STATEMENT OF COMPLIA NCE  
The study will be conducted in compliance with this clinical study protocol, Good Clinical 
Practices (GCP) as outlined by ICH E6(R2), and all applicable local and national regulatory 
requirements.  Enrollment at any clinical study site may not begin prior to that site receiving 
approval from the ethics committee of record for the protocol and all materials provided to 
potential participants.  
Any amendments to the protocol or changes to the consent document will be approved before 
implementation of that amen dment.  Reconsent of previously enrolled participants may be 
necessary depending on the nature of the amendment.  
The Principal Investigator will ensure that changes to the study plan as defined by this protocol 
will not be made without prior agreement from  the Sponsor and documented approval from the 
ethics committee of record, unless such a change is necessary to eliminate an immediate hazard to 
the study participants.  
All personnel involved in the conduct of this study have completed Human Patients  Protec tion and 
GCP Training as outlined by their governing institution.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 3 
 CONFIDENTIAL   
 SPONSOR’S APPROVAL  
Title  A Global , Multicenter, Randomized, Placebo -Controlled Phase 3 Trial to Compare 
the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus 
Best Supportive Care in Patients with Refractory Metastatic Colorectal Cancer 
(FRESCO -2) 
Protocol Number  2019 -013-GLOB1  
Amendment  4 
Version Number  
(for sponsor’s use only)  1 
 
The design of this study as outlined by this protocol has been reviewed and approved by the 
sponsor’s responsible personnel as indicated in the signature table below.  
Name : [last name, first name]  Title : 
 Chief Medical Officer , Managi ng Director  
HUTCHMED  International  Corp  
Signature : 
See appended signature page  Date : [DD Month YYYY]  
 
Name : [last name, first name]  Title : 
 Chief Scientific Officer  
Hutchison MediPharma Limited  
Signature : 
See appended signature page  Date : [DD Month YYYY]  
 

Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 4 
 CONFIDENTIAL   
 INVESTIGATOR’S AGREE MENT  
I have read the protocol, appendices, and accessory materials related to Study 2019 -013-GLOB1  
and agree to the following:  
• To conduct this study as described by the protocol and any accessory materials  
• To protect the rights, safety, and welfare of the participants under my care  
• To provide oversight of all personnel to whom study activities have been delegated  
• To control all investigational products provided by the sponsor  and maintain records 
of the disposi tion of those products  
• To conduct the study in accordance with all applicable local and national regulations, 
the requirements of the ethics committee of record for my clinical site, and Good 
Clinical Practices as outlined by ICH E6(R2).  
• To obtain approval  for the protocol and all written materials provided to participants 
prior to initiating the study at my site  
• To obtain informed consent – and updated consent in the event of new information or 
amendments – from all participants enrolled at my study site p rior to initiating any 
study -specific procedures or administering investigational products to those 
participants  
• To maintain records of each patient ’s participation and all data required by the 
protocol  
Name:  Title:  Institution:   
   
Signature:  Date:   
  
 
  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 5 
 CONFIDENTIAL   
 DOCUMENT HISTORY  
All prior amendments of this study protocol are shown in the table below.  
Amendment  Date  
Original Protocol  25 Feb 2020  
Amendment 1  08 Apr 2020  
Amendment 2  30 Oct 2020  
Amendment 3  16 Mar 2021  
Amendment 3.1  25 Mar 2021  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 6 
 CONFIDENTIAL   
 AMENDMENT SUMMARY  
This 2019-013-GLOB1 Protocol Amendment 4  replaces 2019 -013-GLOB1 Protocol 
Amendment  3.1.  This amendment is considered non-substantial based on the criteria set forth in 
Article 10(a) of Directive 2001/20/EC of the European Parliament and  the Council of the European 
Union.  
The primary purpose of Protocol Amendment  4 is to provide clarity for select inclusion/exclusion 
criteria  and the schedule of events, to remove instructions for concomitant proton pump inhibitors 
and H2 -receptor antagoni sts, and to discontinue collection of circulating tumor DNA (ctDNA) due 
to supply chain issues related to COVID -19.  
The major changes incorporated in Amendment  4 relative to Amendment  3.1 are summarized 
below.  Editorial and formatting changes are not incl uded in this summary.  Summaries of prior 
amendments are available in Appendix  11. 
Section  Summary of Change  Rationale for Change  
Section  7.5.3  - Drug -Drug 
Interactions  (Therapies to Avoid or 
Use with Special Caution)  Removed instru ction that subjects 
should avoid proton pump inhibitor 
drugs and H2 blockers  Update made based on recent data 
indicating that concomitant use of 
proton pump inhibitors with 
fruquintinib had no effect on 
pharmacokinetic (PK) parameters  
Section  1 - Synopsis  
Section  5.1 - Recruitment  Revised the planned estimated 
number of study sites from 140 to 
160 Reflect potential increase in number 
of study sites  
Section  1 - Synopsis , Inclusion  
Criterion #4 
Section  5.3 - Inclusion Criteria , #4  For the inclusion criterion requiring 
patients must have received 
treatment with prior therapy, 
including anti -VEGF or anti -EGFR, 
examples of these treatments  were 
added  Clarification  
Section  1 - Synopsis , Exclusion 
Criterion  #5 
Section  5.4 - Exclusion Criteria , #5  Changed the pr otein level for  which 
a 24-hour urine assessment is 
required.  Correction  
Section  1 - Synopsis , Exclusion 
Criterion  #6 
Section  5.4 - Exclusion Criteria , #6  Added in details for blood pressure 
assessment process.  Clarification  
Section  1.2 – Schedule of Events  
Table  1 Schedule of Events  Removed visit window day 21 of 
cycle 2 and cycle 3  Clarification for these particular 
study visits that have study drug 
administration and PK sampling, 
which preclude the use of visit 
window  
Table  2 Schedul e of Events for 
Dense Pharmacokinetic  and 
Electrocardiogram  Evaluations  for 
the Subset of  Appro ximately 120 
Patients  with Evaluable ECGs  Revised title  Added the requirement for 120 
patients to have evaluable ECGs for 
PK/QTc evaluation.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 7 
 CONFIDENTIAL   
 Section  Summary of Change  Rationale for Change  
Table  3 Schedule of Ev ents for 
Sparse Pharmacokinetic and 
Electrocardiogram Evaluations for 
Patients Not Included in  the 
Approximately  120 Evaluable 
Patient s in the Subset  in Table 2  Revised title  Changed the title to harmonize with 
change of title of Table 2 . 
Table  1 Schedule of Events  
Section  1.2.1  - Footnotes for 
Schedule of Events Table  1, #21 
(footnote removed)  
Section 6.1.1.21  - Circulating 
Tumor DNA  Removed requirement for the 
collection of blood to evaluate 
ctDNA.  Further noted that analysis 
of ctDNA samples collected would 
be performed according to the 
statistical analysis plan  Appropriate sample collection tubes 
are unable to be procured due to 
supply chain issues as a result of 
the COVID -19 pandemic.  
Section  6.1.1.17  - 
Electrocardiograms Monitoring  Added that a ny subject with a 
pacemaker should undergo P K and 
safety ECG evaluations according 
to the schedule outlined in Table  3 Clarification to ensure subjects with 
pacemakers undergo sparse 
sampling  
Section 6.1.1.18  - Echocardiogram  Added that e chocardiograms 
completed as standard of care prior 
to signin g the informed consent, but 
within 28 days of first dose of study 
treatment, may be used as baseline 
assessment.  Clarification  
Section  1.2.2  - Footnotes for the 
Schedule of Events Tables 2 and 3 , 
#4 (footnote added)  Added instruction to r efer to the 
Holter Monitor instruction manu al 
for appropriate timing of the start of 
the ECG recording.  Clarification  
Appendix  9 Conversion 
Table s for Urinalysis Results  Added table to aid in conversion of 
proteins measured by urinalysis  for 
assessment of proteinuria  Correct an oversight  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 8 
 CONFIDENTIAL   
 TABLE OF CONTENTS  
A GLOBAL, MULTICENTE R, RANDOMIZED, PLACE BO-CONTROLLED PHASE 3 
TRIAL TO COMPARE THE  EFFICACY AND SAFETY  OF FRUQUINTINIB PLU S 
BEST SUPPORTIVE CARE  TO PLACEBO PLUS BES T SUPPORTIVE CARE IN  
PATIENTS WITH REFRAC TORY META STATIC COLORECTAL CA NCER 
(FRESCO -2) ................................ ................................ ................................ ......................  1 
STATEMENT OF COMPLIA NCE  ................................ ................................ ...............................  2 
SPONSOR’S APPROVAL  ................................ ................................ ................................ ............  3 
INVESTIGATOR’S AGREE MENT  ................................ ................................ .............................  4 
DOCUMENT H ISTORY ................................ ................................ ................................ ...............  5 
AMENDMENT SUMMARY  ................................ ................................ ................................ ........  6 
TABLE OF CONTENTS  ................................ ................................ ................................ ...............  8 
LIST OF TABLES  ................................ ................................ ................................ .......................  13 
LIST OF FIGURES  ................................ ................................ ................................ .....................  14 
LIST OF APPENDICES  ................................ ................................ ................................ ..............  15 
LIST OF ABBREV IATIONS  ................................ ................................ ................................ ...... 16 
1 SYNOPSIS  ................................ ................................ ................................ .......................  20 
1.1 Study Schematic ................................ ................................ ................................ ............  25 
1.2 Schedule of Events  ................................ ................................ ................................ ........  26 
1.2.1  Footnotes for Schedule of Events Table  1 ................................ ................................ . 28 
1.2.2  Footnotes for the Schedule of Events Tables 2 and 3  ................................ ................  32 
2 INTRODUCTION  ................................ ................................ ................................ ...........  33 
2.1 Study Rationale  ................................ ................................ ................................ .............  33 
2.2 Background  ................................ ................................ ................................ ...................  34 
2.2.1  Justification for Dosing Strategy  ................................ ................................ ...............  34 
2.2.2  Supportive Nonclinical Data  ................................ ................................ ......................  35 
2.2.2.1  Pharmacology  ................................ ................................ ................................ .........  35 
2.2.2.2  Metabolism and Pharmacokinetic Drug Interaction  ................................ ...............  35 
2.2.2.3  Toxicology  ................................ ................................ ................................ ..............  36 
2.2.3  Supporti ve Clinical Data  ................................ ................................ ............................  36 
2.2.3.1  Clinical Pharmacokinetics  ................................ ................................ ......................  36 
2.2.3.2  Clinical Safety  ................................ ................................ ................................ .........  37 
2.2.3.3  Clinical Efficacy  ................................ ................................ ................................ ..... 38 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 9 
 CONFIDENTIAL   
 2.2.4  Benefit/Risk Assessment  ................................ ................................ ...........................  39 
2.2.4.1 Risk Assessment  ................................ ................................ ................................ ..... 39 
2.2.4.2  Benefit Assessment  ................................ ................................ ................................ . 40 
2.2.4.3  Overall Benefit/Risk Conclusion  ................................ ................................ ............  40 
3 OBJECTIVES AND ENDPO INTS  ................................ ................................ .................  41 
3.1 Primary Objective  ................................ ................................ ................................ .........  41 
3.2 Secondary Objectives ................................ ................................ ................................ .... 41 
3.3 Exploratory Objectives  ................................ ................................ ................................ . 41 
4 STUDY PLAN  ................................ ................................ ................................ .................  43 
4.1 Study Design  ................................ ................................ ................................ .................  43 
4.1.1  Enrollment  in Study  ................................ ................................ ................................ ... 43 
4.1.2  Electrocardiogram Collection and Pharmacokinetic Sampling  ................................ . 44 
4.1.2.1  Rationale for Electrocardiogram Collection and Pharmacokinetic Sampling 
Schedule  ................................ ................................ ................................ ..................  44 
4.1.2.2  Electrocardiogram Collection and Pharmacokinetic Sampling Schedule  ..............  44 
4.1.2.3  Temporary and Permanent Changes in Pharmacokinetic Sampling, Holter Monitor 
QTc Evaluations, and Circulating Tumor DNA Sample Collection  ......................  44 
5 POPULATION  ................................ ................................ ................................ ................  46 
5.1 Recruitment  ................................ ................................ ................................ ...................  46 
5.2 Definitions ................................ ................................ ................................ .....................  46 
5.3 Inclusion Crit eria ................................ ................................ ................................ ..........  46 
5.4 Exclusion Criteria  ................................ ................................ ................................ .........  47 
6 STUDY CONDUCT  ................................ ................................ ................................ ........  50 
6.1 Study Procedures  ................................ ................................ ................................ ..........  50 
6.1.1  Study Assessments  ................................ ................................ ................................ ..... 50 
6.1.1.1  Informed Consent ................................ ................................ ................................ .... 50 
6.1.1.2  Medical History  ................................ ................................ ................................ ...... 50 
6.1.1.3  Tumor Diagnosis and Treatment History  ................................ ...............................  50 
6.1.1.4  Demographics  ................................ ................................ ................................ .........  51 
6.1.1. 5 Concomitant Medication and Procedures  ................................ ...............................  51 
6.1.1.6  Comprehensive Physical Examination  ................................ ................................ ... 51 
6.1.1.7  Limited Physical Examination  ................................ ................................ ................  51 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 10 
 CONFIDENTIAL   
 6.1.1.8  Eastern Cooperative Oncology Group (ECOG) Performance Status  .....................  51 
6.1.1.9  Vital Signs  ................................ ................................ ................................ ...............  51 
6.1.1.10  Hemat ology  ................................ ................................ ................................ .............  51 
6.1.1.11  Blood Chemistry  ................................ ................................ ................................ ..... 52 
6.1.1.12  Blood Amylase and Lipase  ................................ ................................ .....................  52 
6.1.1.13  Coagulation  ................................ ................................ ................................ .............  52 
6.1.1.14  Thyroid Function  ................................ ................................ ................................ .... 52 
6.1.1.15  Urinalysis  ................................ ................................ ................................ ................  52 
6.1.1.16  Pregn ancy Test  ................................ ................................ ................................ ........  52 
6.1.1.17  Electrocardiograms Monitoring  ................................ ................................ ..............  52 
6.1.1.18  Echocardiogram  ................................ ................................ ................................ ...... 54 
6.1.1.19  Tumor Evaluation/Imaging  ................................ ................................ .....................  54 
6.1.1.20  Tumor Markers  ................................ ................................ ................................ ....... 54 
6.1.1.21  Circulating Tumor DNA  ................................ ................................ .........................  54 
6.1.1.22  Subject Randomization  ................................ ................................ ...........................  55 
6.1.1.23  Quality of Life Assessment  ................................ ................................ .....................  55 
6.1.2  Pharmacokinetics Evaluations  ................................ ................................ ...................  55 
6.1.2.1  Sample Collection and Handling  ................................ ................................ ............  55 
6.1.2.2  Analytical Procedures  ................................ ................................ .............................  55 
6.1.3  End of Treatment Visit ................................ ................................ ...............................  55 
6.1.4  Safety Follow -Up Visit  ................................ ................................ ..............................  55 
6.1.5  Efficacy Follow -Up ................................ ................................ ................................ ... 55 
6.1.6  Survival Follow -Up ................................ ................................ ................................ ... 56 
6.1.7  Long -term Extension  ................................ ................................ ................................ . 56 
6.2 Discontinuation or Withdrawal  ................................ ................................ .....................  56 
6.2.1  Permanent Discontinuation of Treatment  ................................ ................................ .. 56 
6.2.2  Withdrawal from Study ................................ ................................ ..............................  57 
6.2.3  Replacement of Subjects  ................................ ................................ ............................  57 
6.2.4  Subjects Lost to Follow -up ................................ ................................ ........................  57 
6.3 Study Te rmination  ................................ ................................ ................................ ........  57 
6.4 End of Study  ................................ ................................ ................................ .................  57 
7 STUDY DRUGS  ................................ ................................ ................................ ..............  58 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 11 
 CONFIDENTIAL   
 7.1 Study Drug Administration  ................................ ................................ ...........................  58 
7.2 Description of Products ................................ ................................ ................................ . 58 
7.2.1  Formulation, Storage, Preparation and Handling  ................................ ......................  58 
7.2.2  Drug Accountability ................................ ................................ ................................ ... 58 
7.2.2.1  Assignment/Disposal (Study Site)  ................................ ................................ ..........  58 
7.2.2.2  Drug Return (Subject)  ................................ ................................ .............................  59 
7.3 Treatment Assignment and Bias Minimization  ................................ ............................  59 
7.3.1  Treatment Allocation  ................................ ................................ ................................ . 59 
7.3.2  Extent and Maintenance of Blinding  ................................ ................................ .........  59 
7.3.3  Unblinding Procedures ................................ ................................ ...............................  60 
7.3.3.1  Emergency Unblinding  ................................ ................................ ...........................  60 
7.4 Assessment and Verification of Compliance  ................................ ................................  60 
7.5 Prior and Concomitant Therapies  ................................ ................................ .................  60 
7.5.1  Prohibited Therapies  ................................ ................................ ................................ .. 60 
7.5.2  Permitted Therapies  ................................ ................................ ................................ ... 60 
7.5.3  Drug -Drug Interactions (Therapies to Avoid or Use with Special Caution)  .............  61 
7.5.4  Rescue Therapies  ................................ ................................ ................................ ....... 61 
7.5.5  General Dose Adjustment Note  ................................ ................................ .................  61 
7.5.6  Dose Modification Guidance  ................................ ................................ .....................  62 
7.5.6.1  Dose Modification Sequence by Starting Dose and for General Hematologic and 
Non-Hematologic Toxicity  ................................ ................................ .....................  62 
7.5.6.2  Dose Modifications for Important Identified Risks and Potential Risks  ................  63 
8 SAFETY MONITORING  ................................ ................................ ................................  68 
8.1 Definitions ................................ ................................ ................................ .....................  68 
8.1.1  Adverse Event  ................................ ................................ ................................ ............  68 
8.1.2  Serious Adverse Event  ................................ ................................ ...............................  68 
8.2 Adverse Event Reporting  ................................ ................................ ..............................  68 
8.2.1  Adverse Event Reporting Period  ................................ ................................ ...............  68 
8.2.2  Expedited Reporting  ................................ ................................ ................................ .. 68 
8.3 Eliciting Adverse Events ................................ ................................ ...............................  69 
8.4 Assessment of Severity  ................................ ................................ ................................ . 69 
8.5 Causality assessment  ................................ ................................ ................................ ..... 70 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 12 
 CONFIDENTIAL   
 8.6 Documenting Adverse Events ................................ ................................ .......................  70 
8.6.1  Diagnosis versus Symptoms and Signs ................................ ................................ ...... 71 
8.6.2  Adverse Event Occurring Secondary to Other Events  ................................ ...............  71 
8.6.3  Persistent or Recurrent Adverse Events  ................................ ................................ ..... 71 
8.6.4  Abnormal Laboratory Values or Abnormal Vital Signs  ................................ ............  71 
8.6.5  Preexisting Medical Condition  ................................ ................................ ..................  72 
8.6.6  Pregnancy  ................................ ................................ ................................ ...................  72 
8.6.7  Worsening of Solid Tumor  ................................ ................................ ........................  72 
8.6.8  Death  ................................ ................................ ................................ ..........................  73 
8.7 Duration of Follow -up for Adverse Events  ................................ ................................ .. 73 
9 STATISTICAL ANALYSIS  ................................ ................................ ...........................  74 
9.1 Statistics and Analysis Method  ................................ ................................ .....................  74 
9.1.1  Statistical Hypothesis  ................................ ................................ ................................ . 74 
9.1.2  Sample Size Rationale  ................................ ................................ ...............................  74 
9.1.3  Analysis Sets  ................................ ................................ ................................ ..............  75 
9.2 Primary and Secondary Endpoints  ................................ ................................ ................  75 
9.2.1  Primary Endpoint  ................................ ................................ ................................ ....... 75 
9.2.2  Secondary Efficacy Endpoints  ................................ ................................ ...................  75 
9.2.2.1  Key Secondary Endpoint: Progression -free Survival  ................................ .............  75 
9.2.2.2  Objective Response Rate  ................................ ................................ ........................  75 
9.2.2.3  Disease Control Rate ................................ ................................ ...............................  76 
9.2.2.4  Duration of Response  ................................ ................................ ..............................  76 
9.2.3  Secondary Safety Endpoints  ................................ ................................ ......................  76 
9.2.4  Othe r Endpoints  ................................ ................................ ................................ .........  76 
9.2.4.1  Patient Reported Outcomes ................................ ................................ .....................  76 
9.2.4.2  Assessment of Resource Utilization  ................................ ................................ ....... 76 
9.2.5  Statistical Methods  ................................ ................................ ................................ ..... 76 
9.2.5.1  Analysis of Efficacy Endpoints  ................................ ................................ ..............  76 
9.2.5.2  Analysis of Safety Endpoints  ................................ ................................ ..................  77 
9.2.5.3  Analysis of Other Endpoints  ................................ ................................ ...................  78 
9.3 Pharmacokinetic and Pharmacodynamic Analyses  ................................ ......................  78 
9.3.1  Population PK and Exposure -Response Analyses  ................................ .....................  78 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 13 
 CONFIDENTIAL   
 9.3.2  Pharmacodynamic (ECG) Analysis  ................................ ................................ ...........  78 
9.3.2.1  QTc Interv als ................................ ................................ ................................ ..........  79 
9.3.2.2  Heart Rate, QRS, and PR intervals  ................................ ................................ .........  79 
9.3.2.3  T-wave and U -wave Morphology  ................................ ................................ ...........  80 
9.3.3  QTc-PK Analysis  ................................ ................................ ................................ ....... 80 
9.4 Interim Analysis  ................................ ................................ ................................ ............  80 
10 ETHICAL CONSIDERATIO NS ................................ ................................ .....................  81 
10.1  Good Clinical Practice  ................................ ................................ ................................ .. 81 
10.2  Ethics Review  ................................ ................................ ................................ ...............  81 
10.3  Informed Consent ................................ ................................ ................................ ..........  81 
10.4  Data Privacy  ................................ ................................ ................................ ..................  82 
10.5  Disclosure  ................................ ................................ ................................ .....................  83 
10.6  Biological Specimens and Data  ................................ ................................ ....................  83 
10.7  Data Quality Assurance  ................................ ................................ ................................  83 
11 OVERSIGHT  ................................ ................................ ................................ ...................  84 
11.1  Independent Monitoring ................................ ................................ ................................  84 
11.1.1  Independent Data Monitoring Committee  ................................ ................................ . 84 
11.2  Quality Control and Assurance  ................................ ................................ .....................  84 
11.2.1  Monitoring  ................................ ................................ ................................ .................  84 
11.2.2  Audits  ................................ ................................ ................................ .........................  85 
11.2.3  Records  ................................ ................................ ................................ ......................  85 
11.2.3.1  Data Capture and Management  ................................ ................................ ...............  85 
11.2.3.2  Source Documentation  ................................ ................................ ............................  86 
11.2.3.3 Records Retention  ................................ ................................ ................................ ... 86 
11.3  Study Termination or Study Site Closure  ................................ ................................ ..... 86 
12 PUBLICATION POLICY  ................................ ................................ ...............................  88 
13 FINANCING AND INSURA NCE  ................................ ................................ ..................  89 
14 REFERENCES  ................................ ................................ ................................ ................  90 
15 APPENDICES  ................................ ................................ ................................ .................  91 
 
LIST  OF TABLES  
Table  1 Schedule of Events  ................................ ................................ ...............................  27 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 14 
 CONFIDENTIAL   
 Table  2 Schedule of Events for Dense P harmacokinetic and Electrocardiogram 
Evaluations for the Subset of Approximately 120 Patients with Evaluable ECGs 31 
Table  3 Schedule  of Events for Sparse Pharmacokinetic and Electrocardiogram 
Evaluations for Patients Not Included in the Approximately 120 Evaluable 
Patients in the Subset in Table 2  ................................ ................................ ..........  32 
Table  4 Objectives and Corresponding Endpoints  ................................ ............................  41 
Table 5  Information on Investigational Products  ................................ ..............................  58 
Table  6 Dose Modification Sequence by Starting Dose  ................................ ...................  62 
Table  7 Dose Modifications for Hematologic and Non -Hematologic T oxicity  ...............  63 
Table  8 Dose Modification for Potential Risks  ................................ ................................ . 63 
Table  9 Dose Modifications for Dermatological Toxicity  ................................ ................  64 
Table  10 Dose Modifications for Proteinuriaa ................................ ................................ .... 64 
Table  11 Dose Modifications for Hypertension  ................................ ................................ .. 65 
Table  12 Dose Modifications for Decreased Platelet Count  ................................ ...............  65 
Table  13 Dose Modifications for Hemorrhage at Any Site  ................................ ................  66 
Table  14 Dose Modifications for Abnormal Liver Fun ction  ................................ ..............  66 
Table  15 Time Point Response: Patients with Target Lesions (with or without Non -Target 
Lesions)  ................................ ................................ ................................ ..............  101 
Table  16 Time Point Response: Patients with Non -Target Lesions Only  ........................  102 
Table  17 Best Overall Response When Confirmation of Complete Response and Partial 
Response is Required  ................................ ................................ .........................  103 
Table  18 Typical Strong Inhibitors of CYP3A4  ................................ ...............................  107 
Table  19 Typical Strong Inducers of CYP3A4  ................................ ................................ . 108 
Table  20 Sensitive Substrates of P -gp or BCRP  ................................ ...............................  109 
Table  21 Summary of Clinical Trial Program of Fruquintinib in China and the US*  ...... 110 
 
LIST OF FIGURES  
Figure 1  Study Design  Schema  ................................ ................................ ..........................  26 
Figure 2  Severe or Serious Hemorrhagic Events Management Flow Chart  ....................  118 
Figure 3  Schema from American Heart Association/ American College of Cardiology for 
Controlling Hypertension in Adults  ................................ ................................ ... 120 
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 15 
 CONFIDENTIAL   
 LIST OF APPENDICES  
Appendix 1  COVID -19 Risk Assessment  ................................ ................................ ...............  92 
Appendix  2 ECOG Pe rformance Status  ................................ ................................ ..................  94 
Appendix  3 Response Evaluation Criteria in Solid Tumors (RECIST  v1.1)  ..........................  95 
Appendix  4 Prohibited Medication  ................................ ................................ ........................  106 
Appendix  5 Study Plan  ................................ ................................ ................................ ..........  110 
Appendix  6 Clinical Evaluation of Possible Drug -Induced Liver Injury (DILI)  ..................  114 
Appendix  7 Clinical Management of Severe or Serious Hemorrhagic Events  .....................  116 
Appendix  8 Management of Hypertension in Patients Receiving Fruquintinib  ....................  119 
Appendix  9 Conversion Tables for Urinalysis Results ................................ ..........................  124 
Appendix  10 Cockgroft Gault formula  ................................ ................................ ....................  125 
Appendix  11 Amendment History  ................................ ................................ ...........................  126 
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 16 
 CONFIDENTIAL   
 LIST OF ABBREVIATION S 
Abbreviation  Definition  
ADL  Activities of daily living  
AE Adverse event 
ALP  Alkaline phosphatase  
ALT  Alanine aminotransferase/glutamic -pyruvic transaminase  
ANC  Absolute neutrophil count  
aPTT Activated partial thromboplastin time 
AR Adverse reaction  
AST  Aspartate aminotransferase/glutamic -oxalacetic transaminase  
AUC 0-24 Area under the concentration -time curve from 0 to 24 hours after drug 
administration  
BCRP  Breast cancer resistance protein  
BRAF  B-Raf proto -oncogene  
BSC  Best supportive care  
CAM  Chorioallantoic membrane  
CDK  Cyclin -dependent kinase  
CEA  Carcino -embryonic antigen  
CFR  Code of Federal Regulations  
CHL  Chinese Hamster Lung  
CI Confidence interval  
Cmax Maximum plasma concentration  
c-MET  Mesenchymal epithelial cells transforming factor  
COVID -19 Coronavirus Disease 2019  
CR Complete response  
CRC  Colorectal cancer  
CrCl  Creatinine clearance  
CRO  Contract research organization  
CT Computed tomography  
ctDNA  Circulating tumor DNA  
CTCAE  Common Terminology Criteria for Adverse Event  
DCR  Disease control rate  
dMMR  Deficient mismatch repair  
DoR  Duration of response  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 17 
 CONFIDENTIAL   
 Abbreviation  Definition  
DVT  Deep vein thrombosis  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic case report form  
EDC  Electronic data capture  
EGFR  Epidermal growth factor receptor  
EORTC  European Organization for Research and Treatment of Cancer  
EOT  End of treatment  
EC Ethics Committee  
EOT  End of Treatment  
FDA  Food and Drug Administration  
FD&C  The United States  Federal Food, Drug and Cosmetic Act  
FDG -PET Fluorodeoxyglucose positron emission tomography  
fT3 Serum free triiodothyronine  
fT4 Serum free thyroxine  
GCP  Good Clinical Practice  
GI Gastrointestinal  
HA Health Authority  
HBV  Hepatitis B virus  
HCV  Hepatitis C virus  
HIV Human immunodeficiency virus  
HR Hazard ratio  
IB Investigator’s brochure  
IC50 Half maximal inhibitory concentration  
ICF Informed consent form 
ICH International Conference on Harmonization  
IDMC  Independent data monitoring committee  
IEC Independent Ethics Committee  
INR International normalized ratio  
IRB Institutional Review Board  
ITT Intent -to-treat 
IWRS  Interactive web response system  
LDH  Lactic dehydrogenase  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 18 
 CONFIDENTIAL   
 Abbreviation  Definition  
LVEF  Left ventricular ejection fraction  
mCRC  Metastatic colorectal cancer  
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram  
MID  Minimally important difference  
mL Milliliter  
MMR  Mismatch repair  
MRI  Magnetic resonance imaging  
MSI Microsatellite instability  
MSI-H High levels of microsatellite instability  
MTD  Maximum tolerated dose 
MUGA  Multigated acquisition scan  
NCCN  National Comprehensive Cancer Network  
NCI National Cancer Institute  
NCI CTCAE  The National Cancer Institute Common Terminology Criteria for Adverse 
Event  
NE Not evaluable  
NOAEL  No observed adverse effect level  
NSCLC  Non-small -cell lung cancer  
ORR  Objective response rate 
OS Overall survival  
PD  Progressive disease  
PDGFR  Platelet -derived growth factor receptor  
PFS Progression -free survival  
PK Pharmacokinetic  
PO Per os  (oral administration)  
PPE Palmar -plantar erythrodysesthesia  
PR Partial response  
PS  Performance status  
PT Preferred term  
PTT Prothrombin time  
QD Quaque die  (once daily ) 
QoL Quality of life  
RECIST  Response Evaluation Criteria In Solid Tumors  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 19 
 CONFIDENTIAL   
 Abbreviation  Definition  
RP2D  Recommended phase  2 dose  
SAE  Serious adverse event 
SAP Statistical Analysis Plan  
SD Stable disease  
SMQ  Standardized MedDRA Query  
SOC  System organ class  
TEAE  Treatment -emergent adverse event  
Tmax Time of observed maximum plasma concentration  
TQT  Thorough QT  
TSH  Thyroid stimulating hormone  
TTD  Time to deterioration  
TTP Time to progression  
ULN  Upper limit of normal  
US United States  
VEGF  Vascular endothelial growth factor  
VEGFR  Vascular endothelial growth factor receptor  
WHO  World Health Organization  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 20 
 CONFIDENTIAL   
 1 SYNOPSIS  
Title  A Global, Multicenter, Randomized, Placebo -Controlled Phase 3 Trial to 
Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to 
Placebo Plus Best Supportive Care in Patients with Refractory Metastatic 
Colo rectal  Cancer (FRESCO -2) 
Short  Title  A global,  randomized, placebo -controlled phase 3 study of fruquintinib in 
patients with refractory metastatic colorectal cancer  
Acronym  FRESCO -2 
Phase  3 
Study Design  This is a global , randomized, double -blind, placebo -controlled, multicenter 
phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus  best 
supportive care ( BSC ) versus  placebo plus BSC in subject s with refractory 
metastatic colorectal cancer  (mCRC) .  Approximately 687 subjects will be 
randomized in a 2:1 ratio to either the fruquintinib plus BSC  treatment group or 
the placebo plus BSC  treatment group . 
Randomization will be stratified by the following factors:  
• Prior therapy with trifluridine/tipiracil (TAS -102) versus  regorafenib 
versus  both trifluridine/tipiracil (TAS -102) and regorafenib  
• RAS  status (wild type versus  mutant)  
• Duration of metastatic disease (≤ 18 months versus > 18 months ) 
Subjects will receive study treatment with each 4-week cycle consisting of 
3 weeks of daily oral (PO) study medication and 1 week of study drug 
interruption (3 weeks on/1 week off ).  Tumor evaluation will be performed by 
imaging ( computed tomography [ CT] or magnetic resonance imaging [ MRI ] 
scan) every 8 weeks until there is progression of disease (PD) , death, new anti -
cancer treatment, or study completion, whichever comes first .  Safety parameters 
will include adverse events (AE), and results from laboratory tests, vital signs, 
ECG, and echocardiogram.   Post-discontinuation a nti-tumor therapy  and survival 
follow up after PD will also be recorded.  
Rationale  Colorectal cancer (CRC) is the second  most common malignancy in both men 
and women and the third most common cause of cancer -related  death in the US, 
with an estimated 145,600 new cases and 51,0 20 deaths in 2019 .  Similarly, CRC 
is a major global health issue, with an estimated 1.8 million new cases and 
880,000 deaths in 2018 worldwide (Bray 2018 ). 
There is no standard of care for patients who have progressed on approv ed 
standard -of-treatments, including chemotherapy, relevant biologics and  TAS -
102 and/or regorafenib.  Patients who are well enough to receive additional 
therapy following all standard therapies either are considered for treatment on a 
clinical trial when available or are re -challenged with agents such as 5 -FU or 
bevacizumab.   Consequently, there is an unmet medical need for new 
medications that are safe and effective in patients with refractory mCRC who 
have progressed on, or had intolerable toxicity from,  available standard systemic 
therapies, and for whom no effective therapy or standard of care exists.   
Fruquintinib is a novel, potent, and highly selective small molecule tyrosine 
kinase inhibitor of vascular endothelial growth factor receptors ( VEGFR )-1, -2, 
and -3.  In the FRESCO trial conducted in China, fruquintinib improved the 
median overall survival in patients with mCRC in a third -line or later setting 
when compared to placebo (median overall survival 9.3  months  versus  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 21 
 CONFIDENTIAL   
 6.6 months; hazard ratio f or death 0.65 (95% CI: 0.51 -0.83; p < 0.001) (Li 2018 ).  
The results from this pivotal trial  led to fruquintinib’s approval in China . 
The safety profile of fruquintinib from an ongoing phase 1 /1b study in the US is 
consistent with that of clinical studies performed in China, as well as published 
data for other small molecule VEGF  inhibitors.  The pharmacokinetic ( PK) 
profile of fruquintinib in the US phase 1 /1b study is also comparable to the PK 
profile in patients treated with fruq uintinib in China at the same dose and dosing 
regimen ( 5 mg PO, QD , 3 weeks on, 1 week off, for each 4 -week cycle).   
These data showing favorable efficacy and acceptable safety indicates 
fruquintinib is a promising candidate for development as a new treatment for 
patients with refractory mCRC and may address  an unmet medical need  globally . 
This global , multicenter,  randomized, double -blind, placebo -controlled clinical 
trial will compare the efficacy and safety of fru quintinib in combination with 
BSC , to placebo in combination with BSC , in patients with  refractory mCRC  
who have progressed on, or were intolerant to, TAS -102 and/or regorafenib.  
Patients must have also received prior standard therapies, including two lin es of 
chemotherapy (fluoropyrimidine -, oxaliplatin -, and irinotecan -based), a 
biological VEGF inhibitor, and , if RAS wild type,  an EGFR inhibitor.   Patients 
with high microsatellite instability ( MSI-H)/mismatch repair deficient   (dMMR) 
tumors must have als o received an immune checkpoint inhibitor  if approved and 
available and if deemed appropriate . 
Target Population  The study population will consist of subjects  ≥18 years of age with histologically 
and/or cytologically documented metastatic colorectal adenocarcinoma who 
progressed on , or were intolerant to , all standard chemotherapies and relevant 
biologics and TAS -102 and/or regorafenib . 
Inclusion/Exclusion Cri teria  Inclusion Criteria  
Subjects may be enrolled in this study only if they satisfy all the following 
criteria:  
1. Provide written informed consent;  
2. Age ≥18 years;   
3. Histologically and/or cytologically documented  metast atic colorectal 
adenocarcinoma .  RAS, B RAF , and microsatellite instability 
(MSI)/MMR  status must be documented , according to country  level 
guidelines ; 
4. Subjects must have progressed on or been intolerant to treatment with 
either trifluridine/tipiracil (TAS -102) or regorafenib.  Subjects are 
considered intolerant to TAS -102 or regorafenib if they have received 
at least 1 dose of either agent and were discontinued from therapy for 
reasons other than disease progression.  Subjects who have been treated 
with both TAS -102 and regorafe nib are permitted.   
Subjects must also have been previously treated with : 
• standard approved therapies: fluoropyrimidine -, oxaliplatin -, 
and irinotecan -based chemotherapy,  
• an anti-VEGF biological therapy  (eg, bevacizumab, 
aflibercept, ramucirumab)  [Please note that regorafenib is 
NOT a n anti -VEGF biologic ], and,  
• if RAS wild -type, an anti -EGFR  therapy  (eg, cetuximab, 
panitumumab) ; 
5. Subjects with microsatellite -high ( MSI-H) or mismatch repair deficient 
(dMMR) tumors must have been treated with immune checkpoi nt 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 22 
 CONFIDENTIAL   
 inhibitors if approved and available in the subject’s country unless the 
subject is ineligible for treatment with a checkpoint inhibitor ;  
6. Subjects who received oxaliplatin in the adjuvant setting and 
develop ed metastatic disease during or within 6 mont hs of completing 
adjuvant therapy  are considered eligible without receiving oxaliplatin 
in the metastatic setting . Subjects who developed metastatic disease  
more than 6 months after completion of oxaliplatin -containing 
adjuvant treatment must be treated with oxaliplatin -based therapy in 
the metastatic setting to be eligible ; 
7. Body weight ≥40kg;  
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0  
to 1;   
9. Have measurable disease according to RECIST Version 1.1 
(RECIST  v1.1) , assessed locally .  Tumors that were treated with 
radiotherapy are not measurable per RECIST  v1.1, unless there has been 
documented progression of those lesions ; 
10. Expected survival >12 weeks ; 
11. For female subjects of childbearing pot ential and male subjects with 
partners of childbearing potential, agreement to use a highly effective 
form(s) of contraception, that results in a low failure rate (<1% per year) 
when used consistently and correctly, starting during the screening 
period, co ntinuing throughout the entire study period, and for 90 days 
after taking the last dose of study drug.  Such methods include: oral 
hormonal contraception (combined estrogen/ progestogen, or 
progestogen -only) associated with inhibition of ovulation , intraut erine 
device (IUD), intrauterine hormone -releasing system (IUS), bilateral 
tubal ligation, vasectomized partner, or true sexual abstinence  in line 
with the preferred and usual lifestyle of the subject .   Highly effective 
contraception should always be comb ined with an additional barrier 
method (eg, diaphragm, with a spermi cide).  The same criteria are 
applicable to male subjects involved in this clinical trial if they have a 
partner of childbirth potential, and male subjects must always use a 
condom ; 
12. Subjec ts with BRAF -mutant tumors must have been treated with a 
BRAF inhibitor if approved and available in the subject’s country unless 
the subject is ineligible for treatment with a BRAF inhibitor . 
Exclusion Criteria:  
Subjects are not eligible for enrollment into this study if they have any of the  
following criteria:  
1. Absolute neutrophil count (ANC) <1.5×109/L, platelet count 
<100×109/L, or hemoglobin <9.0 g/dL.  Blood transfusion within 1 
week prior to enrollment for the purpose of increasing the likelihood of  
eligibility is not allowed;  
2. Serum total bilirubin >1.5 × the upper limit of normal (ULN).  Subject s 
with previously documented Gilbert syndrome  and bilirubin <2 X ULN  
are eligible;  
3. ALT or AST > 2.5 × ULN in subject s without hepatic metastases; ALT 
or AST >5 × ULN in subject s with hepatic metastases;  
4. Serum creatinine >1.5 × ULN or creatinine clearance < 60 mL/min.   
Creatinine clearance can either be measured in a 24 -hour urine 
collec tion or estimated by the Cockcroft -Gault equation ; 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 23 
 CONFIDENTIAL   
 5. Urine dipstick or urinal ysis with protein ≥2+ or 24-hour urine protein 
≥1.0 g/24-h.  Subjects with 1+ proteinuria must unde rgo a 24 -hour urine 
collection  to assess urine protein level .  For conversion s between 
qualitative and quantitative results, please see Appendix  9; 
6. Uncontrolled hypertension, defined as: systolic blood pressure 
≥140  mm Hg and/or diastolic blood pressure ≥ 90 mm Hg despite 
optimal medical m anagement .  The subject must have blood pressures 
below both limits.   Repeated  assessments are permitted ;  
7. International Normalized Ratio (INR) >1.5 x ULN or activated partial 
thromboplastin time (aPTT) >1.5 × ULN, unless the subject  is currently 
receiving or intended to receive anticoagulants for prophylactic 
purposes;   
8. History  of, or active gastric/duodenal ulcer or ulcerative colitis, active 
hemorrhage of an unresected gastrointestinal tumor, history of 
perforation or fistulas; or  any other condition that could, in the 
investigator’s judgment, result in gastrointestinal hemorrhage or 
perforation; within the 6 months prior to screening;  
9. History or presence of hemorrhage from any other site (eg, hemoptysis 
or hematemesis) within 2 months prior to screenin g; 
10. History of a thromboembolic event, including deep vein thrombosis 
(DVT), pulmonary embolism (PE), or arterial embolism within 
6 months prior to screening ;  
11. Stroke and/or transient ischemic attack within 12 months prior to 
screening ;  
12. Clinically significant cardiovascular disease, including but not limited 
to acute myocardial infarction or coronary artery bypass surgery within 
6 months prior to enrollment, severe or unstable angina pectoris, New 
York Heart Association Class III/IV co ngestive heart failure, ventricular 
arrhythmias requiring treatment, or left ventricular ejection fraction 
(LVEF) <50% by echocardiogram;  
13. Corrected QT interval using the Fridericia method (QTcF) > 480 msec 
or any factors that increase the risk of QTc prolo ngation or risk of 
arrhythmic events such as hypokalemia, congenital long QT syndrome, 
family history of long QT syndrome, or unexplained sudden death under 
40 years of age in a first -degree relative .  
14. Concomitant medications with a known risk of causing Q T prolongation 
and/or torsades de pointes  (Source  list is continuously updated online at 
www. crediblemeds .org) ; 
15. Systemic anti -neoplastic therapies (except for those described in 
Exclusion  Criterion  18) or any investigational therapy within 4 weeks 
prior to the first dose of study drug, including chemotherapy, radical 
radiotherapy, hormonotherapy, biotherapy and immunotherapy;  
16. Systemic small molecule targeted therapies (eg, tyrosine kinase 
inhibitors) within 5 half -lives or 4 weeks (whichever is shorter) prior to 
the first dose of study drug;  
17. Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior 
to the initiation of study drug;  
18. Brachytherapy (ie, implantation of radioactive seeds) within 60 days 
prior to the first dose of st udy drug ; 
19. Use of strong inducers or inhibitors of CYP3A4 within 2 weeks (or 5 
half-lives, whichever is longer) before the first dose of study drug; (see 
Appendix  4 for a list of applicable drugs);  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 24 
 CONFIDENTIAL   
 20. Surgery or invasive procedure (ie, a procedure that includes a biopsy; 
central venous catheter placement is allowed) within 60 days prior to 
the first dose of study drug or unhealed surgical incision;  
21. Any unreso lved toxicities from a previous antitumor treatment greater 
than National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Event ( CTCAE ) v5.0 grade  1 (except for alopecia or 
neurotoxicity grade ≤2); 
22. Known human immunodeficiency virus (HIV) infection;  
23. Known history of active viral hepatitis.  For subject s with evidence of 
chronic hepatitis B virus (HBV) infection, the HBV viral load must be 
undetectable on suppressive therapy, if indicated.  Subject s with HCV 
infection who are currently on treatment are eligible if they have an 
undetectable HCV viral load ; 
24. Clinically uncontrolled active infection requiring IV antibiotics;   
25. Tumor invasion of a large vascular structure (eg, pulmonary artery, 
superior or  inferior vena cava );   
26. Women who are pregnant or lactating;  
27. Brain metastases and/or spinal cord compression untreated with surgery 
and/or radiotherapy, and without clinical imaging evidence of stable 
disease for 14 days or longer; subject s requiring ster oids within 4 weeks 
prior to start of study treatment are excluded;  
28. Other malignancy, except for non -melanoma skin cancer, in situ  
cervical ca ncer or bladder ca ncer (Tis and T1) that have been adequately 
treated during the 5 years prior to screening;  
29. Inability to take medication orally, dysphagia or an active gastric ulcer 
resulting from previous surgery (eg, gastric bypass) or a severe 
gastrointestinal disease, or any other condition that investigators believe 
may affect absorption of the investigational product;  
30. Other disease, metabolic disorder, physical examination anomaly, 
abnormal laboratory result, or any other condition (eg, current alcohol 
or drug abuse) that investigators suspect may prohibit use of the 
investigational product, affect interpretat ion of study results, or put the 
subject  at undue risk of harm based on the investigator’s assessment;  
31. Known hypersensitivity to fruquintinib or any of its (or placebo) 
inactive ingredients including the azo dyes Tartrazine - FD&C Yellow 
5 and Sunset yell ow FCF - FD&C Yellow 6;  
32. Subjects who have received prior fruquintinib ; 
33. Live vaccine ≤28 days before the first dose of study drug(s) . 
Seasonal vaccines for influenza are generally inactivated vaccines and 
are allowed. Intranasal vaccines are live vaccines and are not allowed.  
Number of Subject s Approximately 687 subjects  will be randomized 2:1 (fruquintinib plus BSC: 
placebo plus BSC).  
Length of Participation  Subjects  may continue to receive treatment until they meet a criterion for 
discontinuation.   
Intervention  Investigational Drug:   Fruquintinib (HMPL -013) capsule 5 mg will be 
administered PO, QD , 3 weeks on, 1 week off (4 -week cycles).  Doses may be 
given either in the fasting state or after meals , around  the same time each day .  If 
dose adjustment  is required, 1 mg fruquintinib capsules will be used.  
Reference Drug:   Placebo capsules matching fruquintinib 5 mg will be 
administered PO, QD , 3 weeks on, 1 week off (4 -week cycles).  Doses may be 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 25 
 CONFIDENTIAL   
 given either in the fasting state or after  meals , around  the same time each day .  If 
dose adjustment is required, 1 mg matching placebo capsules will be used . 
Primary Objective  To evaluate the overall survival of fruquintinib plus BSC compared to placebo 
plus BSC in subjects  with refractory mCRC . 
Secondary Objective(s)  • To evaluate progression -free survival (PFS)  of fruquintinib plus BSC 
compared to placebo plus BSC  
• To evaluate the objective response rate (ORR),  disease control rate 
(DCR), and duration of response (DoR)  
• To assess the safety and tol erability of fruquintinib plus BSC compared 
to placebo plus BSC  
• To characterize the PK exposure of fruquintinib  and metabolite M11  in 
subjects with refractory mCRC  
• To evaluate the effect of fruquintinib on cardiac repolarization, as 
detected by changes in electrocardiogram (ECG) QT c intervals , and the  
potential relationship with fruquintinib and M11 plasma concentrations  
• To evaluate the relationship between fruquintinib exposure and 
endpoints for efficacy and safety  
• To evaluate quality of life (QoL) as asse ssed by using QLQ -C30: 
cancer -specific; and EQ -5D-5L questionnaires  
• To assess resource utilization (for example, hospitali zations and  
concomitant medications)  
Exploratory  Objective(s)  To assess potential predictive biomarkers of response to fruquintinib  
Number of Sites  This study will be conducted at approximately 160 sites globally.  
Study Duration  Recruitment period is estimated to take approximately 15 months.  Estimated 
duration for the entire study from time the study is open  to enrollment until 
completion of data analyses is approximately 22 months .   
Independent Data Safety 
Monitoring Committee  The IDMC will be comprised of at least 4 independent  oncologists from 
representative geographies and at least 1 independent statistician.  
 
1.1 Study Schematic  
The study schematic is presented in Figure 1. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4  
 
Hutchison MediPharma   Page 26 
 CONFIDENTIAL   
 Figure 1 Study Design  Schema  
 
1.2 Schedule of Events  
The schedule s of even ts (SOE s) are presented in Table  1, Table  2, and  Table  3. 
 

Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page 29 
 CONFIDENTIAL   
 2. Procedural details for medical history are available in Section  6.1.1.2 .  Tumor diagnosis, tumor treatment history, and 
evaluation of RAS , microsatellite instability ( MSI)/mismatch repair ( MMR ), and BRAF  status is described in Section  6.1.1.3 . 
3. Procedural details for patient demographics, including baseline characteristics are available in Section  6.1.1.4 . 
4. Procedural details for concomitant medications/treatments are available in Section  6.1.1.5 . 
5. Procedural details for comprehensive physical examination are available in Section  6.1.1.6. 
6. Procedural details for limited physical examination are available in Section  6.1.1.7 . 
7. Procedural details for ECOG performance status are available in  Section  6.1.1.8 . 
8. Procedural details for vital signs are available in Section  6.1.1.9 . 
9. Procedural details for h ematology are available in Section  6.1.1.10 . 
10. Procedural details for blood chemistry are available in Section  6.1.1.11 . 
11. Procedural details for amylase and lipase are available in Section  6.1.1.12 . 
12. Coagulation tests include prothrombin time (PT T), international normalized ratio (I NR), and activated partial thromboplastin 
time ( aPTT).  Additional procedural details are available in Section  6.1.1.13 . 
13. Thyroid function tests include serum free triiodothyronine (fT3), serum free thyroxine (fT4) and thyroid stimulating hormone 
(TSH) .  Additional procedural details are available in Section  6.1.1.14 . 
14. Twenty -four-hour urine for quantitative protein should be collected from all patients with 1+ proteinuria during screening .  If 
urine protein ≥2+ during the period of study treatment , a 24 -hour urine protein should be collected wit hin 1 week .  Additional 
procedural details for urinalysis are available in Section  6.1.1.15 . 
15. All female patients of childbearing potential must comple te a blood pregnancy test at screening and at the Safety Follow up 
Visit .  Serum pregnancy test should be repeated for patients with suspected pregnancy  or an equivocal urine pregnancy test .  
This is not applicable for postmenopausal female patients, but t he date of menopause should be recorded instead.  Additional 
procedural details are available in Section  6.1.1.16 . 
16. All female patients of childbearing potential must complete a urine pregnancy test at each day 1-visit starting at cycle 2. 
17. See Table  2 and Table  3 for specific ECG parameters and time points.  Electrocardiogram is to be performed before PK and 
echocardiogram assessments at each relevant visit.  Other p rocedural details for Holter Monitor and 12 -lead ECG are available 
in Section  6.1.1.17 . 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page 30 
 CONFIDENTIAL   
 18. An echocardiogram should be done at Screening, C2D1, and on the first day, every 3 cycles thereafter.  Additional procedural 
details for echocardiogram are available in Section  6.1.1.18 .  MUGA scans are acceptable if an echocardiogram cannot be 
performed.  
19. Baseline tumor assessment should be completed within 28 days prior to enrollment.  P ost-baseline tumor evaluations shall be 
performed on C3D1, C5D1, and day 1 of every other cycle thereafter until progression of disease (PD).  Each tumor 
assessment should document measurable lesions at the scheduled visit  (every 8 weeks  ± 1 week) .  Additi onal procedural 
details are available in Section  6.1.1.19 . 
20. Serum carcino -embryonic antigen ( CEA ) level is collected at screening and at day 1 of every  cycle (±1 week) starting at cycle 
2 until disease progression .  Additional procedural details are available in Section  6.1.1.20 . 
21. 6.1.1.21 See Table  2 and Table  3 for specific PK time  points.   Sampling for PK assessments is described in Section  6.1.2.1 , and 
evaluation procedures are described in Section  6.1.2.2  
22. Patient randomization occu rs on day -2 to day 1.  Additional procedural details on patient randomization are available in 
Section  6.1.1.22 .  
23. For the method of drug dispensatio n and return, see Section  7.2.2 . 
24. Study drug is taken daily on a 3 weeks on, 1 week off schedule for each 28 -day cycle.  On days with PK collection, tr eatment 
should be administered at the site by a delegated study staff member.  
25. After informed consent, but prior to initiation of study drug, all SAEs regardless of attribution will be collected.  After 
initiation of study drug, all SAEs and AEs regardless of attribution will be collected until 30 days after the last dose of study 
drug or a new treatment of anti -tumor therapy, whichever is earlier.  After this period, investigators should report only SAEs 
that are considered related to the study drug.  
26. Surviv al follow -up (by telephone) should be performed every 12 weeks (±2 weeks) after the end of treatment ( EOT ) visit.  All 
subsequent anti -tumor therapy and information about study drug -related SAEs shall be collected.  For the patients that 
discontinue the study without PD, all available tumor assessment results during survival follow up shall be recorded in the 
eCRF until confirmation of PD.  The date and cause of death should be recorded, if applicable.  Patients who w ithdraw consent 
are encouraged to be followed for survival.  If the patient has clearly expressed his/her refusal to be followed after withdrawal 
of consent, he/she will terminate the study and no follow up for survival will be performed.  
27. Events can be per formed up to and including C1D1.  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  31 
 CONFIDENTIAL   
 Table  2 Schedul e of Events for Dense Pharmacokinetic  and Electrocardiogram  
Evaluations  for the Subset of  Appro ximately 120 Patients  with Evaluable 
ECGs  
Study day  Time  Relative 
to Dosing  
(±10 minutes)  Study Drug 
Intake 1 Pharmacokinetic 
Samples  2 Triplicate ECG for 
QTc  Evaluation  
(Holter Monitor4) Safety ECG  
(Standard 
Equipment)  
C1D1  Pre-dose 3  X X - 
0 h X - - - 
1 h  X X - 
2 h  X X - 
3 h  X X - 
4 h  X X - 
C1D21  Pre-dose 3  X X - 
0 h X - - - 
1 h  X X - 
2 h  X X - 
3 h  X X - 
4 h  X X - 
C2D1  Pre-dose 3  X - - 
0 h X - - - 
C2D21  Pre-dose 3  X - - 
0 h X - - - 
2 h  X - X 
C3D1  Pre-dose 3  X - - 
0 h X - - - 
C3D21  Pre-dose 3  X - - 
0 h X - - - 
2 h  X - X 
C5D1 and every 
other cycle 
thereafter  Pre-dose 3  X - - 
0 h X - - - 
C1D1= cycle  1, day 1; C1D21 = cycle  1, day  21; C2D1 = cycle  2, day  1; C2D21 = cycle  2, day  21; C3D1 = cycle  3, day  1; C3D21 = cycle  3, 
day 21; C5D1 = cycle  1, day 1 ECG = Electrocardiogram  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  32 
 CONFIDENTIAL   
 Table  3 Schedule of Ev ents for Sparse Pharmacokinetic and Electrocardiogram 
Evaluations for Patients Not Included in  the A pproximately  120 Evaluable 
Patient s in the Subset  in Table 2  
Study day  Time  Relative to 
Dosing  
(±10 minutes)  Study Drug Intake 1 Pharmacokinetic 
Samples  2 Safety ECG 
(Standard 
Equipment)  
C1D1  Pre-dose 3  X X 
0 h X - - 
2 h  X X 
C1D21  Pre-dose 3  X - 
0 h X - - 
2 h  X X 
C2D1  Pre-dose 3  X - 
0 h X - - 
C2D21  Pre-dose 3  X - 
0 h X - - 
2 h  X X 
C3D1  Pre-dose 3  X - 
0 h X - - 
C3D21  Pre-dose 3  X - 
0 h X - - 
2 h  X X 
C5D1 and every other 
cycle thereafter  Pre-dose 3  X - 
0 h X - - 
C1D1= cycle  1, day 1; C1D21 = cycle 1, day 21; C2D1 = cycle  2, day 1; C2D21 = cycle  2, day 21; C3D1 = cycle  3, day 1; C3D21 = cycle  3, 
day 21; C5D1 = cycle  1, day 1; ECG = Electrocardiogram  
1.2.2 Footnotes for the Schedule of Events Tables 2 and 3  
1. On PK sampling day, study drug must be taken at the investigative site under the supervision 
of the investigator or designee and should not be taken at home on the morning of the visits.  
The date and time of the dose administered on the day of PK collecti on and one day before 
PK collection m ust be recorded in the electronic case report form ( eCRF ). 
2. The actual date and time of the PK samples must be recorded on the eCRF.   There is a 
window of ± 10 m inutes for the PK sampling procedure . 
3. Pre-dose PK and ECG should be performed within 30 minutes BEFORE study drug 
administration.  
4. Refer to  the Holter Monitor instruction manual for appropriate timing of the start of the ECG 
recording.   
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  33 
 CONFIDENTIAL   
 2 INTRODUCTION  
During tumorigenesis, malignancies  release growt h factors to induce angiogenesis, which provides 
nutrients and oxygen for rapid tumor growth.  The immature arrangement of endothelial cells on 
the rapidly growing blood vessels can result in exudation of tumor cells into the circulatory system, 
through wh ich the tumor cells may spread to other tissues, leading to tumor metastasis.  Vascular 
endothelial growth factor receptor  (VEGF R) is one of the key factors known to induce tumor 
angiogenesis , and agents that target  VEGF and the VEGFR are important therapi es for malignant 
solid tumor s, including colorectal cancer  (Duda 2007 , Jayson 2016 ). 
Fruquintinib (HMPL -013) is a small molecul e anti-tumor drug with a novel chemical structure that 
belongs to the quinazoline class  and is  a potent and highly selective tyrosine kinase inhibitor of 
VEGFR s.  In vitro  studies demonstrated  that fruquintinib is highly selective for  VEGFR s-1, -2, 
and -3, which are related to tumor angiogenesis, and possess weak or no measu rable activity 
against other kinases  (Sun 2014 ).  Fruquintinib was discovered  by Hutchison MediPharma Limited 
(hereafter referred to as the sponsor ) through  in vitro  and in vivo biological screening of a large 
number of synthetic  compounds.  
Results  from preclinical and clinical studies have provided evidence that fruquintinib has anti -
cancer activity in solid tumors.  The clinical development program in China has been ongoing 
since 2009.  In the phase 3 clinical trial , FRESCO , that led to the drug’s approval in China, 
fruquintinib improved median overall survival in patients with metastatic colorectal cancer 
(mCRC) in a third -line or later setting when compared to placebo  from 6.6 to 9.3 months  (hazard 
ratio for death 0.65; 95% confidence interval [CI]  0.51-0.83; P < 0.001) (Li 2018 ).  The cumulative 
safety data from the clinical trial program has shown that fruquintinib has an acceptable level of 
toxicity that is consistent with other antiangiogenic drugs , particularly small molecule VEGFR 
inhibitors .  These data provide a strong justification for the investigation of fruquintinib in patients 
with refractory mCRC  globally . 
2.1 Study Rationale  
Colorectal cancer (CRC) is a major global health issue, with an estimated 1.8 million new cases 
and 880,000 deaths in 2018 worldwide ( Bray 2018 ).  The established initial and second -line 
systemic therapy for mCRC consists of fluoropyrimidine -, oxaliplatin, and irinotecan -based 
cytotoxic chem otherapy (eg, FOLFOX: [5 -Fluorouracil, leucovorin, and oxaliplatin] and FOLFIRI 
[5-fluorouracil, leucovorin, and irinotecan]).  In addition, a biologic anti -VEGF therapy is typically 
given with chemotherapy (eg, bevacizumab), and if the tumor is RAS wild t ype, an anti -EGFR 
therapy (eg, cetuximab) is administered.  In the small proportion of patients that are deficient 
mismatch repair (dMMR)/ h igh levels of microsatellite instability  (MSI -H) in the metastatic setting 
(Koopman 2 009), immunotherapy with nivolumab or pembrolizumab may be used ( NCCN 2019 ). 
When there is disease progression after the first two lines of chemotherapy, the established options 
are either:  
• Trifluridine/tipiracil (L ONSURF®, TAS -102), an oral combination of trifluridine, a 
nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor;  
(LONSURF® USPI ) or 
• Regorafenib (S TIVARGA®), a multikinase inhibitor with numerous in vitro  targets that 
include VEGFR  (STIVARGA® USPI ). 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  34 
 CONFIDENTIAL   
 There is no standard of care for patients who have progress ed on chemotherapy, relevant biologics, 
and TAS ‑102 and/or regorafenib.  Accordingly, there  is an unm et medical need for new 
medications that are safe and effective in patients with refractory mCRC who have progressed on, 
or had intolerable toxicity from, available standard systemic therapies, and for whom no effective 
therapy or standard of care exists.  A recent estimation of the median overall survival (OS) for 
patients with mCRC, based on data from phase 3 clinical trials, observation studies, and registries, 
is 30 months ( Grothey 2013 , Mayer 2015 ).  During this time , patients may receive several lines of 
therapy, with one or more “breaks.”  Both TAS -102 and regorafenib are approved in the third -line 
or greater (3+ line) of therapy after progression on chemotherapy, and there are no approved 
treatments following progr ession on these agents.  In this setting, the current options for patients 
with good performance status are to enter a clinical trial or to be re -challenged with prior 
chemotherapy (eg, 5 -FU).  Patients with poor performance status generally enter hospice care.   
Fruquintinib is currently in clinical development for a number of different cancer indications, 
including advanced non -small -cell lung cancer (NSCLC), gastric cancer, and mCRC.  All clinical 
studies of fruquintinib that led to the first approval of  fruquintinib (Elunate ®) capsule , granted on 
04 September 2018 in China for the treatment of patients with mCRC, were conducted in China in 
primarily Asian study populations.  At the time this study was conceived, a phase  1/1b study of 
fruquintinib in the United States ( US) was being  conducted .  Preliminary data indicated that the 
safety profile of fruquintinib from this ongoing phase 1/1b study in the US was consistent with 
those from the clinical studies performed in China.   
This global phase 3 trial (FRESCO -2) is being conducted to confirm the results of the phase 3 
FRESCO trial conducted in China in patients with refractory mCRC.  This randomized, 
double -blind, placebo -controlled, clinical trial will compare the efficacy and safety of fruquintinib 
in co mbination with the best supportive care (BSC) versus placebo in combination with BSC in 
patients with refractory mCRC who have progressed on, or were intolerant to , TAS -102 and/or 
regorafenib.   
2.2 Background  
2.2.1 Justification for Dosing Strategy  
The optimal fruquintinib dose and dosing regimen were determined in two Chinese phase 1 studies , 
2009 -013-00CH1 and 2012 -013-00CH3 , as well as one US phase 1/1b study , 2015 -013-00US1 .  
During dose escalation, study 2009 -013-00CH1 investigated continuous da ily doses of 1  mg, 
2 mg, 4  mg, 5  mg, and 6 mg; in addition, 5 mg QD and 6 mg QD were studied on a regimen of 3 
weeks on , 1 week off (4-week ) cycles.  The maximum -tolerated dose ( MTD )/ recommended 
phase  2 dose ( RP2D ) was 4 mg QD (continuous) or 5  mg QD (3 weeks on , 1 week off).  
In study 2012 -013-00CH3, the safety and tolerability of these two dosing regimens ( 4 mg QD 
continuously v ersus  5 mg QD, 3 weeks on, 1 week off) were  compared in patients with mCRC.  
The safety profile was better in the 5 mg QD (3 weeks on, 1 week off) group than the 4 mg QD 
(continuous) group.  In addition, there was accumulation of drug over time in the 4 mg QD 
(continuous) group.  Thus, the 5 mg PO, QD, 3 weeks on, 1 week off , dose and regimen was 
selected as the RP2D and the dosing regimen to be used in subsequent clinical development  in 
China.  
The RP2D and dos ing regimen were tested in the phase  2 (2012 -013-00CH1 ) and phase 3 (2013 -
013-00CH1 [FRESCO])  studies, which  confirmed that the dose and dosing regimen were  safe and 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  35 
 CONFIDENTIAL   
 effect ive in patients with refractory mCRC .  The 5 mg PO , QD, 3  weeks on, 1  week off , on a 28 
day cycle,  is the standard dose and dosing regimen in all other completed, ongoing, and planned 
studies in patients with advanced cancer.  
In the US phase 1 /1b study (2015 -013-00US1 ), there were 2 dose cohorts  in the dose escalation  
phase , 3 mg PO, QD  (n=7) and 5 mg PO, QD  (n=7).  Fruquintinib was well tolerated in both dose 
cohorts .  Therefore , 5 mg PO, QD , 3 weeks on, 1 week off , on a 28 day cycle,  was confirmed  as 
the RP2D for global studies , as well.  
2.2.2 Supportive Nonclinical Data  
2.2.2.1  Pharmacology  
Fruquintinib is highly selective for  VEGFR s -1, -2, and -3, with a 50% inhibitory concentration 
(IC 50) of 33 nM, 35 nM and 0. 5 nM, respectively.  Fruquintinib was found to have low activity on  
other kinases , with IC 50 greater than 10 μM for cyclin -dependent kinases (CDK s 1, 2, and 5), 
platelet -derived growth factor receptor β (PDGFRβ), epidermal growth factor receptor (EGFR), 
and mesenchymal -epithelial transition factor (c -Met) i n a panel of 264 kinases , which  confirm s 
the selectivity of fruquintinib.  
In cellular assays, fruquintinib inhibited VEGFR family kinases and suppressed VEGFR 
phosphorylat ion with IC 50 at low (nanomolar) levels.  Consistently, in functional assays, 
fruquintinib  blocked VEGF -dependent human umbilical vein endothelial cell (HUVEC) 
proliferation  and tube formation and also exhibited this anti-angiogenic effect in the 
chorioallantoic membrane (CAM) model.  
In animal models, a pharmacokinetic (PK)/pharmaco dynamic study revealed that fruquintinib 
suppressed VEGF -induced VEGFR2 phosphorylation (p -VEGFR2) in lung tissues of nude mouse 
in a drug exposure -dependent manner.  Fruquintinib also achieved near complete target inhibition 
(>80%) , following a single ora l dose of 2.5 mg/kg , which was  maintained for >8 hours with a 
corresponding plasma drug concentration of 176 ng/mL  at the 8-hour time point.  
In multiple human tumor xenograft models in Nu/Nu mice, fruquintinib demonstrated a dose 
dependent anti -tumor activity accompanied by strong anti -angiogenesis effect in tumor tissues.  In 
all tumor models  tested , fruquintinib showed statistically significa nt tumor growth inhibition at 
doses as low as 2 mg/kg/day.  Complete target coverage for more than 8 hours , with  plasma 
concentration over 176 ng/mL maintained for 8 hours , was shown to significantly suppress tumor 
growth.  
The combination of fruquintinib w ith cytotoxic chemotherapies (oxaliplatin or docetaxel) , with 
molecular targeted therapies (EGFR or MET inhibitors) or with an immune checkpoint inhibitor 
(anti-PD-L1) demonstrated a synergistic or additive anti -tumor effect in multiple preclinical tumor 
models.  
2.2.2.2  Metabolism and Pharmacokinetic Drug Interaction  
 
   
 
   
 

Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  36 
 CONFIDENTIAL   
 In vitro , fruquintinib had no significant reversible or  on 
CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5 (IC 50 >10 µM) .  There was also no inducti on of 
CYP1A2 , and CYP3A4 by fruquintinib at concentrations up to  10 µM. 
Accord ing to the investigations on drug  transporters, fruquintinib was not a substrate of P-
glycoprotein (P -gp), breast cancer resistance protein (BCRP) ,  
 
 
 
2.2.2.3  Toxicology  
 
 
            
   
  
  
 
  
  
 
 
   
 
   
 
           
 
 
     
 
  
 
 
 
   
 
2.2.3 Supportive Clinical Data  
2.2.3.1  Clinical Pharmacokinetics  
Single -dose and multiple -dose PK of fruquintinib have been characterized in Chinese and US 
patient populations , and single -dose PK has been evaluated in healthy Chinese males.  

Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  37 
 CONFIDENTIAL   
 In Chinese patients with cancer, plasma fruquintinib exposure increased proportionally over the 
single dose range tested from 1  mg to 6 mg.  Fruquintinib was rapidly absorbed with mean T max 
ranging from 1.5 to 4. 7 hours.  Mean t 1/2 ranging from 35.2  hours  to 48. 5 hours  was observed for 
fruquintinib .  Following continuous dosing of fruquintinib 1, 2, 4, 5, or 6 mg QD, plasma 
fruquintinib concentration reache d steady state by 14  days after dosing with exposure 
accumulating 3 - to 4-fold at steady state compared to day 1.  Following dosing of fruquintinib at 
5 mg QD and 6  mg QD  at the 3 week on/ 1 week off schedule, plasma fruquintinib concentrations 
declined dur ing the off week , as expected.  Preliminary PK results from the US patient population 
(ongoing Study 2015 -013-00US1 ) that received fruquintinib at 3  mg and 5  mg QD 3 weeks 
on/1 week off suggested that there were no meaningful differences in fruquintinib exposure 
between Chinese and US patients.  Following fruquintinib 5  mg QD 3 weeks on/ 1 week off, mean 
fruquintinib  maximum plasm a concentration  (Cmax) and area under the plasma co ncentration -time 
curve over a dosing interval  (AUC tau) values on day  21 were 326  ng/mL and 5969  ng*h/mL in 
Chinese patients ( Study 2012 -013-00CH3 ), respectively , compared with 385 ng/L and 
7530  ng*h/mL in US patients, respectively.  
The effect of a high fat  high calorie meal on the PK of fruquintinib 4 mg (4 x 1 mg capsules) was 
studied in healthy Chinese males (Study 2012 -013-00CH2).  Food delayed T max of fruquintinib by 
2.6 hours.  A slight decrease in fruquintinib C max by 17% was seen , though there was  no observed 
effect on the AUC 0-∞.  These results were  sufficient to recommend dosing of fruquintinib without 
regard to food . 
The results from the mass balance study conducted in healthy Chinese subje cts (Study 2015 -013-
00CH2) indicated that 60.31% of tota l radioactivity was recovered in urine and 29.80% in feces.  
A total of 22 metabolites were identified in the plasma, urine , and feces samples.  The M11 (N -
demethylation product) and M9 (carboxylic acid product) were the main metabolites, where M11 
account ed for 17.31% and M9 accounted for 4.46% of the plasma exposure of total radioactivity.  
Only a small amount of unchanged fruquintinib was detected in urine, which accounted for 0.50% 
of the dose administered.  The amount of fruquintinib in feces accounted  for 5.34% of the dose 
administered.  
M11 is a pharmacologically active metabolite  found to inhibit  VEGFR2  kinase activity and VEGF -
induced VEGFR2 phosphorylation , with a potency  approximately 2  to 10 times lower  than that of 
fruquintinib.  After multiple  doses of fruquintinib 5 mg QD to patients for 21 days (Study 2015 -
013-00US1, preliminary data), M11 reached T max after 1 hour.  The mean ( standard deviation ) 
Cmax and area under the concentration -time curve from 0 to 24 hours after drug administration  
(AUC0-24) values were 144 (56.2 ) ng/mL and 3080 (1250 ) h*ng/mL, respectively.  M11 
accumulated by 31.5 -fold after multiple dosing.  The mean ( standard deviation ) metabolite -to-
parent ratio of M11 was 0.409 (0.135) at steady  state.  Overall, M11 is not expecte d to have 
clinically meaningful contribution to the total pharmacological activity of fruquintinib at 
therapeutic exposure.  
2.2.3.2  Clinical Safety  
As of the data cut -off date ( 03 Sep 2019 ), 7 clinical trials in patients with cancer were completed.  
In order to conduct a comprehensive and robust safety assessment across the fruquintinib clinical 
studies, a pooled dataset has been generated and analyzed, which consists of data from 739 patients 
in 4 completed double -blind studies (2012 -013-00CH1, 2013 -013-00CH1, 2014 -013-00CH1, and 
2015 -013-00CH1) (Table  21 ) who received fruquintinib  monotherapy .  In addition, the safety data 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  38 
 CONFIDENTIAL   
 from 2 completed early ph ase open -label studies ( phase 1 2009 -013-00CH1, phase 1b 2012 -013-
00CH3) and 1 completed phase 1b/2 study (2014 -013-00CH3) has also been analyzed.  
As of the data cut -off date, 5 clinical studies in patients with cancer were ongoing.  The safety 
profile of  fruquintinib from a US phase 1 /1b open -label, multi -center study (2015 -013-00US1), 
from a China p hase 2 open -label study of fruquintinib in combination with gefitinib  (2016 -013-
00CH1), and from a China  phase 1b/2 open -label study of fruquintinib in combination with 
sintilimab (2018 -013-00CH3) are also presented in this section.  No formal analysis is available 
for the safety profile of fruquintinib in the other 2 ongoing studies ; the China randomized phase 3 
study of paclitaxel with o r without fruquintinib in metastatic gastric cancer  (2017 -013-00CH1 ) 
remains blinded , and  no patients have been enrolled into the  China open label single arm study 
evaluating fruquintinib in elderly patients with NSCLC  (2017 -013-00CH2 ). 
Adverse Events  in Completed Studies : 
A total of 739 patients received at least 1  dose of fruquintinib in the 4 completed double -blind , 
placebo -controlled, monotherapy  studies, among whom 729 (98.6 %) patients reported treatment -
emergent adverse events ( TEAEs ).  The incidence of the most commonly reported TEAEs (≥10% 
of patients) are provided in the current investigator’s brochure  (IB). 
In the pooled data of all -causality TEAEs reported, the most commonly reported TEAEs of grade 
≥3 (≥5% of patients) included Hypertension (19.9% ) and Palmar -plantar erythrodysaesthesia 
syndrome ( 10.7% ). 
Serious Adverse Events  in Completed Studies : 
A total of 1 or more serious adverse events ( SAE s) have been reported by 169 (22.9%)  patients 
out of the 739 patients who received fruquintinib .  The most common SAEs (≥1.0%) by MedDRA 
preferred term ( PT) included Infectious pneumonia in 24 (3.2%) patients, intestinal obstruction in 
17 (2.3%) patients, pleural effusion in 9 (1.2%) patients, death in 10 (1.4%) patients, hepatic 
functio n abnormal in 8 (1.1%) patients, and gastrointestinal haemorrhage in 8 (1.1%) patients.  The 
SAEs in more than 1 patient in the pooled data are summarized in  the current IB. 
2.2.3.3  Clinical Efficacy  
Monotherapy Efficacy:  
As of the data cut -off date ( 03 Sep tember  2019 ), the available fruquintinib efficacy data from the 
completed open -label and double -blind studies showed strong  antitumor activity, including 
improved OS and progress ion-free survival (PFS), durable partial response (PR) and durable stable 
disease (S D), and improved overall response rate (ORR) in heavily pre -treated patients with 
advanced cancer.  
Two proof -of-concept studies have been conducted in patients with CRC who were previously 
treated with two or more lines of standard chemotherapeutic regimens (2012 -013-00CH1) and in 
patients with NSCLC who have failed 2 lines of standard chemotherapies (2014 -013-00CH1) .  The 
studies both met their primary efficacy endpoint of PFS  and demonstrated a significant 
improvement in PFS in the fruquintinib arm compared to the placebo arm.  
In addition, the phase 3 pivotal  trial (FRESCO) was completed in patients with CRC who were 
previously treated  with 2 or more lines of standard chemotherapeutic regimens (2013 -013-
00CH1) .  In this study,  fruquintinib significantly prolonged the OS compar ed to placebo with a 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  39 
 CONFIDENTIAL   
 hazard ratio (HR) of 0.65 (95% CI: 0.51 -0.83; 2 -sided p <0.001).  Statistically significant  benefits 
were also seen with fruquintinib in all secondary endpoints, including  as PFS, ORR , and disease 
control rate (DCR).  
One phase 3 study of fruquintinib was completed in patients with NSCLC who had failed second -
line standard chemotherapy (2015 -013-00CH1): there was no significant difference between the 
fruquintinib group and the placebo group in the primary efficacy endpoint (OS).  However, 
fruquintinib significantly prolonged the PFS comparing to placebo with a HR of 0.34 (95% CI: 
0.279, 0.425) wi th p < 0.001 (stratified log -rank test).  Statistically significant benefits were also 
shown  with fruquintinib in ORR and DCR.  
The efficacy data in the ongoing study  of fruquintinib in patients with advanced solid tumors 
(2015 -013-00US1) are not available as of the data cut -off date (03 Sep tember  2019).  
Combination Therapy Efficacy  
A phase 1b/2 study had been conducted to investigate the treatment of fruquintinib , in combination 
with paclitaxel , as second -line therapy in patients with gastric cancer (GC) (2014 -013-00CH3).  
The results showed that the ORR and DCR were 27.3% (9/33) and 63.6% (21/33), respectively.  
The median PFS and median OS at the RP2D (fruquintinib 4 mg + paclitaxel) were 4.0  months  
and 8. 5 months, respectively.  
The efficacy data in 1 ongoing study of fruquintinib in combination with gef itinib in patients with 
NSCLC (2016 -013-00CH1) and in 1 ongoing study of fruquintinib in combination  sintilimab  
patients with  advanced solid tumor s (2018 -013-00CH3)  are not available as of the data cut -off date 
(03 September  2019).  
2.2.4 Benefit/Risk Assessment  
There are robust cumulative efficacy and safety data for fruquintinib from the entire clinical 
program in China, as well as t he ongoing US phase 1/1b study.  As of the data cut -off date 
(03 September  2019 ) a total of 1600 patients and 87 healthy volunteers had received at least one 
dose of fruquintinib or placebo through development programs.  Among them, 955 patients and 
87 healthy volunteers had received at least one dose of fruquintinib, 284 patients had received at 
least one dose of blinded treatment (fruquintinib v ersus placebo), and 361 patients had received at 
least one dose of placebo .  
2.2.4.1  Risk Assessment  
A total of 739 patients received at least 1 dose of fruquintinib in the 4 completed double -blind 
studies, among whom 739 (98.6 %) patients reported TEAEs.  
In the pooled data of all -causality  TEAEs reported in the 3 completed double -blind, monotherapy 
studies, the most co mmonly reported TEAEs of grade  ≥3 (≥5% of patients) included hypertension 
(19.9 %) and palmar -plantar erythrodysaesthesia syndrome ( 10.7 %).  
The incidence of the most commonly reported TEAEs ( ≥10% of patients) is provided in the current 
IB.  
The safety analysis that resulted in the identified risks w as performed on the pooled data set from 
4 completed double -blind studies (N=  739 fruquintinib; N=  361 placebo), in which the incidence 
of adverse events (AEs) in fruquintinib -treated patients was compared wi th those in the placebo -
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  40 
 CONFIDENTIAL   
 treated control patients.  The identified risks presented by Standardized Medical Dictionary for 
Regulatory Activities  (MedDRA ) Query (SMQ ) are presented in Table 54 of the current IB.  
2.2.4.2  Benefit Assessment  
The efficacy data in the phase 1 study conducted in China (2009 -013-00CH1) showed encouraging 
clinical activity for fruquintinib.  A response was observed in the majority of heavily pre -treated 
patients with advanced cancers (see  the current IB).  The results of two phase 2 proof -of-concept 
(POC) studies provided evidence of clinical efficacy in patients with metastatic CRC (2012 -013-
00CH1,  third or later lines therapy ) and NSCLC (2014 -013-00CH1, third -line therapy)  as 
compared with placebo.  The PFS results establishe d POC in both studies by meeting their 
respective primary efficacy endpoints .  Clinical efficacy was also provided by the phase  3, double -
blind, placebo -controlled trial, 2013 -013-00CH1  (FRESCO) . 
2.2.4.3  Overall Benefit/Risk Conclusion  
The safety profile of fruqui ntinib  is consistent with those of other anti -angiogenic therapies, 
particularly the small molecule tyrosine kinase inhibitors (ie, sorafenib, regorafenib, axitinib, and 
sunitinib) , as demonstrated by the identified risks for fruquintinib (Section  2.2.4.1 ).  In addition, 
safety data from the completed and ongoing studies showed that  fruquintinib was well  tolerated , 
with most of the AEs reported as grade  1 to 2 (see current IB).  There have been no new or 
unexpected safety findings from the  ongoing  clinical trials to date.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  41 
 CONFIDENTIAL   
 3 OBJECTIVES AND ENDPO INTS  
3.1 Primary Objective  
To evaluate the overall survival  (OS) of fruquintin ib plus BSC compared to placebo plus BSC in 
subject s with refractory mCRC  
3.2 Secondary Objectives  
• To evaluate PFS of fruquintinib plus BSC compared to placebo plus BSC  
• To evaluate the objective response rate (ORR), disease control rate (DCR) , and duration 
of response (DoR)  
• To assess the safety and tolerability of fruquintinib plus BSC compared to placebo plus 
BSC  
• To characterize the PK exposure of fruquintinib  and metabolite M11  in subjects with 
refractory mCRC  
• To evaluate the effect of fruquintinib on cardiac  repolarization, as detected by changes in 
electrocardiogram (ECG) QT c intervals , and the  potential relationship with fruquintinib 
and M11 plasma concentrations  
• To explore the relationship between fruquintinib exposure and en dpoints for efficacy and 
safety  
• To evaluate quality of life (QoL) as assessed by using QLQ -C30: cancer -specific; and 
EQ-5D-5L questionnaires  
• To assess resource utilization (for example, hospitalizations  and concomitant 
medications)  
3.3 Exploratory Objectives  
• To assess potential predictive b iomarkers of response to fruquintinib  
The objective s and corresponding endpoints are summarized in Table  4. 
Table  4 Objectives and Corresponding Endpoints  
Tier Objectives  Endpoints  
Primary  To evaluate the overall survival (OS) of 
fruquintinib plus BSC compared to placebo 
plus BSC in subject s with refractory mCRC  OS 
Secondary  
 To evaluate progression -free survival (PFS) 
of fruquintinib plus  BSC compared to 
placebo plus BSC  PFS 
To evaluate the objective response rate 
(ORR), disease control rate (DCR) , and 
duration of response (DoR)  • ORR  
• DCR  
• DoR  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  42 
 CONFIDENTIAL   
 Table  4 Objectives and Corresponding Endpoints  
Tier Objectives  Endpoints  
To assess the safety and tolerability of 
fruquintinib plus BSC compared to placebo 
plus BSC  Safety including TEAEs, SAEs, deaths, ECG’s, 
and clinical laboratory abnormalities  
To characterize the pharmacokinetic (PK) 
profile of fruquintinib in subject s with 
refractory mCRC  Observed plasma concentrations , estimated 
population PK and e xposure parameters of 
fruquintinib  and M11  
To evaluate the effect of fruquintinib on 
cardiac repolarization, as detected by 
changes in electrocardiogram (ECG) QTc 
intervals, and the potential relationship with 
fruquintinib and M11 plasma concentrations  QTc interval and plasma concentrations of 
fruquintinib and M11  at specified time  points  
To evaluate  the relationsh ip between 
fruquintinib exposure and endpoints for 
efficacy and safety  Parameters describing exposure -response with 
efficacy (eg, OS) and safety (eg, AEs) 
endpoints  
 To evaluate quality of life (QoL) as 
assessed by using QLQ -C30: cancer -
specific; and EQ -5D-5L questionnaires  Changes in health status (QLQ -C30: cancer -
specific; and EQ -5D-5L) 
 To assess resource utilization (for example, 
hospitalizations  and concomitant  
medications)  Resource utilization including all concomitant 
medi cations, days in hospital  
Exploratory  To assess potential predictive biomarkers of 
response to fruquintinib  • Change from baseline in ctDNA  
• Change from baseline in tumor markers 
(CEA)  
• Pharmacogenomics  
 
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  43 
 CONFIDENTIAL   
 4 STUDY PLAN  
Detailed information on the fruquintinib clinical trial program in China and in the US can be 
found in Appendix  5 and in the fruquintinib IB. 
4.1 Study Desi gn 
This is a  global,  randomized, double -blind, placebo -controlled, multicenter phase 3  clinical trial 
to compare the efficacy and safety of fruquintinib in combination with BSC versus placebo in 
combination with BSC in advanced  colorectal cancer patients w ho have progressed on or were 
intolerant to chemotherapy, biologics and TAS -102 or regorafenib.  
Metastatic colorectal cancer cannot be cured by surgery .  Therefore , treatment principals are 
primarily aimed at controlling disease progression and prolonging survival.  Standard first - and 
second -line therapy includes cytotoxic drugs such as 5 -fluorouracil, oxaliplatin, and irinotecan; 
anti-VEGF therapy; and , if RAS wild type , anti-EGFR therapy.  After the first two lines of 
chemotherapy, standard third -line tr eatment is either TAS -102 or regorafenib.  There are currently 
no effective treatments for patients who have progressed  on standard, approved therapies , and 
treatment options include reuse of prior therapies, clinical trials , or BSC.  Consequently , there i s 
an unmet medical need for additional  safe and effective treatment.  
4.1.1 Enrollment in Study  
After checking the eligibility criteria, subjects  will be randomized into either  fruquintinib in 
combination with BSC group ( fruquintinib  group) or placebo in combination with BSC group 
(placebo  group) in a 2:1  ratio (Figure 1).  
• Fruquintinib  group: Fruquintinib  5 mg PO, QD, plus BSC, 3 weeks on/ 1 week off , every 
4-week cycle).  
• Control group: Matching  placebo 5  mg PO, QD plus BSC, 3  weeks on/ 1 week off , every 
4-week cycle.  
A 2:1 randomization ratio is used in this study  as it is expected that fruquintinib will produce better 
efficacy results and robust safety data compared to the placebo arm.  This is supported by  robust 
efficacy and safety data from  the fruquintinib  clinical program , including from t he pivotal phase 3 
FRESCO trial.   
A treatment cycle is 4 weeks .  Subjects’  safety assessment and drug accountability will be 
performed at each treatment cycle.  Continuous drug safety monitoring and assessmen t will be 
performed through the whole study period (including a 30 -day observation period after the end of 
treatment).  
As described in Section  2.2.3.3 , in the phase 3 FRESCO trial  that led to the drug’s approval in 
China, fruquintinib improved the median OS in patients with mCRC in a third line or later setting 
when compared to placebo ( medi an OS 9.3 v ersus 6.6 months); HR for death was 0.65 (95% CI, 
0.51-0.83; P < 0.001)  (Li 2018 ).  The results of the FRESCO study indicate that fruquintinib is a 
candidate therapy for patients with refractory mCRC globally , and provi des the strongest rationale 
for the current clinical trial.  
Since the current standard of care f or patients with mCRC in the US, EU, and Japan is different 
than it was in China during the conduct of the FRESCO trial, the curren t study  is necessary to  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  44 
 CONFIDENTIAL   
 evaluate fruquintinib in a patient populatio n that is representative of global treatment practices .  In 
FRESCO, prior therapy included the standard first two lines of cytotoxic chemotherapy 
(fluoropyrimidine -, oxaliplatin - and irinotecan -based), but only a bout 30% of patients had received 
prior therapy with a VEGF inhibitor (bevacizumab), and patients with prior exposure to VEGFR 
inhibitors such as regorafenib were excluded.  
4.1.2 Electrocardiogram Collection and Pharmacokinetic Sampling  
4.1.2.1  Rationale for Electrocar diogram Collection and Pharmacokinetic Sampling 
Schedule  
In accordance with International Conference on Harmonization ( ICH) E14 guideline, QT 
evaluation is expected to be routine in oncology drug development, and a thorough QT (TQT) 
study should be conduct ed, if possible.  In the case of fruquintinib , in view of nonclinical (hERG 
and CV safety study) and clinical data suggest ing no apparent relationship between fruquintinib  
and QT prolongation, an alternative design to the TQT study has been chosen.  
In this  study, changes in QT c interval following drug administration will be evaluated relative to 
the baseline measurement.  Electrocardiogram time points have been selected to match the 
expected PK profile of fruquintinib and metabolite M11.  The ECG time point s have also been 
selected to explore a potential relationship between exposure and effect on QTc.  
4.1.2.2  Electrocardiogram Collection and Pharmacokinetic Sampling Schedule  
In order to assess the QTc interval prior to exposure to fruquintinib, baseline triplicate ECG 
assessments will be performed prior to first study drug administration on cycle  1 day 1 (within 
30 minutes before dosing).  A baseline PK sample will also be collected at pre -dose, immediately 
after the EC Gs have been collected and prior to the first d ose of fruquintinib or placebo.  
Subsequently, the purpose of all other ECGs is to assess for potential prolongation of the QTc 
interval and other ECG changes as a result of fruquintinib administration, with ECG collection 
coinciding with PK measurements t o establish correlations between ECG changes and drug 
exposure.  Triplicate ECGs, followed by blood samples for PK assessment, will be collected at 
multiple time  points post -dose around Tmax of fruquintinib and metabolite M11  after the first dose 
and at steady -state as described in Table  2. 
4.1.2.3  Temporary  and Permanent Change s in Pharmacokinetic Sampling, Holter 
Monitor QTc Evaluations, and Circulating Tu mor DNA Sample Collection  
During the conduct of this 2019 -013-GLOB1 study, the COVID -19 pandemic caused significant 
delays in laboratory kit production and delivery from the central vendor.  In order to mitigate the 
delays and allow study sites to screen a nd treat patients , temporary and permanent measures have 
been  implemented as needed  to permit changes in the collection of PK and ctDNA sampling  and 
Holter monitor QTc evaluations  until the supply issues that affect ed the laboratory kits have been  
resolved.   These temporary measures have been  implemented in region -specific addenda  to this 
2019 -013-GLOB1  protocol .  The temporary pause s on blood sample collection and Holter 
monitoring were  terminated  once  the issues that affect ed the laboratory kits had been resolved.  
The details of the country -level changes are detailed in separate country -level addenda.  
Due to a continued shortage  of tubes for ct  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  45 
 CONFIDENTIAL   
 DNA collection , an adequate supply to ensure continued collection of all samples for all patients  
canno t be maintained  and ctDNA collections will be  permanently discontinued in Protocol 
Amendment 4.  
Subjects who do not have PK and ctDNA sampl e collection and  Holter monitor QTc evaluations  
and post -dose safety ECG evaluations performed during the time that an addendum for the region 
is effective  are to have  “Not Done” entered  in the corresponding eCRFs.  Queries are to be issued 
for these pages, and site responses are to include “COVID -19 – supply chain” as the reason for 
missed assessment.  
Pharmacokinetic and ctDNA sampl e collection and Holter monitor QTc evaluations  do not affect 
patient safety and are not required for subject -level treatment decisions on this study.  Additionally, 
with the resumption of PK and ctDNA sample collection and Holter monitor QT c evaluations, the 
integrity of trial data will be preserved and the eventual evaluation of the respective secondary 
objectives will not be compromised.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  46 
 CONFIDENTIAL   
 5 POPULATION  
5.1 Recruitment  
To randomize 687 patients,  approximately  160 sites will be opened globally  for patient 
recruitment.   
5.2 Definitions  
Subjects  officially enter the Screening Period after providing  informed consent , either directly or 
via a legally authorized representative , where permissi ble. 
Subjects  who withdraw from the study after signing the ICF and before the randomization will be 
considered screen failure s.  Subjects  who failed the original  screening may be screened again using  
their original subject number as assigned by interactive web respons e system ( IWRS ).  A subject  
may only be re -screened once .  Randomization will occur centrally using IWRS.  Subjects will be 
assigned randomly in a 2:1 ratio to receive fruquintinib + BSC or placebo + BSC using centrally 
randomized blocks stratified accordi ng to stratification factors.  
A randomized subject  is one who has been deemed eligible and has been assigned to a treatment 
group  by Interactive R esponse Technology /IWRS .  
5.3 Inclusion Criteria  
Subjects may be enrolled in this study only if they  satisfy all the following criteria:  
1. Provide written informed consent;  
2. Age ≥18 years;  
3. Histologically  and/or cytologically documented metastatic colorectal adenocarcinoma .  
RAS,  BRAF , and microsatellite instability ( MSI)/mismatch repair ( MMR ) status for each 
subject must be documented , according to country level  guidelines ; 
4. Subjects must have progressed on or been intolerant  to treatment  with either 
trifluridine/tipiracil (TAS -102) or regorafenib.  Subjects are considered intolerant to 
TAS -102 or regorafenib if they have received at least 1 dose of either agent and were 
discontinued from therapy for reasons other than disease progression.  Subjects who have 
been treated with both TAS -102 and regorafe nib are permitted.  Subjects must also have 
been previously treated with : 
• standard approved therapies: fluoropyrimidine -, oxaliplatin -, and irinotecan -based 
chemotherapy,  
• an anti -VEGF biological therapy (eg, bevacizumab, aflibercept, ramucirumab) . 
[Please  note that regorafenib is NOT an anti -VEGF biologic ], and,  
• if RAS wild -type, an anti -EGFR therapy  (eg, cetuximab, panitumumab) ; 
•  
5. Subjects with microsatellite -high ( MSI-H) or mismatch repair deficient (dMMR) tumors 
must have been treated with immune checkp oint inhibitors if approved and available in 
the subject’s country unless the subject is ineligibl e for treatment with a checkpoint 
inhibitor ; 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  47 
 CONFIDENTIAL   
 6. Subjects who received oxaliplatin in the adjuvant setting and developed metastatic 
disease during or within 6 months of completing adjuvant therapy are considered eligible 
without receiving oxaliplatin in the metastatic setting.  Subjects who developed 
metastatic disease more than 6 months after completion of oxaliplatin -containi ng 
adjuvant treatment must be treated with oxaliplatin -based therapy in the metastatic setting 
to be eligible ; 
7. Body weight ≥40kg;  
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0  to 1;   
9. Have measurable disease according to RECIST Version 1.1 (RECIST v1.1) , assessed 
locally .  Tumors that were treated with radiotherapy are not measurable per RECIST 
v1.1, unless there has been document ed progression of those le sions;  
10. Expected survival >12 weeks;  
11. For female subjects of childbearing potential and male subjects with partners of 
childbearing potential, agreement to use a highly effective form(s) of contraception, that 
results in a low failure rate (<1% per year) whe n used consistently and correctly, starting 
during the screening period, continuing throughout the entire study period, and for 
90 days after taking the last dose of study drug.  Such methods include: oral hormonal 
contraception (combined estrogen/ progest ogen, or progestogen -only) associated with 
inhibition of ovulation, intrauterine device (IUD), intrauterine hormone -releasing system 
(IUS), bilateral tubal ligation, vasectomized partner, or true sexual abstinence in line with 
the preferred and usual lifes tyle of the subject.  Highly effective contraception should 
always be combined with an additional barrier method (eg, diaphragm, with a 
spermicide).  The same criteria are applicable to male subjects involved in this clinical 
trial if they have a partner o f childbirth potential, and male subjects must always use a 
condom ; 
12. Subjects with BRAF -mutant tumors must have been treated with a BRAF inhibitor if 
approved and available in the subject’s country unless the subject is ineligible for 
treatment with a BRAF inhibitor . 
5.4 Exclusion Criteria  
Subjects are not eligible for enrollment into this study if they have any of the following criteria : 
1. Absolute neutrophil count (ANC) <1.5×109/L, platelet count <100 × 109/L, or 
hemoglobin <9.0 g/dL.  Blood transfusion within 1  week prior to enrollment for the 
purpose of increasing the likelihood of eligibility is not allowed;  
2. Serum total bilirubin >1.5 × the upper limit of normal (ULN).  Subject s with previously  
documented Gilbert syndrome  and bilirubin <2 X ULNare eligible;  
3. ALT or AST > 2.5 × ULN in subject s without hepatic metastases; ALT or AST > 5 × ULN 
in subject s with hepatic metastases;  
4. Serum creatinine >1.5 × ULN or creatinine clearance < 60 mL/min.  Creatinine clearance 
can either be measured in a 24 -hour urine collectio n or estimated by the Cock croft-Gault 
equation ; 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  48 
 CONFIDENTIAL   
 5. Urine dipstick or urinalysis with protein ≥2+ or 24-hour urine protein ≥1.0 g/24-h.  
Subjects  with 1+ proteinuria must undergo a 24 -hour urine collection  to assess urine 
protein level .  For conversions between quantitative and qualitative results, please see 
Appendix  9;  
6. Uncontrolled hypertension, defined as: systolic blood pressure ≥ 140 mmHg and/or 
diastolic blood pressure ≥ 90 mm Hg despite optimal medical management .  The subject 
must have blood pressures below both limits .  Repeated  assessments are permitted;  
7. International Normalized Ratio (INR) >1.5 x ULN or activated partial thro mboplastin 
time (aPTT) >1.5 × ULN, unless the subject  is currently receiving or intended to receive 
anticoagulants for prophylactic purposes;  
8. History  of, or active gastric/duodenal ulcer or ulcerative colitis, active hemorrhage of an 
unresected gastrointestinal tumor, history of perforation or fistulas; or any other condition 
that could, in the investigator’s judgment, result in gastrointestinal hemorr hage or 
perforation; within the 6 months prior to screening;  
9. History or presence of hemorrhage from any other site (eg, hemoptysis or hematemesis) 
within 2 months prior to screening;  
10. History of a thromboembolic event, including deep vein thrombosis (DVT),  pulmonary 
embolism (PE), or arterial embolism within 6 months prior to screening ;  
11. Stroke and/or transient ischemic attack within 12 months prior to screening;  
12. Clinically significant cardiovascular disease, including but not limited to acute 
myocardial i nfarction or coronary artery bypass surgery within 6 months prior to 
enrollment, severe or unstable angina pectoris, New York Heart Association Class III/IV 
congestive heart failure, ventricular arrhythmias requiring treatment, or left ventricular 
ejection  fraction (LVEF) <50% by echocardiogram;  
13. Corrected QT interval using the Fridericia method (QTcF) >480 msec or any factors that 
increase the risk of QTc prolongation or risk of arrhythmic events such as hypokalemia, 
congenital long QT syndrome, family his tory of long QT syndrome, or unexplained 
sudden death under 40 years of age in a first -degree relative ; 
14. Concomitant medications with a known risk of causing QT prolongation and/or torsades 
de pointes ( Source  list is continuously updated online at www. credi blemeds .org) ; 
15. Systemic anti -neoplastic therapies (except for those described in Exclusion Criterion  18) 
or any investigational therapy within 4 weeks prior to the first dose of study drug, 
including chemotherapy, radical radiotherapy, hormonotherapy, bioth erapy and 
immunotherapy;  
16. Systemic small molecule targeted therapies (eg, tyrosine kinase inhibitors) within 5 half -
lives or 4 weeks (whichever is shorter) prior to the first dose of study drug;  
17. Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior to the initiation of 
study drug;  
18. Brachytherapy ( ie, implantation of radioactive seeds) within 60 days prior to the first 
dose of study drug ; 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  49 
 CONFIDENTIAL   
 19. Use of strong inducers or inhibitors of CYP3A4 within 2 weeks (or 5 half -lives, 
whichever is longer)  before the first dose of study drug (see Appendix  4 for a list of 
applicable drugs);  
20. Surgery or invasive procedure ( ie, a procedure that includes a biopsy; central venous 
catheter placement is allowed) within 60 days prior to the first dose of study drug or 
unhealed surgical incision;  
21. Any unresolved toxicities from a previous antitumor treatment greater than National 
Cancer Institute (NCI) Common Terminology Criteria for Adverse Event ( CTCAE ) v5.0 
grade  1 (except for alopecia or neurotoxicity gr ade≤2); 
22. Known human immunodeficiency virus (HIV) infection;  
23. Known history of active viral hepatitis.  For subject s with evidence of chronic hepatitis B 
virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, 
if indicated.  Subject s with HCV infection who are currently on treatment are eligible if 
they have an undetectable HCV viral load ; 
24. Clinically uncontrolled active infection requiring IV antibiotics;   
25. Tumor invasion of a large vascular structure (eg, pulmonary artery, sup erior or inferior 
vena cava );   
26. Women who are pregnant or lactating;  
27. Brain metastases and/or spinal cord compression untreated with surgery and/or 
radiotherapy, and without clinical imaging evidence of stable disease for 14 days or 
longer; subject s requir ing steroids within 4 weeks prior to start of study treatment are 
excluded;  
28. Other  malignancy, except for non -melanoma skin cancer, in situ cervical ca or bladder ca 
(Tis and T1) that have been adequately treated during the 5 years prior to screening;  
29. Inability to take medication orally, dysphagia or an active gastric ulcer resulting from 
previous surgery (eg, gastric bypass) or a severe gastrointestinal disease, or any other 
condition that investigators believe may affect absorption of the investigational product;  
30. Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory 
result, or any other condition ( eg, current alcohol or drug abuse) that investigators suspect 
may prohibit use of the investigational product, affect interpretation of study results, or 
put the subject  at undue risk of harm based on the investigator’s assessment;  
31. Known hypersensitivity to  fruquintinib or any of its (or placebo) inactive ingredients  
including the azo dyes  Tartrazine - FD&C Yellow 5  and Sunset yellow FCF - FD&C 
Yellow 6 ; 
32. Subjects who have received prior fruquintinib ; 
33. Live vaccine ≤28 days before the first dose of study drug( s).  
Seasonal vaccines for influenza are generally inactivated vaccines and are allowed. 
Intranasal vaccines are live vaccines and are not allowed.  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  50 
 CONFIDENTIAL   
 6 STUDY CONDUCT  
6.1 Study Procedures  
6.1.1 Study Assessments  
The following procedures will be performed according to th e schedule in  Table  1.  All assessments  
must occur within ±  3 days (±1 day during cycle 1) from the scheduled date, unless otherwise 
noted.  
6.1.1.1  Informed Consent  
All subjects must sign the informed consent form ( ICF) prior to any study -related examinations or 
protocol procedures.  Tumor assessments completed as standard of care prior to signing the 
informed consent, but within 28 days of first dose of study treatment, may be used as baseline 
scans . 
All subjects who si gn ICF are to be entered into the IWRS system.  The system will generate a 
subject identification  number , which will be assigned to the subject.  
6.1.1.2  Medical History  
A complete medical history, including the subject ’s medical history, disease history and prior 
therapies for disease prior to signing of the ICF, should be recorded at screening.  Comorbidities 
that began prior to signing the ICF should be recorded and followed as medical history.  
6.1.1.3  Tumor Diagnosis and Treatment History  
Tumor diagnosis should include the date of primary diagnosis of CRC and its type , disease stage, 
the date of first metastasis , type of previous treatment, start  and end date /s, best overall response, 
date of PD , adverse reaction with severity ≥ grade 3.  Prior use (yes/no) of trifluridi ne/tipiracil 
(Lonsurf®, TAS -102), regorafenib (Stivarga®), or both of these drugs , prior use of 
fluoropyrimidine -, oxaliplatin, and irinotecan -based chemotherapy  must be documented .  Prior use 
of a biological anti -VEGF therapy  (yes versus  no), prior RAS ge ne status (mutant versus  wild 
type)  and prior use of a biologic anti -EGFR therapy (yes versus no) must also be documented . 
RAS, BRAF, and MSI)/MMR status for each subject must be documented, if available.  If the 
RAS gene test was not performed previously,  it should be performed  during screening .  Unless 
medically contraindicated or not available in the  subject’s  country of residence, the  following 
therapies  should have been r eceived based on tumor types in order to be considered eligible : 
• Subject s with a RAS wild type  tumor  must have received an anti-EGFR therapy . 
• Subjects with a BRAF -mutant tumor must have received a BRAF inhibitor . 
• Subjects with a MSI/MMR deficient  tumor must have received a n immune  checkpoint 
inhibitor . 
The subject ’s history of r adiatio n therapy , includ ing the start and end date /s and the site of radiation 
must be recorded.  Surgical history, including  operations and less -invasive diagnostic or 
therapeutic procedures (such as GI endoscopy, biopsy, etc.) , the start and end date /s, name of  each 
procedure and operation site must also be recorded at screening and in the appropriate eCRF.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  51 
 CONFIDENTIAL   
 6.1.1.4  Demographics  
Demographic characteristics, including year of birth, sex, ethnic group/race, and any relevant 
lifestyle habits should be recorded at screening and in the applicable eCRF (as permitted by local 
regulations).  
6.1.1.5  Concomitant Medication and Procedures  
Concomitant therapy includes any prescription medications or over -the-counter preparations used 
by a subject .  All concomitant medications within 28 days before randomization must be recorded 
in the eCRF, including the generic name of the drug and daily dose , the reason /s for using th e 
medication , as well as the  start and stop date /s of the medication.   Concomitant medications should 
be reviewed during the study according to the schedule in Table  1. 
6.1.1.6  Comprehensive Physical Examination  
A comprehensive physical examination includes subject  height, weight and g eneral condition, as 
well as an examination of the head, heart, chest (including the lungs), abdomen, extremities, skin, 
lymph nodes, nervous system and additional areas/systems as clinically indicated.  
6.1.1.7  Limited Physical Examination  
Limited physical examina tion includes vital signs and any change from baseline, any new 
abnormalities, examination of  the thorax, abdomen, and additional areas/systems as clinically 
indicated.  In order to assess changes from baseline and to evaluate for new abnormalities, the 
limited physical examination should assess for new or changed skin lesions, enlarged lymph nodes, 
palpable masses, and appropriate examination to address any subject -reported symptoms.  
6.1.1.8  Eastern Cooperative Oncology Group (ECOG) Performance Status  
Subject  performance status will be graded according to the ECOG PS scale at study visits as 
detailed in Table  1.  It is recommended that ECOG PS scores be evaluated by the same investigator 
throughout the study.  Details on the ECOG assessment and grading scale are available in  
Appendix  2. 
6.1.1.9  Vital  Signs  
Vital signs include blood pressure, heart rate, respiration rate , temperature , and weight .  For 
subject s with a baseline history of hypertension or hypertension that develops on study, blood 
pressure should be monitored per institutional standard pr actice.  
6.1.1.10  Hematology  
Hematology assessments include red blood cell count, hemoglobin, hematocrit, platelet count, 
white blood count with differential (absolute counts).   
Note:  If neutrophil count ≤1.0×109/L or platelet count≤  25 ×109/L, hematology assessments 
should be conducted per institutional standard practice.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  52 
 CONFIDENTIAL   
 6.1.1.11  Blood Chemistry  
The blood chemistry panel includes sodium, potassium, chloride, bicarbonate, blood urea nitrogen, 
creatinine, glucose, calcium, magnesium, phosphorus, tota l bilirubin, ALT, AST, alkaline 
phosphatase ( ALP ), lactate dehydrogenase, non-fasting total cholesterol, triglycerides, uric acid, 
total protein , and albumin.  
Blood  chemistry tests for subject s with ALT or AST increase by >3 x ULN, or increase by >2 x 
baseli ne value should performed per institutional standard practice.  
Creatinine clearance (C rCl) rate (units, mL/min) should be calculated using the baseline serum 
creatinine (Scr) value according to the Cockroft -Gault formula  (Appendix  10). 
6.1.1.12  Blood Amylase and Lipase   
Tests for blood amylase and lipase will be performed during the study according to the schedule 
of events in Table  1. 
6.1.1.13  Coagulation  
Coagulation tests include prothrombin time  (PTT) , international normalized ratio (INR), and 
activated partial thromboplastin time (APTT).  
6.1.1.14  Thyroid Function  
Thyroid functi on tests include serum free triiodothyronine (fT3), serum free thyroxine (fT4) and 
thyroid stimulating hormone (TSH).  
6.1.1.15  Urinalysis  
Urinalysis parameters include urine pH, protein, glucose, and blood; microscopic for white blood 
cell and red blood cell count.   A 24-hour urine for quantitative protein must  be collected from all 
subject s with  1+ proteinuria  during screening .  If urine protein ≥ 2+ during the period of study 
treatment , a 24 -hour urine protein should be collected within 1 week .  For conversions between 
quantitative and qualitative results, please see  Appendix  9. 
6.1.1.16  Pregnancy Test  
All female subject s of childbearing potential must complete a blood pregnancy test at screening 
and within 30 days at the Safety Follow Up Visit, and a urine pregnancy test on day 1 of every 
cycle starting at cycle 2.  Serum pregnancy test should be repeated for women  with suspected 
pregnancy  or an equivocal urine pregnanc y test .  This is not applicable for postmenopausal female 
subject s (ie, no menses for 12 months without an alternative medical cause), and the  date of 
menopause should be recorded instead .  Pregnancy testing and contraception are not required for 
women wit h documented permanent sterilization (eg , hysterectomy, bilateral salpingectomy and 
bilateral oophorectomy, or tubal ligation ). 
6.1.1.17  Electrocardiograms Monitoring  
Single 12 -lead ECG will be collected in all subject s using standardized equipment , as described in 
Table  1 and Table  3 during cycles 1 to 3.  Any ECGs from standard equipment will be evaluated 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  53 
 CONFIDENTIAL   
 for safety by the principal investigator.  All ECGs for the purposes of screening will be performed 
using standard, local equipment.  
In addition, continuous 12 -lead Holter monitor will be used for QTc evaluation during cycle 1 in 
a subset of subject s and will be sent for central reading (see below in Continuous 12 -Lead Holter 
Monitor for QTc Evaluation for details).  From cycle 4 onward , ECG will only be performed as 
clinically indicated.  Vital signs will be measured, a symptom -directed physical exam will be 
conducted, and safety related blood samples will be collected as per the time  points in Table  1.  
These assessments should be completed before  the start of any ECG recordings.  
Continuous 12 -Lead Holt er Monitor  for QTc Evaluation  
As described in Section 4.1.2.3 , continuous ECG recordings using 12 -lead Holter monitoring was 
planned to be collected from the first approximately 120 subjects  (80 fruquintinib, 40  placebo) 
enrolled in the study to evaluate the effects of fruquintinib on ventricular repolarization.  However, 
the COVID -19 pandemic caused significant delays in laboratory kit production and delivery from 
the central vendor starting  in October 2020.  In order to allow sites to screen and treat subjects 
without  delay, a US and Europe Addendum to 2019 -013-GLOB1, version 1, was issued on 13 
November 2020 to pause collection of blood for PK sampling and ctDNA and Holter  monitoring 
for QT c evaluations.  Due to continued supply chain issues in January 2021 , version 2  of the 
addendum  was issued on 22 January 2021 to extend the hold on blood sample collection and Holter 
monitoring to 01 April 2021.  Blood sample collection for PK sampling and  ctDNA and Holter 
monitor collection was resumed in 2019 -013-GLOB1 Amendment 3.   Continuous ECG recordings 
using 12 -lead Holter monitoring will be collected from approximately 120 evaluable subjects (80 
fruquintinib, 40 placebo) enrolled in the study to evaluate the effects of fruquintinib  on ventricular 
repolarization .  The assessments will be conducted at pre -dose and post -dose on cycle 1 day 1 and 
cycle 1 day 21 at specific time points summarized in Table  2.   
Any subject  with a pacemaker  will not be a candidate for Holter monitor evaluation according to 
Table 2.  If a subject has a pacemaker, please contact the Sponsor for consideration of ECG and  
PK assessments according to the schedule in Table 3.  
Subject s should reside in a quiet setting without distractions (eg, television, cell phones , and staff 
talking) at each scheduled time  point for ECG measurements.  Subject s should rest in a supine 
position for at least 10  minutes before and 5  minutes after the scheduled time  point and should 
refrain from talking or moving arms or legs.  Skin preparation should be optimal to obtain high 
quality ECGs; if deemed appropriate, the chest should be shaved and prep ared with light abrasion.  
Continuous digital 12 -lead Holter ECGs will be recorded as described in the ECG/Holter manual.  
Good quality 12 -lead ECG selection and extraction will occur during a 10 -minute timeframe 
starting 5 minutes before and ending  5 minutes after the scheduled ECG time  point.  All Holter 
recorder devices (as supplied by the central ECG laboratory) will be of the same brand and model 
with the same software, and would have been recently serviced and calibrated.  Documentation 
describ ing the brand, type, software , and service/calibration history of Holter recorders will be 
provided by the central ECG laboratory and archived at the site as well as in the sponsor’s study 
file.  Transfer of the Holter recordings and extraction of the ECG tracings will be performed as 
described in the ECG/Holter manual.  
Ten-second digital ECG tracings will be extracted from the Holter device in triplicate by the 
central ECG laboratory according to the following principles:  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  54 
 CONFIDENTIAL   
 • The actual time of dosing will be communicated to the central ECG laboratory on the 
Holter acquisition form completed by the site.  
• Using visual inspection or automated tools as appropriate, the central ECG laboratory 
will identify a period of stable heart rate  on the continuous Holter trac ing within ±5 
minutes of the nominal ECG time  point (determined relative to the actual dosing time 
for an individual subject ).  Three 10 -second ECGs will be extracted in close 
succession from this identified segment.  
• The scheduled time  points for triplicat e ECG extraction are summarized in Table  2. 
Unless warranted by a specific safety endpoint of the study, the Holter tracings will not be routinely 
analyz ed for rhythm and conduction abnormalities.  These analyses will only be performed on 
individual subject ’s Holter if warranted by TEAEs (eg, syncope).    
6.1.1.18  Echocardiogram  
An echocardiogram should be done at Screening, cycle 2 day 1, and on day 1, every 3  cycles 
thereafter.  Assessment parameters include left ventricular ejection fraction and general assessment 
of cardiac function.  MUGAs are permitted if echocardiograms cannot be performed.  
Echocardiograms completed as standard of care prior to signing the  informed consent, but within 
28 days of first dose of study treatment, may be used as baseline assessment.  
6.1.1.19  Tumor Evaluation/Imaging  
Tumor assessments (local) will be performed at study visits specified in Table  1. 
All measurable and evaluable lesions should be assessed and documented using image -based 
evaluation.  All subject s are to be evaluated utilizing contrast -enhanced computed tomography 
(CT) scan of the chest, abdomen, and pelvis , or other acceptable cross -sectional imaging per 
RECIST v1.1.  Evaluations should include other areas of the body, as clinically indicated.  Disease 
status will be assessed by the investigator or designated site staff usin g RECIST v1.1.  The same 
imaging procedure used to define measurable lesions at baseline must be used throughout the study 
for each subject , unless medically contra -indicated.  At the investigator’s discretion, other methods 
of assessment of measurable disease as per RECIST v1.1 may be used.   
Tumor assessments completed as standard of care prior to signing the informed consent, but within 
28 days of first dose of study treatment, may be used as baseline scans.  
Imaging for all subject s will also be collected for central storage.  Please refer to the study -specific 
central imaging manual for collection and shipping instructions.  
6.1.1.20  Tumor Markers  
Assessment of s erum carcino -embryonic antigen ( CEA ) level s will be performed according to the 
schedule in Table  1.  The dates of blood sampling must be re corded in the eCRF.  
6.1.1.21  Circulating Tumor DNA  
Blood samples for circulating Tumor DNA will no longer be collected as of Protocol 
Amendment 4 due to continued shortage of collection tubes.  All previously collected samples 
will be analyzed according to the stat istical analysis plan (SAP).  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  55 
 CONFIDENTIAL   
 6.1.1.22  Subject Randomization  
On day -2 to day 1, after verifying the subject’s  eligibility, the site will log into the IWRS and the 
subject will be randomized by the system .  The system will generate a serial number matching a 
bottle  of investigational product in the site’s inventory.  The s ite will take investigational product 
with the serial number assigned by IWRS from inventory and dispense it to the subject.  The first 
dose should be administered on cycle 1 day 1. 
6.1.1.23  Quality of Life  Assessment  
A quality of life assessment, using QLQ -C30: cancer -specific; and EQ -5D-5L: general, must be 
performed during the screening visit as well as day 1 of each cycle until treatment is discontinued.  
6.1.2 Pharmacokinetic s Evaluations  
6.1.2.1  Sample Collection and  Handling  
Samples for PK analysis will be collected in all subject s according to the schedule in Table  2 and 
Table  3.  The actual  dates and times of PK sampling should be recorded in appropriate eCRF .  In 
addition, the dates and times of the dose administered on the day of PK collection and one day 
before PK collection must be recorded in the eCRF.  
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory m anual that will be provided to the sites.  Collection, handling, storage, and shipment 
of samples must be under the specified, and where applicable, controlled temperature conditions 
as indicated in the laboratory manual . 
6.1.2.2  Analytical Procedures  
Plasma sampl es will be analyzed to determine concentrations of fruquintinib and its active 
metabolite M11 using a validated, specific, and sensitive Liquid Chromatography -Tandem Mass 
Spectrometry (LC MS/MS) method.  
If required, then plasma samples may be analyzed to d ocument the presence of circulating 
metabolites using a qualified research method.  
6.1.3 End of Treatment Visit  
Subject s who have completed the study or have discontinue d study treatment will be asked to 
return to the investigational site to receive safety exam inations and assessments within 7 (±3) days 
after the last dose of study drug.  
6.1.4 Safety Follow -Up Visit  
All subjects who have completed an End of Treatment Visit  will have a Safety Follow -Up Visit .  
The Safety Follow -Up Visit will be conducted at 30 (±7) day s from the EOT Visit.  
6.1.5 Efficacy Follow -Up 
Any subject who discontinues study treatment for any reason other than disease progression should 
be followed until progression is document ed or until a new anti -cancer treatment  is initiated  for 
PFS assessment and until death for OS assessment . 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  56 
 CONFIDENTIAL   
 6.1.6 Survival Follow -Up 
Every 12  weeks  (±2 weeks ) after the End of Treatment Visit  the investigator or their designee 
should call  the subject  to collect  information related  to survival status and  their use of other anti-
cancer  treatments, including drug name, dosage , treatment start and end dates, and efficacy.  
Information related to radiotherapy received after disease progression is also needed, including 
radiotherapy location, radiation dose, start date, and end d ate. 
6.1.7 Long -term Extension  
Subject s who are still on study treatment at the time of study completion may continue to receive 
study treatment if they are experiencing clinical benefit and no undue risks.  
Continued access will apply to this study only if at le ast 1subject  is still on study treatment when 
study completion occurs.  The sponsor will notify investigators when the continued access period 
begins.  
6.2 Discontinuation or Withdrawal  
6.2.1 Permanent Discontinuation of Treatment  
The investigator has the right to discontinue a subject from the study for any medical condition 
that the investigator determines is in the best interest of the subject , reasons of non -compliance 
(eg, missed doses, visits), or pregnancy.  
Any subject who d iscontinues treatment should be encouraged to return to the study site for an 
End of Treatment Visit and continue with the remaining study visits outlined in Table  1.  The 
primary reason for discontinuation must be recorded on the appropriate eCRF.  
Subjects could  be discontinued from treatment for any of the following reasons : 
1. Disease progression (according to RECIST v1.1).  If the subject is experiencing  a 
treatment benefit , in the opinion of the investigator, the subject may continue study 
treatment beyond radiographic progression until clinical progression.  Determination of 
clinical progression is at the discretion of the investigator and may include b oth objective 
and subjective data .  The continuation decision should be made by the investigator in 
consultation with the sponsor;  
2. Withdrawal  of consent;  
3. Intolerable toxicity  or AEs that warrant withdrawal of study treatment as determined by 
the principal  investigator ; 
4. Poor subject compliance;  
5. Use of other antitumor treatment during the study;  
6. Pregnancy;  
7. Subject is lost to follow -up; 
8. The investigator or sponsor determines it is in the best interest of the subject;  
9. Study is terminated by the sponsor ;  
10. Death; 
11. End of this study . 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  57 
 CONFIDENTIAL   
 6.2.2 Withdrawal from Study  
All study participants have the right to withdraw from the study at any time.  During the treatment 
period and follow -up period, a subject  who withdraws consent to continue participation in the 
study will not b e followed for any reason after consent has been withdrawn.  Every effort should 
be made to obtain information on subject s who discontinue study treatment but who do not 
withdraw consent to continue participation in the study.  If a participant withdraws consent for 
disclosure of future information, the sponsor may retain and continue to use any data collected 
before such a withdrawal of consent.  
If a participant withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records.  
6.2.3 Replacement of Subjects  
Subject s will not be replaced in this study.  
6.2.4 Subjects Lost to Follow -up  
A participant will be considered lost to follow -up if he or she repeatedly fails to return f or 
scheduled visits and is unable to be contacted by the study site.  
Before a participant is deemed lost to follow up, the investigator or designee must make every 
effort to regain contact with the participant (where possible, 3 telephone calls and, if nec essary, a 
certified letter to the participant’s last known mailing address or local equivalent methods) .  These 
contact attempts should be documented in the participant’s medical record.  
Should the participant continue to be unreachable, he/she will be con sidered to be withdrawn from 
the study.  
6.3 Study Termination  
The sponsor has the right to terminate the study prematurely.  Reasons may include efficacy, 
safety, or futility, among others.  Should the sponsor decide to terminate the study, the 
investigator(s ) will be notified in writing.  
6.4 End of Study  
The end of the study defined as the last visit of the last subject in the study .  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  58 
 CONFIDENTIAL   
 7 STUDY DRUGS  
7.1 Study Drug Administration  
Fruquintinib (at a dose of 5 mg) or matching placebo will be administered PO, QD, on a 3 weeks 
on, 1 week off schedule .  One treatment cycle is 4 weeks .  The administration time should be 
recorded accurately.   Study drug  may be given either in the fasting state or after meals , around the 
same time each day .  If dose adjustment is required, 1  mg fruquintinib or matching placebo 
capsules will be used.  
On days  with PK collection , treatment should be administered at the site by a delegated study staff 
member.  
If vomiting occurs after dosing, study drug  doses should not be replaced.   If a dose is mi ssed, the 
missed dose can be taken within a 12 -hour window of time the subject typically takes the dose.  A 
double dose should not be administered to make up for missed individual doses.   
7.2 Description of Products  
Fruquintinib will be provided as 1 mg or 5 mg capsules for oral administration .  Matching placebo 
capsules for each strength will also be provided .   
7.2.1 Formulation, Storage, Preparation and Handling  
The investigational drug s are formulated  as capsules , which are packaged  in labeled bottles .  The 
drug information is provided in Table 5.  Additional information is available in the pharmacy 
manual.  
Table 5 Information on Investigational Products  
Name  Dosage  
Form  Specification  Administration Method  
Fruquintinib  Capsule  5 mg Oral 
Fruquintinib  Capsule  1 mg Oral 
Matching  placebo*  Capsule  5 mg Oral 
Matching  placebo *  Capsule  1 mg Oral 
* The appearance of the matching placebo is identical to that of the study drug.  
All the investigational  drugs  should  be sealed and stored in a secure , limited access area  under 
appropriate conditions.  The storage temperature should be between 10 ℃ to 30℃ .  Investigational 
drugs  should not be used beyond expiration date provided by the manufacturer.  
The temperature -monitoring  log should be recorded and filed in the study binder.  
7.2.2 Drug Accountability  
7.2.2.1  Assignment/Disposal (Study Site)  
All study drug required for this study will be provided by Hutchison MediPharma  Limited .  The 
recipient will  acknowledge receipt of the drug by returning the appropriate documentation form 
indicating shipment content and condition.  Damaged supplies will be replaced.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  59 
 CONFIDENTIAL   
 Accurate records of all study drug received at, dispensed from, returned to and disposed of by the 
study site should be recorded by using the Drug Inventory Log . 
Study drug will be disposed of at the study site according to the study site’s institutional standard 
operating procedure or ret urned to H utchison MediPharma Limited  or a Hutchison identified entity 
with appropriate documentation, as determined by the study site.  If the study site chooses to 
destroy study drug, the method of destruction must be documented . 
7.2.2.2  Drug Return (Subject)  
On day -2 to day 1, only subject  randomization and drug assignment will be performed.   Subjects 
will be provided with a pill diary at randomization and be instructed on how to account for each 
day’s dose  appropriately .  Subjects  should return all unused study dr ug and containers from the 
previous cycle on day 1 (date of scheduled visits) of each subsequent cycle, and new study drug 
will be dispensed on the same day.  Site study staff should review  subjects pill diary and provide 
a new diary if necessary at the day 1 visit of each cycle.  
If a dose adjustment is required (eg, decrease  from 5  mg QD to 4 mg QD), the subject  must return 
to the investigational site and return all unused study drug.  The s ite must  log into the IWRS, adjust 
the dose, reassign the drug ser ial number, and dispense new study drug  dose (in 1 mg capsules) to 
the subject .  If the dose is adjusted a second time, ie, from 4  mg QD to 3 mg QD, the site must  log 
into the IWRS and record the second dose adjustment.  On this occasion, it is not necessary to 
reassign a new drug serial number.  If tumor evaluation shows PD during the previous cycle and 
new drug has been dispensed, the subject  must return all unuse d study drug on the 30 -day safety 
visit after EOT.  
7.3 Treatment Assignment and Bias Minimization  
7.3.1 Treatment Allocation  
Treatment will be allocated using IWRS randomization strategy and procedure (refer to the IWRS 
manual ).  After screening, subjects who meet t he eligibility criteria will be randomized into the 
fruquintinib  or pla cebo group in a 2:1  ratio.  Randomization will be stratified by :  
• Prior therapy with trifluridine/tipiracil (TAS -102) v ersus  regorafenib v ersus  both 
trifluridine/tipiracil (TAS -102) and regorafenib ;  
• RAS status (wild type versus  mutant) ; and  
• Duration of metastatic disease ( ≤ 18 months versus  > 18 months) .  
7.3.2 Extent and Maintenance of Blinding  
The s tudy subject , investigators, and study site personnel will remain blinded to all randomization 
assignments throughout the study except for the specific circumstances described in Section  7.3.3 .  
The sponsor’s study director, study monitor, and any other sponsor and contract research 
organization (CRO) personnel who are in regular contact with the study site will remain blinded 
to all subject randomization assignments , except sponsor pharmacovigilance personnel  for the 
purpose of IND safety reports . 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  60 
 CONFIDENTIAL   
 7.3.3 Unblinding Procedures  
7.3.3.1  Emergency Unblinding  
Unblinding of the study treatment can occur in emergency cases  and should not occur unless it is 
needed to manage a su bject’s medical condition.  
• In an e mergency, when specific knowledge of the subject’s treatment assignment is 
needed to manage a subject’s medical condition, the Investigator can unblind the subject 
using the IWRS  to obtain the subject ’s treatment assignment. It is recommended that the 
Investigator then inform the Sponsor’s Medical Monitor of the case.  
• In a non -emergent situation, the Investigator is encouraged to contact the Sponsor’s 
Medical Monitor to discuss the case prior to unblinding.  
Once un blinded, the subject should discontinue the treatment but will continue to be followed for 
safety and efficacy.  The investigator should record the event in the source document . 
7.4 Assessment and Verification of Compliance  
The investigator is responsible for ensuring the subject ’s treatment compliance.  The sponsor will 
provide supervision through on -site monitoring visits made by its representatives.  The 
investigators should maintain complete and accurate records of drug  use.  The dosing regimen and 
subject ’s actual dosing should be recorded in the original treatment records as well as the eCRF.  
At each treatment visit, the investigators or study staff should comprehensively assess the subject 's 
treatment compliance accord ing to the drug dispensing and return status at each visit and the actual 
dosing conditions, such as missed doses and overdosing reported by the subject .  The subject s must 
return all drug bottles and remaining capsules at the end of the study.  The invest igational sites 
must return all remaining supplies and drugs to the sponsor or provide evidence of destruction at 
the conclusion of the study.  
7.5 Prior and Concomitant Therapies  
7.5.1 Prohibited Therapies  
Any therapy intended for the treatment of cancer (with the exceptions as noted in Section  7.5.2 ), 
whether currently marketed or experimental, is prohibited.  This includes, but is not limited to, the 
followin g: chemotherapy, hormonal therapy, biologic therapy, radiotherapy, or herbal therapy.  
Concomitant use of medications that have a known risk of causing QT prolongation and/or 
torsades de pointes (see “combined” list at http://www. crediblemeds .org, with attention to those 
drugs listed as KR (“known risk”)  are prohibited .  
Live vaccines are prohibited during the study and for 3 months after the last dose of study drug(s). 
Seasonal vaccines for influenza are generally inactivated vaccines and are allowed.  Intranasal 
vaccines are live vaccines and are not allowed.  
7.5.2 Permitted Therapies  
Concomitant therapy includes any prescription medications or over -the-counter preparations used 
by a subject .  All concomitant therapy  within  28 days prior to randomization  and to the Safety 
Follow Up visit should be reported to the investigator and recorded on the appropriate eCRF.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  61 
 CONFIDENTIAL   
 Subject s who use oral contraceptives, hormone -replacement therapy, or othe r allowed 
maintenance therapy may continue their use if indicated.  
Prophylactic use of anticoagulation for the maintenance of patency of permanent indwelling 
central venous access devices or for subject s at high risk of venous thromboembolism is permitted 
during study treatment.  If subject s are receiving anti -coagulation, they should be very closely 
monitored for potential hemorrhage . 
Please see  Appendix  7 for additional information on the clinical management of severe or serious 
hemorrhagic AEs.  
Subject s that develop arterial thromboembolic events should discontinue the study drug.  If a 
subjec t suffers a venous thromboembolic event while still receiving study drug, it may still be 
possible for him or her to remain on study treatment under close monitoring and dose modification 
of study drug.  
Prophylactic antiemetic, granulocyte colony stimulati ng factors, granulocyte macrophage colony -
stimulating factors, platelet simulating factors or erythropoietin are permitted as clinically 
indicated.  
Palliative radiation for symptom control is allowed provided it does not compromise tumor 
assessments of tar get lesions.  However, study  treatment should be suspended during the radiation 
period and not resumed until at least 7 days after radiation only after meeting the following criteria:  
• Radiation related toxicities resolves to grade  ≤2; 
• No disease progression observed.  
All supportive measures consistent with optimal subject  care will be given throughout the study.  
7.5.3 Drug -Drug Interactions  (Therapies to Avoid or Use with Special Caution)  
In vitro  metabolism data  indicate that CYP3A plays an important role in the metabolism of 
fruquintinib.  The potential effects of medications that can affect the PK of fruquintinib via the 
CYP3A pathway have not been tested in the clinic.  Therefore, medications that are strong inhibitor 
or strong inducer  of CYP3A should not be administered concomitantly with fruquintinib .  
Examples of the se medications  to avoid are listed in Appendix  4.  
In vitro , fruqui ntinib is shown to have the potential to inhibit P -gp and BCRP (see Section  2.2.2.2 ).  
Avoid concomitant use with medications that are sensitive substrates of P -gp or BCRP where 
possible.  If used together, monitor subject s more frequently for adverse reactions, and consider 
dose reduction of the P -gp or BCRP substrate medication.  Examp les of the medications that are 
sensitive substrates of P -gp and BCRP are listed in Appendix  4. 
7.5.4 Rescue Therapies  
Not applicable.  
7.5.5 General Dose Adjustment Note  
The severity of AEs will be graded according to the NCI CTCAE v 5.0.  Reasons for dose 
modifications or delays, the supportive measures taken, and the outcome should be documented 
in the subject ’s chart and recorded in the eCRF.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  62 
 CONFIDENTIAL   
 • For any concomitant conditions already apparent at baseline, the dose modifications 
will apply according to the corresponding shift in toxicity grade, if the investigator feels 
it is appropriate.  For example, if a subject  has grade 1 asthenia at baseline that increases 
to grade  2 during treatment, this will be considered a shift of one grade and treated as 
grade 1 toxicity for dose -modification purposes.  
• For toxicities that are considered by the investigator to be unlikely to develop into 
serious or life -threatening events, treatment can be continued at the same dose.  
• To recover from acute toxicity, unless otherwise indicated, the treatment can be  delayed  
for up to 14 days.  If a treatment delay longer than 14 days is required, treatment  should 
be disconti nued.  Continuation/resumption of fruquintinib treatment after an 
interruption of more than 14 days must be discussed with the medical monitor or his or 
her designee.  
• Where several toxicities with different grades or severity occur at the same time, the 
dose modifications should be according to the highest grade observed.  
7.5.6 Dose Modification Guidance  
7.5.6.1  Dose Modification Sequence by Starting Dose and for General Hematologic and 
Non-Hematologic Toxicity  
The d ose reduction sequence  by starting dose is shown in Table  6.  Subjects  are allowed to have  
no more than  2 dose reductions: one reduction from 5 mg QD to 4 mg QD, and if not tolerated, 
then a second reduction  from 4 mg QD to 3  mg QD (see Table  6).  Once a dose has been 
reduced, it cannot be re -escalated.  
Table  6 Dose Modification Sequence  by Starting Dos e  
Dose Level 0 * 
(Original dose)  5 mg QD 3 weeks on, 1 week off  Fruquintinib of 5  mg, 1 capsule, or 
1 capsule of the matching  placebo  
Dose Level -1* 
(the 1st dose reduction)  4 mg QD 3 weeks on, 1 week off  Fruquintinib of 1  mg, 4 capsules, or 
4 capsules of the  matching  placebo  
Dose Level -2* 
(the 2nd dose reduction)  3 mg QD 3 weeks on, 1 week off  Fruquintinib of 1  mg, 3 capsules, or 
3 capsules of the matching  placebo  
* Doses are daily, on days 1-21 each 28 -day cycle  (3 weeks on, 1 week off)  
QD = once daily  
 
Dose reduction guidelines for hematologic and non -hematologic toxicities, other than Palmar -
plantar erythrodysesthesia (PPE), Proteinuria , Hypertension , Decreased platelet count, 
Hemorrhage , and liver function impairment, are shown in are shown in Table  7.  Treatment should 
be held until AE/toxicity resolves or improves to ≤ grade 1.  If a subject has a grade  3 toxicity that 
is expected to be manageable and reversible with a dose reduction, treatment should be held until 
toxicity resolves to ≤grade 1.  Subjects with grade  3 non -hematologic toxicity not described below 
that does not resolve to ≤grade 1 within 14 days should permanently discontinue the study drug  
unless approval to continue is obtained in writing from the sponsor . 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  63 
 CONFIDENTIAL   
 Table  7 Dose Modification s for Hematologic and Non -Hematologic Toxicit y 
NCI CTCAE v 5.0 Toxicity Grading  Action  
Grade 1 or 2a None  
Grade 3b Interrupt the dose until the toxicity resolved to ≤ grade  1 or baseline 
level within 14 days, then reduce the dose to a lower dose level  
Grade 4  Discontinue treatment permanently  
a. If amylase and/or lipase are elevated, and if clinically indicated, further evaluation for pancreatitis should be 
performed.  
b. Including grade 3 diarrhea and stomatitis, etc. that are ineffectively treated by drug therapies, but excluding 
grade 3 menstrual cycl e extension.     
 
7.5.6.2  Dose Modification s for Important Identified Risks  and Potential Risks  
This section provides details  of the recommended dose modifications  for the currently identified 
and potential risks that have been determined in both clinical and nonc linical studies.   The dose 
modification and treatment suggestions for both potential  risks  and specific  important  identified 
risks are provided in  Table  8 (potential risks) Table  9(dermatological toxicity ), Table  10 
(proteinuria), Table  11 (hypertension), Table  12 (decreased platelet count), Table  13 (hemorrhage 
at any site), and Table  14 (abnormal liver function).  
Table  8 Dose Modification for Potential Risks  
AE Dose Adjustment  
Gastrointestinal perforation  Study drug should be discontinued.  
Arterial Thrombosisa Study drug should be discontinued.  
 
Reversible Posterior Leukoencephalopathy Syndrome 
(RPLS)b If suspected as RPLS, the study drug should be 
discontinued . 
Delayed Wound Healing  The general guidance for dose 
interruptions/reductions/discontinu ations in response to 
AEs should be followed.  
RPLS = Reversible Posterior Leukoencephalopathy Syndrome.  
a. The event term of arterial thrombosis encompasses the preferred terms ( PT) of Aortic thrombosis, 
Cerebrovascular insufficiency, Embolism arterial, Peripheral embolism, Retinal artery occlusion, 
Subclavian artery thrombosis, and Transient ischemic attack.  
b. The signs and symptoms of RPLS include seizure, headache, altered mental st atus, visual impairment or 
cortical blindness with or without hypertension.  The diagnosis of RPLS must be verified using brain 
magnetic resonance imaging (MRI).  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  64 
 CONFIDENTIAL   
 Table  9 Dose Modification s for Dermatological Toxicity  
AE Grading Standard  Dose Adjustment  Treatment Suggestions  
Grade 1  None.  Active supportive treatment can be adopted 
to relieve the symptoms; for example, 
moisturizing skin cream, lotion, or 
hydrophilic urea ointment can be used.  
Grade 2  • Hold treatment . 
• If the AE recovers to 
grade 1 or baseline 
level within 14 days , 
resume treatment at the 
same dose level . Active supportive treatment can be adopted 
to relieve the symptoms; for example, 
moisturizing skin cream, lotion, or 
hydrophilic urea ointment can be used.  
Grade 3  • Hold treatment .  
• If the AE recovers to 
grade 1 or baseline 
level within 14 days , 
resume treatment with 
a dose reduction to the 
next lower dose level . Active supportive treatment can be adopted 
to relieve the symptoms; Should the same AE 
occu r for 3 times or still occurs after 2 times 
of dose reduction, the drug should be 
terminated.  
Grade 4  • Permanently 
discontinue study 
treatment.  Emergent medical treatment.  
AE = adverse event  
 
Table  10 Dose Modification s for Proteinuriaa 
AE Grading Standard  Dose Adjustment  Treatment Suggestions  
Grade 1 : Proteinuria 1+ by 
urinalysis;  
24-hour urine  protein  
quantitation  <1.0 g  None  Follow up at scheduled study visits.  
Grade 2 : Proteinuria 2+ by  
urinalysis;  
24-hour urine  protein  
quantitation  is between 1.0 to 
<2.0 g  None  Provide s upportive treatment and increase 
the frequency of urine monitor to once a 
week; consult nephrologist if necessary.  
Grade 2 : Proteinuria 2+ or 
above by urinalysis;  
24-hour urine  protein  
quantitation  is between 2.0 to 
<3.5 g (excluding 3.5 g)  • Hold treatment.   
• If the AE recovers to 
grade 1 or baseline level 
within 14 days , resume 
treatment with a dose 
reduction to the next 
lower dose level . Provide supportive treatment and increase 
the frequency of urine monitor to once a 
week; consult nephrologist if necessary.  
Grade 3 : 24-hour urine  protein  
quantitation  ≥3.5 g  • Hold treatment.   
• If the AE recovers to 
grade 1 or baseline level 
within 14 days , resume 
treatment with a dose Provide supportive treatment and increase 
the frequency of urine monitor to once or 
twice a week; consult nephrologist if 
necessary.  Should the same AE occur for 
3 times or still occurs after 2 times of dose 
reduction, the drug should be terminated.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  65 
 CONFIDENTIAL   
 Table  10 Dose Modification s for Proteinuriaa 
AE Grading Standard  Dose Adjustment  Treatment Suggestions  
reduction to the next 
lower dose level . 
AE =  adverse event.  
a: If protein ≥ 2+ on urinalysis  during  the study, a 24 -hour urine test should be conducted within 1 week , and dose 
modification will be done by the result of 24 -hour urine protein quantitation.  
 
Table  11 Dose Modification s for Hypertension  
AE Gradi ng Dose adjustment  Treatment Suggestions  
Grade 1  None.  Follow up as planned schedule  
Grade 2 :  None.  Treatment objective: lower the 
blood pressure to <140/90  mm Hg 
(or <130/80  mm Hg in subject s 
with chronic renal disease and/or 
diabetes).  
 
Refer to Appendix  8.   
Grade 3 :  • If BP >160/100mmHg lasts for > 7 
days after initiation of anti -
hypertensive treatment or 
modification of current anti -
hypertensive treatment, treatment 
should be held .   
• If hypertension resolves to grade 1 
or baseline level within 14 days, 
resume treatment with a dose 
reduction to the next lower  dose 
level . Treatment objective: lower the 
blood pressure to <140/90  mmHg 
(or <130/ 80 mm Hg in subject 
with chronic renal disease and/or 
diabetes).  
 
Refer to Appendix  8. 
Grade 4 :  Permanently d iscontinue study 
treatment . Emergent medical treatment.  
BP = Blood pressure  
 
Table  12 Dose Modification s for Decreased Platelet Count  
AE Grading  Dose Adjustment  Treatment Suggestions  
Grade 1 :  
 None.  Perform follow up visit as scheduled.  
Grade 2 :  
 • Hold treatment .   
• If the AE recovers to grade  1 or 
baseline level within 7 days , 
resume treatment at the same 
dose level . Hematology test should be monitored every 
2-3 days; active treatment for platelet 
elevation  is recommended.  
• Hold treatment .   
• If the AE recovers to grade 1 or 
baseline level within 14 days , 
resume treatment with a dose Hematology test should be monitored every 
2-3 days; active treatment for platelet 
elevation  is recommended.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  66 
 CONFIDENTIAL   
 Table  12 Dose Modification s for Decreased Platelet Count  
AE Grading  Dose Adjustment  Treatment Suggestions  
reduction to the next lower 
dose level . 
Grade 3:  
 • Hold treatment .   
• If the AE recovers to grade 1 or 
baseline level within 14 days , 
resume treatment with a dose 
reduction to the next lower 
dose level . Hematology test should be monitored every 
2-3 days; active treatment (platelet 
transfusion) to elevate the platelet count is 
recommended.  
Hematology examination should be 
performed once every week in the follow up 
visit.  
Grade 4:  
 Permanently discontinue study 
treatment . Hematology test should be performed once 
daily until the AE recovers to grade  2 or a 
lower grade; platelet transfusion or other 
active treatment should be provided  
AE = Adverse event  
 
Table  13 Dose Modification s for Hemorrhage at Any Site  
AE Grading  Dose Adjustment  Treatment Suggestions  
Grade 1  None  Perform follow up visit as 
scheduled.  
Grade 2  • Hold treatment.  
• If the AE recovers  to grade 1 or baseline level within 14 
days, resume treatment with a dose reduction to the next 
lower dose level . Provide active treatment  
Grade 3 or 
above  a Permanently discontinue study treatment . Emergent medical 
interven tion 
AE = Adverse event  
a Refer to  Appendix  7 for clinical management of severe or serious hemorrhage.  
 
 
Table  14 Dose Modification s for Abnormal Liver Function  
AE Gradinga Dose Adjustment  Treatment Suggestions  
Grade 1  None . Follow up per planned 
schedule.  
Grade 2  or 3 (Liver 
function is abnormal but 
the biochemical criteria for 
Hy’s Lawb are not met)  • Hold treatment.  
• If the AE recovers to grade 1 or baseline 
level within 14  days, resume treatment 
with a dose reduction to the next lower 
dose level.  
 Provide supportive care and 
increase the frequency of liver 
function monitoring to 1 -2 
times a week.  
Grade 2 or 3 (Liver 
function is abnormal and 
the biochemical criteria for 
Hy’s Lawb are met)  The study drug should be terminated  
immediately.  Provide supportive care and 
increase the frequency of liver 
function monitoring to 2 -3 
times a week.  Urgent medical 
intervention indicated.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  67 
 CONFIDENTIAL   
 Table  14 Dose Modification s for Abnormal Liver Function  
AE Gradinga Dose Adjustment  Treatment Suggestions  
Grade 4  The study drug should be terminated.  Urgent medical intervention 
indicat ed. 
AE = adverse event . 
a Including increasing of ALT, AST, and total bilirubin, whether or not the biochemical criteria for Hy’s Law 
have been met.  
b Hy’s Law is an increase in serum AST or ALT ≥3 × ULN together with total bilirubin ≥2 × ULN, and no other 
reaso n can be found to explain the biochemical changes, for example, new or worsening hepatobiliary 
metastases, elevated serum alkaline phosphatase indicating  cholestasis, viral hepatitis, another suspect drug, or 
any other specific cause of severe hepatocellular injury.  The elevation in transaminases must precede or be 
coincident with (ie, on the same day as) the elevation in total bilirubin, but there is no specified timeframe 
within which the elevations in transaminases and total bilirubin must occur.  See Section  8.2.2  for special 
reporting requirements  and Appendix  6 for additional information regarding Hy’s Law.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  68 
 CONFIDENTIAL   
 8 SAFETY MONITORING  
8.1 Definitions  
8.1.1 Adverse Event  
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with 
the use of an investigational medicinal product or other protocol -imposed intervention, whether 
or not  considered  related to the medicinal product .  Adverse events will be assessed according to 
the NCI C TCAE v 5.0. 
8.1.2 Serious Adverse Event  
An AE is considered “serious” if, in the view of either the investigator or sponsor , it results in 
any of the following outcomes:  
• Death  
• A life-threatening AE .  An event is considered “life-threatening ” if, in the view of the 
investigator , its occurrence places the subject  at imm ediate risk of death.  It does not 
include an AE or suspected adverse reaction (AR) that, had it occurred in a more severe 
form, might have caused death.  
• Inpatient hospitalizatio n or prolongation of existing hospitalization  
• A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions  
• A congenital anomaly/birth defect  
• Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the subject  or patient  and may require medical or surgical  
intervention to prevent one of the outcomes listed in this defin ition.  Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient 
hospitalization, or the development of drug dependency or d rug abuse.  
8.2 Adverse Event  Reporting  
8.2.1 Adverse Event Reporting Period  
After informed consent, but prior to initiation of study drug, all serious adverse events ( SAEs ) 
regardless of attribution will be collected.   After initiation of study drug, all  SAEs and AEs 
regardless of attribution will be collected until 30  days after the last dose of study drug  or a new 
treatment of anti -tumor therapy, whichever is earlier.   After this period , investigators should report 
only SAEs that are considered to be related to the study drug.  
8.2.2 Expedited Reporting  
Certain events require immediate reporting to allow the sponsor to take appropriate measures to 
address potential new risks in a clinical trial.  The investigator must report such events (both initial 
and follow -up) t o the sponsor immediately; under no circumstances should reporting take place 
more than 24 hours after the investigator learns of the event.  The following is a list of events that 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  69 
 CONFIDENTIAL   
 the investigator must report to the sponsor within 24 hours after first lea rning of the event, 
regardless of relationship to study drug:  
• SAEs  (from informed consent to 30 days following the last dose of study drug or a new 
treatment of anti -tumor therapy),  
• Abnormal hepatic function is defined as serum AST or ALT ≥3 × ULN together  with total 
bilirubin ≥2 × ULN, regardless of seriousness.  
o For management for hepatic function abnormal event , refer to Table  14 (Dose 
Adjustment for Abnormal Liver Function) .  Hy’s Law is an increase in serum AST 
or ALT ≥3 × ULN together with total bilirubin ≥2 × ULN, and no other reason can 
be found to explain the biochemical changes, for example, new or worsening 
hepatobiliary metastases, elevated se rum ALP indicating cholestasis, viral hepatitis, 
another suspect drug, or any other specific cause of severe hepatocellular injury.  
The elevation in transaminases must precede or be coincident with (ie, on the same 
day as) the elevation in total bilirubin , but there is no specified timeframe within 
which the elevations in transaminases and total bilirubin must occur.  See 
Appendix  6 (Clinical Evaluation o f Possible Drug -Induced Liver Injury [DILI ]) for 
additional information regarding Hy ’s Law.  
• CTCAE grade ≥3 hemorrhagic event,  
o When there is a grade ≥3 hemorrhagic event per NCI CTCAE (Version 5.0).  The 
management of severe or serious hemorrhagic events will be conducted according 
to Appendix  7 (Clinical Management of Severe or Serious Hemorrhagic Events ).   
• Pregnancy,  
8.3 Eliciting Adverse Events  
A consistent methodology of non -directive questioning for eliciting AEs at all subject evaluation 
time points should be adopted.  Examples of non -directive questions include:  
• “How have you felt since your last clini c visit? ” 
• “Have you had any new or changed health problems since you were last here?”  
8.4 Assessment of Severity  
Investigators will seek information on AEs and SAEs at each subject contact.  All AEs and 
SAEs, whet her reported by the subject  or noted by authori zed study personnel, will be recorded 
in the subject ’s medical record and on the appropriate AE/SAE form.  
For each AE and SAE recorded on the applicable eCRF, the investigator will make an assessment 
of severity through clinical description by referring to the five -grade determination standard in the 
NCI CTCAE v5.0.  Please use the guideline below for the assessment of severity when the 
observed or reported  AE is not listed in the NCI CTCAE v 5.0: 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  70 
 CONFIDENTIAL   
 • Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
• Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age -
appropriate i nstrumental activities of daily living (ADL)*.  
• Grade 3: Severe or medically significant but not immediately life  threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self -care 
ADL**.  
• Grade 4: Life -threatening consequences; urgent intervention indicated.  
• Grade 5: Death related to AE.  
Note:  
*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, 
etc. 
**Self -care ADL refer to bathing, dressing and undress ing, feeding self, using the toilet, taking medications, and not 
bedridden.  
8.5 Causality assessment  
Investigators should use their knowledge of the subject , the circumstances surrounding  the AE, 
and an evaluation of any potential alternative causes to determi ne whether or  not an AE is 
considered to be related to the study drug.  To ensure consistency of  causality assessments, 
investigators should apply the general guidelines in provided as below:  
 
• Related: There is a reasonable possibility that the event may h ave been caused by the  
product under investigation .  Factors that point toward this assessment include but  are not 
limited to: a positive re -challenge, a reasonable temporal sequence between  administration 
of the drug and the event, a known response pattern of the suspected  drug, improvement 
following discontinuation or dose reduction, a biologically  plausible relationship between 
the drug and the AE, or a lack of an  alternative explanation for the AE. 
 
• Not Related:  There is not a reasonable possibili ty that the administration of the study 
intervention caused the event, there is no temporal relationship between the study 
intervention and event onset, or an alternate etiology has been established.  
Ambiguous cases should be considered as being a “reasona ble possibility ” of a causal 
relationship unless further evidence becomes available to refute this .  Causal relationship in cases 
where the disease under study has deteriorated due to lack of effect should be classified as no 
reasonable possibility.  
8.6 Docume nting Adverse Events  
When an AE or SAE is recorded, the preferred medical terminology or concept should be used.  
Abbreviations and colloquialisms (eg, jargon or slang)  should be avoided.  
All AEs (including SAEs) should be recorded on the AE eCRF, and the check box for “Serious” 
should be ticked for entries that fit the criteria for SAEs.  The investigator should also complete 
an SAE report and submit this to the sponsor or its designee within 24 hours of knowledge of the 
event.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  71 
 CONFIDENTIAL   
 Only one medical concept sh ould be recorded in the event field on the eCRF.  
8.6.1 Diagnosis versus  Symptoms and Signs  
If known, a diagnosis should be recorded on the eCRF rather than individual signs and symptoms 
(eg, hepatic failure should be recorded instead of  jaundice, asterixis, and elevated transaminases) .  
However, if a constellation of signs and/or symptoms cannot be medically characterized as a single 
diagnosis or syndrome at the time of reporting, each individual event should be recorded as an AE 
or SAE on the eCRF.  If a diagnosis is subsequently established, it should be reported as follow -
up information.  
8.6.2 Adverse Event Occurring Secondary to Other Events  
In general, AEs occurring secondary to other events ( eg, cascade events or clinical sequelae) 
should  be identified by their primary cause with the exception of severe or serious secondary 
events.  For example, if severe diarrhea is known to have resulted in dehydration, it is sufficient to 
record only diarrhea as an AE or SAE on the eCRF if the dehydrati on is mild.  
However, medically significant AEs occurring secondary to an initiating event that are separated 
in time should be recorded as independent events on the eCRF.  For example, if a severe 
gastrointestinal hemorrhage leads to renal failure, both ev ents should be recorded separately on 
the eCRF.  
8.6.3 Persistent or Recurrent Adverse Events  
A persistent AE is one that extends continuously, without resolution between subject evaluation 
time points.  Such events should only be recorded once in the eCRF  unless  the severity changes .  
If a persistent AE becomes more or less severe, it should be recorded again in a new eCRF  entry .  
Please refer to the eCRF Completion Guidelines for information on completing each eCRF.   
A recurrent AE is one that occurs and resolve s between subject evaluation time points and 
subsequently recurs.  All recurrent AEs should be recorded on the eCRF respectively.  
8.6.4 Abnormal Laboratory Values  or Abnormal Vital Signs  
Not every laboratory abnormality /abnormal vital sign  qualifies as an AE.  A laboratory test 
result /abnormal vital sign  must be reported as an AE if it is a change from baseline and meets any 
of the following criteria:  
• Accompanied by clinical symptoms,  
• Results in a change in study treatment ( eg, dosage modification, treatment interruption, or 
treatment discontinuation),  
• Results in a medical intervention ( eg, potassium supplementation for hypokalemia) or a 
change in concomitant therapy,  
• Clinically significant in the investigator ’s judgment.  
Investigators are responsible for reviewing  all laboratory findings  and abnormal vital signs  and 
determining whether or not each abnormality should be reported as an AE . 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  72 
 CONFIDENTIAL   
 If the clinically significant laboratory abnormality is a sign of a disease or syndrome (eg, ALP and 
bilirubin 5 × ULN associated with cholecystitis), only the diagnosis ( eg, cholecystitis) needs to be 
recorded on the eCRF.  
If the clinically significant laboratory abnormality is not a sign of a disease or syndrome, the 
abnormality itself shou ld be recorded as an AE or SAE on the eCRF .  If the laboratory abnormality 
can be characterized by a precise clinical term, the clinical term should be recorded as the AE or 
SAE.  For example, an elevated serum potassium level of 7.0  mmol/L should be recor ded as 
“hyperkalemia.”  
Observations of the same clinically significant laboratory abnormality from visit to visit should 
not be repeatedly recorded as AEs or SAEs on the eCRF, unless their severity, seriousness, or 
etiology changes.  
8.6.5 Preexisting Medical Con dition  
A preexisting medical condition is one that is present at screening .  Such conditions should be 
recorded on the eCRF as medical history.  A preexisting medical condition should be recorded as 
an AE or SAE only if the frequency, severity, or characte r of the condition worsens during the 
study (excluding deterioration of the study disease conditions).  When such events are recorded on 
the eCRF, it is important to convey the concept that the preexisting condition has changed by 
including applicable desc riptors ( eg, “more frequent headaches”).  
8.6.6 Pregnancy  
A female subject  must be instructed to stop taking the study drug and immediately inform the 
investigator if she becomes pregnant during the study.  The investigator should report all 
pregnancies within 24 hours of awareness to the sponsor (the reporting period for pregnancy 
continues up to 30 days after completion of the study drug).  The investigator should counsel the 
subject  and discuss the risks o f continuing with the pregnancy and the possible effects on the fetus.  
Monitoring of the subject  should continue until outcome  of the pregnancy.  Pregnancies occurring 
up to 30 days after the completion of the study drug must also be reported to the inves tigator.  
Male subject s must also be instructed to inform the investigator immediately if their partner 
becomes pregnant during the study or within 90 days after the last dose of study drug.  If such an 
event occurs, it should be reported as described above . 
Pregnancy loss of any kind  should always be classified as serious AE (as the sponsor considers 
these medically significant), recorded on the eCRF, and expeditiously reported to sponsor.  
Any congenital anomaly/birth defect in a child born to a female subject or female partner of a male 
subject  exposed to the investigational product should be recorded and reported as an SAE.  
8.6.7 Worsening of Solid Tumor  
Worsening and/or progression of the subject ’s solid tumor should not be recorded as an AE or 
SAE.  These data will be captured as efficacy assessment data only.  If there is any uncertainty 
about an AE being related only to the disease under study, it should be reported as an AE or SAE.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  73 
 CONFIDENTIAL   
 8.6.8 Death  
All deaths that occur during the protocol -specified AE report ing period must have the underlying 
cause reported to the sponsor  as an SAE with death listed as the outcome .  Deaths due to the 
progression of disease must also be reported to the sponsor  as an SAE .  Death events that occur 
after 30 days following last dose of study drug must be reported to the sponsor  as an SAE only if 
it is confirmed as related to study drug.  If the primary cause of death is unknown and cannot be 
ascertained at the time of reporting , please record “Unknown cause death” on the eCRF, and the 
“unexplained/unknown death” should be reported expeditiously as an SAE .  The SAE should be 
reported  before the specific cause of death  has been determined . 
8.7 Duration of Follow -up for Adverse Events  
The investigator will follow all unresolved AEs and SAEs until the events are resolved or 
stabilized, the subject is lost to follow -up, subject  death, or end of study .  Resolution of AEs and 
SAEs (with dates) should be documented on the appropriate eCRF an d in the subject ’s medical 
record to facilitate source data verification (SDV).  For SAEs, if, after follow -up, return to baseline 
status or stabilization cannot be established, an explanation should be recorded in the additional 
case details section of th e eCRF.  
For some SAEs, additional case details deemed necessary to appropriately evaluate the SAE report 
(eg, hospital discharge summary, consultant report, or autopsy report) may be followed -up by 
telephone, fax, email, and/or a monitoring visit.  
All preg nancies that occur during the study should be followed until pregnancy outcome.   
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  74 
 CONFIDENTIAL   
 9 STATISTICAL  ANALYSIS  
9.1 Statistics and Analysis Method  
A separate statistical analysis plan (SAP) will provide specific details on analytical methods.  
9.1.1 Statistical Hypothesis  
This study is designed to demonstrate superiority of fruquintinib plus BSC  (fruquintinib  arm) over 
placebo plus BSC  (placebo arm ) in prolonging OS for subject s with refractory mCRC .  The study 
is designed to test the null hypothesis H0: λ=1.0 versus the al ternative hypothesis H a: λ < 1.0, 
where λ is the hazard ratio ( treatment arm /placebo arm ). 
9.1.2 Sample Size Rationale  
The total sample size and number of OS events  required for efficacy assessment  in the ITT 
population  is calculated based on the following assum ptions:  
• A one -sided significance level of 0.025;  
• Assuming an OS HR ( fruquintinib  arm/placebo arm) of 0.73, this sample size yields 
approximately 90% statistical power to detect superiority of the fruquintinib  arm over 
placebo arm.  If the true median OS for the placebo arm is 5 months, then the HR of 0.73 
corresponds to median OS of 6.8 months in the fruquintinib  arm (median OS improvement 
of 1.8 months) ;   
• An enrollment rate of 30 subjects per month during the first 3 months and 50  subjects per 
month thereafter;  
• Yearly dropout rate of 10%;  
• Randomization ratio = 2:1  (fruquintinib  arm vs placebo arm) .     
• Data maturity = 70%;  
• One interim futility analysis when 1/3 of the total number of OS events  (ie, 160 OS 
events) have occurred , the Lan -DeMets spending  function is used in the calculation .  
Under the premise of thes e assumptions, approximately 687 subjects  will be randomized to this 
study  over approximately 15 months in this study .  OS will be analyzed  when 480 OS events are 
observed , which is expected to occur  in approximately 7 months after the end of  enrollment.  East® 
version 6.5 software ( www.cytel.com ) was utilized for the calculation .  In clinical practic e, 
TAS -102 is used more commonly than regorafenib.   To ens ure that the subject  population is 
representative of clinical practi ce, post-regorafenib subjects  will be capped at 344 subjects if there 
is an unanticipated enrichment of that population.  This will ensure that at least 50% of the subjects 
will be post-TAS.  Subjects are considered in post -TAS -102 or post -regorafenib populations if 
they have received at least one dose of either agent , respectively,  prior to entering the study.  Based 
on the similar mechanisms of action between regorafenib and fruqu intinib , it will be of clinical 
interest to evaluate the magnitude of benefit in each of the populations when compared to the ITT 
population . 
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  75 
 CONFIDENTIAL   
 9.1.3 Analysis Sets  
Intent -to-Treat (ITT) Population   
All randomized subjects will be included in the ITT population.  Subjects will be analyzed by 
treatment arm as randomized.  The ITT population will be the primary population for evaluating 
all efficacy endpoints and patient characteristics.   
Safety Analysis Population  
All randomized subjects who received at least one d ose of study  treatment will be included in the 
safety analysis population .  Subjects in this population  will be  analyzed according to the treatment 
they actually receive d.  This population will be used for all safety analyses.  
9.2 Primary and Secondary Endpoints  
9.2.1 Primary Endpoint  
The primary endpoint of the study is OS, defined as the time (months)  from date of randomization 
to death from any cause .  Subjects  without report of death at the time of analysis will be censored 
at the date last known alive.   Subjects  lacking data beyond the date of randomization will have 
their survival time censored at the date of randomization.  OS will not be censored if a subject  
receives subsequent anticancer treatments after discontinuation of the study drugs.  
9.2.2 Secondary Efficacy Endpoints  
Secondary efficacy end points include PFS, ORR, DCR , and DoR.  
9.2.2.1  Key Secondary Endpoint: Progression -free Survival  
PFS is defined as the time (months) from randomization until the first radiographic documentation 
of objective progression as  assessed by investigator using RECIST  v1.1, or death from any cause , 
whichever comes first .  More specifically, PFS will be determined using all data until the last 
evaluable visit prior to or on the date of : (i) radiographic disease progression per RECIS T v1.1; 
(ii) withdrawal of consent to obtain additional scans on study; or (iii) initiation of subsequent 
anticancer therapy other than the study drugs, whichever is earlier.   Censoring rules for subjects  
who do not experience PD or death will be described  in the study SAP.   Additional sensitivity 
analyses may be conducted and will be specified in the SAP.   
9.2.2.2  Objective Response Rate  
Objective response rate  is defined as  the proportion of subject s achieving a best overall response 
of confirmed complete response (CR) or partial response (PR) , per RECIST  v1.1, as determined 
by the investigator.   
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  76 
 CONFIDENTIAL   
 9.2.2.3  Disease Control Rate  
Disease control rate  is defined as proportion of subject s achieving a best overall response of 
confirmed CR, PR , or SD, per RECIST v1.1 , as determined by the investigator .  To be qualified 
for SD, the duration of SD should last for at least 7 weeks.  
9.2.2.4  Duration of Response  
Duration of response is defined as the time ( months ) from the first occurrence of PR or CR, 
whichever comes first, until the date of radiographic PD or death .  The duration of response will 
be determined for subjects with best overall response of confirmed CR or PR . 
9.2.3 Secondary Safety Endpoints  
Safety endpoints include AE, laboratory tests, vital signs and weight, ECG, 
echocardiogram /MUGA (especially LVEF) and ECOG PS.  
All AEs, whether related to the drug or not, will be recorded in the eCRF including the start/end 
date, measures taken, treatment affected (yes v ersus  no) and the outcome.  For all the events, the 
causality with  the treatment and the severity will be determined by the investigator.  
9.2.4 Other Endpoints  
9.2.4.1  Patient Reported Outcomes  
Quality of life will be assessed using European Organization for Research and Treatment of Cancer 
(EORTC ) QLQ -C30 and EQ -5D-5L questionnaires.   Quality of life score, change from baseline, 
subject s achieving minimally important difference (MID)  cut-off, and time to deterioration (TTD) 
will be assessed.  
9.2.4.2  Assessment of Resource Utilization  
Health care resource utilization assessments such as physic ian visits, emergency room visits, 
hospital care ( eg, inpatient and outpatient), drug prescriptions etc. will be assessed.  
9.2.5 Statistical Methods  
9.2.5.1  Analysis of Efficacy Endpoints  
Efficacy analyses will be based on ITT population.  All secondary endpoints based on radiological 
assessments of tumor burden will be derived from investigator assessment  using RECIST v1.1.  
Additional sensitivity analyses may be performed and will be outlined in the SAP.  
9.2.5.1.1  Primary Endpoint - Overall Survival  
A 1-sided stratified log -rank test will be used for the comparison of OS of the fruquintinib with 
placebo group at a significance level of 0.0 25.  The same stratification  factors used for 
randomization (Section  7.3.1 ) will be used for analysis .  Kaplan -Meier methodology will be used 
to estimate the median OS and its 2-sided 95% Confidence Interval (CI) for each treatment arm .  
Plots will be produced b y treatment arm.  The HR between the 2 treatment groups (fruquintinib vs 
placebo), together with its 95% CI, will be calculated from a stratified Cox proportional hazard 
model stratified by  the randomization stratification factors . 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  77 
 CONFIDENTIAL   
 9.2.5.1.2  Secondary Effic acy Endpo ints (PFS, ORR, DCR, Do R)  
First secondary endpoint is to evaluate PFS in subject s with refractory mCRC  treated with 
fruquintinib plus BSC versus  placebo plus BSC .  Kaplan -Meier methodology will be used to 
estimate the median PFS and its 2-sided 95% CI for  each treatment arm .  Plots will be produced 
by treatment arm.  
The hazard ratio (HR) between the 2 treatment groups ( fruquintinib vs placebo), together with its 
95% CI, will be calculated from a stratified Cox proportional hazard model stratified by the 
randomization stratification factors .    
The estimate s of DCR and ORR in each treatment group and their 2-sided 95% CI s will be 
presented .  Comparison of DCR and ORR  between treatment groups will be performed using 
stratified Cochran -Mantel -Haensze l test.  The CI  of difference in DCR and ORR between 
treatment groups will be calculated using the approximate normal distribution method of binomial 
distribution.  
Duration of response (Do R) will only be determined for subjects who responded ( confirmed best 
overall  response of CR or PR) .  Statistical test will not be conducted,  as subject s with response are 
not randomized.  Descriptive  analysis will be adopted for Do R.  For each treatment group, results 
will be presented by Kaplan -Meier estimates and distribution cu rve. 
9.2.5.1.3  Multiplicity  Adjustment for the Primary Endpoint OS and Key Secondary 
Endpoint PFS  
To ensure strong control of family -wise Type I error rate among the analyses for the primary 
endpoint OS and the key secondary endpoint PFS at a 2 -sided 𝛼=0.05 level, a fixed -sequence 
procedure will be applied.  In this testing procedure, the analyses of OS will be conducted first  and 
once the statistical significance is established for OS at a 2-sided 0.05 level, the analysis of PFS 
can then be performed at a 2-sided 0.05 level.  
9.2.5.1.4  Subgroup Analyses  
Subset analyses may be conducted, for example, by age, performance status, prior lines of therapy, 
prior use of TAS -102, prior use of regorafenib, region, and others as deemed appropriate . 
9.2.5.2  Analysis of Safety Endpoints  
All safety parameters will be summarized and listed by using the safety population.  
TEAEs will be summarized by MedDRA system organ class (SOC) and PT .  The incidence and 
percentage of subject s with at least 1 occurrence of a preferred term will be includ ed according to 
the most severe NCI-CTCAE version  5.0.  Relationship to study therapy (causality) will be 
summarized separately.  If more than one AE was recorded for a subject within a PT, the subject  
will be counted once in the most severe grade.   
Labor atory data will be summarized by visit .  All TEAEs and abnormal laboratory variables shall 
be evaluated by the NCI CTC AE Version 5.0 Classification System.  Other  safety data including 
vital signs, ECG, ECOG PS will be summarized using descriptive statist ics. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  78 
 CONFIDENTIAL   
 9.2.5.3  Analysis of Other Endpoints  
9.2.5.3.1  Subject Reported Outcomes  
Subject  reported outcomes will be assessed using EORTC QLQ -C30 and EQ -5D-5L 
questionnaires .  The number and percentage of subject s who completed the questionnaires will be 
summarized for each treatment arm by visit.  Reasons for non -completion will be presented.  
Quality of life scores  and change from baseline scores will be compared between treatment arms 
using mixed model repeated measures approach adjusting for covariates.  For each scale, 
appropriate minimally important difference (MID) cut -off will be determined and number and 
percent of subject s achieving the MID will be presented.  In addition, time to deterioration (TTD) 
will be summarized using Kaplan -Meier methodology .  
9.2.5.3.2  Resource Utiliz ation  
Health care resource utilization  data including  number and percent of subject s hospitalized, 
reasons for hospitalizations, emergency room visits, drug prescriptions will be summarized.  
9.3 Pharmacokinetic and Pharmacodynamic Analyses  
9.3.1 Population PK and Ex posure -Response Analyses  
Descriptive statistics (including but not limited to arithmetic mean, standard deviation , coefficient 
of variation, median, minimum, maximum  and geometric mean ) will be provided for the observed 
concentrations for fruquintinib and metabolite M11.  
Population PK analysis of plasma concentration -time data of fruquintinib and metabolite M11  will 
be performed using nonlinear mixed -effects modeling.  The population PK modeling will include 
all subjects with sufficient and interpretable PK  assessments.  The data from the population PK 
samples may be combined together with the data from other studies for the population PK analysis .  
If relevant and  sufficient data are available, the relationship of exposure to fruquintinib  and M11  
to measure s of efficacy and AEs may also be analyzed.  Details of the population PK and/or 
exposure -response analysis will be given in a population PK/ pharmacodynamic  analysis plan .  The 
results of the population PK/ pharmacodynamic  analysis will be presented in a separate report.  
9.3.2 Pharmacodynamic ( ECG ) Analysis  
Subjects who 1) receive at least 1 dose of study drug, and 2) have baseline and at least 1 post-dose 
ECG measurement will be  evaluable for pharmacodynamic (ECG) evaluation.  Subjects who had 
reduced dosage, p rolonged dose interruption of >2  days in cycle  1, or who  had any dose 
interruption within 7 days before cycle  1 day 21, or were discontinued from the study prior to the 
completion of ECG data collection ( cycle  1 day 21) will be excluded.  For each of the E CG 
parameters, the average values from the 3 readings of a triplicate ECG set will be used in the 
analysis.  
For all ECG parameters, the baseline will be defined as the mean values of the triplicate ECG 
measurements taken at pre -dose on cycle  1 day 1. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  79 
 CONFIDENTIAL   
 9.3.2.1  QTc I ntervals  
The terminology QTc is used in this section as a general notation for corrected QT intervals using 
any of the specified methods.  
The QT interval data will be corrected for heart rate using 2 correction methods (Fridericia – QTcF  
and Bazett – QTcB).  For each QTc correction method, the relationship between QTc and RR at 
baseline will be evaluated graphically by plotting the logarithm of baseline QTc values against the 
logarithm of corresponding RR intervals.  Fridericia will be used a s the primary correction method 
for statistical analysis.  If the correlation between QTc and RR intervals remains significant using 
the Fridericia correction method, an alternative correction method may be considered for statistical 
analysis in addition t o QTcF.  
For the statistical analysis based on the primary correction method ( QTcF ), the mean changes from 
baseline (ΔQTc ) at each time  point will be summarized (mean, standard deviation, median and 
range , 2-sided 90 % confidence interval ).  The difference i n ΔQTc between fruquintinib  and 
placebo ( ΔΔQTc) for each individual will also be calculated at each time point ( individual ΔQTc 
for fruquintinib  – mean ΔQTc for  placebo at the same time point).  Mean values for the difference 
and 2 -sided 90% CI for mean difference will be calculated at each time point . 
The primary analysis will focus on the maximum m ean change from baseline in QTc (ΔQTc ) on 
cycle  1 day 21, which wi ll be estimated by the mean QTc  change at around Tmax, the time when 
the maximum plasma conc entration is reached (ie, steady state) .  The same analysis will be 
performed for ΔQT  data using other correction methods if data warrant .  The m ean change from 
baseline in QTc  (±standard deviation ) over time will be plotted.  
In addition, QTc will be categorized based on ICH E14 guidelines.  Tables will present the number 
and percentage of subjects meeting or exceeding the following categories:  
• QTc interval prolongation:  
− Absolute values > 450 to ≤ 480 msec  
− Absolute values > 480  to ≤ 500 msec  
− Absolute values > 500 msec  
• QTc interval change from baseline:  
− Increase from baseline > 30 to ≤ 60 msec  
− Increase from baseline > 60 msec  
9.3.2.2  Heart Rate , QRS , and PR intervals  
For each treatment and time  point of measurement, heart rate , QRS interval and  PR interval , as 
well as the change from baseline in heart rate , QRS and  PR (HR, QRS, PR), will be 
summarized using descriptive statistics (mean, standard deviation, median, range, and 90% CI).  
The number and percentage of subjects with heart rate  >100 bpm will be tabulated for each time  
point.  The number and percentage of subjects with QRS > 110 msec will be tabulated for each 
time point.  The number and percentage of subjects with PR > 200 msec will be tabulated for each 
time point.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  80 
 CONFIDENTIAL   
 9.3.2.3  T-wave and U -wave Morphology  
The number  and percentage of subjects having T -wave  morphology changes from baseline and/or 
the occurrence of abnormal U -waves that represent the appearance or worsening of the 
morphological abnormality will be summarized.  Subjects with abnormal ECG findings will be 
listed.  Additional analyses will be performed if deemed necessary.  
9.3.3 QTc -PK Analysis  
The potential relationship between QTc and PK will be evaluated using data from all  evaluable 
subjects who have data from baseline and at least 1 post -dose ECG measurement following the 
first dose.  QTc change from baseline before and after correction for placebo ( ΔQTc and ΔΔQTc)  
using the primary correction method (see Section  9.3.2.1 ) at each time  point of measurement will 
be plotted against the corresponding plasma concentrations of fruquintinib and M11 separately.  
Additional plots will be produced, if deemed necessary.  
A linear mixed effects model will be fitted to the QTc and ΔΔQTc  data from cycle  1 day 1 and 
cycle  1 day 21 with either parent or metabolite concentration as a predictor and subject as a random 
effect; if the intercept term is not significant, the model w ill be re -fitted with a zero intercept term.  
Based upon  these relationship s, the predicted population average ΔQTc and ΔΔQTc  as well as 
their corresponding upper 9 0% 2-sided confidence interval bound will be computed at the mean 
maximum plasma concentrations  (ie, C max) of fruquintinib and M11, or other concentrations of 
interest . 
9.4 Interim Analysis  
An independent data monitoring committee ( IDMC) will be convened to review  accumulating 
safety data .  During th e study, safety interim analyses will be performed approximately every 
6 months.  The frequency of safety interim analysis may be modified upon IDMC 
recommendation.   
One interim non-binding futility analysis will be performed when approximately 1/3 of the  total 
number of OS events (ie, 160 OS events) ha s occurred .  The IDMC will be instructed to 
recommend stopping the study for futility if the 1 -sided p -value from a stratified log -rank test is at 
least 0.772 (corresponding to an observed HR of at least 1.1 33).  Otherwise, the study will continue 
with full enrollment.  There is a 22.8% chance of terminating the study for futility at the interim 
analysis if the true median OS in fruquintinib  arm is 5 months, ie, fruquintinib is ineffective .  There 
is a 0.4% chance of stopping for futility, declaring fruquintinib  ineffective at the interim if the true 
median OS in fruquintinib  arm is 6. 8 months, ie, fruquintinib is effective in our study population .  
Although there are no plans to stop the study early for ef ficacy based on OS data at the interim 
analysis, to protect the integrity of the study and to preserve the type 1 error, a fraction of alpha 
(0.0001) will be spent at the interim analysis based on an O’Brien -Fleming stopping boundary . 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  81 
 CONFIDENTIAL   
 10 ETHICAL CONSIDERATIO NS 
10.1 Good Clinical Practice  
The study will be conducted in accordance with the protocol, ICH guidelines, applicable 
regulations and guidelines governing clinical study conduct, consensus and the ethical principles 
derived from international guidelines, includ ing the Declaration of Helsinki and Council for 
International Organizations of Medical Sciences  International Ethical Guidelines, Applicable ICH 
GCP Guidelines that have their origin in the Declaration of Helsinki, and applicable regulations 
and guideline s governing clinical study conduct.  
10.2 Ethics Review  
The Independent Ethics Committee (IEC)/Institutional Review Board (IRB) must review the 
protocol and amendments, investigator’s brochure, informed consent form, study -relevant 
materials (such as advertisements for subject  recruitment) and any other essenti al documents.  
IEC/IRB approval is to be obtained prior to the study.  
All amendments are to be reviewed and approved by the IEC/IRB  and applicable regulatory 
authorities  (as required)  and documented.  All unexpected SAEs should be reported to the sponsor, 
IEC/IRB and applicable regulatory authorities as required.  During the study, protocol deviations 
that may increase a subject ’s risk should be reported to the IEC/IRB in a timely manner.  
Protocols and any substantial amendments to the protocol will require  health authority approval 
(as required)  prior to initiation , except for changes necessary to eliminate an immediate hazard to 
study subject s. 
The Investigator will be responsible for the  following:  
• Providing written summaries of the status of the study to  the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB/IEC . 
• Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
IRB/IEC procedures . 
• Providing oversight of the conduct of the study at the site and adherence to requirements 
of 21 Code of Federal Regulations ( CFR ), ICH guidelines, the IRB/IEC, European 
Regulation 536/2014 for Clinical Studies (if applicable ), European Medical Device 
Regulation 2017/745 for Clinical Device Research (if applicable), and all other applicable 
local regulations . 
10.3 Informed Consent  
The following will be followed for informed consent:  
• Investigators or designees , if locally permissible,  must obtain the signed ICF from 
subjects  prior to  conducting any study -related procedures.  
• The Investigator or his/her representative will explain the nature of the study to the 
subject  or to their legally authorized representative , if locally permissible,  and answer all 
questions regarding the study.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  82 
 CONFIDENTIAL   
 • Subjects  must be informed that their participation is voluntary.  Subjects  or their legally 
authorized representative , if locally  permissible,  will be required to sign a statement of 
informed consent that meets the requirements of 21 CFR 50, local regulations, ICH 
guidelines, Health Insurance Portability and Accountability Act  requirements, w here 
applicable, and the IRB/IEC or study center.  
• Subjects must be informed that they may withdraw consent to participate in the study 
without any limitations.  If the subject  cannot sign the ICF, a legally acceptable 
representative of the subject must sign the ICF if locally permissible .  
• If the subject  and the legally acceptable representative are not able to read and write, an 
impartial witness should be present throughout the whole process of providing informed 
consent. Once the subject  and the legally acceptable representative , if locally permissible,  
give their oral consent, the ICF should be signed by the impartial witness to confirm that 
the subject  and the legally acceptable representative fully understand the study and their 
right to withdraw informed consent without any limitations.  
• Informed consent should be recorded in the eCRF.  
• If the risk /benefit assessment changes after the safety analysis, the ICF must  be reviewed 
and updated , and all updated information should be provided to subjects  (including subjects  
who have already received the study drug).  
10.4 Data Privacy  
All information about fruquintinib (such as patent application, formulation, manufacturing  process 
and basic study information) is considered confidential as long as it is unpublished.  
All information obtained in the study is considered co nfidential.  Hutchison  MediPharma Limited 
will open the information to investigational personnel, the National Medical Products 
Administration , and any other regulatory authority when necessary.  To ensure the completeness 
of the study analysis data, investigational personnel are accountable for providing all results and 
data to the sponsor.  
Investigators must guarantee the privacy of subject s by not disclosing subject -related information 
to third parties wi thout authorization.  eCRFs and other documents submitted to the sponsor should 
not contain the subject ’s name.   
• Subjects  will be assigned a unique identifier by the sponsor.  Any subject  records or 
datasets that are transferred to the sponsor will contain the identifier only; subject  names 
or any information that would make the subject  identifiable will not b e transferred.  
• Subjects  are identified only by the unique identifier .  Investigat ors may retain the 
identification forms, which include subject  numbers, names, and addresses.  ICFs and 
other documents should be documented properly, and should not be given to the Sponsor.  
• Subject s must be informed that his/her personal study -related dat a will be used by the 
sponsor in accordance with local data protection law s.  The level of disclosure must also 
be explained to the subject  who will be required to give consent for their data to be used 
as described in the informed consent.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  83 
 CONFIDENTIAL   
 • Subject s must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities.  
10.5 Disclosure  
Final study re sults will be published on a public clinical trial website according to applicable local 
guidelines and regulations.  
10.6 Biological Specimens and Data  
For subjects who provide informed consent agreeing to participate in future biomedical research, 
any unused samples for study -related research, as well as unused PK samples, may be stored for 
no longer than 15 years , or other period as per local requirements, after the final date of the 
database lock.  After this storage period , any residual samples will be destroyed.  The Sponsor will 
store the samples in a secure storage space with adequate measures to protect confidentiality.  
The results of these future biomedical research analyses will not be shared with subjects and will 
not be presented in the CSR.  
If there are specific site or country requirements involving the pharmacogenomic analyses that the 
sponsor is unable to comply with, samples will not be collected at those sites.  
All samples will be single/double coded as defined by IC H guideline E15.  
10.7 Data Qual ity Assurance  
• To ensure the safety of subjects  in the study, and to ensure accurate, complete , and 
reliable data, the Investigator will keep records of laboratory tests, clinical notes , and 
subject  medical records in the subject  files as original sourc e documents for the study.  
• All subject  data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data).  The 
investigator is responsible for verifying that data ent ries are accurate and correct by 
physically or electronically signing the CRF.  
• Guidance on completion of CRFs will be provided in the CRF Completion Guidelines.  
• The Investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
• Monitoring details describing strategy (eg, risk -based initiatives in operations and quality 
such as Risk Management and Mitigation Strategies and Analytical Risk -Based 
Monitoring), met hods, responsibilities , and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provided in the Monitoring Plan.  
• The Sponsor or designee is responsible for the data management of t his study , including 
quality review  of the data.  
• The Sponsor assumes accountability for actions delegated to other individuals (eg, 
CROs ). 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  84 
 CONFIDENTIAL   
 11 OVERSIGHT  
11.1 Independent Monitoring  
11.1.1  Independent Data Monitoring Committee  
An IDMC will be established in this study.  T he IDMC will consist of at least 4 independent 
clinical oncology physicians and 1 independent  statistician with no conflicts of interest with the 
sponsor.  The IDMC will evaluate the safety data regularly , and  the subjects’ safety will be 
determined by the evaluation of the risk/benefit at a regular review meeting .  The responsibilities 
of the IDMC will include:  
• Regular  (approximately every 6 months)  unblinded review of the study data to provide 
suggestions such as “continue as planned, suspend, protocol amendment, terminate study” 
so as to prevent subjects from being exposed to unsafe dose and treatment regimes.  
• Review of interim analysis data to provid e suggestions such as “continue as planned, 
suspend, protocol amendment, terminate study .” 
Upon completion of the data review, the IDMC will provide suggestions on whether or not to 
continue the study , if modification of the protocol is recommended or if s tudy termination is 
required.  The final decision shall be made by Hutchison MediPharma Limited.   The IDMC 
membership and governance is outlined in a separate IDMC charter.  
11.2 Quality Control and Assurance  
The clinical study will be executed and reported following GCPs, all applicable regulatory 
requirements , and applicable standard operating procedures, including quality control of 
documents.  
The investigator is responsible for supervising any individual or party to whom the investigator 
delegates trial-related duties and functions conducted at the trial site.  The sponsor and investigator 
ensure that any individual or party who performs trial -related duties or functions on behalf of the 
sponsor/investigator is qualified to perform the trial -related  duties or functions.  
The overall procedures for quality assurance of clinical study data are described in the sponsor or 
designee ’s standard operational procedures.  The planned quality assurance and quality control 
procedures for the study are described in the following  section s. 
11.2.1  Monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, the Sponsor’s 
personnel (or designated CRO) will review the protocol and eCRFs with the Investigators and their 
staff.  During the study, the field monitor will visit the site regularly to check the completeness of 
subject  records, the accuracy of entries on the eCRFs, the adherence to the protocol to GCP, the 
progress of enrollment, and to en sure that study treatment is being stored, dispensed, and accounted 
for according to specifications.  Key study personnel, including the Investigator , must be available 
to assist the field monitor during the se visits.  
The Investigator must give the field monitor access to all relevant source documents to confirm 
their consistency with the eCRF entries.  The Sponsor’s monitoring standards require full 
verification of the informed consent, adherence to the inclusion/exclusion criteria, and 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  85 
 CONFIDENTIAL   
 documentation of SAEs.  Additional checks of the consistency of the source data with the eCRFs 
are performed according to the study -specific monitoring plan.  
11.2.2  Audits  
Authorized representatives of the sponsor , a regulatory/competent authority, and/or an IRB/IEC 
representativ e may visit the site to perform audits or inspections, including source data verification.  
Should this occur, the Investigator is responsible for:  
• Informing the sponsor of a planned inspection by the authorities as soon as notification is 
received and aut horizing the Sponsor’s participation in the inspection  
• Providing access to all necessary facilities, study data, and documents for the inspection 
or audit  
• Communicating any information arising from inspection by the regulatory authorities to 
the Sponsor im mediately  
• Taking all appropriate measures requested by the Sponsor to resolve the problems found 
during the audit or inspection  
• Documents subject to audit or inspection include but are not limited to all source 
documents, CRFs, medical records, corresponde nce, ICFs, IRB/EC files, documentation 
of certification and quality control of supporting laboratories, and records relevant to the 
study maintained in any supporting pharmacy facilities.  Conditions of study material 
storage are also subject to inspection .  In addition, representatives of the Sponsor may 
observe the conduct of any aspect of the clinical study or its supporting activities both 
within and outside of the Investigator ’s institution.  
In all instances, the confidentiality of the data must be res pected.  
11.2.3  Records  
11.2.3.1  Data Capture and Management  
The term ca se report form (CRF ) or eCRF should be understood to refer to electronic data capture 
(EDC) system.  The EDC system is the database where pertinent study data are collected.  For all 
subjects, includin g screen failures, data will be collected on source documents first.   The Principal  
Investigator is responsible for assuring that the data  entered into  eCRFs is complete, accurate, and 
that entry and updates are performed in a timely manner .  Blood and tumor samples for PK and 
biomarkers assessments will be collected by  study  sites and sent to the  designated central 
laboratory for processing.   Data from  ECG  assessments will be collected at the  study  sites,  and the 
data will be transmitted to a designated  CRO for centralized analysis, as well as  for further 
processing and data reconciliation .  Imaging data will be collected at the  study  sites,  and a 
designated CRO will perform  further processing, data reconciliation , and holding.  
At all times, the Principa l Investigator has final responsibility for the accuracy and authenticity of 
all clinical and laboratory data entered in the EDC.  Subject source documents are the 
Investigator's /physician's subject records maintained at the study site.  In cases where the  source 
documents are the hospital or the physician's chart, the information collected in the EDC must 
match those charts.  All final data recorded in EDC system will be copied onto CDs and kept by 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  86 
 CONFIDENTIAL   
 the Sponsor .  A copy of these CDs will also be kept at the  clinical site.  All data recorded on source 
documents will be kept at the clinical site.  
The completed pages of the EDC system are the sole property of the Sponsor and should not be 
made available in any form to third parties without written permission fr om the Sponsor , except 
for authorized representatives of the Sponsor  or appropriate regulatory authorities.  
11.2.3.2  Source Documentation  
• The Investigator/institution should maintain adequate and accurate source documents and 
study records for all subjects  that support the information entered in the CRF.  
• Source data should be attributable, legible, contemporaneous, original, accurate, and 
complete.  Changes to source data should be traceable  and not obscure the original entry .   
• All information recorded on eCRFs must be traceable to source documents in the 
subject’s  file.  Any changes  should be explained if necessary (eg, via an audit trail).  
11.2.3.3  Records Retention  
Records and documents, including signed ICFs, source do cuments, study drug documents, 
monitoring visit records, regulatory documents, and all other correspondence and documents 
pertaining to the conduct of this study must be retained by the Investigator for at least 5 years after 
study completion, unless local regulations or institutional policies require a longer retention period.  
If the documents cannot be stored properly at the investigational site, the documents can be 
transferred by the Investigator and Sponsor to an approved storage facility.  The document s must 
be sealed for storage and easily found for review in the case of a  regulatory authority audit.  No 
records may be transferred to another location or party without written notification to the Sponsor . 
No records may be destroyed during the retention period following study completion or 
discontinuation without the written approval of the Sponsor .  Records must be destroyed in a 
manner that ensures confidentiality.   
11.3 Study Termination or Study Site Closur e 
The Sponsor and the Investigator have the right to close  out a site prematurely.  
Investigator’s Decision   
The Investigator must notify the Sponsor of a desire to close  out a site in writing, providing at least 
30 days’ notice .  The final decision should be made through mutual agreement with the 
Sponsor .  Both parties will arrange the close  out procedures after review and consultation  
Sponsor’s Decision  
The Sponsor will notify the Investigator (s) of a decision to close  out a study site in writing .  
Reasons  may include the following, among others:    
• The Investigator has received all items and information necessary to perform the 
study, but has not enrolled any subject within a reasonable  period of time   
• The Investigator has violated any fundamental obligatio n in the study agreement, 
including but not limited to, breach of this protocol (and any applicable amendments), 
breach of the applicable laws and regulations, or breach of any applicable ICH 
guidelines    
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  87 
 CONFIDENTIAL   
 • The total number of subjects required for the study  are enrolled earlier than expected   
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
investigator s, the ECs/IRBs, the regulatory authorities, and any CRO s used in the study of the 
reason for termination or suspens ion, as specified by the  applicable regulatory requirements.  The 
investigator shall promptly inform the subject and should assure appropriate subject therapy and/or 
follow -up.  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  88 
 CONFIDENTIAL   
 12 PUBLICATION POLICY  
The study results may be published in scientific journals.   The names of investigators who make 
an important contribution to the study implementation and management, and personnel who make 
an important contribution to the study design, analysis,  and interpretation (such as staff or 
consultants) will be listed in the publication.  The Sponsor agrees to provide the article to 
investigators for review prior to publishing any study results.  Investigators must obtain approval 
from the Sponsor before contributing to any related articles or abstracts.  
The Sponsor will comply with the requirements for publication of study results.  In accordance 
with standard editorial and ethical practice, the sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data.  In th is case, a coordinating 
investigator will be designated by mutual agreement.  
Authorship will be determined by mutual agreement and in line with International Committee of 
Medical Journal Editors authorship requirements.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  89 
 CONFIDENTIAL   
 13 FINANCING AND INSURA NCE  
Financing an d insurance information  will be addressed in a separate agreement.  
  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  90 
 CONFIDENTIAL   
 14 REFERENCES  
American Cancer Society, Key Statistics for Colorectal Cancer, 2019. URL:   www.cancer.org/ 
cancer/ colon -rectal -cancer/about/key -statistics.html; accessed February 12, 2019.  
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: 
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.  
CA Cancer J Clin .  2018 Nov;68(6):394 -424  
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 
1976;16(1):31 -41. 
Duda DG, Batchelor TT, Willett CG, Jain RK.  VEGF -targeted cancer therapy strategies: current 
progress, hurdles and future prospects.  Trends Mol Med . 2007 Jun;13(6):223 -30. 
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, 
Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, GoldbergRM, Sargent DJ, 
Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group.  Regorafenib monothe rapy 
for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, 
randomised, placebo -controlled, phase 3 trial.  Lancet  2013 Jan 26;381(9863):303 -12. 
Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP. 
Management of hypertension in angiogenesis inhibitor -treated patients.  Ann Oncol . 2009 
May;20(5):807 -15. 
Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status 
and future directions.  Lancet .  2016 Jul 30 ;388 (10043):518 -29. 
Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, Punt 
CJ, van Krieken JH.  Deficient mismatch repair system in patients with sporadic advanced 
colorectal cancer.  Br J Cancer .  2009 Jan 27;100(2):266 -73. 
Li J, Qin S, Xu R, et al. Effect of fruquintinib vs placebo on overall survival in patients with 
previously treated metastatic colorectal cancer.  JAMA . 2018;319(24):2486 -96. 
LONSURF® (trifluridine and tipiracil) Prescribing Information.  Taiho Pharmaceuti cal Co, Taiho 
Oncology, Inc. Princeton NJ, USA.  Revised Feb 2019  
Mayer R, Van Cutsem E, Falcone A, et al. Randomized Trial of TAS -102 for Refractory 
Metastatic Colorectal Cancer  (RECOURSE ). N Engl J Med  2015;  372: 1909 -19. 
National Comprehensive Cancer Ne twork (NCCN), Version 20 19.  
STIVARGA® (regorafenib) Prescribing Information.  Bayer HealthCare Pharmaceuticals, Inc, 
Whippany NJ, USA.  Revised Apr 2017.  
Sun Q, Zhou J, Zhang Z, Guo M et al., Discovery of fruquintinib, a potent and highly selective 
small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol 
Ther . 2014;15 (12):1635 -45. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  91 
 CONFIDENTIAL   
 15 APPENDICES  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  92 
 CONFIDENTIAL   
 APPENDIX 1 COVID -19 RISK ASSES SMENT  
Hutchison MediPharma acknowledges that the subject s to be enrolled in this study are patients 
with refractory cancer, and therefore, may be at higher risk for complications if they contract 
COVID -19.  Available data indicate that the elderly and people with underlying health conditions 
such as chronic res piratory, cardiovascular , or kidney disease ; diabetes ; active cancer ; and more 
generally severe chronic diseases are more vulnerable to experience complications.  However, 
there is an unmet medical need for new medications that are safe and effective in pa tients with 
refractory cancer who have limited treatment options.  
During the COVID -19 pandemic, patients may be at additional risk  as a result of going to a 
healthcare facility and interacting with healthcare staff and providers.   Patients may be screened 
and enrolled if the site has procedures in place to test and appropriately follow new patients on 
trial and to ensure patient safety and data integrity.  Potential patients with a known or suspected 
COVID -19 infection are ineligible.  Patients with a known  COVID -19 infection may be considered 
for participation following 2 subsequent negative tests per guidelines. It is at the principal 
investigator’s discretion to balance the risk/benefit to determine when enrollment is appropriate, 
and patient safety shoul d always be considered.  
The r isk management and mitigation steps being taken by Hutchison MediPharma Limited and its 
designee  are as follows.  These steps were developed to align with COVID -19 guidance on clinical 
trials issued by the US Food and Drug Admi nistration and European Medicines Agency.  
1. Subject safety  
a. Patient education on COVID -19-related risks will be provided by the principal 
investigator (ie, using cancer patient guidelines at European Society for Medical 
Oncology web site).  
− Patient time in clinic should be minimized when possible.   Blood sampling/visits may 
be performed at another location if this can be done within local restrictions on social 
distancing to reduce site burden and risk for infection (eg, utilizing a local laboratory, 
a home nurse, or a satellite site).  The laborat ory results must be reviewed by the 
principal investigator, and laboratory normal ranges must be collected and 
documented .  
− Study visits may be conducted with patients using telemedicine, where the principal 
investi gator and site personnel can videoconference with the patient.  In this setting, 
the principal investigators should perform as many assessments as possible, including 
any adverse events (AEs), concomitant medications, and Eastern Cooperative 
Oncology Group  performance status.  
b. Reduce the risk for COVID -19 infection associated with traveling to and from the 
clinic by providing a safer option to avoid public transportation (eg, car/taxi service) 
if necessary and permitted by local process.  
c. If a patient enrol led into the study subsequently tests positive for COVID -19, the data 
will be entered into the eCRF as an AE, with proper source documentation.  
2. Investigational Medicinal Product handling  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  93 
 CONFIDENTIAL   
 Investigational Product may be delivered to the patient’s house if permitted under the 
site’s Standard Operating Procedures and patient chain of custody and patient privacy is 
protected.  
3. Management of protocol deviations due to the COVID -19 pandemic  
Hutchison MediPharma and its designee will adhere to all  applicable healt h authority 
guidelines for documenting and reporting any protocol deviations due to the COVID -19 
pandemic.  The deviations will be reported to the authorities or institutional review 
boards/independent ethics committees  as instructed . 
4. Remote monitoring  
Hutchison MediPharma and its designee agree to perform remote monitoring where 
feasible and permitted.  For remote source data verification, country legislation will be 
followed and performed only where allowed with written agreement of the principal 
investig ator.  The planned site -level procedures will be described in detail and approvals 
sought as required.  If a site cannot support remote monitoring with Electronic Medical 
Record access, the site will not be permitted to consent new patients.  Remote visits  will 
also be conducted to facilitate site selection, initiation and training.  
5. External factors related to COVID -19  
Central supply chains  may be affected, and tubes used for ctDNA may not reach the 
study sites in adequate time for the enrollment of subjec ts.  In these cases, tests should be 
performed, if po ssible, using investigator site -supplied equipment.  If this is not possible, 
deviations should be appropriately documented as in number 3 above.   If other tests are 
problematic due to local conditions  related to COVID -19, please check with the sponsor.  
The benefit -risk balance  for patients to enroll  into this study  according to the inclusion and 
exclusion criteria defined in the protocol and according to the defined COVID -19 risk mitigation 
measures in this document remains favorable.  
Hutchison MediPharma and its designee will continue to evaluate the impact of COVID -19 on the 
ability of each site to initiate and execute the trial.  Site-specific positions will be evaluated prior 
to the site initiation v isit, with the outcomes and any resultant actions documented and filed in the 
Trial Master File.  
As the COVID -19 situation may be temporary, regulatory guidance will be continuously 
reevaluated and any changes will be communicated when  necessary.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  94 
 CONFIDENTIAL   
 APPENDIX  2 ECOG PERFORMANCE ST ATUS  
Grade  Activity Level  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature, eg, light house work, office work  
2 Ambulatory and capable of all self -care but unable to carry out any work 
activities.  Up and about more than 50% of waking hours  
3 Capable of only limited self -care, confined to bed or chair more than 50% of 
waking hours  
4 Completely disabled, cannot carry on any self -care, totally confined to bed or 
chair  
5 Death  
  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  95 
 CONFIDENTIAL   
 APPENDIX  3 RESPONSE EVALUATION  CRITERIA IN SOLID T UMORS 
(RECIST  V1.1)  
Selected sections from the Response Evaluation Criteria in Solid Tumors (RECIST), Version  1.1, 
are presented below.  
1 Measurability of Tumor at Baseline  
1.1 Definitions  
At baseline, tumor lesion s/lymph nodes will be categorized as measurable or non -measurable as 
described below.  
1.1.1 Measurable Tumor Lesions  
Tumor lesions must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a  minimum size as follows:  
• 10  mm by CT or magnetic resonance imaging (MRI) scan (CT/MRI scan slice 
thickness/interval no greater than 5 mm)  
• 10-mm caliper measurement by clinical examination (lesions that cannot be accurately 
measured with calipers should b e recorded as non -measurable)  
• 20 mm by chest X -ray 
• Malignant lymph nodes : To be considered pathologically enlarged and measurable, a 
lymph node must be 15 mm in the short axis when assessed by CT scan (CT scan slice 
thickness recommended to be no greater than 5 mm).  At baseline and follow -up, only the 
short axis will be measured and followed.  
1.1.2 Non -Measurable Tumor Lesions  
Non-measurable tumor lesions encompass small lesions (longest diameter  10 mm or pathological 
lymph nodes with short axis  10 but  15 mm) as well as truly non -measurable lesions.  Lesions 
considered truly non -measurable include leptomeningeal disease, ascites, pleural or pericardia l 
effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, peritoneal 
spread, and abdominal mass/abdominal organomegaly identified by physical examination that is 
not measurable by reproducible imaging techniques.  
1.1.3 Special Cons iderations Regarding Lesion Measurability  
Bone lesions, cystic lesions, and lesions previously treated with local therapy require particular 
comment, as outlined below.  
Bone Lesions : 
• Bone scan, positron emission tomography (PET) scan, or plain films are not considered 
adequate imaging techniques for measuring bone lesions.  However, these techniques can 
be used to confirm the presence or disappearance of bone lesions.  
• Lytic bone lesion s or mixed lytic –blastic lesions, with identifiable soft tissue components, 
that can be evaluated by cross -sectional imaging techniques such as CT or MRI can be 
considered as measurable lesions if the soft tissue component meets the definition of 
measurabi lity described above.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  96 
 CONFIDENTIAL   
 • Blastic bone lesions are non -measurable.  
Cystic Lesions:  
• Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non -measurable) since they are, 
by definition, simple cysts.  
• Cystic lesions thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above.  However, if non -
cystic lesions are present in the same patient, these a re preferred for selection as target 
lesions.  
Lesions with Prior Local Treatment:  
• Tumor lesions situated in a previously irradiated area, or in an area subjected  to other 
loco-regional therapy, are usually not considered measurable unless there has been 
demonstrated progression in the lesion.  Study protocols should detail the conditions 
under which such lesions would be considered measurable.  
1.2 Specifications by Methods of Measurements  
1.2.1 Measurement of Lesions  
All measurements should be recorded in m etric notation, using calipers if clinically assessed.  All 
baseline evaluations should be performed as close as possible to the treatment start and never more 
than 4 weeks before the beginning of the treatment.  
1.2.2 Method of Assessment  
The same method o f assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during the study.  Imaging -based evaluation should 
always be the preferred option.  
Clinical Lesions.  Clinical lesions will only be consi dered measurable when they are superficial 
and  10 mm in diameter as assessed using calipers ( eg, skin nodules).  For the case of skin lesions, 
documentation by color photography including a ruler to estimate the size of the lesion is 
suggested.  
Chest X -Ray.  Chest CT is preferred over chest X -ray, particularly when progression is an 
important endpoint, since CT is more sensitive than X -ray, particularly in identifying new lesions.  
However, lesions on chest X -ray may be considered measurable if t hey are clearly defined and 
surrounded by aerated lung.  
CT, MRI.  CT is the best currently available and reproducible method to measure lesions selected 
for response assessment.  This guideline has defined measurability of lesions on CT scan based on 
the assumption that CT slice thickness is 5 mm or less.  When CT scans have slice thickness greater 
than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.  MRI is 
also acceptable.  
If prior to enrollment it is known that a patie nt is unable to undergo CT scans with intravenous 
(IV) contrast because of allergy or renal insufficiency, the decision as to whether a non -contrast 
CT or MRI (without IV contrast) will be used to evaluate the patient at baseline and during the 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  97 
 CONFIDENTIAL   
 study shoul d be guided by the tumor type under investigation and the anatomic location of the 
disease.  For patients who develop contraindications to contrast after baseline contrast CT is done, 
the decision as to whether non -contrast CT or MRI (enhanced or non -enhan ced) will be performed 
should also be based on the tumor type and the anatomic location of the disease, and should be 
optimized to allow for comparison with the prior studies if possible.  Each case should be discussed 
with the radiologist to determine if substitution of these other approaches is possible and, if not, 
the patient should be considered not evaluable from that point forward.   Care must be taken in 
measurement of target lesions on a different modality and interpretation of non -target disease or  
new lesions, since the same lesion may appear to have a different size using a new modality.  
Ultrasound.   Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement.  
Endoscopy, Laparoscopy, Tumor Markers, Cytol ogy, Histology.  The utilization of these 
techniques for objective tumor evaluation cannot generally be advised.  
2 Tumor Response Evaluation  
2.1 Assessment of Overall Tumor Burden and Measurable Disease  
To assess objective response or future progression, i t is necessary to estimate the overall tumor 
burden at baseline and use this as a comparator for subsequent measurements.  Measurable disease 
is defined by the presence of at least one measurable lesion, as detailed above.  
2.2 Baseline Documentation of Target and Non -Target Lesions  
When more than one measurable lesion is present at baseline, all lesions up to a maximum of five 
lesions total (and a maximum of two lesions per organ) representative of all involved organs should 
be identified as target lesio ns and will be recorded and measured at baseline.  This means that, for 
instances in which patients have only one or two organ sites involved, a maximum of two lesions 
(one site) and four lesions (two sites), respectively, will be recorded.  Other lesions (albeit 
measurable) in those organs will be recorded as non -measurable lesions (even if the size is 10 mm 
by CT scan).  
Target lesions should be selected on the basis of their size (lesions with the longest diameter) and 
be representative of all involved o rgans, but in addition should lend themselves to reproducible 
repeated measurements.  It may be the case that, on occasion, the largest lesion does not lend itself 
to reproducible measurement, in which circumstance the next largest lesion that can be measu red 
reproducibly should be selected.  
Lymph nodes merit special mention since they are normal anatomical structures that may be visible 
by imaging even if not involved by tumor.  As noted above, pathological nodes that are defined as 
measurable and may be i dentified as target lesions must meet the criterion of a short axis of 
15 mm by CT scan.  Only the short axis of these nodes will contribute to the baseline sum.  The 
short axis of the node is the diameter normally used by radiologists to judge if a node is involved 
by solid tumor.  Nodal size is normally reported as two dimensions in the plane in which the image 
is obtained (for CT this is almost always the axial p lane; for MRI the plane of acquisition may be 
axial, sagittal, or coronal).  The smaller of these measures is the short axis.  For example, an 
abdominal node that is reported as being 20 mm  30 mm has a short axis of 20 mm and qualifies 
as a malignant, me asurable node.  In this example, 20 mm should be recorded as the node 
measurement.  All other pathological nodes (those with short axis 10 mm but 15 mm) should 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  98 
 CONFIDENTIAL   
 be considered non -target lesions.  Nodes that have a short axis of 10 mm are considered non -
pathological and should not be recorded or followed.  
A sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum of diameters.  If lymph nodes are to be 
included in the sum, then, as noted above, only the short axis is added into the sum.  The baseline 
sum of diameters will be used as a reference to characterize further any objective tumor regression 
in the measurable dimension of the disease.  
All other lesion s (or sites of disease), including pathological lymph nodes, should be identified as 
non-target lesions and should also be recorded at baseline.  Measurements are not required and 
these lesions should be followed as “present,” “absent,” or in rare cases “u nequivocal progression.”  
In addition, it is possible to record multiple non -target lesions involving the same organ as a single 
item on the Case Report Form ( eCRF) (eg, “multiple enlarged pelvic lymph nodes” or “multiple 
liver metastases”).  
2.3 Response Cr iteria  
2.3.1 Evaluation of Target Lesions  
This section provides the definitions of the criteria used to determine objective tumor response 
for target lesions.  
• Complete response (CR): Disappearance of all target lesions.  Any pathological lymph nodes 
(wheth er target or non -target) must have reduction in short axis to  10 mm.  
• Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking 
as reference the baseline sum of diameters  
• Progressive disease (PD): At least a 20% incr ease in the sum of diameters of target lesions, 
taking as reference the smallest sum on study (nadir), including baseline.  In addition to the 
relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.  
The appearance of  one or more new lesions is also considered progression.  
• Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum on study  
2.3.2 Special Notes on the Assessment of T arget Lesions  
Lymph Nodes.   Lymph nodes identified as target lesions should always have the actual short axis 
measurement recorded (measured in the same anatomical plane as the baseline examination), even 
if the nodes regress to  10 mm on study.  This means that when lymph nodes are included as 
target lesions, the sum of lesions may not be zero even if complete response criteria are met, since 
a normal lymph node is defined as having a short axis of  10 mm.  
Target Lesions That Become Too Small to Measure.   During the study, all lesions (nodal and 
non-nodal) recorded at baseline should have their actual measurements recorded at each 
subsequent evaluation, even when very small (eg, 2 mm).  However, sometimes lesions or lymph 
nodes that are recorded a s target lesions at baseline become so faint on CT scan that the radiologist 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  99 
 CONFIDENTIAL   
 may not feel comfortable assigning an exact measure and may report them as being too small to 
measure.  When this occurs, it is important that a value be recorded on the eCRF, as follows:  
• If it is the opinion of the radiologist that the lesion has likely disappeared, the 
measurement should be recorded as 0 mm.  If the lesion is believed to be present and is 
faintly seen but too small to measure, a default value of 5 mm should be as signed and 
BML (below measurable limit) should be ticked. (BML is equivalent to a “less than” 
sign.) (Note: It is less likely that this rule will be used for lymph nodes since they usually 
have a definable size when normal and are frequently surrounded by fat such as in the 
retroperitoneum; however, if a lymph node is believed to be present and is faintly seen 
but too small to measure, a default value of 5 mm should be assigned in this circumstance 
as well and BML should also be ticked).  
To reiterate, howev er, if the radiologist is able to provide an actual measure, that should be 
recorded, even if it is below 5 mm, and in that case BML should not be ticked . 
Lesions That Split or Coalesce on Treatment.   When non -nodal lesions fragment, the longest 
diameters of the fragmented portions should be added together to calculate the target lesion sum.  
Similarly, as lesions coalesce, a plane between them may be maintained that would aid in obtaining 
maximal diameter measurements of each individual lesion.  If the les ions have truly coalesced 
such that they are no longer separable, the vector of the longest diameter in this instance should be 
the maximum longest diameter for the coalesced lesion.  
2.3.3 Evaluation of Non -Target Lesions  
This section provides the definitions of the criteria used to determine the tumor response for the 
group of non -target lesions.  While some non -target lesions may actually be measurable, they need 
not be measured and instead should be assessed only qualita tively at the time point s specified in 
the protocol.  
• Complete response (CR): Disappearance of all non -target lesions and (if applicable) 
normalization of tumor marker level.  All lymph nodes must be non -pathological in size 
( 10 mm short axis).  
• Non-CR/Non -PD: Persistence of one or more non -target lesions and/or (if applicable) 
maintenance of tumor marker level above the normal limits  
• Progressive disease (PD): Unequivocal progression of existing non -target lesions.  The 
appearance of one or more new lesions  is also considered progression.  
2.3.4 Special Notes on Assessment of Progression of Non -Target Disease  
When the Patient Also Has Measurable Disease.   In this setting, to achieve unequivocal 
progression on the basis of the non -target disease, there must be  an overall level of substantial 
worsening in non -target disease in a magnitude that, even in the presence of SD or PR in target 
disease, the overall tumor burden has increased sufficiently to merit discontinuation of therapy.  A 
modest increase in the siz e of one or more non -target lesions is usually not sufficient to qualify for 
unequivocal progression status.  The designation of overall progression solely on the basis of 
change in non -target disease in the face of SD or PR of target disease will therefor e be extremely 
rare. 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  100 
 CONFIDENTIAL   
 When the Patient Has Only Non -Measurable Disease.   This circumstance arises in some phase 3 
trials when it is not a criterion of study entry to have measurable disease.  The same general 
concepts apply here as noted above; however, in this instance there is no measurable disease 
assessment to factor into the interpretation of an increase in non -measurable disease burden.  
Because worsening in non -target disease cannot be easily quantified (by  definition: if all lesions 
are truly non -measurable), a useful test that can be applied when assessing patients for unequivocal 
progression is to consider if the  increase in overall disease burden based on the change in non -
measurable disease is comparable in magnitude to the increase that would be required to declare 
PD for measurable disease, that is, an increase in tumor burden representing an additional 73% 
increase in volume (which is equivalent to a 20% increase in diameter in a measurable lesion).  
Examples include an increase in a pleural eff usion from “trace” to “large” or an increase in 
lymphangitic disease from localized to widespread, or may be described in protocols as “sufficient 
to require a change in therapy.”  If unequivocal progression is seen, the patient should be 
considered to hav e had overall PD at that point.  While it would be ideal to have objective criteria 
to apply to non -measurable disease, the very nature of that disease makes it impossible to do so; 
therefore, the increase must be substantial.  
2.3.5 New Lesions  
The appearance of new malignant lesions denotes disease progression; therefore, some comments 
on detection of new lesions are important.  There are no specific criteria for the identification of 
new radiographic lesions; however, the finding of a new lesio n should be unequivocal, that is, not 
attributable to differences in scanning technique, change in imaging modality, or findings thought 
to represent something other than tumor (for example, some “new” bone lesions may be simply 
healing or flare of preexis ting lesions).  This is particularly important when the patient’s baseline 
lesions show partial or complete response.  For example, necrosis of a liver lesion may be reported 
on a CT scan report as a “new” cystic lesion, which it is not.  
A lesion identifie d during the study in an anatomical location that was not scanned at baseline is 
considered a new lesion and will indicate disease progression.  
If a new lesion is equivocal, for example because of its small size, continued therapy and follow -
up evaluation will clarify if it represents truly new disease.  If repeat scans confirm there is 
definitely a new lesion, then progression should be declared using the date of the initial scan.  
(18) F -Fluorodeoxyglucose Positron Emission Tomography (FDG -PET)  
While FDG -PET response assessments need additional study, it is sometimes reasonable to 
incorporate the use of FDG -PET scanning to complement CT scanning in assessment of 
progression (particularly, possible “new” disease).  New lesions on the basis of FDG -PET imaging  
can be identiﬁed according to the following algorithm:  
A negative FDG -PET scan at baseline with a positive FDG -PET scan during the study is a sign of 
PD based on a new lesion.  
In the case of no FDG -PET scan at baseline and a positive FDG -PET scan during t he study:  
• If the positive FDG -PET scan during the study corresponds to a new site of disease 
conﬁrmed by CT, this will be considered PD.  
• If the positive FDG -PET scan during the study is not conﬁrmed as a new site of disease on 
CT, additional follow -up CT s cans are needed to determine whether there is truly 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  101 
 CONFIDENTIAL   
 progression occurring at that site (if so, the date of PD will be the date of the initial 
abnormal FDG -PET scan).  
• If the positive FDG -PET scan during the study corresponds to a preexisting site of disease  
on CT that is not progressing on the basis of the anatomic images, this will not be 
considered PD.  
2.4 Evaluation of Response  
2.4.1 Time  Point Response (Overall Response)  
It is assumed that at each protocol -specified time  point, a response assessment occu rs.  Table  15 
provides a summary of the overall response status calculation at each time  point for patients who 
have measurable disease at baseline.  
Whe n patients have non -measurable (therefore non -target) disease only, Table  16 is to be used.  
Table  15 Time  Point Response: Patients with Target Lesions (with or without Non -
Target Lesions)  
Target Lesions  Non-Target Lesions  New Lesions  Overall Response  
CR CR No CR 
CR Non-CR/non -PD No PR 
CR Not evaluated  No PR 
PR Non-PD or not all evaluated  No PR 
SD Non-PD or not all evaluated  No SD 
Not all evaluated  Non-PD No NE 
PD Any Yes or no  PD 
Any PD Yes or no  PD 
Any Any Yes PD 
CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable 
disease.  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  102 
 CONFIDENTIAL   
 Table  16 Time Point Response: Patients with Non -Target Lesions Only  
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non -PD No Non-CR/non -PD a 
Not all evaluated  No NE 
Unequivocal PD  Yes or no  PD 
Any Yes PD 
CR = complete response; NE = not evaluable; PD = progressive disease.  
a “Non -CR/non -PD” is preferred over “stable disease” for non -target disease since stable disease is increasingly 
used as an endpoint for assessment of efficacy in some trials; thus, assigning “stable disease” when no lesions can 
be me asured is not advised.  
2.4.2 Missing Assessments and Not -Evaluable Designation  
When no imaging/measurement is done at all at a particular time  point, the patient is not evaluable 
at that time  point.  If only a subset of lesion measurements are made at an assessment, usually the 
case is also considered not evaluable at that time  point, unless a convincing argument can be made 
that the contribution of the individual missing lesion(s) would not change the assigned time  point 
response.  This would be most like ly to happen in the case of PD.  For example, if a patient had a 
baseline sum of 50 mm with 3 measured lesions and , during the study , only 2 lesions were 
assessed, but those gave a sum of 80 mm, the patient will have achieved PD status, regardless of 
the c ontribution of the missing lesion.  
If one or more target lesions were not assessed either because the scan was not done or the scan 
could not be assessed because of poor image quality or obstructed view, the response for target 
lesions should be “unable to  assess” since the patient is not evaluable.  Similarly, if one or more 
non-target lesions are not assessed, the response for non -target lesions should be “unable to assess” 
except where there is clear progression.  Overall response would be “unable to ass ess” if either the 
target response or the non -target response is “unable to assess” except where this is clear evidence 
of progression, as this equates with the case being not evaluable at that time  point.  
2.4.3 Best Overall Response: All Time Points  
The best overall response is determined once all the data for the patient is known.  Best response 
determination in trials where confirmation of complete or partial response IS NOT required: Best 
response in these trials is defined as the best response acr oss all time points (for example, a patient 
who has SD at first assessment, PR at second assessment, and PD on last assessment has a best 
overall response of PR).  When SD is believed to be best response, it must also meet the protocol 
specified minimum ti me from baseline.  If the minimum time is not met when SD is otherwise the 
best time point response, the patient’s best response depends on the subsequent assessments.  For 
example, a patient who has SD at first assessment, PD at second and does not meet m inimum 
duration for SD, will have a best response of PD.  The same patient lost to follow -up after the first 
SD assessment would be considered inevaluable.  
Best response determination in trials where confirmation of complete or partial response IS 
required : Complete or partial responses may be claimed only if the criteria for each are met at a 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  103 
 CONFIDENTIAL   
 subsequent time point as specified in the protocol (generally 4 weeks later).  In this circumstance, 
the best overall response can be interpreted as in Table  17. 
Table  17 Best Overall Response When Confirmation of Complete Response  and 
Partial Response is  Required  
Overall response  
First time point  Overall response  
Subsequent time point  BEST overall response  
CR CR CR 
CR PR SD，PD or PRa 
CR SD SD provided minimum criteria for SD duration met, 
otherwise, PD  
CR PD SD provided minimum criteria for SD duration met, 
otherwise, PD  
CR NE SD provided minimum criteria for SD duration met, 
otherwise NE  
PR CR PR 
PR PR PR 
PR SD SD 
PR PD SD provided minimum criteria for SD duration met, 
otherwise, PD  
PR NE SD provided minimum criteria for SD duration met, 
otherwise NE  
NE NE NE 
 
CR = complete response, PR = partial response, SD = stable disease, PD =progressive disease, and NE = inevaluable.  
a: If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR 
criteria relative to baseli ne, makes the disease PD at that point (since disease must have reappeared after CR).  Best 
response would depend on whether minimum duration for SD was met.  However, sometimes ‘CR’ may be claimed 
when subsequent scans suggest small lesions were likely st ill present and in fact the patient had PR, not CR at the first 
time point.  Under these circumstances, the original CR should be changed to PR and the best response is PR.  
 
Special Notes on Response Assessment  
When nodal disease is included in the sum of target lesions and the nodes decrease to “normal” 
size ( 0 mm), they may still have a measurement reported on scans.  This measurement should be 
recorded even though the nodes are normal in order not to overstate progression should it be based 
on increase  in size of the nodes.  As noted earlier, this means that patients with CR may not have 
a total sum of “zero” on the eCRF.  
Patients with a global deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression at that time should be reported as “symptomatic 
deterioration.”   Every effort should be made to document objective progression even after 
discontinuation of treatment.  Symptomatic deterioration is not a descriptor of an objective 
response; it is a reason for stopping study therapy.  The objective response status of such patients 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  104 
 CONFIDENTIAL   
 is to be determined by evaluation of target and non -target disease as shown in Table  15 and 
Table  16. 
For equivocal findings of progression ( eg, very small and uncertain new lesions; cystic changes or 
necrosis in exis ting lesions), treatment may continue until the next scheduled assessment.  If at the 
next scheduled assessment, progression is confirmed, the date of progression should be the earlier 
date when progression was suspected.  
In studies for which patients with  advanced disease are eligible ( ie, primary disease still or partially 
present), the primary tumor should also be captured as a target or non -target lesion, as appropriate.  
This is to avoid an incorrect assessment of complete response if the primary tumor  is still present 
but not evaluated as a target or non -target lesion.  
2.5 Frequency of Tumo r Re-evaluation  
Frequency of tumo r re-evaluation while on treatment should be protocol specific and adapted to 
the type and schedule of treatment.  However, in the context of phase 2 studies where the beneficial 
effect of therapy is not known, follow -up every 6 –8 weeks (timed to coincide with the end of a 
cycle) is reasonable.  Smaller or greater time intervals than these could be justified in specifi c 
regimens or circumstances.  The protocol should specify which organ sites are to be evaluated at 
baseline (usually those most likely to be involved with metastatic disease for the tumo r type under 
study) and how often evaluations are repeated.  Normally,  all target and non -target sites are 
evaluated at each assessment.  In selected circumstances certain non -target organs may be 
evaluated less frequently.  For example, bone scans may need to be repeated only when complete 
response is identified in target d isease or when progression in bone is suspected.  
After the end of the treatment, the need for repetitive tumo r evaluations depends on whether the 
trial has as a goal the response rate or the time to an event (progression/death).  If ‘time to an event’ 
(eg, time to progression, disease -free survival, progression -free survival) is the main endpoint of 
the study, then routine scheduled re -evaluation of protocol specified sites of disease is warranted.  
In randomiz ed comparative trials in particular, the schedu led assessments should be performed as 
identified on a calendar schedule (for example: every 6 –8 weeks on treatment or every 3 –4 months 
after treatment) and should not be affected by delays in therapy, drug holidays or any other events 
that might lead to i mbalance in a treatment arm in the timing of disease assessment.  
2.6 Confirmatory measurement/duration of response  
2.6.1 Confirmation  
In non -randomiz ed trials where response is the primary endpoint, confirmation of PR and CR is 
required to ensure responses  identified are not the result of measurement error.  This will also 
permit appropriate interpretation of results in the context of historical data where response has 
traditionally required confirmation in such trials (see the paper by Bogaerts et al. in t his Special 
Issue10).  However, in all other circumstances, for example  in randomiz ed trials (phase 2 or 3) or 
in studies where stable disease or progression are the primary endpoints, confirmation of response 
is not required since it will not add value to  the interpretation of trial results.  However, elimination 
of the requirement for response confirmation may increase the importance of central review to 
protect against bias, in particular in studies that are not blinded.  
In the case of SD, measurements m ust have met the SD criteria at least once after study entry at a 
minimum interval (in general not less than 6 –8 weeks) that is defined in the study protocol.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  105 
 CONFIDENTIAL   
 2.6.2 Duration of overall response  
The duration of overall response is measured from the time mea surement criteria are first met for 
CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease is 
objectively documented (taking as reference for progressive disease the smallest measurements 
recorded on study).  
The dura tion of overall complete response is measured from the time measurement criteria are first 
met for CR until the first date that recurrent disease is objectively documented.  
2.6.3 Duration of stable disease  
Stable disease is measured from the start of the t reatment (in randomiz ed trials, from date of 
randomiz ation) until the criteria for progression are met, taking as reference the smallest sum on 
study (if the baseline sum is the smallest, this is the reference for calculation of PD).  
The clinical relevance  of the duration of stable disease varies in different studies and diseases.  If 
the proportion of patients achieving stable disease for a minimum period of time is an endpoint of 
importance in a particular trial, the protocol should specify the minimal ti me interval required 
between two measurements for determination of stable disease.  
Note: The duration of response and stable disease as well as the progression -free survival are 
influenced by the frequency of follow -up after baseline evaluation.  It is not  in the scope of this 
guideline to define a standard follow -up frequency.  The frequency should take into account many 
parameters including disease types and stages, treatment periodicity and standard practice.  
However, these limitations of the precision of the measured endpoint should be taken into account 
if comparisons between trials are to be made.  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  106 
 CONFIDENTIAL   
 APPENDIX  4 PROHIBITED MEDICAT ION  
A series of strong inducers and strong inhibitors of CYP3A are listed in Table 18 and Table  19 
below.  Examples of sensitiv e substrates of P -gp and BCRP are listed in  Table  20. 
Patients who received a CYP3A strong inducer or strong inhibitor within 2 weeks ( 3 weeks for 
hyperforin perforatum /St. John’s Wort  treatment) prior to the first dose of the study drug will no t 
be allowed to participate in the study.   During the study, co-administration of strong inducers and 
inhibitors of CYP3A with fruquintinib  should be avoided  unless investigators consider it 
necessary.  In this case, fruquintinib efficacy reduction or toxicity increases resulting from the 
interaction should be closely monitored.  
Not all the medications are listed in the following tables.  Other drugs known possibly to affect 
CYP3A activity and to be substrates of P -gp and BCRP should be used with caution.  When 
combining fruquintinib with other drugs the prescription information of all concomitant 
medications should be reviewed.  
  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  107 
 CONFIDENTIAL   
 Table 18 Typical Strong Inhibitors of CYP3A4  
Strong Inhibitors of CYP3A4  
Boceprevir  
Clarithromycin  
Conivaptan  
Elvitegravir/Ritonavir  
Fluconazole  
Grapefruit juicea,b 
Indinavir  
Itraconazole  
Ketoconazole  
Lopinavir/Ritonavir  
Mibefradil  
Nelfinavir  
Posaconazole  
Ritonavir  
Saquinavir  
Telaprevir  
Telithromycin  
Tipranavir/Ritonavir  
Troleandomycin  
Voriconazole  
a Super -concentrated g rapefruit juice  
b During the study, patients should not consume large amounts of grapefruit or lime (or products that include 
these f ruits, such as grapefruit juice, Seville oranges, and orange jam).  No more than one cup (120 mL) of 
grapefruit juice, half a grapefruit or a spoon full (15 g) of orange jam should be consumed each day.  
  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  108 
 CONFIDENTIAL   
 Table  19 Typical Strong Inducers of CYP3A4  
Strong Inducers of CYP3A4  
Apalutamide  
Avasimibe  
Carbamazepine  
Enzalutamide  
Mitotane  
Phenobarbital  
Phenytoin  
Rifabutin  
Rifampin (or r ifampicin ) 
St. John’s wort  
  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  109 
 CONFIDENTIAL   
 Table  20 Sensitive Substrates of P -gp or BCRP  
Substrates of P -gp Substrates of BCRP  
Aliskiren  
Ambrisentan  
Colchicine  
Dabigatran etexilate  
Digoxin  
Everolimus  
Fexofenadine  
Imatinib  
Lapatinib  
Maraviroc  
Nilotinib  
Posaconazole  
Ranolazine  
Saxagliptin  
Sirolimus  
Sitagliptin  
Talinolol  
Tolvaptan  
Topotecan  Methotrexate  
Mitoxantrone  
Imatinib  
Irrinotecan  
Lapatinib  
Rosuvastatin  
Sulfasalazine  
Topotecan  
 
  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  111 
 CONFIDENTIAL   
 Table  21 Summary of Clinical Trial Program of Fruquintinib in China and the US * 
Study Number  
NCT#  
(Name)  
Indication  Study Title  Study Objectives  
and Phase  Study Subjects  
 Study  Design  
2012 -013-00CH1  
[STUDY_ID_REMOVED]  
3rd line mCRC  A Randomized, Double -blind, 
Placebo -controlled, Multi -
center Phase II Clinical Trial 
to Evaluate the Efficacy and 
Safety of Fruquintinib  Plus 
Best Supportive Care in 
advanced colorectal cancer 
patients who have progressed 
after second -line 
chemotherapy  PFS (Fruquintinib 
versus  PBO),  OS, 
ORR, safety Phase 2  Fruquintinib: 
N=47; Placebo: 
N=24  
Total N=71  Randomized, 
double -blind, 
placebo -controlled, 
multicenter study  
 
2014 -013-00CH1  
[STUDY_ID_REMOVED]  
3rd line NSCLC  A Randomized,  Double -blind, 
Placebo -controlled, Multi -
center Phase II Clinical Trial 
to Evaluate the Efficacy and 
Safety of Fruquintinib Plus 
Best Supportive Care in 
Patients With Advanced Non -
squamous Non -small Cell 
Lung Cancer  (Fruquintinib versus  
PBO), OS, ORR, 
safety Phase 2  Fruquintinib 
N=61. Placebo: 
N=30  
Total N=91  Randomized, 
double -blind, 
placebo -controlled, 
multicenter study  
 
2015 -013-00CH1  
[STUDY_ID_REMOVED]  
(FALUCA)  
3rd line NSCLC  A Randomized, Double -blind, 
Placebo -controlled, Multi -
center Phase III Clinical Trial 
in Patients With Advanced 
Non-squamous Non -small 
Cell Lung Cancer Treated 
With Fruquintinib  Confirmatory efficacy 
and safety NSCLC. 
Phase 3  Fruquintinib 
N=352  
Placebo N= 171  
Total N=523  Randomized, 
double -blind, 
placebo -controlled, 
multicenter study  
 
2017 -013-00CH1  
[STUDY_ID_REMOVED]  
2nd line gastric 
cancer  A Phase III Study to Evaluate 
the Efficacy  and Safety of 
Fruquintinib in Combination 
With Paclitaxel Versus 
Paclitaxel Alone in Second 
Line Gastric Cancer  Phase 3  N=544 
(planned)  
 Randomized, 
double -blind, 
placebo -controlled, 
multicenter study  
 
2014 -013-00CH3  
[STUDY_ID_REMOVED]  
2nd line gastric 
cancer  
 A Phase Ib/2 Clinical Study 
to Evaluate the Safety, 
Pharmacokinetic 
Characteristics and 
Preliminary Efficacy of 
Fruquintinib Combined With 
Paclitaxel in Patients With 
Advanced Gastric Cancer  (Fruquintinib + 
paclitaxel combo), 
safety, tolerability, 
PK, preliminary 
efficacy Phase 1b/2  N=34  Two-stage, open -
label, multicenter 
study. Stage 1: dose 
escalation. Stage 2: 
selected dose 
regimen expansion  
(comb inatio n  + 
paclitaxel)   
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  113 
 CONFIDENTIAL   
 Table  21 Summary of Clinical Trial Program of Fruquintinib in China and the US * 
Study Number  
NCT#  
(Name)  
Indication  Study Title  Study Objectives  
and Phase  Study Subjects  
 Study  Design  
2014 -013-00CH5  
 A Single Center, Open -label, 
Randomized, Two -period 
Crossover Study to Evaluate 
the Pharmacokinetics and 
Bioequivalence in Healthy 
Male Chinese Volunteers 
Following Single Doses of 
Fruquintinib Capsules 
Produced by Two Different 
Manufacturers  Primary: to assess the 
bioequivalence of 
fruquintinib produced 
at two manufacturers; 
Secondary: safety, 
explore metabolism 
and excretion  
Phase 1  Healthy Males  
N=24  Randomized, open -
label, two -period 
crossover, two -stage, 
single center study.  
 
2015 -013-00CH2  
[STUDY_ID_REMOVED]  
 Absorption, Metabolism and 
Excretion of [14C] 
Fruquintinib in Healthy Male 
Volunteers after a Single Oral 
Administration of 5mg/100 
μCi/Subject of [14C] 
Fruquintinib  Evaluate mass 
balance in healthy 
male volunteers 
following a single 
oral administration of 
5 mg/100 μCi/Subject 
of [14C] fruquintinib  
Phase 1  Healthy Males  
N=6 To investigate the 
absorption, drug 
biotransformation 
and mass balance 
and to evaluated the 
PK and safety of 
fruquintinib. To 
identify the 
compound's major 
metabolites  
Source:  Fruquintinib Investigator’s Brochure  
*See the Fruquintinib Investigator’s Brochure  for up -to-date information.  
  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  114 
 CONFIDENTIAL   
 APPENDIX  6 CLINICAL EVALUATION  OF POSSIBLE DRUG -INDUCED LIVER 
INJURY (DILI)  
If ALT or AST is elevated to higher than 3 x ULN and bilirubin is elevated to higher than 2 X 
ULN, treatment should be discontinued immediately, and supportive treatment should be given.  
This combination of lab abnormalities meets the biochemical criteria for Hy’s law, which is 
associated with a markedly i ncreased possibility of severe drug -induced liver injury (DILI), and 
may progress to liver transplantation or death (FDA Guidance for Industry - Drug -Induced Liver 
Injury: Premarketing Clinical Evaluation. FDA, 2009).  
If the biochemical criteria for Hy’s l aw are met, fruquintinib should be immediately discontinued, 
and patients need to be very closely monitored (bilirubin, ALP, AST, and ALT measured 2 -3 times 
weekly until the results return to baseline or normal), and other causes of liver injury evaluated 
(eg, new or worsening hepatobiliary metastases; non -malignant biliary obstruction; viral hepatitis 
A, B, or C; alcoholic or autoimmune hepatitis; preexisting or acute liver disease; ischemic liver 
injury; right -sided congestive heart failure; new or worsen ing liver metastases; or concomitant 
medication that could cause the observed injury).  Consultation with a gastroenterologist or 
hepatol ogist should be considered.  
If the biochemical criteria for Hy’s Law have been met, expedited reporting is required (se e 
Section  8.1), before waiting for the evaluation of other causes to be completed.  
Recommended Data Collection for Suspected DILI  
The investigator is recommended to obtain the following information, so as to further evaluate and 
follow up and complete the clinical data.  Data should be recorded on eCRFs where possible, and 
supplemented by investigator reporting as text in the clinica l database:  
• Medical history of the patient  
o Detailed history of current symptoms, diagnosis of complications and medical history  
o Previous medical history (viral hepatitis, alcoholic hepatitis, autoimmune disease, 
biliary tract disease and cardiovascular dis ease, etc.)  
o History of concomitant medication (including OTC and prescription drugs, herbal 
medicine and dietary supplements), alcohol consumption, recreational drugs and 
special diet  
o History of exposure to potentially hepatotoxic chemicals  
• Complete the fo llowing laboratory tests:  
o Hematology  
o Clinical biochemistry: ALT, AST, bilirubin (including total bilirubin and direct 
bilirubin), ALP, albumin, PTT or INR, amylase, lipase, fasting blood glucose, 
cholesterol and triglycerides  
o Other Serum Tests: Hepatitis A  (Anti -IgM and Anti -IgG), hepatitis B (HbsAg, Anti -
HBs and HBV DNA), hepatitis C (Anti -HCV, and HCV RNA test is required for any 
patient with positive test result), hepatitis D (Anti -IgM and Anti -IgG), hepatitis E 
(Anti -HEV and Anti -HEV IgM).  
• Complete app ropriate auxiliary examination:  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  115 
 CONFIDENTIAL   
 o Patients with confirmed elevation of ALT/AST combined with TBili are required to 
receive abdominal ultrasonography or other clinically applicable imaging examination 
within 48 hours (to exclude biliary tract, pancreatic, or intrahepatic causes, such as new 
or worsening hepatobiliary metastases or biliary calculi) and obtain the liver imaging 
result as soon as possible.  If an alternative cause (such as biliary tract, pancreatic, or 
intrahepatic causes) of abnormal hepatic res ults cannot be confirmed by imaging, 
consultation with a gastroenterologist or hepatologist should be considered ;  
o If suspected cardiovascular causes exist, cardiac ultrasonography is recommended to 
exclude cardiovascular dysfunction ( ie, right heart failure);  
Long -term follow -up: Perform close monitoring on the patient through repetitive tests of ALT, 
AST and bilirubin (including total bilirubin and direct bilirubin) two to three times weekly until 
the laboratory ALT and/or AST abnormalit y becomes stable or recovers, and then proceed 
according to the protocol.  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  116 
 CONFIDENTIAL   
 APPENDIX  7 CLINICAL MANAGEMENT  OF SEVERE OR SERIOU S 
HEMORRHAGIC EVENTS  
If hemorrhagic events are evaluated as severe (CTCAE grade  ≥3) or SAE s,  study treatment should 
be discontinued or interrupted immediately, and appropriate treatment measures initiated to control 
bleeding ( eg transfusion, radiologic, endoscopic, or elective operative intervention as indicated).  
When the patient is not well enough to  tolerate an invasive procedure or operation, best supportive 
care is given (see Section  7.5.6.2 ).  Patients need to be very closely monitored, both clinically 
(continuously), and by relevant laboratory testing (INR, aPTT, platelet count, hemoglobin) every 
2-3 days until the results return to baseline or normal).  During the initial assessment, a focused 
history and physical examination, with collectio n of vital signs and laboratory evaluation and 
imaging evaluation should be obtained, aimed at determining the time of onset, location, severity 
of bleeding, and whether bleeding is ongoing.  Clinicians should be mindful of comorbidities and 
concomitant tr eatments (eg. anti -platelet therapy and/or thrombocytopenia, or liver disease)  that 
could also contribute to bleeding and manage them as appropriate.  Consultation with other 
department clinicians should be considered when necessary.  
If a hemorrhagic event is evaluated as a severe (CTCAE grade  ≥3) or SAE  after taking fruquintinib, 
the investigator is required to report the event in an expedited fashion (within 24 hours of first 
awareness) to sponsor (see Section  8.2.2 ).  
See Figure 2 below for guidance on the management of severe  or serious hemorrhage at any site.  
Recommended Data Collection for Severe or Serious Hemorrhagic Events:  
The investigator is recommended to obtain the following information, so as to further evaluate and 
follow up and complete the clinical data.  Data should be recorded on SAE/AESI report form 
where possible, and supplemented by  Bleeding Event Follow -Up Questionnaire:  
• Medical history of the patient  
o Detailed history of current symptoms, diagnosis of complications and medical history  
o Previous medical his tory  
o History of concomitant medication (  
▪ Vitamin K antagonists ( eg warfarin)  
▪ NSAIDs ( eg aspirin)  
▪ Anti-platelet drugs (eg , clopidogrel/glycoprotein GPIIb/IIIa 
inhibitors/dipyridamole)  
▪ Other anticoagulants ( eg heparin/thrombolytics/SSRIs)  
▪ Food and herbal supplements with anticoagulant property  
▪ Immunosuppressants  
▪ Alcohol consumption  
▪ Recreational drugs and special diet  
o Family history of bleeding events  
• Complete the following laboratory tests:  
o Hematology: hemoglobin, platelet, hematocrit, reticulocyte count  
o Clinical biochemistry: bleeding time, PTT, aPTT, INR  
• Complete appropriate auxiliary examination:  
o Patients with confirmed bleeding are required to receive upper or lower GI endoscopy, 
bronchoscopy or other clinically applicable procedure or radiologic imag ing within 48 
hours, to confirm the site of bleeding.  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment 4   
Hutchison MediPharma   Page  117 
 CONFIDENTIAL   
 o If suspected cardiovascular causes exist, cardiac ultrasonography is recommended to 
exclude cardiovascular dysfunction (ie, right heart failure).  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment  4   
 
Hutchison MediPharma   Page 119 
 CONFIDENTIAL   
 
 APPENDIX  8 MANAGEMENT OF HYPER TENSION IN PATIENTS RECEIVING 
FRUQUINTINIB  
Hypertension is a common AE that has been reported in patients taking angiogenesis inhibitors 
(Izzedine 2009 ), including fruquintinib.  Grade 3 AEs have been reported in 16% of patients treated 
with fruquintinib; no Grade 4 events have been reported to date.  It appears that hypertension is a 
class -effect of VEGFR inhibi tors (either antibodies or small molecules).  
There is no standard therapy for angiogenesis inhibitor -induced hypertension because there have 
not been any published controlled clinical trials with specific agents.  Therefore, one can take an 
approach based on the clinical characteristics of particular patients.  Calcium channel blockers and 
angiotensin converting enzyme inhibitors (ACEI) are a reasonable first choice in most cases.  For 
patients with proteinuria, chronic renal disease or metabolic disease, a n ACE inhibitor or 
angiotensin II receptor blockers (ARB) may be preferred; for elderly patients, dihydropyridine 
calcium channel blockers may be preferred.  In this appendix is a summary of the most recent 
American Heart Association (AHA)/American College  of Cardiology (ACC) hypertension 
treatment guidelines.  A cardiologist may be consulted if appropriate.  
The objective of antihypertensive therapy in general is to control the blood pressure to a target 
level <140/90 mmHg.  For high -risk populations, such as patients with chronic renal disease and/or 
diabetes, it may be appropriate to aim for a target blood pressure < 130/80 mmHg.  On the 
following two pages  (Figure 3), please see a summary of the most recent AHA/ACC hypertension 
treatment guidelines.  
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment  4   
 
Hutchison MediPharma   Page 120 
 CONFIDENTIAL   
 
 Figure 3 Schema from American Heart Association/ American College of Cardiology 
for Controlling Hypertension in Adults  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment  4   
 
Hutchison MediPharma   Page 123 
 CONFIDENTIAL   
 
 Hypertension Guidelines From: Go A, Bauman M, Coleman King S, et al. An Effective Approach to High Blood 
Pressure Control. A Science Advisory from the American Heart Association, the American College of Cardiology, and 
the Centers for Disease Control and P revention . J Am Coll Cardiol  2014; 63:1230 -8. 
 
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment  4   
 
Hutchison MediPharma   Page 124 
 CONFIDENTIAL   
 
 APPENDIX  9 CONVERSION TABLE S FOR URINALYSIS RESU LTS  
Blood  Leucocytes  
Negative  0 0 cells/ μL Negative  0 <10 mg/dL  
Trace  1+ 1-24 cells/ μL Trace  1+ 11-99 mg/dL  
Small  2+ 25-79 cells/ μL Small  2+ 99-299 mg/dL  
Medium  3+ 80-199 cells/ μL Medium  3+ 300-999 mg/dL  
Large 4+ ≥ 200 cells/ μL large  4+ >1000  mg/dL  
 
Proteinuria  
NCI-CTCAE Grade  Protein by urinalysis  24-hour protein quantitation  
1 1+ <1.0g  
2 2+ <2.0g  
2 ≥2+ <3.5 g (excluding 3.5 g)  
3 N/A ≥3.5 g  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment  4   
 
Hutchison MediPharma   Page 125 
 CONFIDENTIAL   
 
 APPENDIX  10 COCKGROFT GAULT FOR MULA  
 
The Cockcroft -Gault formulas are as follows:  
• CrCl (male) = ([140 -age] × weight in kg)/(serum creatinine × 72)  
• CrCl (female) = CrCl (male) × 0.85  
 
Source:  Cockcroft 1976  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment  4   
 
Hutchison MediPharma   Page 126 
 CONFIDENTIAL   
 
 APPENDIX  11 AMENDMENT HISTORY  
Amendment 3.1 (25 March 2021)  
This 2019 -013-GLOB1 Protocol Amendment 3 .1 was an administrative amendment  to correct a 
formatting numbering error in the Inclusion Criteria (Section  5.3) and to add a clarification in 
Table  14 in the 2019 -013-GLOB1 Protocol Amendment  3.   
 
Amendment 3 (16 March 2021)  
Section  Summary of Change  Rationale for Change  
Section  4.1.2.3 - Temporary 
Change of Pharmacokinetic 
Sampling, Holter Monitor QTc 
Evaluations, and Circulating Tumor 
DNA Sample Collection  Addition of notes regarding 
temporary change of PK sampling, 
electrocardiogram (ECG) 
collection, and ctDNA sample 
collection  Delays in laboratory kit production 
and delivery resulting from 
COVID -19-related disruption s 
Section 6.1.1.17 - 
Electrocardiograms Monitoring  Addition of notes regarding 
temporary change of PK sampling, 
ECG collection, and ctDNA sample 
collection  Delays in laboratory kit production 
and delivery resulting from 
COVID -19-related disruptions  
Table  2 Schedule of Events for 
Dense Pharmacokinetic and 
Electrocardiogram Evaluations for 
the Subset of Approximately 120 
Patients (revised title)  
Table 3  Schedule of Events for 
Sparse Pharmacokinetic and 
Electrocardiogram Evaluations for 
Patients Not Included  in the 
Approximately 120 Patients in the 
Subset in Table 2 (revised title)  Revised table titles to reflect that 
first 120 patients did not have dense 
PK sampling  Due to COVID -related supply chain 
issues, dense PK sampling and 
concurrent Holter ECG monitor ing 
were not performed on first 120 
patients in the study but will be 
sampled in approximately 120 
patients  
Section 1 - Synopsis, Exclusion 
Criteria #5  
Section 5.4 - Exclusion Criteria #5  Added urinalysis along with urine 
dipstick for initial evaluation for 
protein in urine during screening  To align with current clinical 
practice as dipsticks are not used 
universally  
Section 9.2.5.1.1 - Primary 
Endpoint - Overall Survival  Specified that t he hazard ratio 
between the fruquintinib and 
placebo  groups  will be  calculated 
from a stratified Cox proportional 
hazard model stratified by the 
randomization stratification factors  Clarification  
Section 1 - Synopsis, Exclusion 
Criteria #14  
Section 5.4 - Exclusion Criteria #14  Deleted the reference to 
Appendix  4 for concomitant 
medications with a known risk of 
causing QT prolongation and/or 
torsades de pointes  as these details 
are not located in the appendix  Clarification of the location from a 
reference to Appendix 4 to 
appropriate web site  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment  4   
 
Hutchison MediPharma   Page 127 
 CONFIDENTIAL   
 
 Section  Summary of Change  Rationale for Change  
Table 1  Schedule of Event s Added the option of conducting 
some assessments up to and 
including Cycle 1, Day 1  Providing the sites with flexibility 
for timing of assessments  
Section 7.1 - Study Drug 
Administration  Specified that study drug should be 
administered around the same ti me 
each day and that a missed dose can 
be administered within 12 hours of 
usual administration time  Clarification  
Section 7.3.3.1 - Emergency 
Unblinding  Language changed to encourage, 
but not require, consultation with 
the sponsor prior to emergency 
unbli nding of a patient’s study 
treatment allocation  Request by the UK Medicines and 
Healthcare Products Regulatory 
Agency (MHRA)  
Section 7.5.1 - Prohibited Therapies  Added specification to prohibit live 
vaccines during  the study  and for 
3 months after  the last dose of study 
drug(s)  Request by the UK MHRA  
Section 9.2.5.1.2 - Secondary 
Efficacy Endpoints (PFS, ORR, 
DCR, DoR)  Clarified statistical methods  Request by the US Food and Drug 
Administration (FDA)  
Section 2.1 - Study Rationale 
(formerly Section 2.2)  
Section 2.2 - Background (formerly 
Section 2.1)  Moved Study Rationale to the 
beginning of the Introduction, 
revised and removed text that was 
redundant with Background  To align with sponsor -approved 
template text across all clinical 
study protocols  
Secti on 10.1 - Good Clinical 
Practice (revised section header)  
Section 10.2 - Ethics Review  
Section 10.3 - Informed Consent  
Section 10.4 - Data Privacy  
Section 10.7 - Data Quality 
Assurance (formerly Section 10.6)  Revised and updated text in Ethical 
Considerations section.  To align with sponsor -approved 
template text across all clinical 
study protocols  
Section 10.3 – Ethical Conduct of 
the Study (deleted section)  
Section 11.2.3 – Protocol Deviation 
(deleted section)  
Section 11.2.4.2 – Study Files 
(deleted section)  Deleted sections  To remove text that was redundant 
with other sections in other section 
of Section 10 and align with 
sponsor -approved template text 
across all clinical study protocols   
Section 10.6 - Biological 
Specimens and Data  Added section  To align with sponsor -approved 
template text across all clinical 
study protocols  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment  4   
 
Hutchison MediPharma   Page 128 
 CONFIDENTIAL   
 
 Section  Summary of Change  Rationale for Change  
Section 11.2 - Quality Control and 
Assurance  
Section 11.2.1 - Monitoring  
Section 11.2.2 - Audits  
Section 11.2.3.2 - Source 
Documentation  
Section 11.2.3.3 - Records 
Retention  Revised subsections under 
Oversight  To align with sponsor -approved 
template text across all clinical 
study protocols  
Section 2.1.1 – Administration 
Regimen (deleted section)  Deleted section  To remove text that was redundant 
with information in S ection 7.1 and 
align with sponsor -approved 
template text across all clinical 
study protocols  
 
Amendment 2 (30 Oct ober  2020)  
Section  Summary of Change  Rationale for Change  
Section 1 - Synopsis - Study Design  
Section 5.1 - Recruitment  
Section 9.1.2 - Sample Size 
Rationale  Changed estimated number of 
subjects to 687 . Change made to increase the 
statistical power of the study from 
80% to 90%.  
Section 1 - Synopsis – Inclusion 
Criteria #3  
Section 5.3 - Inclusion Criteria #3  Provided country level flexibility 
for molecular characterization of 
MSI/MMR status . MSI/MMR status not available for 
determination in every country.  
Section 1 - Synopsis – Inclusion 
Criteria #6  
Section 5.3 - Inclusion Criteria #6  Added clarifying language for the 
inclusion of  subjects post receipt of 
oxaliplatin in the adjuvant setting.  Clarified language .  
Section 1 - Synopsis – Inclusion 
Criteria #11  
Section 5.3 - Inclusion Criteria #11  Clarified contraception language.  Change made per Belgian Health 
Authority ( HA) reques t. 
Section1 - Synopsis - Inclusion 
Criteria #12  
Section 5.3 - Inclusion Criteria #12  Added new inclusion criterion  to 
address previous treatment with 
BRAF inhibitor.  Per German HA request.  BRAF 
inhibitors are not approved and 
available in every country.  
Section1 - Synopsis - Exclusion 
Criteria #5  
Section 5.4 - Exclusion Criteria #5  Added clarifying language . To correct inconsistency  
Section 1 - Synopsis - Exclusion 
Criteria #19  
Section 5.4 - Exclusion Criteria #19  Added “(or 5 half -lives) ” to the 
“within 2 weeks” amount of time 
from use of CYP3A4 inhibitors 
prior to first dose of study drug.  Belgian HA request  
Section 1 - Synopsis - Exclusion 
Criteria #31  
Section 5.4 - Exclusion Criteria #31  Added “including the azo dyes 
Tartrazine - FD&C  Yellow 5 and 
Sunset yellow FCF - FD&C Yellow 
6” to the Exclusion Criteria . Belgian and German HA request  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment  4   
 
Hutchison MediPharma   Page 129 
 CONFIDENTIAL   
 
 Section  Summary of Change  Rationale for Change  
Section 1 - Synopsis - Exclusion 
Criteria #32  
Section 5.4 - Exclusion Criteria #32  Added in Exclusion Criteria for 
previous treatment with 
fruquintinib.  Clarification  
Section 1 - Synopsis - Exclusion 
Criteria #33  
Section 5.4 - Exclusion Criteria #33  Added in an exclusion criteri on for 
vaccine use prior to enrollment . Additional detail  
Section 1 - Synopsis - Number of 
Sites  Increased planned number of sites 
from 100 sites to 140 sites . Change to reflect the planned 
increase in number of patients in 
study . 
Section 1 - Synopsis - Study 
Duration  Increased study duration .   Change to reflect the planned 
increase in number of subjects .  
Section 1.1 - Study Schematic  Updated Figure 1 by adding “Prior 
treatment with an immune 
checkpoint inhibitor of BRAF 
inhibitor, if indicated”.  Clarified language for alignment . 
Table 1  Schedule of Events and 
Footnote 2  
Section 6.1.1.3 - Tumor Diagnosis 
and Treatment History  Added in characterization of 
MSI/MMR and BRAF mutation in 
the Tumor Diagnosis and Treatment 
History assessment . Clarified language for alignment . 
Table 1  Schedule of Events and 
Footnote 11 (footnote added)  
Section 6.1.1.12 - Blood Am ylase 
and Lipase (section added)  Added assessments for amylase and 
lipase . Per German HA request . 
Table 1  Schedule of Events  
Section 6.1.1.16 - Pregnancy Test  Added “or an equivocal urine 
pregnancy test” in pregnancy 
testing requirements.  To ensure an equivocal urine test is 
followed -up by a more sensitive 
serum pregnancy test.  
Table 2  Schedule of Events for 
Dense Pharmacokinetic and 
Electrocardiogram Evaluations for 
the Subset of Approximately 120 
Patients  
Table 3  Schedule of Events for 
Sparse Pharmac okinetic and 
Electrocardiogram Evaluations for 
Patients Not Included in the 
Approximately 120 Patients in the 
Subset in Table 2  Added in a ±10 -minute time 
window for acquisition of PK 
samples . Provide more flexibility for sites 
and less chance of deviation s. 
Section 4.1.1 - Enrollment in Study  Added additional rationale for 2:1 
randomization.   Belgian HA request  
Section 5.2 - Definitions  Additional details of randomization.  Belgian HA request  
Section 6.1.1.17 - 
Electrocardiograms Monitoring  Added “All E CGs for the purposes 
of screening will be performed 
using standard, local equipment.”  Clarified language  
Section 6.1.1.3 - Tumor Diagnosis 
and Treatment History  Clarified requirements for RAS, 
BRAF, MSI/MMR status.  Italian HA request, to align with IC 
#3.   
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment  4   
 
Hutchison MediPharma   Page 130 
 CONFIDENTIAL   
 
 Section  Summary of Change  Rationale for Change  
Section 6.2.1 - Permanent 
Discontinuation of Treatment 
reason #3  Added discontinuation details to 
intolerable toxicity  German HA request  
Section 7.1 - Study Drug 
Administration  Added instructions for study drug  if 
subject vomits  Added for clarity  
Section 7.3.3.1 - Emergency 
Unblinding  Added language to request sponsor 
medical monitor notification if 
possible before emergency 
unblinding  German HA request  
Section 7.5.2 - Permitted Therapies 
– Permitted Therapies  
Table 13  Dose Adjustment for 
Hemorrhage at Any Site  
Appendix 6  Clinical 
Evaluation of Possible Drug -
Induced Liver Injury (DILI)  Removed paragraph and footnote 
about monitoring subjects receiving 
anti-platelet and/or anti -thrombotic 
drugs.  Belgian HA reque st 
Section 7.5.6.2 - Dose Modification 
for Important Identified Risks and 
Potential Risks  Changed title of section to “Dose 
Modification for Important 
Identified Risks and Potential Risks  Belgian HA request  
Section 7.5.6.2 - Dose Modification 
for Important Identified Risks and 
Potential Risks  
Table 9  Dose Modification for 
Dermatological Toxicity (revised 
table heading)  Changed Palmar Plantar 
Erythrodysethesia and abbreviation 
of PPE to more broad term of 
Dermatological Toxicity.  Belgian HA request  
Section 9.1.2 - Sample Size 
Rationale  
Section 9.2.1 - Primary Endpoint  
Section 9.2.2.1 - Key Secondary 
Endpoint: Progression -free Survival  
Section 9.2.5.1.1 - Primary 
Endpoint - Overall Survival  
Section 9.2.5.1.2 - Secondary 
Efficacy Endpoints (PFS, ORR, 
DCR, DoR)  
Section 9.2.5.1.3 - Multiplicity 
Adjustment for the Primary 
Endpoint OS and Key Secondary 
Endpoint PFS  
Section 9.4 - Interim Analysis  Additional details added  Clarification of statistical methods  
Section 11.3.2  – Protocol 
Deviations  Edited langu age Clarification of responsibilities  
Table 1  Schedule of Events  Removed the visit window for 
cycle 1 day 21  Reflect need for PK sampling 1 day 
before and 1 day after cycle 1 day 
21 visit  
Clinical Study Protocol 2019 -013-GLOB1  Fruquintinib  
Amendment  4   
 
Hutchison MediPharma   Page 131 
 CONFIDENTIAL   
 
  
Amendment 1 (08 Apr il 2020)  
Section  Summary of Change  Rationale for Change  
Section 1 Synopsis - Inclusion 
Criteria, #3  
Section 5.3 Inclusion Criteria, #3  Provided additional detail for 
molecular characterization of RAS, 
BRAF , and MSI/MMR status  Requested by CHMP  
Section 6.2.1 Permanent 
Discontinuation of Treatment  Added statement that patients may 
continue to receive treatment 
following progressive disease by 
RECIST  Provide clarity as requested by 
FDA  
Section 1 Synopsis - Inclusion 
Criteria, #4  
Section 5.3 Inclusion Criteria, #4  Modified requirement for prior 
treatment with TAS -102 or 
regorafenib  Provide additional clarity as 
requested by FDA  
Section 7.5.6.2 Dose Modification 
for Important Identified Risks  
Table 9  Dose Modification for 
Dermatological Toxicity  
Table 10  Dose Modification for 
Proteinuria  
Table 11  Dose  Modification for 
Hypertension  
Table 12  Dose Adjustment for 
Decreased Platelet Count  
Table 13  Dose Adjustment for 
Hemorrhage at Any Site  Edited “Dose Adjustment” 
requirements in Table 8, Table 9, 
Table 10, Table 11, and Table 12 to 
provide clear guidance  Provide clarity for dose 
modification requirements for 
specific adverse events as requested 
by FDA  
Section 1 Synopsis - Exclusion 
Criteria, #4  
Section 5.4 Exclusion Criteria, #4 
(deleted)  Removed exclusion criterion #4  Revised in response to FDA 
comment.  Exclusion criterion #4 
was redundant with criterion #22 
(currently # 21), which provides 
appropriate guidance for resolution 
of toxicity from prior therapy  
Section 1 Synopsis - Inclusion 
Criteria, #5  
Section 5.3 Inclusion Criteria, #5  Added additional deta il regarding 
prior treatment with immune 
checkpoint inhibitors  Provide additional clarity  
Section 8.6.3 Persistent or 
Recurrent Adverse Events  Removed section  Avoid potential confusion.  Details 
on data entry will be addressed in 
CRF Completion Guidelines . 
 
Signature Page for VV-CLIN-000381 v1.0
Signature Page for VV-CLIN-000381 v1.0Approval
MO
01-Jul-2021 21:21:57 GMT+0000
Approval
CSO
02-Jul-2021 14:47:22 GMT+0000

Statistical Analy sis Plan Summa ry of Changes  
 
Amendment 4 
Section  Summary of Change 
Section 7.5.3 - Drug- Drug Interactions 
(Therapies to Avoid or Use with Special Caution)  Removed instruction that subjects should avoid proton pump 
inhibitor drugs and H2 blockers  
Section 1 - Synopsis  
Section 5.1 - Recruitment  Revised the planned estimated number of study sites from 
140 to 160  
Section 1 - Synopsis , Inclusion Criterion # 4  
Section 5.3 - Inclusion Criteria , #4  For the inclusion criterion requiring patients must have 
received treatment with prior therapy, including anti -VEGF or 
anti-EGFR, examples of these treatments were added  
Section 1 - Synopsis , Exclusion Criterion # 5  
Section 5.4 - Exclusion Criteria, #5  Changed the protein level for which a 24- hour urine 
assessment is required.  
Section 1 - Synopsi s, Exclusion Criterion # 6  
Section 5.4 - Exclusion Criteria , #6  Added in details for blood pressure assessment process.  
Section 1.2 – Schedule of Events  
Table 1 Schedule of Events  Removed visit window day 21 of cycle 2 and cycle 3  
Table 2 Schedule of Events for Dense 
Pharmacokinetic and Electrocardiogram 
Evaluations for the Subset of Approximatel y 
120 Patients with Evaluable ECGs  Revised title  
Table 3 Schedule of Events for Sparse 
Pharmacokinetic and Electrocardiogram Evaluations for Patients Not Included in t he 
Approximately 120 Evaluable Patients in the Subset in Table 2  Revised title  
Table 1 Schedule of Events  
Section 1.2.1 - Footnotes for Schedule of Events 
Table 1 , #21 (footnote removed)   
Section 6.1.1.21 - Circulating Tumor DNA  Removed requirement for the collection of blood to evaluate 
ctDNA. Further noted that analysis of ctDNA samples 
collected would be performed according to the statistical 
analysis plan  
Section 6.1.1.17 - Electrocardiograms 
Monitoring  Added that any subject with a pacemaker should undergo PK 
and safety ECG evaluations according to the schedule outlined in Table 3  
Section 6.1.1.18 - Echocardiogram  Added that echocardiograms completed as standard of care 
prior to signing the informed consent, but within 28 days of  
first dose of study treatment, may be used as baseline assessment.  
Section 1.2.2 - Footnotes for the Schedule of 
Events Tables 2 and 3 , #4 (footnote added)  Added instruction to refer to the Holter Monitor instruction 
manual for appropri ate timing of the start of the ECG 
recording.  
Appendix 9 Conversion Tables for Urinalysis 
Results  Added table to aid in conversion of proteins measured by 
urinalysis for assessment of proteinuria  
  Amendment 3.1 (25 March 2021) 
This 2019- 013- GLOB1 Protocol Amendment 3.1 was an administrative amendment to correct a formatting 
numbering error in the Inclusion Criteria (Section 5.3) and to add a clarification in Table 14 in the 2019 -013- GLOB1 
Protocol Amendment 3.  
 
Amendment 3 (16 March 2021) 
Section  Summary of Change 
Section 4.1.2.3 - Temporary Chang e of 
Pharmacokinetic Sampling, Holter Monitor QTc 
Evaluations, and Circulating Tumor DNA Sample Collection 
 Addition of notes regarding temporary change of PK 
sampling, electrocardiogram (ECG) collection, and ctDNA sample collection 
 
Section 6.1.1.17 - Electrocardiograms 
Monitoring  Addition of notes regarding temporary change of PK 
sampling, ECG collection, and ctDNA sample collection  
Table 2 Schedule of Events for Dense 
Pharmacokinetic and Electrocardiogram Evaluations for the Subset of Approximately 120 Patients (revised title)  Table 3 Schedule of Events for Sparse 
Pharmacokinetic and Electrocardiogram 
Evaluations for Patients Not Included in the Approximately 120 Patients in the Subset in Table 2 (revised title) 
 Revised table titles to reflect that first 120 patients did not 
have dense PK sampling  
Section 1 - Synopsis, Exclusion Criteria #5  
Section 5.4 - Exclusion Criteria #5  Added urinalysis along with urine dipstick for initial 
evaluation for protein in urine during screening  
Section 9.2.5.1.1 - Primary Endpoint - Overall 
Survival  Specified that the hazard ratio between the fruquintinib and 
placebo groups will be calculated from a stratified Cox proportional hazard model stratified by the randomization stratification factors 
 
Section 1 - Synopsis, Exclusion Criteria  #14  
Section 5.4 - Exclusion Criteria #14  Deleted the reference to Appendix 4 for concomitant 
medications with a known risk of causing QT prolongation 
and/or torsades de pointes as these details are not located in the appendix  
Table 1 Schedule of Events  Added the option of conducting some assessments up to and 
including Cycle 1, Day 1  
Section 7.1 - Study Drug Administration  Specified that study drug should be administered around the 
same time each day and that a missed dose can be administered within 12 hours of usual administration time  
Section 7.3.3.1 - Emergency Unblinding  Language  changed to encourage, but not require, 
consultation with the sponsor prior to emergency unblinding 
of a patient’s study treatment allocation  
Section 7.5.1 - Prohibited Therapies  Added specification to prohibit live vaccines during the study 
and for 3 months after the last dose of study drug(s)  
Section 9.2.5.1.2 - Secondary Efficacy Endpoints 
(PFS, ORR, DCR, DoR)  Clarified statistical methods  
Section 2.1 - Study Rationale (formerly Section 
2.2)  
Section 2.2 - Background (formerly Section 2.1)  Moved Study Rationale to the beginning of the Introduction, 
revised and removed text that was redundan t with 
Background  
Section 10.1 - Good Clinical Practice (revised 
section header)  
Section 10.2 - Ethics Review  
Section 10.3 - Informed Consent  
Section 10.4 - Data Privacy  Revised and updated text in Ethical Considerations section.  
Section 10.7 - Data Quality Assurance (formerly 
Section 10.6)  
Section 10.3 – Ethical Conduct of the Study 
(deleted section)  
Section 11.2.3 – Protocol Deviation (deleted 
section)  
Section 11.2.4.2 – Study Files (deleted section)  Deleted sections  
Section 10.6 - Biological Specimens and Data  Added section  
Section 11.2 - Quality Control and Assurance  
Section 11.2 .1 - Monitoring  
Section 11.2.2 - Audits  
Section 11.2.3.2 - Source Documentation  
Section 11.2.3.3 - Records Retention  Revised subsections under Oversight  
Section 2.1.1 – Administration Regimen 
(deleted section)  Deleted section  
 
 
Amendment 2 (30 October 2020 ) 
Section  Summary of Change 
Section 1 - Synopsis - Study  Design  
Section 5.1 - Recruitment  
Section 9.1.2 - Sample Size Rationale  Changed estimated number of subjects to 687.  
Section 1 - Synopsis – Inclusion Criteria #3  
Section 5. 3 - Inclusion Criteria #3  Provided country level flexibility for molecular 
characterization of MSI/MMR status.  
Section 1 - Synopsis – Inclusion Criteria #6  
Section 5.3 - Inclusion Crite ria #6  Added clarifying language for the inclusion of subjects post 
receipt of oxaliplatin in the adjuvant setting.  
Section 1 - Synopsis – Inclusion Criteria #11  
Section 5.3 - Inclusion Criteria #11  Clarified contraception language.  
Section1 - Synopsis - Inclusion Criteria #12  
Section 5.3 - Inclusion Criteria #12  Added new inclusion criterion to address previous treatment 
with BRAF inhibitor.  
Section1 - Synopsis - Exclusion Criteria #5  
Section 5.4 - Exclusion Criteria #5  Added clarifying language.  
Section 1 - Synopsis - Exclusion Criteria #19  
Section 5. 4 - Exclusion Criteria #19  Added “(or 5 half -lives)” to the “within 2 weeks” amount of 
time from use of CYP3A4 inhibitors prior to first dose of study 
drug.  
Section 1 - Synopsis - Exclusion Criteria #31  
Section 5.4 - Exclusion Criteria #31  Added “including the azo dyes Tartrazine - FD&C Yellow 5 
and Sunset yellow FCF - FD&C Yellow 6” to the Exclusion 
Criteria.  
Section 1 - Synopsis - Exclusion Criteria #32  
Section 5.4 - Exclusion Criteria #32  Added  in Exclusion Criteria for previous treatment with 
fruquintinib.  
Section 1 - Synopsis - Exclusion Criteria #33  
Section 5.4 - Exclusion Criteria #33  Added in an exclusion criterion for vaccine use prior to 
enrollment.  
Section 1 - Synopsis - Number of Sites  Increased planned number of sites from 100 sites to 140 
sites.  
Section 1 - Synopsis - Study Duration  Increased study duration.  
Section 1.1 - Study Schematic  Updated Figure 1 by adding “Prior treatment with an 
immune checkpoint inhibitor of BRAF inhibitor, if indicated”.  
Table 1 Schedule of  Events and Footnote 2  
Section 6.1.1.3 - Tumor Diagnosis and 
Treatment History  Added in characterization of MSI/MMR and BRAF mutation in 
the Tumor Diagnosis and Treatment History assessment.  
Table 1 Schedule of Event s and Footnote 11 
(footnote added)  
Section 6.1.1.12 - Blood Amylase and Lipase 
(section added)  Added assessments for amylase and lipase.  
Table 1 Schedule of Events  
Section 6.1.1.16 - Pregnancy Test  Added “or an equivocal urine  pregnancy test” in pregnancy 
testing requirements.  
Table 2 Schedule of Events for Dense 
Pharmacokinetic and Electrocardiogram Evaluations for the Subset of Appr oximately 
120 Patients  
Table 3 Schedule of Events for Sparse 
Pharmacokinetic and Electrocardiogram 
Evaluations for Patients Not Included in the Approximately 120 Patients in the Subset in Table 2  Added in a ±10 -minute time window for acquisition of PK 
samples.  
Section 4.1.1 - Enrollment in Study  Added additional rationale for 2:1 randomization.  
Section 5.2 - Definitions  Additional details of randomization.  
Section 6.1.1.17 - Electrocardiograms 
Monitoring  Added “All ECGs for the purposes of screening will be 
performed using standard, local equipment.”  
Section 6.1.1.3 - Tumor Diagnosis and 
Treatment History  Clarified re quirements for RAS, BRAF, MSI/MMR status.  
Section 6.2.1 - Permanent Discontinuation of 
Treatment reason #3  Added discontinuation details to intolerable toxicity  
Section 7.1 - Study Drug Adm inistration  Added instructions for study drug if subject vomits  
Section 7.3.3.1 - Emergency Unblinding  Added language to request sponsor medical monitor 
notification if possible before emergency unblinding  
Secti on 7.5.2 - Permitted Therapies – Permitted 
Therapies  
Table 13 Dose Adjustment for Hemorrhage at 
Any Site  
Appendix 6 Clinical Evaluation of Possible Drug -
Induced Liver Injury (DILI)  Removed paragraph and footnote about monitoring subjects 
receiving anti -platelet and/or anti -thrombotic drugs.  
Section 7.5.6.2 - Dose Modification for 
Important Identified Risks and Potential Risks  Changed title of section to “Dose Modification for Important 
Identified Risks and Potential Risks  
Section 7.5.6.2 - Dose Modification for 
Important Identified Risks and Potential Risks  
Table 9 Dose Modification for Dermatological 
Toxicity (revised table heading)  Changed Palmar Plantar Erythrodysethesia and abbreviation 
of PPE to more b road term of Dermatological Toxicity.  
Section 9.1.2 - Sample Size Rationale  
Section 9.2.1 - Primary Endpoint  
Section 9.2.2.1 - Key Secondary Endpoint: 
Progression- free Survival  
Section 9.2.5.1.1 - Primary Endpoint - Overall 
Survival  
Section 9.2.5.1.2 - Secondary Efficacy Endpoints 
(PFS, ORR, DCR, DoR)  Additional details added  
Section 9.2.5.1.3 - Multiplicity Adjustment for 
the Primary Endpoint OS and Key Secondary 
Endpoint PFS  
Section 9.4 - Interim Analysis  
Section 11.3.2 – Protocol Deviations  Edited language  
Table 1 Schedule of Events  Removed the visit window for cycle 1 day 21  
 
 Amendment 1 (
08 April 2020 ) 
Section  Summary of Change 
Section 1 Synopsis - Inclusion Criteria, #3  
Section 5.3 Inclusion Criteria, #3  Provided additional detail for molecular characterization of 
RAS, BRAF, and MSI/MMR status  
Section 6.2.1 Permanent Discontinuation  of 
Treatment  Added statement that patients may continue to receive 
treatment following progressive disease by RECIST  
Section 1 Synopsis - Inclusion Criteria, #4  
Section 5.3 Inclusion Criteria, #4  Modified require ment for prior treatment with TAS- 102 or 
regorafenib  
Section 7.5.6.2 Dose Modification for Important 
Identified Risks  
Table 9 Dose Modification for Dermatological Toxicity  
Table 10 Dose Modification for P roteinuria  
Table 11 Dose Modification for Hypertension  Table 12 Dose Adjustment for Decreased Platelet Count  Table 13 Dose Adjustment for Hemorrhage at Any Site 
 Edited “Dose Adjustment” requirements in Table 8, Table 9, 
Table 10, Table 11, and Table 12  to provide clear guidance  
Section 1 Synopsis - Exclusion Criteria, #4  
Section 5.4 Exclusion Criteria, #4 (deleted)  Removed exclusion criterion #4  
Section 1 Synopsis - Inclusion Criteria, #5  
Section 5.3 Inclusio n Criteria, #5  Added additional detail regarding prior treatment with 
immune checkpoint inhibitors  
Section 8.6.3 Persistent or Recurrent Adverse 
Events  Removed section  
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 3 of 99 
 I conf rm that I have rev ewed th s document and agree w th the content.  
Approvals 
Syneos Health Approval  
 
    
 
Name, T t e  
Lead  B ostat st c an  / Support 
B ostat st c an  S gnature   Date (DD Mmm YYYY)  
 
    
 
Name, T t e  
Lead  Pharmacok net c st   S gnature   Date (DD Mmm YYYY)  
 
    
 
Name, T t e   S gnature   Date (DD Mmm YYYY)  
Hutchison MediPharma Limited Approval  
 
    
 
 
Sponsor Contact   S gnature   Date (DD Mmm YYYY)  
 
    
 
 
Sponsor Contact   S gnature   Date (DD Mmm YYYY)  
     
 
   
  
 
Sponsor Contact   S gnature   Date (DD Mmm YYYY)  

Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 4 of 99 
 Table of Contents 
Revision History  ............................................................................................................................  2 
Approvals .................................................................................................................................... 3  
 Glossary of Abbreviations  .................................................................................................... 9  
 Purpose  ..............................................................................................................................  13 
 Study Objectives  ................................................................................................................ 15 
 Study Details/Design  .......................................................................................................... 17 
 Endpoints  ...........................................................................................................................  23 

Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 5 of 99 
 
 Analysis Populations  .......................................................................................................... 27 
 General Aspects for Statistical Analysis  ............................................................................ 28 
 Demographic, Other Baseline Characteristics and Medication  .......................................... 35 

Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 6 of 99 
 
 Efficacy  ..............................................................................................................................  43 
 Pharmacokinetics  ............................................................................................................... 56 

Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 7 of 99 
 
 Safety ................................................................................................................................ . 58 
 IDMC Review  ..................................................................................................................... 69 
 Changes from Analysis Planned in Protocol  ...................................................................... 70 
 Reference List  ....................................................................................................................  71 
 Programming Considerations  ............................................................................................  72 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 8 of 99 
 
 Quality Control  ...................................................................................................................  78 
 Appendix  ............................................................................................................................  79 
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 9 of 99 
 
 Glossary of Abbreviations 
Abbreviation Description  
AE Adverse event  
ADaM  Analysis Data Model  
ALP Alkaline phosphatase  
ALT Alanine aminotransferase 
ANCOVA Analysis of covariance  
aPTT Activated Partial thromboplastin time  
AST Aspartate aminotransferase 
ATC 2 Anatomical therapeutic class 2  
AR (1)  Autoregressive (1)   
BMI Body mass index  
BLQ Below  the lower limit of quantification 
BRAF B-Raf proto -oncogene 
BSC Best supportive care  
CEA Carcino -embryonic antigen 
CI Confidence interval  
CMH Cochran -Mantel Ha enszel  
COVID -19 Coronavirus 2019  
ctDNA  Circulating tumor DNA  
CTMS Clinical trial management system  
CR Complete response  
CS Clinically  significant  
CSR Clinical study report  
CV Coefficient of variation  
CRO Clinical research organization  
CT Computed tomography  
CTCAE  Common Terminology Criteria for Adverse Event  
dMMR  Deficient mismatch repair  
DCR Disease control rate  
DoR Duration of response  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 10 of 99 
 Abbreviation Description  
eCRF  Electronic case report form  
ECHO  Echocardiogram  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group 
EDC Electronic data capture  
EGFR Epidermal growth factor receptor  
EORTC European Organization for Research and Treatment of Cancer  
EOT End of treatment 
ERT eResearchTechnology, Inc.  
HR Hazard ratio  
ICF Informed consent form  
IDMC  Independent data monitoring committee 
IND Investigational new drug 
INR International normalized ratio  
IRT Interactive response technology  
ITT Intent- to-Treat 
IWRS  Interactive web response system 
JSMC  Japanese safety monitoring committee 
LDH Lactate dehydrogenase  
LS Least -square  
mCRC  Metastatic colorectal cancer  
MedDRA  Medical Dictionary for Regulatory Activities  
MSI Microsatellite instability  
MSI-H Microsatellite instability-h igh 
MID Minimally important difference  
MMR  Mismatch repair  
MSS  Microsatellite stable  
MMRM Mixed model repeated measures  
MRI Magnetic resonance imaging  
MUGA  Multigated a cquisition  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 11 of 99 
 Abbreviation Description  
NA Not available 
NCS Not clinically significant  
NE Not evaluable  
ORR Objective response rate  
OS Overall survival  
pMMR  Proficient mismatch repair  
PD  Progressive disease  
PID Percentage intended dose  
PFS Progression -free survival  
PK Pharmacokinetic 
PO Per os  (oral administration)  
PR Partial response 
PR PR Interval (ECG Parameter) 
PT Preferred term  
Q1 Lower quartile  
Q3 Upper quartile  
QoL Quality of life 
QD Quaque die  (once  daily)  
QTcB  QT correction Bazett formula  
QTcF  QT correction Fridericia formula  
QRS  A combination of the Q wave, R wave and S wave 
RAS  Rat sarcoma  
REML  Restricted maximum likelihood  
RD Relative dose  
RDI Relative dose intensity  
RECIST  Response Evaluation Criteria In Solid Tumors  
SAE  Serious adverse event  
SAP Statistical analysis plan 
SAS Statistical Analysis System 
SD Stable disease  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 12 of 99 
 Abbreviation Description  
StdDev  Standard deviation 
SDTM  Study Data Tabulation Model  
SE Standard error  
SI International System of Units 
SOC System organ class  
TLFs  Tables, listings and figures  
TSH Thyroid -stimulating hormon e 
TTD Time to deterioration  
TEAE  Treatment -emergent adverse event  
ULN Upper limit of normal  
VAS Visual analogue scale  
VEGF Vascular Endothelial Growth Factor  
WHODD  World Health Organization Drug Dictionary 
 
  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 13 of 99 
 
 Purpose 
The purpose of this statistical analysis plan (SAP) for the study is to ensure that the data listings, summary 
tables and figures that are to be produced, and the statistical methodologies that are used, are complete 
and appropriate to allow valid conclusions rega rding the study objectives.  The  SAP adher es to the proper 
regulatory guidelines and most recent International Council for Harmonisat ion guidelines (E3, E6, E9) . All 
decisions regarding the final analyses, as defined in this SAP document, have been  made prior to locking 
the database; a ny deviations from these guidelines will be documented in the clinical study report (CSR).  
A separate SAP is to be developed for the protocol Japanese Specific Addendum (Safety Lead -In for 
Japan).  
 Responsibilities  
Syneos Health is to perform the statistical analyses and are responsible for the production and quality 
control of all Study Data Tabulation Model (SDTM ) datasets, Analysis Data Model (ADaM ) datasets, and 
the tables, listings, and  figures (TLFs) for efficacy and safety, as well as tabulation of fruquintinib  and M11 
concentrations from PK  (pharmacokinetic) plasma samples.  Details for analysis of circulating tumor DNA 
and pharmacogenomics will be prepared in a separate document. The SAP for population PK , 
Electrocardiogram (ECG ) (pharmacodynamics)  and QTc- PK analysis will be prepared separately by 
another contract research organization (CRO) . 
 Timings of Analyses  
An independent  data monitoring committee  (IDMC) is to  review descriptive summaries of accumulating 
safety  and subject disposition every 6 months , or at a frequency recommended by the IDMC, as described 
in the ID MC Charter  Final Version 1.0 dated 25-A ug-2020.  An unblinded team from Syneos Health 
Biostatistics is to  perform the analyses as described in Section 18 , Content of Open and Closed Sessions 
of the IDMC Charter, in order to maintain the blinding of the study.  
 Interim Analyses  
One interim non-binding  futility analysis is to be performed once  1/3 of the total number of overall survival 
(OS) events (i.e., 160 OS events) have occurred.  This interim analysis is for futility only,  there are no plans 
to stop the study early for efficacy based on OS data at the interim analysis.  
The IDMC is to be instructed to recommend stopping the study for futility if the 1 -sided p -value from a 
stratified log -rank test is at least 0.772 (corresponding to an observed HR of 1.133).  Otherwise, the study 
is to be  continue d with full enrollment.  
There is a 22.8%  chance of terminating the study for futility at the interim analysis if the true median OS in 
fruquintinib arm is 5 months, i .e., fruquintinib is ineffective.  There is a 0.4%  chance of stopping for futility, 
declaring fruquintinib ineffective at the inte rim if the true median OS in fruquintinib arm is 6.8 months, i .e., 
fruquintinib is effective in the  study population.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 14 of 99 
 
 Final  Analys is 
If the study does not stop based on the futility analysis, t he final analysis for the CSR will be conducted 
when at least 4 80 OS events  have been observed . All study data collected up through the time of the final 
analysis will be summarized , unless otherwise specified . Unblinding will occur at the time of the final 
analysis.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 15 of 99 
 
 Study Objectives 
 Primary Objective  
• To evaluate the overall survival (OS)  of fruquintinib  plus best supportive care ( BSC) compared to 
placebo plus BSC in subjects with refractory metastatic colorectal cancer (mCRC) . 
 Secondary Objective(s)  
• To evaluate progression -free survival (PFS) of fruqui ntinib plus BSC compared to placebo plus 
BSC. 
• To evaluate the objective response rate (ORR), disease control rate (DCR), and duration of 
response (DoR) . 
• To assess the safety and tolerability of fruquintinib  plus BSC compared to placebo plus BSC . 
• To characterize the PK exposure of fruquintinib  and metabolite M11 in subjects with refractory 
mCRC . 
• To evaluate the effect of fruquintinib  on cardiac repolarization, as detected by changes in 
electrocardiogram (ECG) QTc intervals, and the potential relationship with fruquintinib  and M11 
plasma concentrations. 
• To explore the relationship between fruquintinib  exposure and endpoints for efficacy and safety . 
• To evaluate quality of life (QoL) as assessed by using European Organisation for Research and 
Treatment of Cancer (EORTC) QLQ- C30: cancer -specific; and EQ -5D-5L questionnaires. 
• To assess resource utilization  (for example, hospitalizations, concomitant medications) . 
 Exploratory Objective  
• To assess potential predictive biomarkers of response to fruquintinib . 
Details of the study objectives and correspondent endpoints is provided in Table 1. 
Table 1. Objectives and Cor responding Endpoints  
Tier Objectives  Endpoints  
Primary To evaluate the overall survival of   
fruquintinib plus BSC compared to placebo 
plus BSC in subjects with refractory mCRC  OS 
Secondary  To evaluate progression -free survival  of 
fruquintinib plus BSC compared to  placebo 
plus BSC  PFS 
To evaluate the objective response rate, 
disease control rate, and duration of response  • ORR 
• DCR 
• DoR 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 16 of 99 
 Tier Objectives  Endpoints  
To assess the safety and tolerability of 
fruquintinib plus BSC compared to placebo 
plus BSC  Safety including  treatment- emergent 
adverse events ( TEAEs) , serious 
adverse events ( SAEs ), deaths, ECG’s,  
and clinical laboratory abnormalities  
To characterize the PK  profile of fruquintinib in 
subjects with  refractory mCRC  Observed plasma concentrations, 
estimated population PK and exposure 
parameters of  fruquintinib and M11  
To evaluate the effect of fruquintinib on  
cardiac repolarization, as detected by  
changes in electrocardiogram (ECG) QTc  
intervals, and the potential relationship with  
fruquintinib and M11 plasma concentrations  QTc interval and plasma concentrations 
of fruquintinib and M11 at specified time 
points  
To evaluate the relationship between  
fruquintinib exposure and endpoints for  
efficacy and safety  Parameters describing exposure -
response with efficacy (e.g. , OS) and 
safety (e .g., adverse events [ AEs]) 
endpoints 
To evaluate quality of life (QoL) as  
assessed by using QLQ- C30: cancer  specific;  
and EQ -5D-5L questionnaires Changes in health status (QLQ -C30: 
cancer  specific;  and EQ -5D-5L) 
To assess resource utilization (for example, 
hospitalizations, medications)  Resource utilization including all 
concomitant  medications, days in 
hospital  
Exploratory  To assess potential predictive biomarkers of  
response to fruquintinib  • Change from baseline in circulating 
tumor DNA  (ctDNA ) 
• Change from baseline in tumor 
markers  (carcino- embryonic antigen 
[CEA]) 
• Pharmacogenomics  
 
  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 17 of 99 
 
 Study Details/Design 
 Brief Description  
The study is a global, randomized, double -blind, placebo- controlled, multicenter phase 3 clinical trial to 
compare the efficacy and safety of fruquintinib  plus BSC versus placebo plus BSC in subjects with mCRC .  
Approximately 687 subjects  are to be randomized in a 2:1 ratio to either the fruquintinib  plus BSC treatment 
group or the placebo plus BSC treatment group . 
Randomization is stratified by the following factors:  
• Prior therapy with trifluridine/tipiracil (TAS -102) versus regorafenib versus both trifluridine/tipiracil 
(TAS -102) and regorafenib . 
• RAS (rat sarcoma)  status (wild type  versus mutant). 
• Duration of metastatic disease ( ≤18 months versus >18 months) . 
Subjects are to receive study treatment,  with each 4 -week cycle consisting of 3 weeks of daily oral  study 
medication and 1 week of study treatment  interruption (3 weeks on/1 week off) .  Tumor evaluation is 
performed by imaging (computed tomography [CT]  or magnetic resonance imaging [MRI] scan) every 8 
weeks until there is progressive disease (PD), death, new anti- cancer  treatment, study treatment 
discontinuation or study completion,  whichever comes first .  Safety parameters include assessment of 
adverse events (AE), laboratory tests, vital signs, ECG, Echocardiogram  (ECHO), physical examination, 
Eastern Cooperative Oncology Group  (ECOG) performance status, EORTC QLQ- C30 and EQ -5D-5L 
questionnaires.  Post-discontinuation anti- tumor treatment and  survival follow -up after PD is also recorded.  
 Subject Selection 
The study is conducted at approximately 140 international study sites with a study population of subjects 
≥18 years of age with histologically and/or cyto logically documented metastatic colorectal adenocarcinoma 
who progressed on, or were intolerant to, all standard chemotherapies and relevant biologics and TAS -102 
and/or regorafenib.  
 Inclusion Criteria  
Refer to Section 5.3 Inclusion Criteria of the study  protocol.  
 Exclusion Criteria 
Refer to Section 5. 4 Exclusion Criteria of the study protocol.  
 Statistical Hypothesis  
This study is designed to demonstrate superiority of fruquintinib plus BSC (fruquintinib arm) over placebo 
plus BSC (placebo arm) in prolonging OS for subjects with refractory mCRC. The study is designed to test the null hypothesis H0: λ=1.0 versus the alternative hypothesis Ha: λ < 1.0, where λ is the hazard ratio (treatment arm/placebo arm).
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 18 of 99 
 
 Determination of Sample Size  
With regards t o the study, the  total sample size and number of OS events required for efficacy assessment 
in the intent- to-treat population is calculated based on the following assumptions:  
• A one -sided significance level of 0.025;  
• Assuming an OS hazard ratio (HR) of 0.73 ( fruquintinib arm/placebo arm ), this sample size yields 
approximately 90% statistical power to detect superiority of the fruquintinib  arm over placebo arm .  
If the true median OS for the placebo arm is 5 months, then the HR of 0.73 corresponds to median 
OS of 6.8 months in the fruquintinib  arm (median OS improvement of 1.8 months) .   
• An enrollment rate of 30 subjects per month during the first 3 months and 50 subjects per month 
thereafter; 
• Yearly dropout rate of 10%;  
• Randomization ratio = 2:1  (fruquintinib arm /placebo arm ); 
• Data maturity = 70%;  
• One interim futility analysis when 1/3 of the total number of OS events (i .e., 160 OS events) have 
occurred, the Lan -DeMets spending function is used in the calculation. 
Under the premise of these assumptions, approximately 687 subjects are to be randomized to this study 
over approximately 1 5 months in this study .  OS is to be analyzed when 480 OS events have been  
observed, which is expected to occur in approximately 7 months after the end of enrollment.  EAST version 6.5 was utilized for the calculation.  
In clinical practice, TAS -102 is used more commonly than regorafenib .  To ensure that the subject 
population is  representative of clinical practice, post -regorafenib (regorafenib or both trifluridine/tipiracil 
(TAS -102) and regorafenib ) subjects  are to be capped at 344.  This ensure s that at least 50% of the subjects 
are post -TAS.   
Subjects are considered in post -TAS-102 or post -regorafenib populations if they have received at least one 
dose of either agent, respectively, prior to entering the study .  Based on the similar mechanisms of action 
between regorafenib and fruquintinib, it is to be of clinical interest to evaluate the magnitude of benefit in 
each of the populations when compared to the intent- to-treat population.  
 Treatment Assignment and Blinding 
The study subject, investigators, and study site personnel are to remain blinded to all randomization 
assignments throughout the study.  The sponsor’s study director, study monitor, and any other sponsor and 
Syneos Health  personnel who are in regular contact with the study site are to remain blinded to all subject 
randomization assignments , except sponsor phar macovigilance personnel for the purpose of 
Investigational New Drug  (IND) safety reports.  Treatment is allocated using Interactive Web Response 
System (IWRS)  randomization strategy and procedure  defined in the IWRS manual.    
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 19 of 99 
 Unblinding can occur in emerg ency cases .  If unblinding is required for treatment of a subject for a n SAE, 
the investigator must first contact the sponsor’s medical monitor before unblinding, and then unblind the 
subject using the IWRS .  Once unblinded, the subject should discontinue the treatment but continue to be 
followed for safety and efficacy.  The investigator should record the event in the source document.  
The interim futility analysis maintains blinding at IDMC meetings during the Open Sessions following the procedures described in Section 18, Content of Open and Closed Sessions of the latest version of the IDMC Charter.  
 Administration of Study Medication 
Fruquintinib  (HMPL -013) capsule 5 mg is administered orally (PO) once daily (QD), 3 weeks on, 1 week off 
(4-week cycles) .  Subjects are randomized into either fruquintinib  in combination with BSC group ( treatment 
group) or placebo in combination with BSC group (control group) in a 2:1 ratio ( Figure 1). 
If study treatment dose adjustment is required, t he site must log into the IWRS, adjust the dose, reassign 
the drug serial number, and dispense new study treatment dose (in 1 mg capsules) to the subject.   If the 
dose i s adjusted a second time, i .e., from 4 mg QD to 3 mg QD, the site must log into the IWRS and record 
the second dose adjustment.   On this occasion, it is not necessary to reassign a new drug serial number. 
If tumor evaluation shows PD during the previous cycle and new drug has been dispensed, the subject must return all unused study treatment on the 30- day safety visit after end of treatment (EOT). 
• Treatment group: fruquintinib  5 mg PO, QD, plus BSC, 3 weeks on/ 1 week off, every 4 -week cycle.  
• Control group: Matching placebo 5 mg PO, QD plus BSC, 3 weeks on/ 1 week off, every 4 -week 
cycle.  
Subjects are allowed to have no more than 2 dose reductions: one reduction from 5 mg QD to  4 mg QD, 
and if not tolerated, then a second reduction from 4 mg QD to 3 mg QD .  Once a dose has been reduced, 
it cannot be re- escalated.  The dose reduction sequence by starting dose is shown in  Table 2 below.   
Table 2.  Dose Modification Sequence by Starting Dose  
Dose Level 0*  
(Original dose)  5 mg QD 3 weeks on, 1 week off  fruquintinib  of 5 mg, 1 capsule, or 1 
capsule of the matching placebo  
Dose Level -1* 
(the 1st dose reduction)  4 mg QD 3 weeks on, 1 week off  fruquintinib  of 1 mg, 4 capsules, or 4 
capsules of the matching placebo  
Dose Level -2* 
(the 2nd dose reduction)  3 mg QD 3 weeks on, 1 week off  fruquintinib  of 1 mg, 3 capsules, or 3 
capsules of the matching placebo  
 
Reasons for d ose modifications includes the following :  
• Hematologic and non- hematologic toxicity. 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 20 of 99 
 • Palmar -Plantar Erythrodysethesia. 
• Proteinuria. 
• Hypertension . 
• Decreased platelet count . 
• Hemorrhage at any site . 
• Abnormal live function. 
Dose modification guidelines are detailed in Section 7.5.6 of the protocol.  
 Study Procedures and Flowchart  
The study contains the following procedures.  
• Screening Period: This period contains two visits windows of -28 to -1 days and -7 to -1.  
• Study Treatment Period: This period contains treatment cycles, with a visit window of +/ - 3 days for 
each scheduled visit starting at Cycle 2 day 1.  
o Cycle 1 includes cycle 1 day 1 and cycle 1 day 21 visits;  
o Cycle 2 includes cycle 2 day 1 and cycle 2 day 21 visits;  
o Cycle 3 includes cycle 3 day 1 and cycle 3 day 21 visits;  
o Cycle 4 and beyond include cycle 4 day 1, cycle 5 day 1, etc.   
• Follow- Up: This period contains the following.  
o Post treatment : 7 days after last dose with a visit window of +/ - 3 days,  
o Safety Follow- up: 30 days after EOT visit with a visit window of +/- 7 days, and 
o Survival Follow -up: 12 weeks from EOT visit with a visit window of +/- 14 days.  
o EOT: last non-missing assessment during the treatment period  (treatment period is from 
the date of the first study drug administration until 37 days after last dose ) 
The protocol activities include the following throughout the periods listed above.   
• Informed Consent . 
• Demographics . 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 21 of 99 
 • Medical History, Disease History , and molecular characterization of RAS, B-Raf proto -oncogene 
(BRAF) , Microsatellite Instability (MSI)/ Mismatch Repair (MMR) status . 
• Prior and Concomitant Medication/Concomitant Procedure . 
• Comprehensi ve Physical Examination . 
• Limited Physical Examination . 
• ECOG . 
• Vital Signs. 
• Hematology . 
• Blood Chemistry. 
• Blood amylase and lipase . 
• Coagulation . 
• Thyroid Function. 
• Urinalysis . 
• Serum Pregnancy Test . 
• Urine Pregnancy Test. 
• 12-lead ECG . 
• ECHO /Multigated acquisition ( MUGA ). 
• Tumor Evaluation/Imaging . 
• Tumor Markers . 
• Circulating Tumor DNA , excluded from  Japanese Specific Addendum .  
• PK Plasma S ampling . 
• Subject  Randomization , excluded from Japanese Specific Addendum . 
• Drug/Dispense/Return . 
• Study Treatment . 
• Adverse Event . 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 22 of 99 
 • Survival Follow -up. 
• EORTC  QLQ- C30 Questionnaire, excluded from Japanese Specific Addendum . 
• EQ-5D-5L Questionnaire, excluded from Japanese Specific Addendum . 
Details of study procedures can be found in the following tables within the protocols.  
• Table 1. S chedule of Events . 
• Table 2. Schedule of Events for Pharmacokinetic and Electrocardiogram Evaluations for the First 
Approximately 120 Subjects, and  
• Table 3.  Schedule of Events for Pharmacokinetic and Electrocardiogram Evaluations for Subject s 
Enrolled After the First Approximately 120 .  
The study schematic is presented in Figure 1. 
Figure 1.  Study Design Schema  
 

Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 23 of 99 
 
 Endpoints   
 Primary Efficacy Endpoint  
The primary endpoint of the study is OS, defined as the time (months) from date of randomization to death 
from any cause. That is, OS is calculated as (date of death or last known alive – date of randomization + 
1)/30.4375.    Subjects without report of dea th at the time of analysis are censored at the date last known 
alive.   Subjects lacking data beyond the date of randomization have their survival time censored at the date 
of randomization.  OS will not be  censored if a subject receives subsequent anticanc er treatments after 
discontinuation of the study treatments . Date of last known alive defined in Section 7.2.4  and date of death 
is defined in Section 7.2.5  of the SAP.  
 Secondary Efficacy Endpoints  
• Key secondary efficacy endpoint: PFS.  
PFS is defined as the time (months) from randomization until the first radiographic documentation of objective progression as assessed by in vestigator using Response Evaluation Criteria In Solid Tumors  
(RECIST ) v1.1, or death from any cause. More specifically, PFS will be determined using all the assessment 
data up until the last evaluable visit prior to or on the date of (i) disease progression as defined by RECIST Version 1.1 or death; or (ii) withdrawal of consent; or (iii) receiving subsequent anti -cancer therapy, 
whichever is earlier . Subjects without report of PD or death from any cause at the time of analysis are 
censored as described in Table 3 below.  
The PFS time will always be derived based on scan dates not tumor assessment dates. If PD is documented between scheduled visits, the actual date of documented progression will be used as an uncensored value 
in the analysis of PFS. RECIST assessments/scans contributing towards a particular visit may be performed 
on different dates. The following rules are applied:  
1. Date of progression is determined based on the  earliest of the dates of the component that triggered  
the progression . 
2. When censoring a subject for PFS , the subject is censored at the latest of the dates contributing to 
a particular overall visit assessment . 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 25 of 99 
 • The additional anti- tumor s econdary efficacy endpoints include ORR, DCR, and DoR. The 
derivation of the best overall response is detailed in Section 9.2.3 .  
o ORR is defined as the proportion of subjects achieving a best overall response of confirmed 
complete response (CR) or partial response (PR), per RECIST v1.1, as determined by the 
investigator.  
Objective response rate (ORR) will be calculated using two differe nt ways:  
§ Scenario #1: ORR will be calculated using a strict interpretation of RECIST Version 
1.1. Objective response will be derived as no/yes variable. Subject s with a BOR of 
confirmed CR or PR will be assigned ‘Yes’. Subject s not having a BOR of 
confirmed CR or PR will be assigned ‘No’. Hence, ORR is defined as the proportion 
of subjects with objective response being “Yes”.  
§ Scenario #2: ORR UNCONF RMED  will be calculated using all responses regardless of 
confirmation. Objective response will be derived as no/yes variable.  Subject s with 
a BOR of confirmed CR, confirmed PR, unconfirmed CR or unconfirmed PR will be assigned “Yes”.  All subjects with other BOR values will be assigned “No”.  
Hence, ORR
UNCONF RMED  is defined as the  proportion of subjects with objective 
response being “Yes”.  
o DCR is defined as proportion of subjects achieving a best overall response of confirmed 
CR, PR, or SD  (for at least 7 weeks) , within each treatment group , per RECIST v1.1, as 
determined by the in vestigator.  To be qualified for SD, the duration of SD should last for 
at least 7 weeks.  
o DoR is defined as the time (months) from the first occurrence of PR or CR  by RECIST 
Version 1.1, until the first date that progressive disease is documented by RECIST Version 
1.1, or death, whichever comes first . Only those subjects with confirmed responses of CR 
or PR will be included in this analysis. Censoring will follow the rules outlined for PFS in Table 3 in this section for those subjects who do not have censored DoR, it is calculated 
as (date of death or PD or last assessment – date of first occurrence of confirmed CR or 
PR + 1)/30.4375.  
• Changes in health status (QLQ -C30: cancer specific; and EQ -5D-5L). 
• Resource utilization including all concomitant medications, days in hospital . 
 Exploratory Endpoints  
• Change from baseline in circulating tumor DNA (ctDNA) , analysis to be included in a separate 
document . 
• Change from baseline in tumo r markers (carcino -embryonic antigen [CEA]) . 
• Pharmacogenomics ,  analysis to be included in a separate document . 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 26 of 99 
 
 Safety Endpoints  
• Safety including  treatment- emergent adverse events ( TEAEs) , serious adverse events ( SAEs ), 
deaths, ECG’s,  and clinical laboratory abnormalities . 
 Pharmacokinetic Endpoints  
• Observed plasma concentrations, estimated  population PK and exposure parameters of  
fruquintinib and M11 . 
• QTc interval and plasma concentrations of fruquintinib and M11 at specified time points.  
 Pharmacodynamic Endpoints  
• Parameters describing exposure -response with efficacy (e.g., OS) and safety (e.g., AEs) 
endpoints. 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 27 of 99 
 
 Analysis Populations 
 Screened  Population  
The Screened population include s all subjects who signed informed consent form (ICF).   
 Intent- to-Treat Population  
The Intent- to-Treat (ITT) population includes all randomized subjects.  Subjects are analyzed by treatment 
group as randomized.  The ITT population is the primary population for evaluating all efficacy endpoints 
and subject  characteristics.   
 Safety Population  
The Safety population includes all randomized subjects who received at least one dose of study  treatment.  
Subjects in this population are analyzed according to the treatment they actually received.  This population 
is used for all safety analyses.   
 Pharmacokinetic  (PK) Population  
The PK population includes all subjects who receive at least one dose of study treatment and have at least 
one post -dose PK sample obtained and analyzed.  The PK population is used for tabulation of fruquintinib 
and M11 concentrations from PK plasma samples. 
 Non- COVID -19 Impacted Population  
The Non- COVID -19 Impacted population includes all randomized subjects who do not have any 
Coronavirus 2019 (COVID -19)-related protocol deviations.  The Non -COVID -19 Impacted population is 
used for sensitivity analyses for the primary and secondary efficacy endpoints.  
 Per Protocol (PP) Population  
The per -protocol (PP) analysis set will include only those subjects  in ITT who have no major protocol 
deviations (as described in Section 6. 7) and who received the treatment to which they were randomized or 
assigned. For subjects who took the wrong treatment for part of the study, their data will be excluded from 
the PP population. PP population is used for sensitivity analyses of OS and PFS, and may be used to 
analyze selected endpoints to test the robustness of results. The criteria for inclusion in the PP subset will 
be finalized and documented prior to unblinding of the study. 
 Protocol Deviations  
Protocol d eviations are recorded in the clinical trial management system (CTMS) as outlined in the latest 
version of the Protocol Deviation and Non -compliance Management Plan.  Protocol deviations are 
categorized as minor or major before database lock.  
Protocol devi ations including deviations that are related to COVID -19 are recorded in the CTMS as outlined 
within the Protocol Deviation and Non -Compliance Plan.   
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 28 of 99 
 
 General Aspects for Statistical Analysis 
 General Methods  
• Summaries are presented for each treatment group and overall for subjects’ disposition, 
demographics and baseline characteristics, medical history, disease history, prior medications, and 
concomitant medications  tables.  Summaries are presented for each treatment group for other 
tables.  
• All data listings that contain an evaluation date contain s a relative study day  as defined in Section 
7.2.3. 
• For categorical variables, summary tabulations of the number and percent of subjects  within e ach 
category  of the parameter as seen on the electronic case report form (eCRF ) are to be presented.  
Percentage calculations are based on the number of subjects within treatment group and overall, 
unless otherwise specified .  Percentages are rounded to 1 decimal place, unless otherwise 
specified .  The category Missing is included in subject -level demographics and disease history 
tables when the count is greater than zero for missing subjects.  
• For continuous variables, the number of subjects, mean, standar d deviation (StdDev) , median, 
lower quartile ( Q1), upper quartile  (Q3), minimum, and maximum values are presented.  The 
precision of summary statistics, unless otherwise specified, is as follows:  
o Minimum, maximum: same decimal places as the raw data . 
o Mean , median , Q1, and Q3  : 1 more decimal place than the raw data. 
o Standard deviation, standard error:   2 decimal places more than the raw data .  
• For results from a mixed model repeated measures, least -square (LS) mean and LS mean 
difference are presented with one decimal place, and standard error (SE) of LS means and SE of LS mean difference  are presented with two decimal  places.   
• Comparison  between treatment groups  are calculated as fruquintinib plus BSC versus placebo plus 
BSC. 
• Two-sided 95% confidence intervals (CI) are provided and rounded to 2 decimal places , unless 
otherwise specified. 
• 2- sided p -values are presented with 3 decimal places . 
• Any rounding will be done after all calculations are made. 
 Key Definitions  
 First Dose Date 
First dose date is defined as the day of first dose of study treatment received after randomization . 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 29 of 99 
 
 Last Dose Date 
Last dose date is defined as day of  the last dose of study treatment.   
For subjects ongoing for the treatment period at time of analysis prior to database lock , the last dose date 
is the date of the most recent study visit in the database for that subject . 
 Study Day  
The study day is determined relative to the date of first dose of study treatment, unless otherwise specified.  
The day of the f irst dose of study treatment  is defined as study day 1.  The day prior to the first dose of 
study treatment  is study day -1.  There is no study d ay 0.  
For events that occur before the first dose of study treatment ,  
study day = date of  the event – first dose date;  
for events that occur on or after the first dose of study treatment ,  
study day = date of the event – first dose date + 1.  
 Date of Last Known Alive  
The date of last known alive is defined as the last alive date of contact from  the Survival Follow -up page on 
the eCRF.  For subjects ongoing at time of analysis, the date of last known alive is the date of the most 
recent study visit in the database for that subject.  
More specifically , the last known alive date will be derived for subjects not known to have died at the 
analysis cut -off date using the latest date (including complete and partial date with Month and Year 
information) among the following data:  
- All assessment dates (e.g. laboratory, vital signs assessments, ECG, ECOG, pe rformance status 
assessment, tumor assessment dates etc.).  
- Medication dates including study medication, concomitant medications, anticancer therapies 
administered after study treatment discontinuation. 
- Adverse events start and end date , and the date of adverse event becoming serious . 
- Date latest known alive collected during the survival follow -up. 
- Randomization date.   
 Date of Death  
Date of death is defined as the date of death from the Death Detail page on the eCRF.  Date of death is 
cross- checked with AEs where outcome is ‘Fatal’, if applicable.  In rare case, if year and month of death 
date are known but the day is unknown, day will be imputed as 15. For example, if a subject  is reported to 
die on Dec2017, the death date will be imputed as 15 Dec2017.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 30 of 99 
 
 Baseline and Change from Baseline  
For all change from baseline variables, t he baseline is defined as the last non -missing assessment prior to 
or on the day of randomization, and must be prior to the first administration of study treatment, including 
scheduled and unscheduled visits, unless otherwise specified.  Hence, c hange from baseline = post -
baseline value – baseline value.  
The baseline value for analyses of qualitative parameters (e.g.,  normal/abnormal) is defined as the last 
evaluation prior to or on the day of randomization, and must be prior to the first administration of study 
treatment. 
 Treatment -emergent Events  
An AE is considered a TEAE if the onset date is on or after the start of study treatment or if the onset date 
is missing , or if the AE has an onset date before the start of study treatment but worsened in severity after 
the study treatment until 37 days after the last dose of study treatment or a new treatment of anti -tumor 
therapy, whichever is earlier. After this period, treatment- related SAEs will also be considered as TEAEs. 
AEs with an unknown/not reported onset date will also be included. 
 Missing Data  
All available data o f the subjects who withdraw from the study for any reasons is analyzed.  Missing data is 
assumed to be missing at random.  Category ‘Missing’ is displayed for qualitative assessments, where 
applicable.  
For demographic and baseline characteristics, each var iable will be analyzed and/or summarized using the 
available data. Unless otherwise specified, subjects with missing data will be excluded only from analyses 
for which data are not available.  
There is no imputation of missing data for the analysis purpose,  unless otherwise stated.  
 Imputation of the Missing  Dates  
Imputation rules described in this section are applicable to partial dates of AEs, concomitant medications, 
anti-cancer therapy, primary diagnosis and metastatic disease diagnosis . However, imputation of missing 
AE and concomitant medication onset and stop dates will be used to determine the status of each AE and the prior/concomitant status of each medication, the imputed dates should not be shown in listings.  
Incomplete Start Date of AEs : 
- If the AE onset date is completely missing, the AE start date will be imputed as the reference start 
date (i.e. first dosing date) ; 
- If the AE onset date is partial missing, then  
§ If both the year and the month are available and the year and the month are the corresponding year and month of the reference start date , then the AE start date will be imputed as the 
reference start date ;  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 31 of 99 
 § If both the year and the month are available and the year and the month are not equal to the 
corresponding year and month of the reference start date , then the AE start date will be imputed 
as the 1st day of the month;  
§ If only the year is available and the  available year is the corresponding year of the reference start 
date, then the AE start date will be imputed as the reference start date ; 
§ If only the year is available, and the available year is not equal to the corresponding year of the reference start date, then the AE start date will be imputed as the January 1
st of the year . 
Incomplete Stop Date of AEs :  
AE end date will be imputed as below for the partial date only, the imputation rules only apply when the 
AE is not ongoing:  
- If both the year and the month are available, AE end date will be imputed as the last day of the 
month;  
- If only the year is available, AE end date will be imputed as the December 31st of the year.  
If the imputed AE end date is after the death date for subjects is know to be de ad at end of study or cut 
off date, the date of the death will be used for AE end date. If the imputed AE end date is after the last 
known alive date for subjects alive at the end of study or cut off date, the date of last known alive date will be use for AE end date.  
For AE continuing at the cut -off date, the end date will not be imputed and instead will be reported as 
“ongoing”.  
Concomitant Medication/Procedure/Surgery with onset/end dates  
Concomitant Medication/Procedure/Surgery with onset/end dates th at are partially/completely missing will 
be imputed as follows.  
(i) start date:  
- 1st day of the month will be used to impute the start date if only the day is missing . 
- January 1st will be used to impute  the start date if both the day and month are missing . 
- If the date is completely missing , then the day before the reference start date will be imputed as the 
start date.  
(ii) end date:  
- Last day of the month will be used to impute the end date if only the day is missing . 
- December 31st of the year will be used to impute the end date if both the day and month are missing . 
- If the date is completely missing, assign ‘continuing’ status to the end date . 
If the imputed end date is after the death date or last known alive date, the date of the death or last known 
alive date will be imputed as the Concomitant medication/procedure/surgery  end date.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 32 of 99 
 Subsequent Anti -cancer Therapy Date ( collected during Survival Follow -Up) 
When a partial new anti -tumor therapy start date is reported, every effort will be made to identify the 
precedence relationship of starting date of new anti -tumor therapy relative to the reference end date  (i.e. 
last dose date). Below rules will be used:  
- If the date is completely missing, new anti -tumor therapy date will be imputed as reference end date + 
1; 
- If only the day is missing, 15th day will be imputed as the new anti -tumor therapy date;  
- If both the day and the month are missing, then July 1st will be imputed as the new anti -tumor therapy . 
If the imputed start date is prior to  the reference end  date for subjects, the reference end date + 1  will be 
used as the imputed start date of the subsequent anti -cancer therapy.   
Primary Diagnosis Date and Metastatic Disease Diagnosis Date  
When a partial date of primary diagnosis for advanced colorectal cancer or a partial date of first 
metastatic disease diagnosis is reported, the below imputation  rules will be used:  
- If the date is completely missing, no imputation will be conducted;  
- If only the day is missing, 15th day will be assigned; 
- If both the day and the month are missing, then July 1st will be assigned. 
 
 Visit Windows  
It is expected that there will be a variation between subjects in the actual number of study days from the 
start of administration of study drug within each cycle - defined as Day 1 - to the dates that the scheduled 
visits occurs. To handle this, for tables and figures where data are grouped by visit, assessments will be 
categorized using visit windows based on study days (relative to the Day 1 of each cycle). The visit -window 
mapping is described in Table 4. Visit-based summaries will be based on the windowed visits. All data, 
whether or not within the visit windows, will be presented in subjects listings.  
For windowed visits during the treatment cycles, if more than 1 vis it occurs during a visit window, the visit 
closest to the scheduled day will be assigned to the windowed visit. If two visits are equidistant from the scheduled day, the later visit will be assigned to the windowed visit. If there are multiple assessments on 
the same day, the worst case will be used.  For the treatment completion visit, the last assessment in the window will be included in the summary.  
For a subject  who prematurely discontinues the study, the premature visit will be slotted accordingly. The 
window for post treatment visit will be " last dose date of last cycle to last dose date of last cycle + 10  days " 
and the window for safety follow -up visit will be “Last dose date of last cycle + 11 days to last dose date of 
last cycle + 37 days”.
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 34 of 99 
 
 Pooling of Centers  
Data from all study centers is combined for analysis .   
 Outliers  
Data Management are to be notified of outliers, if identified during TLF reviews, for query.  Syneos Health 
Biostatistics and Programming do not change or remove outliers from the data.  
 Data Sources  
Randomization number s, stratification factors, and treat ment assignments derived from IWRS are 
reconciled with the dummy randomization schedule prior to database lock and unblinding, and with the 
actual randomization schedule after database lock and unblinding.  
After the study is unblinded, fruquintinib and M11  concentrations from PK plasma samples are provided by 
Covance and mapped onto SDTM PC domain.  Syneos Health then transfers SDTM PC domain to Certara.  
Protocol deviations are recorded in the clinical trial management system  and provided as an Excel 
document.  Protocol deviations are to be reviewed prior to database lock.  
CRF data are extracted from Rave database.  
Laboratory data are provided by local labs.  
Imaging data are provided by  eResearchTechnology, Inc.  (ERT). 
Interactive Response Technology (IRT) data are provided by Endpoint.  
Quality of life data using EORTC QLQ -C30 and EQ -5D-5L questionnaires are collected via Electronic 
Clinical Outcome Assessment (eCOA) and provided by ERT.  
 
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 35 of 99 
 
 Demographic, Other Baseline Characteristics and Medication 
 Subject Disposition and Withdrawals  
The following summaries will be presented  for all enrolled subjects to reflect the s ubject disposition: 
- Number of subjects who signed the informed consent .  
- Number of screen failures . 
- Reason for screen failure . 
- Number of subjects who are randomized .  
- Number of subjects who do not receive study drug. 
- Number of subjects who received study drug.  
- Subject s still on treatment (i.e., missing end- of treatmen t information). 
- Reason for study drug discontinuation (for study drug) . 
- Number of subjects going into Survival follow -up if there are any assessments after the last dose 
date + 37 days.  
- Number and percentage of subjects still on study (i.e., missing end -of-study information). 
- Number and percentage of subjects who discontinue d the study. 
- Reason for study discontinuation . 
A separate table will be presented  for the ITT population to show the subjects included in each analysis set 
and proper reason s for exclusion from an analysis set.   
A separate table will be presented for the ITT population to show the concordance of randomization 
schedule stratification factors and C RF collected factors of prior t herapy, duration of metastatic disease, 
and RAS status. The following summaries will be presented: 
- Number of subjects with all randomization schedule stratification factors concordant with CRF 
collected factors . 
- Number of subjects with at least one randomization schedule stratification factor discordant with 
CRF collected factors . 
o Number of subjects with discordance in prior therapy, duration of metastatic disease, and 
RAS status . 
- Prior therapy ( Trifluridine/Tipiracil (TAS -102), Regorafenib , or Both Trifluridine/Tipiracil (TAS -102) 
and Regorafenib ) based on randomization schedule stratification factors and prior therapy based 
on CRF collected factors. 
- Duration of metastatic disease ( ≤ 18 months, > 18 months) based on randomization schedule 
stratification factors, and duration of metastatic disease based on CRF collected factors . 
- RAS status (Wild Type, Mutant) based on randomization schedule stratification factors, and RAS 
status based on CRF collected factors . 
Subject discontinuation status and analysis population are also listed. 
 Protocol Deviations  
Protocol deviations are summarized descriptively for subjects with at least 1 major protocol deviation and 
subjects with at least 1 minor protocol deviation for eac h treatment group  and overall .  Each protocol 
deviation is also summarized descriptively within major and minor protocol deviations for each treatment 
group and overall  of the ITT population.  A subject can have multiple major and/or minor deviations  and 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 36 of 99 
 counted once per major and/or minor deviation.  COVID -19-related protocol deviations are summarized 
descriptively for each treatment group  and overall  of the ITT population.  
A listing of protocol deviations, including COVID -19-related  protocol deviations, is provided.  
 Demographic and Baseline Characteristics  
The following parameters are summarized descriptively for each treatment group and overall for the ITT 
population.  
• Age (years)  at ICF date, Age Categories (< 65 years, ≥ 65 years) . 
• Sex (Female, Male); If female, Child Bearing Potential .  
• Race (American Indian or Alaskan Native, Asian, Black or African American , Native Hawaiian or 
Other Pacific Islander , White, Other, Multiple Races, Not Reported, Unknown). A subject can have 
multiple races and is summarized in the  multiple race category.  
• Ethnicity ( Hispanic or Latino, Not Hispanic or Latino, Not Reported, Unknown ).  
• Region (North America, Europe , and Asia ).  
• Baseline Height (cm ). 
• Baseline W eight (kg). 
• Baseline body mass index [ BMI] (kg/m2): it is calculated as Weight  at Baseline (kg)/ [Height at 
Baseline (m)]2. 
o BMI category: < 18.5, ≥ 18.5 and < 24, ≥ 24 kg/m2. 
• Baseline ECOG Performance Status: 0, 1. 
Age (years) at ICF date is calculated by site personnel as the number of years from date of birth up to date 
of informed consent.  For example,  
Date of Birth  Date of Informed 
Consent  Original Age  Age to be entered into IWRS  
01MAR1985 01JUL2020 35 years 4 months 35 
01AUG1985 01JUL2020 34 years 11 months  34 
 
A separate tabl e presenting number and percentage of subjects  by site and country will be produced  for 
the ITT population. 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 37 of 99 
 Demographic data and baseline characteristics , randomization scheme and codes, informed consent data, 
and inclusion/exclusion criteria are listed  by subject . 
 Disease History  
History of colorectal cancer of the ITT population is summarized descriptively for each treatment group and 
overall for the following. 
• Time (months) since First Diagnosis of Colorectal Cancer : it is calculated as (date of randomization 
– date of first diagnosis of colorectal cancer)/30.4375 .   
• Stage of C olorectal Cancer at First Diagnosis  (stage I, stage II, stage III, stage IV) . 
• Primary T umor Location at First Diagnosis . 
o Colon.  
§ Colon – Right (cecum, ascending colon, and hepatic flexure) . 
§ Colon – Left (splenic flexure, descending colon, transverse colon, sigmoid colon) . 
§ Colon – Right and Left. 
§ Colon – Unknown. 
o Rectum. 
o Colon and Rectum . 
§ Colon – Right (cecum, ascending colon, and hepatic flexure) . 
§ Colon – Left (splenic flexure, descending colon, transverse colon, sigmoid colon) .  
§ Colon – Right and Left . 
§ Colon – Unknown . 
o Unknown . 
• Primary Site at First Diagnosis  (Colon  Left, Colon  Right, Both Colon  Left and Right, Colon  
Unknown, Rectum Only, Unknown ). 
• Duration of Metastatic Disease (months): it is calculated as (date of randomization – date of 
diagnosis of metastasis disease)/30.4375 . 
o Duration of Metastatic Disease Categories (≤ 18 months, > 18 months) . 
• Prior Oncology Tre atments ( Prior Anti -cancer Medication, Prior Anti -cancer Radiotherapy, Prior 
Anti-cancer Procedures ). 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 38 of 99 
 • RAS Status (Wild Type, Mutant) . 
• BRAF Status ( Wild Type, V600 E Mutation, Other ). 
• M icrosatellite/M ismatch Repair Status  (Microsatellite stable [MSS ] and/or  proficient mismatch 
repair [pMMR ], microsatellite instability- high [MSI-H] and/or deficient mismatch repair [ dMMR ]). 
• Prior Therapy with T rifluridine/Tipiracil (TAS -102) and/or Regorafenib (Trifluridine/Tipiracil (TAS -
102), Regorafenib, Both Trifluridine/Tipiracil (TAS -102) and Regorafenib ). 
• Number of Prior Treatment Lines (≤ 3, > 3) . 
• Number of Prior T reatment Lines for M etastatic Disease (≤ 3, > 3) . 
• Prior Treatment with Vascular Endothelial Growth Factor (VEGF) Inhibitors (Yes, No). 
• Prior Treatment with Epidermal Growth Factor Receptor (EGFR) Inhibitors (Yes, No) . 
• Prior  Treatment with EGFR/VEGF Inhibitors .  
o No anti -VEGF and no anti -EGFR. 
o Anti-VEGF, or anti -EGFR, or both. 
§ Anti-VEGF and no anti -EGFR. 
§ Anti-EGFR and no anti -VEGF. 
§ Both anti-VEGF and anti -EGFR. 
• Prior Treatment with Immune Checkpoint Inhibitors for MSI -H/dMMR (Yes, No) . 
• Prior Treatment with BRAF Inhibitors for BRAF V600E Mutation  (Yes, No) . 
• Liver Metastases  at Baseline (Yes, No): obtained based on whether the liver organ was involved 
in the target and non -target lesion tumor scan assessment at the baseline . 
• Number of Metastatic Sites Other than Colon or Rectum  (Single, Multiple ): obtained based on the 
number of  sites/organs  was involved in the target and non -target l esion tumor scan assessment at 
the baseline. If only one is involved, that would be single; if more than one are involved, it will be 
multiple . For this derivation, paired organs, such as lung, kidney, ovaries, and lymph nodes will be 
considered as one org an, irrespective of the number of parts they may be made up of  (i.e. tumors 
in the left lung and right lung will be counted as in one site) .  
• Number of Metastatic Sites (Single, Multiple): obtained based on the number of sites/organs  was 
involved in the target and non -target lesion tumor scan assessment at the baseline. If only one is 
involved, that would be single; if more than one are involved, it will be multiple . For this derivation, 
paired organs, such as lung, kidney, ovaries, and lymph nodes will be considered as one organ, 
irrespective of the number of parts they may be made up of  (i.e. tumors in the left lung and right 
lung will be counted as in one site) .   
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 39 of 99 
 
 Medical History  
The conditions/diseases from medical history are thos e conditions/diseases that stopped prior to the study 
entry.  Medical history is coded using the  Medical Dictionary for Regulatory Activities (MedDRA ) version 
23.0 or higher.  Medical history is summarized using discrete summary statistics for each MedDRA  system 
organ class ( SOC) and preferred term (PT) b y treatment group and overall for the ITT population.  Subjects 
with multiple medical histories in the same SOC or PT are counted only once for the respective SOC or PT.    
Summaries are ordered in alphabetic al order of SOC and then, within an SOC, in decreasing frequencies 
by PT in overall column. If the frequencies tie, an alphabetic order will be applied.   
A listing of medical history by subject is provided.   
 Prior and Concomitant Medication  
Prior and concomitant medications are classified by Anatomical Therapeutic Classification  (ATC) 
therapeutic subgroup (Level 2)  and PT using the World Health Organization Drug Dictionary (WHODD) 
version March2020 or later .  Medications with partial start or stop dates are imputed as described in Section 
7.3.1 prior to be determined whether the medication is prior or  concomitant medication. 
Medications taken prior to the first dose of study treatment are denoted “Prior”. Medications taken prior to 
the first dose of study treatment and continuing beyond the first dose of study treatment or those 
medications started on or after the first dose of study treatment but no later than 37 days after the last dose 
are denoted “Concomitant”.  Medication with start date/time being partially or completely missing will be 
assumed to be concomitant if it cannot be definitely shown tha t the medication did not occur during the 
treatment period. 
The use of prior and concomitant  medications will be  summarized using discrete summary statistics in each 
treatment group and overall for the ITT population.  If a subject took a specific medication multiple times or 
took multiple medications within a specific ATC or PT, the subject is counted only once for  the respective 
ATC or PT.  
Summaries are ordered in alphabetical order of ATC and then, within an ATC , in decreasing frequencies 
by PT in overall column. If the frequencies tie, an alphabetic order will be applied.  
A listing of prior medication and concom itant medication by subject is provided.  
 Concomitant Medical or Surgical Procedure  
Medical or surgical procedures that occurs after first dose date but no later than 37 days after the last dose 
are denoted “Concomitant” .  Concomitant medical or surgical procedures are classified using the MedDRA  
version 23.0 or higher .  
The use of concomitant  medical or surgical procedures will be  summarized using discrete summary 
statistics in each treatment group and overall for the ITT population.  If a subject took a specific medication 
multiple times or took multiple medications within a specific SOC or PT, the subject is counted only once 
for the respective SOC or PT.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 40 of 99 
 Summaries are ordered in alphabetical order of SOC and then, within an SOC , in decreasing frequencies 
by PT in overall column. If the frequencies tie, an alphabetic order will be applied.  
A listing of concomitant medical or surg ical procedures by subject is provided.  
 Prior Oncology Treatment  
Prior oncology treatments including prior anti -cancer mediation, prior anti- cancer radiotherapy,  prior anti-
cancer procedure or surgery are summarized descriptively for each treatment group and overall for the ITT 
population.   
 Prior Anti -cancer Medication  
Summary of prior anti -cancer medication for the ITT population includes the following: 
• The number and percent of subjects with at least one prior anti -cancer medication . 
• The total number of prior anti-cancer medications. 
• The number of prior lines of therapy and its categories of 0, 1, 2, 3, >  3.  
Prior anti -cancer medication s are classified using the WHODD version March  2020 or later.  
The use of prior anti -cancer medications will be summarized  by ATC and PT using discrete summary 
statistics in eac h line of therapy, each treatment group and overall for the ITT population.  Within each line 
of therapy, a subject with multiple prior medication entries in the same ATC (PT) is only counted once within 
a particular ATC (PT). With each line of therapy, resul ts are sorted by ATC followed by PT in decreasing 
order of frequency (by Total column). If the frequencies are tied, an alphabetic order is applied.  
 Prior Anti -cancer Radiotherapy  
Summary of prior anti -cancer radiotherapy  for the ITT population includes th e following . 
• The number and percent of subjects with at least one prior anti -cancer radiotherapy . 
• The total number of prior anti -cancer radiotherapy. 
 Prior Anti -cancer Procedure or Surgery  
Summary of prior anti -cancer procedure or surgery  for the ITT population includes the following 
• The number and percent of subjects with at least one prior anti -cancer procedure or surgery. 
• The total number of prior anti -cancer procedures or surgery.  
The number and percent of subjects for each purpose of prior anti-cancer procedure or surgery . A 
subject with multiple occurrences  of the same purpose will be co unted only once for the purpose, 
and a subject with multiple purposes will be counted once in each category of purpose.    
Prior an ti-cancer procedure or surgery is coded  (MedDRA ) version 23.0 or higher.  
The number and percent of subjects with each procedure or surgery will be summarized using discrete 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 41 of 99 
 summary statistics in each treatment group and overall for the ITT population by SOC and PT. If a subject  
had a procedure multiple times or had multiple procedures  within a specific SOC or PT, the subject is 
counted only once for the respective SOC or PT. Summaries are ordered in alphabetical order of SOC and 
then, within an SOC, in de creasing frequencies by PT in overall column. If the frequencies tie, an alphabetic 
order will be applied. 
 Extent of Exposure   
Exposure of study treatment is descriptively summarized for each treatment group as follows. Table 5 
details the parameters of study treatment exposure.  
Table 5. Extent of Exposure Parameters  
Parameter  Definition  
Duration of Exposure (days)  Last dose date of study drug – first dose date of study drug + 8. 
Number of Days with Recorded 
Dose  Sum of days with recorded doses  
Number of Cycles Treatment 
Received  Subjects are considered to have started a cycle if they have 
received at least one dose of any study treatment.  
Number of Cycles Treatment 
Received Categories  1, 2, 3, 4, 5,  6 and > 6 
Cumulative Dose (mg)  Sum of doses administered in all cycles. The total dose 
administered in each cycle is defined as: the sum of (number of 
5 mg capsules taken × 5 + number of 1 mg capsules taken)  
where number of capsules taken = total capsules dispensed – 
total capsules returned. 
Dose Intensity (mg/day)  Cumulative Dose (mg) / Duration of Exposure (day)  
Target dose intensity is 3.75 mg  
Relative dose intensity (RDI) (%)  100 * [Dose Intensity (mg/day) / (5 × 21/28 (mg/day))]   
RDI Categories  < 50%  
50 - < 70%  
70 - < 90%  
90 - < 110%  
 ≥ 110%.  
Relative Dose (RD) (%)  100 * [Cumulative dose (mg) / (5×21× number of cycles  
treatment received  (mg)] 
 
RD Categories  < 50%  
50 - < 70%  
70 - < 90%  
90 - < 110%  
 ≥ 110%.  
Percentage Intended Dose (PID) (%)  100 * [(number of days with any recorded doses) /duration of 
exposure ]  
Target PID is 75%. Number of days with any recorded doses  
 
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 42 of 99 
 The following s ummary for  dose adjustment  will be summarized for each treatment group.  
o Study drug is administered orally on days 1 -21 of each 28 -day cycle. A cycle will be called 
cycle delay if the duration of the  cycle is longer than 28 days. However, the last cycle will 
not be evaluated for cycle delay. Reason for delay is not collected. Hence, the total number 
of cycle delay will be calculated for each subject.  Number of subjects with any cycle delay, 
and the frequency of cycle delay (0, 1, 2, 3, 4, 5, 6, > 6) will be summarized.  
o Number of subjects with any dose modification (including both drug interruption and dose 
reduction) ; 
o Frequency of dose modification: 0, 1, 2, 3, 4, 5, 6, >  6. 
o Drug interrupted (number of subjects experienced drug interruption  and reasons for drug 
interruption ; frequency of drug interruptions: 0, 1, ≥ 2) . 
o Drug withdrawn  (number of subjects experienced drug withdrawn and reasons for drug 
withdrawn ). 
o Dose reduced  (Number of subjects with any dose reduction and reasons for dose 
reduction; and frequency of dose reduction: 0, 1, 2, ≥  3), also the dose reduction category 
below will be summarized .  
§ Reduction from 5mg to 4mg .  
§ Reduction from 4mg to 3mg .  
Study treatment accountability, study treatment administration are extent of exposure are listed by subject 
and visit.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 43 of 99 
 
 Efficacy 
Efficacy analyses are based on the ITT population.   All secondary endpoints based on radiological 
assessments of tumor burden are derived from investigator assessment using Response Evaluation 
Criteria In Solid Tumors  (RECIST) version 1.1 ( Eisenhauer et al 2009) . 
 Primary and Key Se condary Efficacy Endpoint  and Analysis  
 Primary Efficacy Endpoint  and Analysis  
The primary endpoint of the study is OS, defined in Section  5.1 of the SAP and calculated as (date of death 
or last known alive – date of randomization + 1)/30.4375. 
The Kaplan- Meier plots will be produced and the median, 25% and 75% percentile of time -to-event will be 
estimated using Kaplan- Meier method with their corresponding 95% CI  which are calculated from a log -log 
transformation based on the method by Brookmeyer and Crowley (1982). Additionally, estimates will be 
provided for the survival probability along with their 95% CIs which are calculated using linear 
transformation  based on the method by Brookmeyer and Crowley (1982)  at selected landmarks, for 
example, at 3, 6, 9, 12, and 18 months. Example Statistical Analysis System (SAS) code is provided in 
Appendix 5 . 
The two- sided p -value to test t he treatment effect will be calculated  using a stratified log- rank test 
accounting for randomization  schedule  stratification factors. Example SAS code is provided in Appendix 6 . 
The hazard ratio (HR) between the 2 treatment groups (fruquintinib vs placebo), together with its 95% CIs, 
will be calculated from a stratified Cox proportional hazard model (i.e. accounting for  randomization  
schedule  stratification factors ) in which the treatment group is the only covariate in the model. A HR < 1 
indicates a favorable clinical benefit from fruquintinib over the placebo group.  Example SAS code is 
provided in Appendix 7 . 
Duration of follow -up is defined as the time (months) from date of randomization to the last date known to 
be alive for subjects who have not yet been reported to have died by the time of the analysis. Subjects who were reported to have died by the time of the analysis are censored at date of death. That is, duration of follow -up is calculated as (date of death or last known alive – date of randomization + 1)/30.4375. The 
duration of follow -up will be calculated using the Kaplan -Meier method.  
All OS data are provided in listings by subject.  
 Key Se condary Efficacy Endpoint  and Analysis 
The key secondary efficacy endpoint is PFS.  PFS is defined in Section 5.2  and calculated as (date of death 
or radiographic PD or last assessment – date of randomization + 1)/30.4375 . 
The number and percent of subjects who had progression -free events, the number and percent of 
subjects censored, and reasons for censoring are presented for each treatment group.  Reasons for censoring include the following.  
a. No baseline nor post -baseline assessment  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 44 of 99 
 b. No death nor PD  
c. Drop -out before end of study 
d. New anti -tumor therapy started prior to PD  
e. Death or PD occurred after two or more consecutive missed assessment  
The Kaplan- Meier plots will be produced and the median, 25% and 75% percentile of time -to-event will be 
estimated using Kaplan- Meier method with their corresponding 95% CI  which are calculated from a log -log 
transformation based on the method by Brookmeyer and Crowley (1982). Additionally, estimates will be 
provided for the survival probability along with their 95% CIs which are calculated using linear 
transformation  based on the method by Brookmeyer and Crowley (1982) at selected landmarks, for 
example, at 3, 6, 9, 12, and 18 months.  
The two- sided p -value to test the treatment effect will be calculated using a stratified log -rank test 
accounting for randomization schedule  stratification factors. The hazard ratio (HR) between the 2 treatment 
groups (fruquintinib vs placebo), together wi th its 95% CIs, will be calculated from a stratified Cox 
proportional hazard model  (i.e. accounting for  randomization schedule  stratification factors ) in which the 
treatment group is the only covariate in the model. A HR < 1 indicates a favorable clinical benefit from 
fruquintinib over the placebo group.  
A Kaplan- Meier plot of the time to censoring, where the censoring  indicator of the primary PFS analysis is 
reversed, will be presented.   
All PFS data is provided in listings by subject.  
 Multiplicity Adjustments  
The clinical trial evaluates the objectives defined in terms of the comparison of fruquintinib + BSC versus 
placebo + BSC on the primary and key secondary efficacy endpoints in Section 9.1.1 and Section 9 .1.2. 
The multiplicity problem includes 2 hypotheses of no effect : 
• Hypothesis 𝐻!. Comparison of fruquintinib + BSC versus placebo + BSC for OS.  
• Hypothesis 𝐻". Comparison of fruquintinib + BSC versus placebo + BSC for PFS.  
The 2-sided p -values for the 2 comparisons will be used for the multiple testing procedure.  Example SAS 
code in Appendix 6 . 
A fixed-sequence (hierarchical) testing procedure  is used to control the overall type I error rate at 0.05 .  If 
the resulting 2 -sided p- value from the analysis of primary endpoint OS is ≤ 0.05, then, a superiority test of 
for PFS will be conducted at the two -sided significance  level of 0.05.  
 Sensitivity Analysis for OS and PFS  
The following sensitivity analyses for OS and PFS will be performed , in which the p -value will always be 
obtained from the stratified  log-rank test and the  hazard ratio (HR) between the 2 treatment groups 
(fruquintinib v s placebo), together with its 95% CIs will be calculated from the model  in Section 9.1.1  and 
Section  9.1.2 for OS and PFS, respectively, unless otherwise specified.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 45 of 99 
 - using ITT population, unstratified Cox proportional hazard model  in which the randomization 
schedule  stratification factors  and treatment group are included in the model as covariates ; 
- using ITT population, stratified analysis  for both log -rank test and Cox proportional hazard model, 
but using the stratification factors collected on the case report form (CRF); 
- using ITT population, unstratified Cox proportional hazard model  in which the stratification factors 
collected on the CRF and treatment group are included in the model as covariates ; 
- using Non- COVID -19 Impacted population, 
- using ITT population,  subjects with primary cause of death attributed to COVID -19 will be censored 
at the last known alive date prior to the death date for OS; and will follow the censoring rule defined 
in Table 3 for PFS  and will use the data prior to the date of death .  
- using PP population 
- using PP population, unstratified Cox proportional hazard model  in which the randomization 
schedule  stratification factors and treatment group are included in the model as covariates ;  
- using PP population, stratified analysis for both log -rank test and Cox proportional hazard model 
using the stratification factors collected on the CRF;  
- using ITT population, multivariate Cox’s proportion hazard model with treatment and randomization 
schedule  stratification factors (i.e. prior therapy, RAS status, and duration of metastatic disease ) 
included in the model as covariate and,  adjust for key prognostic factors using stepwise selection 
process with level of enter alpha= 0.15 and level of remove alpha= 0.15.  Key prognostic factors 
include a set of potential prognostics/predictive factors as described in Section 9.1.5. 
An additional sensitivity analyses for OS will be performed  
- using ITT population, based on the first exact 480 deaths and the additional dead su bjects will be 
censored at the date of last known alive before their death . 
- using ITT population,  subjects who take the subsequent anti -cancer therapy and are still alive will 
be censored at the date of initiating the subsequent anti -cancer therapy  for OS.  
The following additional sensitivity analyses for PFS will be performed , and all those sensitivity analyses 
defines the PFS event in an alternative way.  
- For Rule 7 of Table 3, subjects who take  new anti -cancer therapy are considered as a progression, 
and the date of progression is on the date of initiating the new anti -cancer therapy. However, if the 
new anti -cancer therapy is initiated after two or more consecutive missed/non -evaluable tumor 
assessments, the subjects will still be  censored at date of last radiological assessment before the 
missed assessments.  Then, the same analysis methods outlined in Section 9.1.2 will be conducted.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 46 of 99 
 - For Rule 8 of Table 3, ignore the missing tumor assessments , that is, subjects with PD or death 
after two or more consecutive missed/non -evaluable tumor assessments  will be considered as PFS 
event, and the event date for PD or death will be obtained as usual. Then, the same analysis 
methods outlined in Section 9.1.2 will be conducted.   
 E xamination of Subgroups  
Subgroup analyses will be conducted as stated in the OS analysis and progression free survival sections. It should be noted that the study was not designed to detect treatment differences with high statistical 
power within subgroups. For OS and PFS subgroup analysis, if a subgroup is too small, it may be pooled with others. If the number of events in a subgroup is not sufficient, analysis will not be performed.  
The following subgroups will be as sessed for OS and PFS:  
• Age: < 65 years, > = 65 years 
• Sex: Female, Male  
• Region: North America,  Europe , Asia  
• Race: White, Asian, Black or African American, Other ( including American Indian or Alaska Native, 
Native Hawaiian or Other Pacific Islander, Other as  recorded on the Demographics eCRF, and 
subjects with multiple races selected )  
• Baseline ECOG Performance Status: 0, 1 
• Prior Therapy with T rifluridine/Tipiracil (TAS -102) and/or Regorafenib : Trifluridine/ Tipiracil (TAS -
102), Regorafenib, Both Trifluridine/ Tipiracil (TAS -102) and Regorafeni b 
• RAS Gene Status: Wild Type, Mutant  
• BRAF Status: Wild Type, V600 E Mutation, Other  
• Microsatellite/Mismatch Repair Status: Microsatellite Stable (MSS) and/or proficient mismatch repair (pMMR) , Microsatellite In stability- High (MSI -H) and/or deficient mismatch repair (dMMR)  
• Duration of metastatic disease (time  from 1st Metastatic Diagnosis to Randomization) : ≤ 18 months , 
> 18 months  
• Number of Prior Chemotherapy Treatment Lines: ≤ 3, > 3  
• Number of Prior Chemotherapy Treatment Lines for Metastatic Disease: ≤ 3, > 3  
• Prior Treatment with Vascular Endothelial Growth Factor (VEGF) Inhibitors: Yes, No  
• Prior Epidermal Growth Factor Receptor (EGFR) Inhibitors: Yes, No  
• Prior target treatment  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 47 of 99 
 o No anti -VEGF and no anti -EGFR 
o Anti-VEGF, or anti -EGFR, or both 
§ Anti-VEGF and no anti -EGFR 
§ Anti-EGFR and no anti -VEGF 
§ Both anti -VEGF and anti -EGFR 
• Prior Treatment with Immune Checkpoint Inhibitors for MSI -H/dMMR: Yes, No  
• Prior Treatment with BRAF Inhibitors for BRAF V600E Muta tion: Yes, N o 
• Primary Tumor Location at First Diagnosis:  
o Colon, Rectum, Colon and Rectum, Unknown  
• Primary Tumor Site at First Diagnosis:  
o Colon L eft (Splenic flexure, descending colon, transverse colon, sigmoid colon and 
rectum), Colon R ight (Cecum, ascen ding colon and hepatic flexure) , Colon L eft and Right, 
Colon U nknown, Rectum Only, Unknown  
• Liver Metastases at Baseline: Yes, No  
• Number of Metastatic Tumor Sites Other than Colon or Rectum: Single, Multiple  
• Number of Metastatic Tumor Sites: Single, Multiple  
The values of stratification factors used for subgroup analysis are actual values of strata collected through 
eCRF.  
 
All the sensitivity and the subgroup analysis for both OS and PFS will be considered exploratory and may 
only be supportive of the  primary analysis of OS and PFS.  Forest plot will also be used to graphically show 
the results.  
 Secondary Efficacy Endpoints and Analyses  
Secondary efficacy endpoints include ORR, DCR, and DoR . 
 Objective Response Rate  and Disease Control Rate  
The 95% CIs of ORR and ORR UNCONF RMED are calculated using the Clopper- Pearson exact binomial method  
for each treatment group . 
The adjusted proportion difference and along with its 95% CI in ORR between treatment groups will  be  
calculated using the Wald  method to account for the randomization schedule  stratification factors , and p-
value of comparing treatment groups  is based on a stratified Cochran -Mantel Hanzel  (CMH) test stratified 
by the randomization schedule  stratification factors .  If the number of objective response s is not sufficient 
to utilize the CMH test, a stratified exact CMH test is performed instead.  Example SAS code is provided in 
Appendix 8  and Appendix 9 . 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 50 of 99 
 2. Five f unctional scales: Physical functioning, Role functioning, Emotional functioning, Cognitive 
functioning, Social functioning  
3. Three symptom scales: Fatigue, Nausea and vomiting, Pain  
4. Six s ingle items: Dyspnea, Insomnia, Appetite loss, Constipation, Diarrhea, Financial difficulties  
Each subscale/single item is scored in accordance to the EORTC QLQ -C30 Scoring Manual  (Aaronson et 
al, 1993 ).  All scales and single- item meas ures range in score from 0 to 100 after linear transformation.  A 
technical summary of scoring can be found in  Appendix 1 .  Higher score for the Global health status/QoL 
and functioning scales represent higher functioning (i.e. a better state).   However, the direction is opposite 
in symptom scales and single items. Higher scores on symptom and single- item scales represent higher 
levels of symptoms (i.e. a worse state).  
The number and percent  of subjects who completed the questionnaires  are summarized by visit and each 
treatment group.   
9.2.5.1.  Analysis of Change from Baseline in 15 Subscales 
Change  from baseline in the scores of each of the 15 subscales are summarized by visit and each treatment 
group.   
Analysis of change from baseline in the scores of each of the 15 subscales are performed  by visit (i.e. 
cycle) , using a restricted maximum likelihood (REML) -based mixed model repeated measures (MMRM) 
approach. The MMRM model will include treatment group, visit  (i.e. cycle), treatment group by visit 
interaction,  baseline value of scale, and randomization schedule  stratification factors as fixed effects.  An 
unstructured variance- covariance structure will be used to model within -subject errors.  The Kenward- Roger 
approximation will be used to estimate denominator degrees of freedom and adjust standard errors.  MMRM 
is based on the assumption of missing at random and the assumption that dropouts would behave similarly 
to other subjects in the same treatment group, and possibly with similar covariate values, had they not 
dropped out.  Example SAS code is provided in Appendix 10 . To ensure the proper amount of data utilized 
in the model for each visit, the following steps will be implemented  to identify data to be included in the 
model.  
(1) C alculate the number of subjects with non -missing assessments for each cycle . 
(2) Identify the last cycle with at least 20 subjects in any of the treatment groups  and no subsequent cycles 
having at least  20 subjects in any of the treatment groups.  
(3) A ssessments after the cycle ident ified in St ep 2 will not be included in the model.  
If there is a convergence issue with the unstructured covariance model, Toeplitz, Autoregressive (1)  (AR 
(1)) covariance structure is used, following this sequence until convergence is achieved.  If the model still 
does not converge with AR (1) structure, no results are reported. When the covariance structure is not 
unstructured, the sandwich estimator for the variance -covariance matrix is derived, using the EMPIRICAL 
option in the PROC MIXED statement in SAS.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 51 of 99 
 The visit windowing rules defined in Section 7.4 will be applied to identify the record for a cycle of eac h 
subject, and hence to be included in the analysis. The comparison are between fruquintinib plus BSC to 
placebo plus BSC  at each scheduled post -baseline visit .  The tabulation of MMRM includes  estimates of 
least- square (LS) means, standard errors (SE), and 2- sided 95% CIs for each treatment group.  Estimates 
of the LS mean difference, SE of the difference, 2 -sided 95% CI of the difference between treatment groups, 
and p- value are also presented.  As a sensitivity analysis, subjects who have more than one assessment in 
a cycle (i.e., a quality of life assessment at an unscheduled visit), the worst score for that cycle is used in 
the analysis of change from baseline in the 15 subscales.  The above analysis is replicated using these 
substituted values.  
9.2.5.2.  Analysis of Minimally Important Difference and T ime to D eterioration  
Depending on each scale and item, the minimally import ant difference (MID) cut- off for QoL improvement 
is defined as a change of at least 6.35 to 14.24 points from baseline, based on a recent validation study on 
subjects with mCRC ( Musoro et al. , 2020 ) and the study (Osoba et al., 1998) cited in the EORTC- QLQ- 30 
Scoring Manual.   The MID cut -off for QoL deterioration, stable, and improvement and in each scale and 
item are listed in Table 8.  
Table 8. Summary of MID for EORTC QLQ- C30 Questionnaire  
Scale/item  Deterioration  Stable  Improvement  
Global health status/QoL  -6.38 -6.38 < and < 8.34  8.43 
Physical functioning -7.47 -7.47 < and < 7.81  7.81 
Role functioning  -10.66 -10.66 < and < 14.24 14.24 
Emotional functioning * -10 -10 < and <10  10 
Cognitive functioning * -10 -10 < and < 10  10 
Social  functioning  -6.18 -6.18 < and < 9.23  9.23 
Fatigue -7.38 -7.38 < and < 10.79  10.79 
Nausea and vomiting -6.62 -6.62 < and < 7.75  7.75 
Pain*  -10 -10 < and < 10  10 
Dyspnoea*  -10 -10 < and < 10  10 
Insomnia* -10 -10 < and < 10  10 
Appetite loss  -9.78 -9.78 < and < 12.28  12.28 
Diarrhea  -7.96 -7.96 < and 6.35 6.35 
Constipation  -10* -10* < and <12.75  12.75 
Financial difficulties * -10 -10 < and < 10  10 
*The MID of these sca e/ tems were not reported n (Musoro et a . , 2020). Instead, the MID for these sca e/ tems were arb trar y 
determ ned at 10 po nts, fo ow ng the study  (Osoba et a . , 1998 ) c ted n EORTC QLQ 30 Scor ng Manua . Osoba et a . reported “a 
tt e” change as a change of 5 10 po nts, and “moderate” change as 10 20 po nts.     
The number and percent of subjects achieving MID  for each scale (by categories defined in Table 8) are 
summarized by visit and treatment group.   
In addition, for each scale and single item , time to deterioration (TTD) is defined as  the time (months) from 
randomization until the first change of at least 6.18 to 10.66 points (depending on each scale and item) 
from baseline (Table 8), or death, whichever comes first.  Any s ubject who does not experience TTD at the 
time of analysis is censored at the date of the most recent study visit in the database for that subject.   
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 52 of 99 
 TTD is calculated as ( date of the first reduction of at least 6.18 to 10.66 points from baseline, death or most 
recent visit – date of randomization + 1)/30.4375. 
Kaplan -Meier estimates for TTD are tabulated by treatment group, using 25th, 50th (median), and 75th 
percentiles with associated 2 -sided 95% CIs.  In addition, the two -sided p- value will be obtained from the 
stratified Kaplan -Meier method to account for the stratification factors. The hazar d ratio (HR) between the 
two treatments (fruquintinib vs placebo), together with its 95% CIs will be calculated from a  stratified  (i.e. 
accounting for  randomization schedule  stratification factors ) Cox hazard model  in which treatment and 
baseline value of scale will be included as fixed effects . 
Data of EORTC QLQ -C30 questionnaire and subscales are  listed by subject and visit.  
9.2.5.3.  Handling Missing Data for EORTC QLQ -C30 Questionnair e 
The number of and percent subjects of missing data on each of the 15 subscales are presented by visit and 
also for the overall trial.  Subjects who have died are included in this count.  
As a simple sensitivity analysis of the impact of intercurrent events  such as death and drop -out, an analysis 
of covariance ( ANCOVA) will be conducted using the change from baseline to the last available assessment 
for each subject  during the period  from the date of randomization to the 37 days after the date of last dose. 
The ANCOVA model, include  baseline scale score, randomization schedule  stratification factors , treatment, 
and a baseline score and treatment interaction as fixed -effect  variables.    
 EQ-5D-5L Questionnair e  
The EQ -5D is a generic preference- based measure that indirectly measures the utility for  health that 
generates an index -based summary score based upon societal preference weights  (Pickard et al 2007). The 
EQ-5D-5L consists of 5 items that cover 5 main dimensions including mobility, self -care, usual activities, 
pain/discomfort , and anxiety/depression , and a general visual analogue scale (VAS)  for health status. The 
range of VAS scoring is from 0 (the worst health imaginable ) to 100 (the best health imaginable ).   
Each of the 5 dimensions comprising the EQ -5D descriptive system is divided into 5  levels of perceived 
problems as follows.  
• Level 1: indicating no problem  
• Level 2: indicating slight problems  
• Level 3: indicating moderate problems  
• Level 4: indicating severe problems  
• Level 5: indicating extreme problems  
The response levels collected from the EQ -5D-5L five dimensions  as a health profile are converted into an 
EQ-5D-5L index (utility) scores to represent subjects’ utility value.  The EQ-5D-5L index -based score is 
typically interpreted along a continuum where a  utility value of 1 represents perfect health, 0 represents a  
state equal to death and a negative value represents a state worse than dead.    
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 53 of 99 
 The UK value set and scoring algorithm are used to derive the EQ-5D-5L index score for this analysis 
(Devlin et al., 2018).  The detailed scoring algorithm can be found in Appendix 2 .  
The number and percent of subjects who completed the questionnaires are summarized by visit for each 
treatment group.  
9.2.6.1.  Analysis of Change from Baseline in VAS and Index Scores  
Change from baseline in VAS and index scores are summarized  by visit and for each treatment group. The 
MMRM analysis and the sensitivity analysis described in Section 9.2.5.1 can be similarly applied to the 
endpoints of  
- change from baseline in VAS with the bas eline VAS score as covariate;  
- change from baseline in EQ-5D-5L index score with the bas eline EQ-5D-5L index score as 
covariate  
To ensure the proper amount of data utilized in the model for each visit, the following steps will be 
implemented to identify data to be included in the model.  
(1) C alculate the number of subjects with non- missing assessments for each cycle . 
(2) Identify the last cycle with at least 20 subjects in any of the treatment groups and no subsequent cycles 
having at least 20 subjects in any of the treatment groups.  
(3) A ssessments after the cycle iden tified in  Step 2 will not be included in the model.  
9.2.6.2.  Analysis of Minimally Important Difference and T ime to D eterioration  
The appropriate MID cut -off for VAS is defined as a reduction of at least 7 points from baseline, based on 
a study of 534 cancer subjects evaluated by UK -based scoring algorithm ( Pickard  et al, 2007).  
The appropriate MID cut -off for index score  is defined as a reduction  of at least 0.063 points from baseline, 
based on the study on the scoring algorithm from England ( McClure et al. , 2017). McClure et al.  reported 
the MID in the England population has a mean (standard deviation) of 0.063 (0.013 ), and a median of 0.0 64 
(interquartile range: 0.0 55 to 0.0 73).  
The MID cut -off for VAS and index scores for QoL deterioration, stable, and improvement are listed in Table 
9.  
Table 9. Summary of MID for EQ -5D-5L Questionnaire  
Scale/item  Deterioration  Stable  Improvement  
VAS -7 -7 < and < 7  7 
Index Score  -0.063 -0.063 < and <0.063  0.063 
 The number and percent of subjects achieving MID are summarized by visit for each treatment group.   
In addition, TTD of VAS is defined as the time (month) from randomization until the first reduction of at least 
7 points from baseline or death, whichever comes first.  TTD of index score is defined as the time (month) 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 54 of 99 
 from randomization until the first reduction of at least 0.063  points from baseline or death, whichever comes 
first.  
TTD for VAS is calculated as ( date of the first reduction of  at least  7 points from baseline, PD, death or 
most recent visit – date of randomization + 1)/30.4375. 
TTD for EQ-5D-5L index score is calculated as ( date of the first reduction of  at least  0.063 points from 
baseline, PD, death or most recent visit – date of randomization + 1)/30.4375. 
Subjects who does not experience TTD at the time of analysis are censored at the last visit.  Then, for the 
two time -to event endpoints 
- TTD for VAS  
- TTD for EQ-5D-5L index score  
The Kaplan -Meier method will be used to obtain the descriptive statistics of median, 25% and 75% 
percentiles along with their 95% CIs by treatment group.  In addition, the two- sided p -value will be obtained 
from the stratified Kaplan -Meier method to account for the randomization stratification factors. The hazard 
ratio (HR) between the two treatments (fruquintinib vs placebo), together with its 95% CIs will be calculated 
from a stratified (i.e. accounting for randomization schedule  stratification factors)  Cox hazard model in which 
treatment and baseline value of scale will be included as fixed effects.  
Results from the descriptive system of 5 dimensions are summarized descriptively by visit for each 
treatment group.  A shift table from baseline for the levels within e ach of the 5 dimensions is provided by 
visit and treatment group . 
Data of EQ-5D-5L questionnaire are listed by subject and visit.  
9.2.6.3.  Handling Missing Data for EQ-5D-5L Questionnair e 
The number of and percent subjects of missing data on the VAS and index score are presented by visit and 
for the overall trial.  Subjects who have died are included in this count.  
The sensitivity ANCOVA analysis described in Section 9.2.5.3  will be similarly applied to the endpoints of  
- change from baseline in VAS for each subject  during the period from the date of randomization to 
the 37 days after the date of last dose with the bas eline VAS score as covariate;  
- change from baseline in EQ-5D-5L index score for each subject  during the period from the date of 
randomization to the 37 days after the date of last dose with the bas eline EQ-5D-5L index score 
as covariate 
 Health Resource Utilization  
Data of heath resource utilization including primary reason for visit, type of resource, duration of visit (days)  
which is calculated as stop date – start date +1 , number of visits, concomitant medication prescribed 
(Yes/No) , and special transportation required are summarized descriptively for each treatment group.  Each 
subject may have multiple health care visit during the study period, and the non -missing value from eac h 
visit will be utilized in the analysis .  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 55 of 99 
 In addition, in the analysis of primary reason for visit, type of resource, concomitant medication prescribed 
(Yes/No), and special transportation required (Yes/No), only the unique response categories for a subject 
will be summarized. For example, a subject may have 10 health care visits, the response ca tegories from 
those 10 visits are just 8 times of “ Adverse Event ” and 2 times of  “Management of mCRC ”, hence, this 
subject will only be counted in those two categories instead of summarizing  10 times in the aforementioned 
analysis.  
Data of heath resource utilization are listed by subject.  
 Exploratory Efficacy Endpoints  
 Circulating Tumor DNA  
The analysis of ctDNA will be documented separately, and is not covered in this SAP . 
 Tumor Marker  
Change from baseline in serum CEA will be summarized by visit and  for each treatment group . 
Data of CEA  is listed by subject and visit.   
 
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 56 of 99 
 
 Pharmacokinetics 
PK population is used for tabulation as  specified in this section.   
 PK Sampling Schedule  
The PK sampling schedule for the first approximately 120 subjects is displayed in Table 2 in the study 
protocol .  Furthermore, the PK sampling schedule for subjects enrolled after the first approximately 120 
subjects is displayed in Table 3 in the protocol .  
 Data Handling  
 Handling of Missing Data  
Missing concentration data for all subjects who are administered scheduled study treatments is considered 
as non -informative missing and is not imputed.  No conce ntration estimates are provided for missing sample 
values.  
 Handling of below the lower limit of quantification ( BLQ) Data  
For PK concentration summary, the following rules apply:  
• PK concentrations below the lower limit of quantification (BLQ) in pre-dose samples and in samples 
taken before the time of the first quantifiable value are set to zero;   
• The PK concentrations BLQ after quantifiable concentration are set to zero  
 Handling of the Difference between the Scheduled (nominal time)  and the Actual Sampling 
Times  (actual time)  
For all sampling times, the actual sampling times relative to dosing  are calculated as the difference 
between the actual clock time of sampling and the actual clock time of dosing.  The actual pos t-dose 
sampling times relative to dosing expressed in hours and rounded off to two decimal digits are used, except 
for pre -dose samples occurring prior to dosing, which are reported as zero (0.00), regardless of the time 
difference.  Scheduled sampling times are listed  but will not be summarized.  If the actual time of sampling 
is missing, it is  reported as NR (not recorded) in the listing, the nominal  time is used for summary statistics. 
 Listing and Presentation of Individual PK Data   
PK data are presented by subject, cycle and day (for instance, C1D1, C1D21, C2D1, etc.),  and time 
point . 
1. Concentration data for fruquintinib and M11 are presented to the same decimal place and in original 
units as reported by the b ioanalytical lab, e.g., ng/mL;   
2. Listing of PK sampling times including nominal and actual time elapsed from dose with the deviation 
from the nominal time . 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 57 of 99 
 
 Summary of PK Concentration Data  
The observed concentrations fo r fruquintinib  and metabolite M11 are summarized descriptively at each 
scheduled timepoint and dose level including . Summaries are presented by cycle and day (for instance , 
C1D1, C1D21, C2D1 , etc.) and time point  using descriptive statistics.  
• If the time deviation is greater than ± 20%, the PK concentration value is excluded from the 
summary  descriptives.  
PK plasma concentration data at each scheduled timepoint and dose level is  presented using the following 
desc riptive statistics . 
• n  
• arithmetic mean and StdDev  
• coefficient of variation ( CV)% 
• m edian 
• m inimum and maximum  
• geometric mean and geometric CV%  
• number and percent of subject with BLQ  
The conventions presented in Table 1 0 below are used for the presentation of the descriptive statistics of 
plasma concentrations.  
Table 1 0. PK Reporting Precision 
Variable  Summarized  with:  
Minimum, Maximum 3 significant  digits  or as needed based on actual  
measured  values   
Mean  (arithmetic and  geometric), M edian 3 significant  digits 
StdDev  3 significant  digits 
CV% and Geometric CV% 1 decimal  point  
 
  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 58 of 99 
 
 Safety 
The Safety population is used to evaluate the safety endpoints including  AEs, clinical laboratory data, vital 
signs, single 12- lead ECG parameters, ECHO/MUGA parameters, physical examinations, ECOG 
performance status, extent of exposure and compliance, survival follow- up, and death.  Unless otherwise 
specified, the safety data during the treatment period will be evaluated, and the treatment period is defined 
as the duration from the date of the first study drug administration until 37 days after last dose.  
 Adverse Events  
AEs are  collected throughout the study, commencing from the time the ICF is signed  until 30 ± 7 days after 
the last dose day of study treatment, or start of a new treatment of anti -tumor therapy, whichever is earlier.  
AEs related to COVID- 19 are determined by si tes and recorded in electronic data capture (EDC), as 
deemed appropriate.  
AEs are coded by SOC and PT using MedDRA  version 23.0 or higher.  An AE is considered a TEAE  if  
1. the onset date is on or after the start of study treatment or if the onset date is mi ssing, or  
2. if the AE has an onset date before the start of study treatment but worsened in severity after the study treatment until 37 days after the last dose of study treatment or a new treatment of anti -tumor 
therapy, whichever is earlier. After this period, treatment -related SAEs will also be considered as 
TEAEs.    
TEAEs related to COVID -19 are also flagged in AE analysis dataset.  
An AE is considered treatment -related in the summaries if it is assessed as related to the study treatment 
by the investigator or if the assessment of relationship to study treatment is missing.  
Severity of AEs is graded from Grade 1 to Grade 5 according to the National Cancer Institute Common 
Termi nology Criteria for Adverse Event (CTCAE) version 5.0. Missing severity grade is imputed as Grade 
3.   
AESIs including  hepatotoxicity, haemorrhage, hypertension, thyroid dysfunction, proteinuria, 
dermatological toxicity, cardiac ischemia and infarction, arterial or venous thromboembolic events, and gastrointestinal perforation  are listed in Appendix 3 . 
 Overview of TEAEs   
An overall summary of the number and percent  of subjects along with the total number of adverse events 
each treatment group is provided for the categories listed in Table 11. 
 
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 59 of 99 
 Table 11. Overview of TEAEs 
Category  Sub-category  
All TEAEs  CTCAE Grade  ≥3 
Treatment -related  
Leading to Dose Reduction 
Leading to Dose Interruption  
Leading to Treatment Discontinuation  
Treatment -related Leading to Dose Reduction  
Treatment -related Leading to Dose Interruption  
Treatment -related Leading to Treatment Discontinuation  
Leading to Death 
Serious TEAEs  CTCAE Grade ≥ 3 
Treatment -related  
Leading to Dose Reduction 
Leading to Dose Interruption  
Leading to Treatment Discontinuation  
Treatment -related Leading to Dose Reduction  
Treatment -related Leading to Dose Interruption  
Treatment -related Leading to Treatment Discontinuation  
Leading to Death 
Treatment -emergent AESIs 
 CTCAE Grade  ≥ 3 
Serious  
Treatment -related  
Leading to Dose Reduction 
Leading to Dose Interruption  
Leading to Treatment Discontinuation  
Treatment -related Leading to Dose Reduction  
Treatment -related Leading to Dose Interruption  
Treatment -related Leading to Treatment Discontinuation  
Leading to Death 
COVID -19-related TEAEs  CTCAE Grade ≥ 3 
Serious  
Treatment -related  
Leading to Dose Reduction 
Leading to Dose Interruption  
Leading to Treatment Discontinuation  
Treatment -related Leading to Dose Reduction  
Treatment -related Leading to Dose Interruption  
Treatment -related Leading to Treatment Discontinuation  
Leading to Death 
 
A subject with two or more AEs in a category is counted only once for the subject count.  
 TEAEs by SOC and PT  
The number and percent  of subjects experiencing a TEAE within each of the categories and sub -categories 
listed in Table 11 are also summarized by SOC, PT, and highest CTCAE grade for each treatment group. 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 60 of 99 
 A subject with two or more adverse events for each combination of SOC and PT is counted only once for 
the combination .   
The summary is s orted in descending order of frequency of SOC according to the sum of Fruquintinib + 
BSC and Placebo + BSC columns. Wit hin SOC, sort by descending frequency of PT in according to the 
sum of Fruquintinib + BSC and Placebo + BSC columns.  
In addition, the number and percent  of subjects are summarized by PT and highest CTCAE grade and by 
PT and CTCAE grade >=3  for each treatment group.  
 Treatment -emergent Adverse Events of Special Interest  
Treatment -emergent AESI are also summarized by highest CTCAE grade for each treatment group and 
the subgroups listed below . 
Time  (days) to  onset of first treatment- emergent AESI are descriptively summarized for each AESI and 
treatment group. Time to first AESI is defined as time interval from date of first administration of study 
treatment to the earliest onset date a mong TEAEs within the same AESI categories. That is, if a subject  
has multiple AEs occurrences under the same AESI category, the earliest AE onset date will be used as 
the first onset date to the AESI category.   
Adverse events of special interest (AESI) are summarized for the following subgroups.  
• Age: < 65 years, > = 65 years 
• Sex: Female, Male  
• Region: North America (including USA ), Europe (including Austria, Belgium, France , Germany, 
Hungary , Italy, Spain , and Unite d Kingdom) ; Asia ( including  Japan ) 
• Race: White, Asian, Black or African American, Other  
• BMI (kg/m2): < 18.5, >=  18.5 to < 24, >=  24 
• Prior Therapy: Trifluridine/Tipiracil (TAS -102), Regorafenib , Both Trifluridine/Tipiracil (TAS -102) 
and Regorafenib   
• RAS Status: Wild Type, Mutant  
• Duration of metastatic disease: <= 18 months, > 18 months  
• Liver Metastases at Baseline: Yes, No  
For AEs falling into the AESI category “h epatotoxicity”, a summary table will also be provided by SOC, PT, 
and highest CTCAE for subjects with the following liver function category at baseline. Each liver function 
category will be evaluated separately to identify the subjects meeting the criteria. A listing of hepatotoxicity 
AEs will also be produced for subjects who me et any of the liver function category criteria at baseline (i.e. 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 61 of 99 
 aspartate aminotransferase  [AST] or alanine aminotransferase [ ALT] >3x upper limit of normal [ ULN] or 
total bilirubin >2xULN, or a lkaline phosphatase [ALP] <2xULN).  
• AST or ALT >3xULN  & ≤ 5xULN;  
• AST or ALT > 5xULN;  
• Total bilirubin  >2xULN;  
• AST or ALT > 3xULN and Total bilirubin  >2xULN;  
• AST or ALT >3xULN, Total bilirubin  >2xULN and ALP <2xULN  
 Subgroup analysis of AE 
Analysis by BMI category (<18.5, ≥18.5 and <24 and ≥24 ) will be performed for the following AE summary : 
 
• TEAE overview summary  
• SAE summary 
• Summary of TEAE leading to drug discontinuation  
• Summary of TEAE with CTCAE grade ≥3.  
 Laboratory Evaluations  
Blood and urine samples for the determination of clinical chemistry, hematology, and urinalysis laboratory 
variables described in Table 12 will be measured.   
Clinical laboratory results w ill be graded according to CTCAE criteria, Version 5.0.Any graded changes  that 
occurs following the initiation of study drug and represents at least a 1 -grade change  from the baseline 
assessment is defined as treatment emergent. Any assessment,  for which CTCAE toxicity grades are not 
available, will not be included in any analyses for which toxicity grades are required. Grade 0 is assigned 
to all laboratory values except missing values and not already assigned another grade.  Missing values are  considered missing.  
The non -protocol specified tests and urinalysis results will not be summarized; they will only be included in 
listings. Data recorded by the laboratory will be converted to the International System of Units (SI) and all 
presentations will use SI units. Quantitative laboratory measurements reported as “< X”, i.e. below the lower limit of quantification (LLQ), or “>  X”, i.e. above the upper limit of quantificati on (ULQ), will be converted 
to X for the purpose of quantitative summaries, but will be presented as recorded, i.e. as “< X” or “> X” in 
the listings. Quantitative data collected between after date of first dose administration  and up to 37 days 
following the last dose of study medication will be used for analysis.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 62 of 99 
 Table 12. List of Laboratory Parameters  
Laboratory Category Parameters  
Hematology  Hemoglobin, Hematocrit, Red Blood Cell Count (RBC), Platelet Count, White 
Blood Cell Count (WBC), Absolute Neutrophil Count, Neutrophils %, Absolute Lymphocyte Count, Lymphocytes %, Absolute Monocyte Count, Monocytes %, Absolute Eosinophil Count, Eosinophils %, Absolute Basophil Count, Basophils % 
Blood Chemistry Albumin, Blood urea nitrogen (BUN), Cr eatinine, Aspartate transaminase 
(AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Total 
Bilirubin, Lactate dehydrogenase (LDH), Uric acid, Sodium, Potassium, 
Chloride, Bicarbonate, Glucose, Calcium, Magnesium, Phosphorus, Total cholestero l, Triglycerides, Total Protein 
Blood Chemistry – 
Thyroid Function Free triiodothyronine (fT3) , Serum free thyroxine (fT4), Thyroid -stimulating 
hormone (TSH)  
Urinalysis  pH, Glucose, Protein, White blood cell, Red blood cell 
Urinalysis Microscopy  Microscopic White Blood cell count, Microscopic Red Blood cell count , Other 
Coagulation  Activated Partial thromboplastin time (aPTT) , Prothrombin time , International 
normalized ratio (INR) 
 
All summaries of hematology, blood chemistry (including thyroid function), urinalysis and coagulation 
parameters are based on the results of SI units , where applicable.  Thyroid function parameters are 
analyzed under blood chemistry category.  
Summary tables for hematology, blood chemistry, coagulation, and urinalysis (pH  only) laboratory variables 
include descriptive statistics for result values and change from baseline for all continuous variables by visit 
and treatment group.   
Toxicities for clinical lab s will be characterized according to CTCAE, Version 5.0 (Table 18 of Appendix 4  
when possible), and the frequency and percentage of subjects with each CTCAE grade for each visit during 
the treatment period will b e described. Moreover, any occurrence of grade 3 or grade 4 during the treatment 
period will be summarized, and shift in grade from baseline to the worst post -baseline value will be 
summarized.  
Summary table and listing are also provided for treatment -emergent hepatotoxicity and subjects with or 
without liver metastasis by each treatment group. Hepatotoxicity is based on the pre -specified thresholds 
below:  
1. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3x upper limit of normal 
(ULN) and ≤ 5x ULN  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 63 of 99 
 2. AST > 3,5,8,10, and 20x ULN, AST  > 5x ULN for more than 5 weeks  
3. ALT > 3,5,8,10, and 20x ULN, ALT > 5x ULN for more than 5 weeks  
4. AST and/or ALT > 3,5,8,10, and 20x ULN , > 5x ULN for more than 5 weeks  
5. Total bilirubin elevations > 1.5x, 2x ULN  
6. Po tential Drug -Induced Liver Injury  (DILI): AST and/or ALT > 3x ULN and total bilirubin > 2x ULN  
7. Hy's Law criteria : AST and/or ALT > 3x ULN and total bilirubin > 2x ULN and ALP < 2x ULN 
An edish plot presenting peak total bilirubin and peak ALT values will also be produced.  
Qualitative assessments of urinalysis parameters are summarized for all subjects  using the number of 
subjects  with results of negative, trace, or positive.  
Summary of clinical significance (Abnormal not clinically significant [ NCS] and Abnormal clinically significant 
[CS]) is also  provided by visit  and treatment group . Shift from baseline to the worst post -baseline 
investigators’ assessment (i.e. normal, NCS,  and CS for quantitative measurements and categorical 
measurements)  will be presented . 
All laboratory results (including hematology, blood chemistry,  blood chemistry – thyroid function, urinalysis, 
coagulation, hepatitis, amylase and lipase, and serum/urine pregnancy test data)  in SI units are presented 
in data listings.  Tests are listed in alphabetical order within their respective panels (hematology, blood 
chemistry, urinalysis, and coagulation) .   
 Vital Signs  
Vital signs includ e systolic blood  pressure, diastolic blood pressure, respiratory rate, body temperature, 
pulse rate, weight , body mass index (BMI) will be computed as weight (kg)/[height (m)]2 .   
For vital signs, change from baseline to each post -baseline visit and timepoint will be calculated. The 
potentially clinically significant findings of vital signs will also be defined based on criteria defined in Table 
13.  
Vital signs are summarized with descriptive statistics for the observed values at each visit and change from 
baseline to post -baseline visits values by treatment group.  The criteria of potentially clinically significant 
findings are defined in Table 13. The frequency and percentage of subjects with any potentially clinically 
significant findings during the treatment period will be presented.   
 
  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 64 of 99 
 Table 13.  Potentially Clinically Significant Criteria for Vital  Signs   
Variable  Criterion value   
SBP (mmHg)  Increase from baseline of  
˃ 0 - ≤ 20  
˃ 20 - ≤ 40  
˃ 40  
Decrease from baseline of  
˃ 0 - ≤ 20  
˃ 20 - ≤ 40  
˃ 40  
 
DBP (mmHg)  Increase from baseline of  
˃ 0 - ≤ 20  
˃ 20 - ≤ 40  
˃ 40  
Decrease from baseline of  
˃ 0 - ≤ 20  
˃ 20 - ≤ 40  
˃ 40  
 
Heart rate (bpm)  Increase from baseline of  
˃ 0 - ≤ 20  
˃ 20 - ≤ 40  
˃ 40  
Decrease from baseline of  
˃ 0 - ≤ 20  
˃ 20 - ≤ 40  
˃ 40  
 
Weight (kg)  Percentage increase from baseline of  
˂ 5%  
≥ 5 – < 10%  
≥ 10 - < 20%  
≥ 20%  
Percentage decrease from baseline of  
˂ 5%  
≥ 5 – < 10%  
≥ 10 - < 20%  
≥ 20%  
 
 
Vital signs are listed by subject and visit.  
 Electrocardiogram  
Electrocardiogram (ECG) parameters include heart rate, PR interval, and QT,  QT correction Bazett formula  
(QTcB ), QT correction Fridericia formula ( QTcF ) and a combination of the Q wave, R wave and S wave  
(QRS ) intervals. Potentially clinically significant ECG findings will be identified using the criteria which are 
included in Table 14.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 66 of 99 
 
 Echocardiogram  
ECHOs are performed at Screening, cycle 2 day 1, and on day 1, every 3 cycles thereafter .  Assessment 
parameters include left ventricular ejection fraction and overall interpretation  of cardiac function.  MUGAs 
are permitted if ECHOs  cannot be performed .   
Categorical summaries of overall interpretation and change from baseline of l eft ventricular ejection fraction 
of ECHO /MUGA results at each visit are summarized.  A shift from baseline to the worst post-baseline table 
for overall interpretation is also provided.   
ECHO /MUGA data is listed by subject and visit.    
 Physical Examination  
A comprehensive physical examination at Screening includes subject general appearance, eyes, ears, 
nose and throat, head and neck, respiratory, cardiovascular, abdomen ( gastrointestinal), skin, genitourinary 
system, lymph nodes, m usculoskeletal, neurological  assessments.  
Limited physical examination  at scheduled visits is a subset the comprehensive physical examination as 
deemed appropriate by the investigator . 
Results of physical examination are listed by subject and visit.  
 ECOG Performance Status  
ECOG per formance status is be summarized descriptively using counts and percentages by visit for each 
treatment group.  A shift from baseline to worst post -baseline value table is also provided.   
ECOG performance status is listed by subject and visit.  
 Other Safe ty Endpoints  
 Survival Follow -up  
Subjects received any anti -cancer medications, radiotherapy, and procedures during survival follow -up and 
survival status are summarized descriptively for each treatment group.   
Data of survival follow -up are listed by subject and visit.  
 Anti-cancer Medication during Survival Follow -up 
Anti-cancer medication  during survival follow -up are classified using the WHODD version March  2020 or 
later. 
The use of anti -cancer medication during survival follow -up will be summarized using  discrete summary 
statistics, each treatment group and overall for the safety  population.  If a subject took a specific medication 
multiple times or took multiple medications within a  specific ATC or PT, the subject is counted only once for 
the respective ATC or PT.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 67 of 99 
 Summaries are ordered in alphabetical order of ATC and then, within an ATC, in decreasing frequencies 
by PT in overall column. If the frequencies tie, an alphabetic order will be applied. 
Data of anti-cancer medication  during survival follow -up are listed by subject.  
 Anti-cancer Procedure during Survival Follow -up 
The anti-cancer procedures during survival follow -up are coded using MedDRA  version 23.0 or higher .  
The use of anti -cancer procedures during survival follow -up will be summarized using  discrete summary 
statistics in each treatment group and overall for the safety  population.  If a subject had a specific procedure 
multiple  times or had multiple procedures  within a specific SOC or PT, the subject is counted only once for 
the respective SOC or PT.  
Summaries are ordered in alphabetical order of SOC and then, within an SOC, in decreasing frequencies 
by PT in overall column. If the frequencies tie, an alphabetic order will be applied.  
Data of anti -cancer procedure during survival follow- up are listed b y subject.  
 Anti-cancer Radiotherapy during Survival Follow -up 
The number and percent of subjects with at least one anti -cancer radiotherapy  during survival  follow -up are  
summarized for each treatment group . 
Data of anti-cancer radiotherapy during survival follow -up are listed by subject.  
 Deaths   
Primary cause of death and whether autopsy was performed are summarized descriptively for each 
treatment group.  Similarly, the deaths happening during the t reatment period, defined as the period from 
the d ate of the first study drug administration until 37 days after last dose, will also be tabulated. Data of 
deaths are listed by subject.  On-treatment death will be flagged.  
 Impact of COVID -19 
The study is conducted during the COVID -19 pandemic, additional data is collected for evaluating the 
impact of COVID -19.  
To eliminate potential hazards to subjects and study staff due to the COVID -19 pandemic while ensuring 
subjects safety and maintaining  data integrity, subjects are allowed remote visits during the pandemic.  
The planned protocol deviation analyses are described in Section 8.2 ; planned sensitivity analyses for the 
PFS and OS are described in Section 9.1.4 , and the s ummary for COVID -19-related  TEAEs are included  
in Section 11.1.1 .  
 
Additional  summar ies related to the COVID -19 pandemic from the following aspects  will be produced  for 
ITT:  
• Type of impact on s tudy visit  (missing entire visit; Interrupted and/or o ut of window in -person visit at 
site; remote visit ( virtual or telephone); or other) 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 68 of 99 
 • Reason related to COVID -19 (subject diagnosed with COVID- 19; quarantined due to COVID -19; site 
closed or access restricted due to COVID -19; site open but subject unwilling or unable to come to site 
due to COVID -19; or other) 
• Study drug discontinuation due to COVID -19 
ITT population will be used for the planned analyses described above . The number of subjects  impacted 
by COVID -19 during the study investigation period as well as at any time  will be summarized by treatment 
group and overall.  The study investigation period is defined as the period from the date of randomization 
to the 37 days after the date of last study treatment administration.   
Supporting listings for the described analyses above will be provided.   
 Interstitial Lung Disease 
Interstitial lung disease data collected, including chest x -ray results and oxygen saturation, are listed by 
subject.  
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 69 of 99 
 
 IDMC Review  
A subset of TLFs  for the study final analysis will be used  for IDMC meetings.  The specific content of the 
TLFs submitted to the IDMC are determined by the IDMC members.  The results to be reviewed by  the 
IDMC will be primarily  based on the safety data.  Efficacy data is also  provided for the purpose of the 
planned interim futility analysis after 1/3 of OS events has occurred.  
For open sessions , the tables are presented with column Total only and the listings contains no treatment 
header.  For closed sessions , the tables are presented with columns Treatment A + BSC, Treatment B + 
BSC, and Total , and the listings contain treatment headers.  The unblended statistic ian to be involved in the 
closed sessions of the IDMC will share the actual treatment information for Treatment A  an Treatment B.  
The IDMC may request to be unblinded by treatment group or per -subject basis at any time.  The unblinded 
biostatistician provides the information to unmask.  These communications are maintained in the IDMC 
workspace and submitted to the Trial M aster File at the end of the study.  
The s tudy is to be terminate d in the case of confirmed futility after evaluation of 1/3 of OS events  (i.e., 160 
OS events) . 
At any time, the IDMC may request any other safety -related information deemed necessary to contribute 
to an appropriate review of safety.  
Further details of content for open and closed sessions are provided in Section 18 , “Content of Open and 
Closed Sessions ”, of the IDMC Charter in order to maintain the blinding of the study.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 70 of 99 
 
 Change s from Analysis Planned in Protocol 
• Not applicable . 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 71 of 99 
 
 Reference List 
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman 
SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F. The European Organisation for Research and Tr eatment of Cancer A quality -of-life instrument 
for use in international clinical trials in oncology. Journal of the National Cancer Institute  1993; 85: 365- 376. 
Brookmeyer R., and Crowley J. (1982). A confidence interval for the median survival time. Biome trics, 29 -
41. 
Devlin et al., Valuing health -related quality of life: An EQ -5D-5L value set for England. Health Economics. 
2018;27:7– 22. https://doi.org/10.1002/hec.3564 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid  tumors: revised 
RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228 -247. 
European Organization for Research and Treatment of Cancer . EORTC QLQ -C30 Scoring Manual . 
https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf  
EuroQol Research Found ation. EQ -5D-5L User Guide. Version 3.0; September 2019. 
https://euroqol.org/wp -content/uploads/2019/09/EQ -5D-5L-English -User -Guide_version -3.0-Sept-2019-
secured.pdf 
Kim, Y., & Won, S. (2013). Adjusted proportion difference and confidence interval in strat ified randomized 
trials. PharmaSUG 2013. https://www.pharmasug.org/proceedings/2013/SP/PharmaSUG- 2013- SP04.pdf  
McClure et al., Instrument -Defined Estimates of the Minimally Important Difference for EQ -5D-5L Index 
Scores. Value Health. 2017 Apr;20(4):644- 650. doi: 10.1016/j.jval.2016.11.015. Epub 2017 Jan 10. PMID: 
28408007.  
Musoro et al., Minimally important differences for interpreting European Organisation for Research and 
Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 s cores in subjects with ovarian 
cancer,  Gynecologic Oncology,  10.1016/j.ygyno.2020.09.007,  (2020).  
Osoba et al., Interpreting the significance of changes in health -related quality -of-life scores. J Clin Oncol. 
1998 Jan;16(1):139- 44. doi: 10.1200/JCO.1998.16.1.139. PMID: 9440735.  
Pickard et al.,  Estimation of minimally important differences in EQ -5D utility and VAS scores in 
cancer.  Health Qual Life Outcomes.  2007;5:70. doi: 10.1186/1477- 7525-5- 70. 
Pickard AS, Wilke CT, Lin HW, Lloyd A. Health Utilities Using  the EQ -5D in Studies of Cancer. 
PharmacoEconomics  2007;25:365– 84 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 72 of 99 
 
 Programming Considerations 
All TLFs  and statistical analyses are generated using SAS for Windows, Release 9.4 (SAS Institute Inc., 
Cary, NC, USA). Computer -generated table, listing and figure outputs  adhere to the following specifications.   
 General Considerations  
• One SAS program can create several outputs  
• Each output is stored in a separate file  
• Output files are  delivered as follows 
o Two compiled pdf files (with bookmark and TOC)  – one for tables and figures, and one for 
listings]; 
o Individual rtf file for the TLFs (this is only applicable to the final delivery, e.g. final interim 
analysis delivery, final database lock delivery for clinical study report ); 
o For figures, include the individual .tiff file (this is only applicable to the final delivery, e.g. 
final IA delivery, final DBL delivery for CSR)  
• Numbering of TLFs follow s ICH E3 guidance  
 Table, Listing, and Figure Format  
 General  
• All TLFs are produced in landscape format on American letter paper size . 
• All TLFs  are produced using the Courier New font, size 8 which is the smallest acceptable point size 
for the Regulatory Authorities.  
• The data displays for all TLFs  have a minimum blank 1-inch margin on all 4 sides. 
• Headers and footers for figures are in Courier New font, size 8 which is the smallest acceptable point 
size for the Regulatory Authorities . 
• Legends are used for all figures with more than 1 variable, group, or item displayed.  
• Table and listings are  in black and white (no color).  Figures are in colors, where applicable.  
• Only standard keyboard characters are used in the TLFs.  Special characters, such as non -printable 
control characters, printer- specific, or font- specific characters, are not  used.  Hexadecimal -derived 
characters are used, where possible, if they are appropriate to help display math symbols (e.g., μ) .  
Certain subscripts and superscripts (e.g., cm2, Cmax) are employed on a case- by-case basis.  
• Mixed case is used for all titles, footnotes, column headers, and programmer -supplied formats, as 
appropriate.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 73 of 99 
 
 Headers  
• TLFs  are internally paginated in relation to the total length (i.e., the page number should appear 
sequentially as page n of N, where N is the total n umber of pages in the table).  
• The date output was generated should appear along with the program name as a footer on each 
page.  
15.2.2.1.  Headers  for Study  
• All output should have the following header at the top of each page:  
Hutchison MediPharma Limited   
Protocol No.: 2019 -013-GLOB1 Page X of Y 
    Data Cut- off Date: DDMMMYYYY  
15.2.2.2.  Headers  for Study – Interim Analysis  
• All output should have the following header at the top of each page:  
Hutchison MediPharma Limited   
Protocol No.: 2019 -013-GLOB1 – Interim Analysis 
 Page X of Y 
Data Cut- off Date: DDMMMYYYY  
15.2.2.3.  Headers  for IDMC Meeting  
• All output should have the following header at the top of each page:  
Hutchison MediPharma Limited   
Protocol No.: 2019 -013-GLOB1 - IDMC Meeting 
 Page X of Y 
   Data Cut- off Date: DDMMMYYYY  
15.2.2.4.  Headers  for Japan Safety Lead- in Cohort 
• All output should have the following header at the top of each page:  
Hutchison MediPharma Limited   
Protocol No.: 2019 -013-GLOB1 - Japan Safety Lead- in Cohort 
 Page X of Y 
Data Cut- off Date: DDMMMYYYY  
15.2.2.5.  Headers  for Japan Safety Monitoring Committee (JSMC) Meeting  
• All output should have the following header at the top of each page:  
Hutchison MediPharma Limited   
Protocol No.: 2019 -013-GLOB1 – J SMC Meeting 
 Page X of Y 
Data Cut- off Date: DDMMMYYYY  
 Display Titles  
• Each TLF are identified by the designation and a numeral.  (i.e., Table 14.1.1).  A decimal system (x.y and x.y.z) are used to identify TLFs with related contents.  The title is centered.  The analysis set are identified on the li ne immediately following the title.  The title and table designation are single -
spaced.  A solid line spanning the margins separate the display titles from the column headers.  
There is 1 blank line between the last title and the solid line.  Parameters or Visits, if applicable, are 
between the last title and the solid line. 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 74 of 99 
 Table x.y.z 
First Line of Title 
Second Line of Title if Needed 
(Intent -to-Treat Population) 
 Column Headers  
• Column headings are displayed immediately below the solid line described above in initial upper -
case characters .  
• In the case of efficacy tables, the variable (or characteristic) column is on the far left followed by the 
treatment group  columns.  P -values are presented under  the ‘Fruquintinib  + BSC’ column. 
• For numeric variables, include “unit” in column or row heading when appropriate.  
• Analysis set sizes are presented for each treatment group  in the column heading as (N=xx) (or in the 
row headings , if applicable).  This is d istinct from the ‘n’ used for the descriptive statistics representing 
the number of subjects in the analysis set.  
• The order of treatments in the tables and listings is ‘Placebo + BSC’ first then ‘Fruquintinib  + BSC’, 
followed by a ‘Total’ column, where  applicable.  
 Body of the Data Display  
15.2.5.1.  General Conventions  
Data in columns of a table or listing are formatted as follows:  
• Alphanumeric values are left -justified; 
• Whole numbers (e.g., counts) are right- justified; and 
• Nu mbers containing fractional portions are decimal aligned.  
15.2.5.2.  Table Conventions  
• Units are included where available  
• If the categories of a parameter are ordered, then all categories between the maximum and minimum 
category are presented in the table, even if n=0 for all treatment group s in a given category that is 
between the minimum and maximum level for that parameter.  For example, the frequency 
distribution for symptom severity would appear as: 
Severity Rating  N 
severe 0 
moderate  8 
mild 3 
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 75 of 99 
 Where percentages are presented in these tables, zero percentages are presented and so counts of 0 are 
presented as 0 and not as 0 (0%).  
• If the categories are not ordered (e.g., Medical History, Reasons for Discontinuation from the Study, 
etc.), then only those categories for which there is at least 1 subject represented in 1 or more groups are included. 
• An Unknown or Missing category are a dded to each parameter for which information is not available 
for 1 or more subjects.   
• Unless otherwise specified, the estimated mean , median , Q1, and Q3  for a set of values are printed 
out to 1 more significant digit than the original values, and standard deviations are printed out to 2 
more significant digits than the original values .  The minimum and maximum should report the same 
significant digits as the original values .  For example, for systolic blood pressure: 
N   XX 
Mean  (StdDev ) XXX.X (X.XX)  
Median XXX.X 
Min, Max  XXX, XXX  
Q1, Q3  XXX, XXX  
Missing  XXX  
• P-values are output in the format: “0.xxx”, where xxx is the value rounded to 3 decimal places .  Every 
p-value less than 0.001 is presented as <0.   If the p -value is returned as >0.999 , then present as 
>0.999 . 
• Percentage values are printed to one decimal place, in parentheses with no spaces, one space after 
the count (e.g., 7 (12.8), 13 (5.4)).  Unless otherwise noted, for all percentages, the number of 
subjects in the analysis set for t he treatment group  who have an observation is the denominator.  
Percentages after zero counts should not be displayed and percentages equating to 100% are 
presented as 100, without decimal places.   
• Tabular display of data for medical history, prior/concom itant medications, and all tabular displays of 
AE data are presented by the body system, treatment class, or SOC with the highest occurrence in 
the active treatment group  in decreasing order, assuming all terms are coded .  Within the body 
system, drug class and SOC, medical history (by preferred term), drugs (by ATC 2  code), and AEs 
(by preferred term) are displayed in decreasing order .  If incidence for more than 1 term is identical, 
they should then be sorted alphabetically.   
• Missing descriptive statisti cs or p -values which cannot be estimated are reported as “ -”. 
• The percentage of subjects is normally calculated as a proportion of the number of subjects assessed in the relevant treatment group  (or overall) for the analysis set presented .  However, careful 
consideration is required in many instances due to the complicated nature of selecting the denominator, usually the appropriate number of subjects exposed .  Describe details of this in 
footnotes or programming notes.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 76 of 99 
 • For categorical summar ies (number and percent  of subjects) where a subject can be included in 
more than one category, describe in a footnote or programming note if the subject are included in 
the summary statistics for all relevant categories or just 1 category and the criteria  for selecting the 
criteria.  
• Where a category with a subheading (such as system organ class) has to be split over more than 
one page, output the subheading followed by “(cont. )” at the top of each subsequent page .  The 
overall summary statistics for the subheading should only be output on the first relevant page.  
15.2.5.3.  Listing Conventions 
• Listings are sorted for presentation in order of treatment group s as above, subject number, 
visit/collection day, and visit/collection time.  
• Missing data are represented on subject listings as either a hyphen (“ -”) with a corresponding 
footnote (“- = unknown or not evaluated”), or as “N/A”, with the footnote “N/A = not applicable”, 
whichever is appropriate.  
• Dates are printed in SAS DATE9.format (“ddMMMyyyy”: 01JUL2000) .  Missing portions of dates are 
represented on subject listings as dashes (--JUL2000).  Dates that are missing because they are not 
applicable for the subject are output as “N/A”, unless otherwise specified. 
• All observed time values are to be presented using a 24 -hour clock HH:MM .  Time is reported if it 
was measured as part of the study.  
• Units are included where available  
15.2.5.4.  Figure Conventions 
• Unless otherwise specified, for all figures, study visits are displayed on the X- axis and endpoint (e.g., 
treatment mean change from baseline) values are displayed on the Y -axis. 
 Footnotes  
• A solid line spanning the margins separate s the body of the data display from the footnotes.   
• All footnotes are left justified with single -line spacing immediately below the  solid line underneath the 
data display.  Each footnote will end with a period “.”. 
• Footnotes should always begin with “Note:” if an informational footnote, or a, b, c, etc.  if a reference 
footnote.  Each new footnote should start on a new line, where possible.  
• Subject specific footnotes are avoided, where possible.  
• Footnotes are used sparingly and add value to the table, figure, or listing .  If more than six lines of 
footnotes are planned, then a cover page is strongly recommended  to be used to display footnotes, 
and only those essential to comprehension of the data are repeated on each page .   
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 77 of 99 
 • The order of different types of footnotes need to follow the proper order as shown below  
1. Subject s pecific foot note, such as [a] , [b], *, 1, 2, 3, and etc.; 
2. General footnote  starting with “Note: …” , also the text of the footnot es will be properly 
aligned at the place after the phrase “Note:” if the line of footnote will wrap to the next row.  
3. Abbreviation footnote. The abbreviation of the footnote will be or dered alphabetically, In 
addition, each word spelling the abbreviation will use uppercase for the first letter unless it 
is the convention to use lowercase, e.g. “of”, “and”, etc.  Each abbreviation will be separated 
by a “;”  
4. The last line of the footnote s ection is standard source line that indicates the name of the 
program used to produce the data display, date the program was run, and the listing source.  
For example,  
   
  Source: Listing 16.2.x.x  
  Program: xxxx.sas      
Table Generation: DDMMMYYYY HH:MM  
 
 
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 78 of 99 
 
 Quality Control 
SAS programs are developed to produce output such as analysis data sets, summary tables, data listings, 
figures or statistical analyses.  An overview of the development of programs is detailed in Syneos Health 
SOP Developing Statistical Programs ( 3907). 
Syneos Health SOP s Developing Statistical Programs (3907) and Conducting  the Transfer of Biostatistical 
Deliverables ( 3908) describes the quality control procedures that are performed for all SAS programs and 
output .  Quality control is defined here as the operational techniques and activities undertaken to verify that 
the SAS  programs produce the output by checking for their logic, efficiency and commenting and by review 
of the produced output.  
Syneos Health SOP Pharmac okinetic and Related Data Analyses  (3913.01) describes the procedure for 
the generation and reporting of PK and pharmacodynamics data.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 79 of 99 
 
 Appendix  
 Appendix 1. EORTC QLQ- C30 Scoring Algorithm  
The principle for scoring these scales is the same in all cases. The steps for scoring are:     1) Estimate 
the average of the items that contribute to the scale. (i.e. the raw score);  
    2) Use a linear transformation to standardize the raw score , so that scores range from 0 to 100 .  
More specifically , if items 𝐼!,𝐼",…,𝐼# are included in  a scale, the RawScore , RS, is the mean of the 
component items: 
𝑅𝑎𝑤𝑆𝑐𝑜𝑟𝑒 𝑅𝑆 (𝐼!+𝐼"+⋯+𝐼#)/𝑛 
Then apply the linear transformation to 0 -100 to obtain the desired score for the scale, i.e.  
- for Functional scales :  
𝑆𝑐𝑜𝑟𝑒 51(𝑅𝑆 1)
𝑟𝑎𝑛𝑔𝑒9×100 
- for Symptom scales/items  and Global health status/QoL : 
𝑆𝑐𝑜𝑟𝑒 	=(𝑅𝑆 1)
𝑟𝑎𝑛𝑔𝑒>×100 
where  Range  in the formula is the difference between the maximum possible value of RS and the minimum 
possible value. The QLQ -C30 has been designed so that all items in any scale take the same range of  
values. Therefore, the range of RS equals the range of the item values. Most items are  scored 1 to 4, giving 
range  = 3. The exceptions are the items contributing to the global  health status / QoL, which are 7 -point 
questions with range  = 6. More detailed information about the items to be included in eac h scale is 
summarized in Table 15 below.  
To calculate the score for a scale following the aforementioned pri nciples, it is required to at least half of 
the items have been answered, otherwise, the score will be set as missing. However, for single- item s cale, 
set the score to missing if it is not answered. For example, role functioning and cognitive functioning each 
contain 2 items, and so  these scales can be estimated whenever one of their constituent items is present; 
physical functioning contains 5 ite ms, and so at least 3 need to have been completed.   
  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 80 of 99 
 Table 15. Scoring the EORTC QLQ- C30 version 3.0  
 Scale  Number of 
items  Item range  Version 3.0  
Item numbers  
Global health status / QoL      
Global health status/QoL (revised)  QL2 2 6 29, 30 
Functional scales      
Physical functioning (revised)  PF2 5 3 1 to 5 
Role functioning (revised)  RF2 2 3 6, 7 
Emotional functioning EF 4 3 21 to 24 
Cognitive functioning  CF 2 3 20, 25 
Social functioning SF 2 3 26, 27 
Symptom scales / items      
Fatigue FA 3 3 10, 12, 18 
Nausea and vomiting  NV 2 3 14, 15 
Pain PA 2 3 9, 19 
Dyspnoea  DY 1 3 8 
Insomnia  SL 1 3 11 
Appetite loss  AP 1 3 13 
Constipation  CO 1 3 16 
Diarrhoea  DI 1 3 17 
Financial difficulties  FI 1 3 28 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 81 of 99 
 
 Appendix 2. Scoring the  EQ-5D-5L Descriptive System  
The EQ -5D-5L descriptive system can be scored as an example in Figure 2 below . There should be only 
one response for each dimension.  
Figure 2. Example of Scoring the EQ -5D-5L Descriptive System  
 

Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 82 of 99 
 Then, the EQ -5D-5L index score is a weighted linear combination over 5 dimensions of health status.  The 
coefficient for the weighting for each level of domains are presented in Table 16. 
Table 16. EQ-5D-5L weighting coefficient scheme  from England for the response of eac h 
dimension (Devlin et al., 2018)  
Score level of dimension Coefficient for each level of dimension  
Mobility   
Self-care Usual 
activities Pain/  
discomfort  Anxiety/  
depression 
Level 1: no problem  0 0 0 0 0 
Level 2: slight  0.027 0.023 0.023 0.029 0.036 
Level 3: moderate  0.035 0.037 0.029 0.039 0.048 
Level 4: severe 0.096 0.076 0.075 0.128 0.132 
Level 5: unable or extreme [a]  0.127 0.094 0.085 0.155 0.134 
[a] For dimen sions (Mobility, Self -care, and Usual activities), it takes value “Unable”. For dimensions 
(Pain/discomfort and Anxiety/depression), it takes value “Extreme”.  
The EQ -5D-5L index score is calculated using the equation  
EQ-5D-5L index score 12.159×∑coeffici ent	value 	assigned 	to	the	response 	of	each 	dimention  
If any of the 5 dimension scores is missing, the index score will be set to missing.  
For example, for a value of health state 23245, the EQ -5D-5L index score is calculated as 
EQ-5D-5L index score =1−2.159×
∑coefficient 	value 	assigned 	to	the	response 	of	each 	dimention =	1−2.159×
∑(0.027+0.037+0.023+0.128+0.134)=0.247	 
 
  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 84 of 99 
 Preferred Terms:  
Acute hepatic failure,  
Acute yellow liver atrophy,  
Ascites,  
Asterixis,  
Bacterascites,  
Biliary cirrhosis,  
Biliary cirrhosis primary,  
Biliary fibrosis,  
Cholestatic liver injury,  
Chronic hepatic failure,  
Coma hepatic,  
Cryptogenic cirrhosis,  
Diabetic hepatopathy,  
Drug -induced liver injury,  
Duodenal varices,  
Gallbladder varices,  
Gastric varices,  
Gastric varices haemorrhage,  
Hepatectomy,  
Hepatic at rophy,  
infiltration eosinophilic,  
Hepatic lesion,   
Hepatic necrosis,  
Gastroduodenal haemorrhage,  
Gastric ulcer haemorrhage,  
Duodenal ulcer haemorrhage,  
Gastrointestinal ulcer haemorrhage,  
Hepatic calcification,  
Hepatic cirrhosis,  
Hepatic encephal opathy,  
Hepatic encephalopathy prophylaxis,  
Hepatic failure,  
Hepatic fibrosis,  
Hepatic hydrothorax,  
Hepatic Hepatic steatosis,  
Hepatitis fulminant,  
Hepatobiliary disease,  
Hepatocellular foamy cell syndrome,  
Hepatocellular injury,  
Hepatopulmonary syndrome,  
Hepatorenal failure,   
Hepatorenal syndrome,  
Hepatotoxicity,  
Intestinal varices,  
Liver and small intestine transplant,  
Liver disorder,  
Liver injury,  
Liver operation,  
Liver transplant,  
Lupoid hepatic cirrhosis,  
Mixed liver injury,  
Nodul ar regenerative hyperplasia,  
Non-alcoholic steatohepatitis,  
Oedema due to hepatic disease,  
Oesophageal varices 
haemorrhage,  
Peripancreatic varices,  
Portal fibrosis, Portal hypertension,  
Portal hypertensive enteropathy,  
Portal hypertensive gastropath y,  
Portal triaditis,   
Portal vein cavernous transformation,  Portal vein dilatation,  
Portopulmonary hypertension,  
Renal and liver transplant,  
Retrograde portal vein flow,  
Reye's syndrome,  
Reynold's syndrome,  
Splenic varices,  
Splenic varices haemor rhage,  
Subacute hepatic failure,  
Varices oesophageal,  
Varicose veins of abdominal wall,  
Anorectal varices,  
Anorectal varices haemorrhage,  
Intrahepatic portal hepatic venous fistula,  Peritoneovenous shunt,  
Portal shunt,  
Small -for-size liver syndrom e,  
Spider naevus.  
        
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 85 of 99 
 Haemorrhage Description:  
Any bleeding event, including skin, respiratory, gastrointestinal, genitourinary tracts, brain, tumor or any other 
site bleeding, or PLT decreased or PT \APTT\ INR prolongation with corresponding PT as listed in “Preferred 
Term” column, without a bleeding sy mptom.  
 
Analysis method:  
The overall incidence of the risk of hemorrhage with Fruquintinib compared to placebo will be evaluated using 
the standardized categories of Hemorrhages, and categorized by CTCAE grades.  
Preferred Terms:  
Blood urine present,  
Blood urine,  
Gastric occult blood positive, 
Occult blood positive, Haemorrhage,  
Haematoma,  
Haemorrhagic diathesis, Haemorrhagic disorder, Spontaneous haemorrhage, Haemorrhagic stroke, Gastrointestinal haemorrhage, Upper gastrointes tinal 
haemorrhage,  
Lower gastrointestinal haemorrhage,  
Gastric haemorrhage,  
Ulcer haemorrhage,  
Rectal haemorrhage,   
Anal haemorrhage, Haematochezia,  
Melaena,  
Gingival bleeding,  
Lip haemorrhage,  
Mouth haemorrhage,  
Mucosal haemorrhage,  
Epistaxis,  
Haemoptysis,  
Pulmonary haemorrhage, Respiratory tract haemorrhage, Haemothorax,  
Pericardial haemorrhage, Haematuria,  
Renal haemorrhage,  
Urethral haemorrhage,  
Urinary bladder haemorrhage, Menorrhagia,   
Metrorrhagia,  
Postmenopausal haemorrhage,  
Uterine haemorrhage,  
Vaginal haemorrhage,  
Skin haemorrhage,  
Skin ulcer haemorrhage,  
Soft tissue haemorrhage, Subcutaneous haematoma, Haemorrhage subcutaneous,  
Nail bed bleeding,  
Ear haemorrhage,  
Eye contusio n,  
Eye haemorrhage,  
Eyelid bleeding,  
Retinal haemorrhage,  
Hepatic haemorrhage,  
Splenic haemorrhage, Haemarthrosis,  
  
Retroperitoneal haematoma,  
Blood blister,  
Bloody discharge,  
Ecchymosis,  
Contusion,  
Purpura,  
Thrombocytopenic purpura, Injection site haemorrhage, Injection site haematoma,  
Injection site bruising,  
Infusion site haemorrhage,  
Infusion site haematoma,  
Infusion site bruising,  
Traumatic haemorrhage,  
Wound haemorrhage,  
Tumor haemorrhage, 
Disseminated intravascular coagulation. 
        
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 86 of 99 
 Hypertension Description:  
Any event of hypertension or blood pressure increased, with or without any sign or symptom, corresponding PT 
are listed in “Preferred Term” column.  
 
Analysis method:  
The overall incidence of hypertension with Fruquintinib compared to placebo will be evaluated using the 
standardized categories of Hypertension. It will be categorized by CTCAE grades.  
Preferred Terms:  
Hypertension,  
Blood pressure increased,  
Blood pressure diastolic increased,  
Blood pressure systolic increased,  
Blood pressure inadequately 
controlled,   
Blood pressure management,  
Blood pressure orthostatic increased,  Orthostatic hypertension,  
Essential hypertensi on,  
Hypertensive crisis,   
Hypertensive emergency,  
Malignant hypertension,  
Hypertensive encephalopathy,  
Labile hypertension,  
Prehypertension,  
Procedural hypertension,   
Renal hypertension,  
Secondary hypertension,  
Systolic hypertension,  
Withdrawal hypertension,  
Blood pressure fluctuation.  
        
Thyroid Dysfunction  Description:  
Any event of hypothyroidism or other thyroid dysfunction; or  
Lab TSH increase with T3 or T4 decrease, with or without any symptom. Corresponding  PT are listed in 
“Preferred Term” column 
 
Analysis method:  
The overall incidence of thyroid dysfunction with Fruquintinib compared to placebo will be evaluated using the 
MedDRA SMQ of Hypothyroidism. It will be categorized by CTCAE grades.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 87 of 99 
 Preferred Terms:  
Hypothyroidism,  
Thyroid disorder,  
Thyroxine therapy,  
Thyroid therapy,  
Thyroid atrophy,   
Thyroid function test abnormal,  
Thyroxine abnormal,  
Thyroxine decreased,  
Thyroxine free abnormal,  
Thyroxine free decreased,   
Tri-iodothyronine abnormal,  
Tri-iodothyronine free decreased,  
Iodine uptake abnormal,  
Iodine uptake decreased,  
Tri-iodothyronine uptake abnormal,   
Tri-iodothyronine uptake 
decreased,  
Anti-thyroid antibody positive,  
Anti-thyroid antibody.  
        
Proteinuria  Description:  
Any event of proteinuria, 24hrs urinary protein high, urinary protein test positive, corresponding PT are listed in 
“Preferred Term” column.  
 
Analysis method:  
The overall incidence of proteinuria with Fruquintinib compared to placebo will be evaluated using a group of 
MedDRA PTs regarding proteinuria (PT listing will be defined upon the cleaned and coded AE data). It will also 
be categorized by CTCAE grades.  
Preferred Terms:  Protein urine present,  Proteinuria.     
        
Dermatological Toxicity  Description:  
Any event of hand -foot syndrome or other severe skin reactions, corresponding PT are listed in “Preferred 
Term” column.  
 
Analysis method:  
The overall incidence of HFS and rash with Fruquintinib compared to placebo will be evaluated using a group of 
MedDRA PTs regarding HFS and rash (PT listing will be defined upon the cleaned and coded AE data). It will 
also be categorized by CTCAE grades.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 88 of 99 
 Preferred Terms:  
Palmar -plantar 
erythrodysaesthesia syndrome,  
Palmar erythema,  
Dermatitis bullous,  
Dermatitis allergic,  
Dermatitis psoriasiform,  
Dermatitis acneiform,  
Blister,  
Rash,  
Rash erythematous,   
Rash maculo -papular,  
Skin reaction,  
Skin disorder,  
Skin exfoliation,  
Erythrosis,  
Nail disorder,  
Nail bed bleeding,  
Acute generalised exanthematous pustulosis,  
Cutaneous vasculitis,   
Dermatitis exfoliative generalized,  
Dermatitis exfoliative,  
Drug reaction with eosinophilia and 
systemic symptoms,  
Epidermal necrosis,  
Erythema multiforme,  
Exfoliative rash,  
Oculomucocutaneous syndrome,  
Skin necrosis,  
Stevens -johnson syndrome,   
Toxic epidermal necrolysis,  
Toxic skin eruption,  
Acquired epidermolysis bullosa,  
Blister rupture,  
Bullous impetigo,  
Drug eruption,  
Epidermolysis bullosa,  
Epidermolysis,  
Skin erosion.  
        
Cardiac Ischemia and Infarction  Description:  
A group of Acute Cardiac Syndrome (ACS) relevant symptoms, such as chest pain, tightness or discomfort, 
accompanied with dyspnoea, nausea, vomiting…, OR  
Any diagnosis event of angina, ACS ,or cardiac ischemia or infarction. Corresponding PT are listed in 
“Preferred Term” column.  
 
Analysis method:  
The overall incidence of cardiac ischemia and infarction with Fruquintinib compared to placebo will be 
evaluated using the MedDRA SMQ of Ischaemic heart disease. It will be categorized by CTCAE grades. 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 89 of 99 
 Preferred Terms:  
Acute coronary syndrome,  
Acute myocardial infarction,  
Angina unstable,  
Blood creatine phosphokinase MB 
abnormal,  
Blood creatine phosphokinase MB increased,  Coronary artery embolism,  
Coronary artery occlusion,  
Coronary artery thrombosis,  
Myocardial infarction,   
Myocardial n ecrosis ,  
Troponin increased,  
Troponin I increased,  Troponin T increased,  Infarction,  
Blood creatine phosphokinase abnormal,  
Blood creatine phosphokinase increased,  Cardiac enzymes increased,   
Electrocardiogram ST segment elevation,  
Electrocardiogram ST -T segment 
elevation,  
Angina pectoris,  
Angina unstable,  
Arteriosclerosis coronary artery,  
Arteriospasm coronary,  
Coronary angioplasty,  
Coronary arterial stent insertion,  
Coronary artery bypass,   
Percutaneous coronary intervention,  
Coronary artery disease,  
Coronary artery insufficiency,  
Coronary artery stenosis,  
ECG signs of myocardial ischaemia,  Ischaemic cardiomyopathy,  
Myocardial ischaemia,  
Prinzmetal angina,  
Subendocardial ischaemia.  
        
Arterial/Venous 
Thromboembolic Events  Description:  
Any arterial or venous thromboembolic event, including but not limited to, arterial thrombosis, pulmonary 
embolism, deep vein thrombosis, retinal vein occlusion or thrombosis.  Corresponding PT are listed in 
“Preferred Term” column 
 
Analysis method:  
The overall incidence of thromboembolic events with Fruquintinib compared to placebo will be evaluated using 
the MedDRA SMQ of Embolic and thrombotic events. It will be categorized by CTCAE grades.  
Preferred Terms:  
Acute aortic syndrome,  
Acute myocardial infarction,  
Aortic embolus,  
Aortic thrombosis,  
Arterial occlusive disease,  
Arterial thrombosis,  
Basal ganglia infarction,  
Basilar artery occlusion,   
Ischaemic stroke,  
Lacunar infarction,  
Leriche syndrome,  
Mesenteric arterial occlusion,  
Mesenteric arteriosclerosis,  
Mesenteric artery embolism,  
Mesenteric artery stenosis,  
Mesenteric artery thrombosis,   
Subclavian artery occlusion,  
Subclavian artery thrombosis,  
Superior mesenteric artery syndrome,  
Thrombotic microangiopathy,  
Thrombotic thrombocytopenic purpura,  
Transient ischaemic attack,   
Portal vein thrombosis,  
Post procedural pul monary 
embolism,  
Post thrombotic syndrome,  
Postoperative thrombosis,  
Pulmonary embolism,  
Pulmonary infarction,  
Pulmonary microemboli,  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 90 of 99 
 Basilar artery thrombosis,  
Blindness trans ient,  
Brachiocephalic artery occlusion,  
Carotid arterial embolus,  
Carotid artery occlusion,  
Carotid artery thrombosis,  
Cerebellar artery occlusion,  
Cerebellar artery thrombosis,  
Cerebral artery embolism,  
Cerebral artery occlusion,  
Cerebral artery thrombosis,  
Cerebral hypoperfusion,  
Cerebrovascular insufficiency,  
Cerebrovascular stenosis,  
Coeliac artery occlusion,  
Coronary artery embolism,  
Coronary artery occlusion,  
Coronary artery reocclusion,  
Coronary artery thrombosis,  
Embolism arterial,  
Femoral artery embolism,  
Femoral artery occlusion,  
Hepatic artery embolism,  
Hepatic artery occlusion,  
Hepatic artery thrombosis,  
Iliac artery embolism,  Iliac artery occlusion,  
Intraoperative cerebral artery occlusion,  
Ischaemic cerebral infarction,  
 Myocardial infarction,  
Myocardial necros is,  
Papillary muscle infarction,  
Penile artery occlusion,  
Peripheral arterial occlusive 
disease,  
Peripheral arterial reocclusion,  Peripheral artery thrombosis,  
Peripheral embolism,  
Popliteal artery entrapment syndrome,  
Post procedural myocardial infarction,  
Pulmonary artery thrombosis,  
Renal artery occlusion,  
Renal artery thrombosis,  
Renal embolism,  
Retinal artery embolism,  
Retinal artery occlusion,  
Retinal artery thrombosis,  
Silent myocardial infarction,  
Spinal artery embolism,  
Spinal art ery thrombosis,  
Splenic artery thrombosis,  
Splenic embolism,  
Stress cardiomyopathy,  
Subclavian artery embolism,  
Subclavian artery occlusion,  
Stress cardiomyopathy,  
Subclavian artery embolism,  Truncus coeliacus thrombosis,  
Vertebral artery occlusion,  
Vertebral artery thrombosis,  
Visual acuity reduced transiently,  
Axillary vein thrombosis,  
Cavernous sinus thrombosis,  
Cerebral venous thrombosis,  
Deep vein thrombosis,  
Deep vein thrombosis 
postoperative,  
Embolism venous,  
Hepatic vein occlusion,  
Hepatic vein thrombosis,  
Iliac vein occlusion,  
Inferior vena cava syndrome,  
Inferior vena caval occlusion,  
Intracranial venous sinus thrombosis,  
Jugular vein thrombosis,  May-Thurner syndrome,  
Mesenteric vein thrombosis,  
Mesenteric venous occlusion,  
Obstetrical pulmonary embolism,  
Obstructive shock,  
Ophthalmic vein thrombosis,  
Ovarian vein thrombosis,  
Paget -Schroetter syndrome,  
Pelvic venous thrombosis,  
Penile vein thrombosis,  
Portal vein occlusion,   Pulmonary thrombosis,  
Pulmonary vein occlusion,  
Pulmonary veno -occlusive disease,  
Pulmonary venous thrombosis,  
Renal vein embolism,  
Renal vein occlusion,  
Renal vein thrombosis,  
Retinal vein occlusion,  
Retinal vein thrombosis,  
Splenic vein occlusion,  
Splenic vein thrombosis,  
Subclavian vein thrombosis,  
Superior sagittal sinus thrombosis,  
Superior vena cava o cclusion,  
Superior vena cava syndrome,  
Thrombophlebitis, 
Thrombophlebitis migrans,  
Thrombophlebitis neonatal,  Thrombophlebitis superficial,  
Thrombosed varicose vein,  
Thrombosis corpora cavernosa,  
Transverse sinus thrombosis,  
Vena cava embolism,  
Vena cava thrombosis,  
Venogram abnormal,  
Venoocclusive disease,  
Venoocclusive liver disease,  
Venous occlusion,  
Venous thrombosis,  
Venous thrombosis limb.  
        
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 91 of 99 
 Gastrointestinal Perforation  Description:  
Any event of gastrointestinal perforation.  
 
Analysis method:  
The overall incidence of gastrointestinal perforation with Fruquintinib compared to placebo will be evaluated 
using the MedDRA SMQ of Gastrointestinal perforation. It will be categorized by CTCAE grades.  
Preferred Terms:  
Abdominal abscess,  
Abdominal hernia perforation,  
Abdominal wall abscess,  
Abscess intestinal,  
Acquired tracheo -oesophageal 
fistula,  Anal abscess,  
Anal fistula,  
Anal fistula excision,  
Anastomotic ulcer perforation,  
Anovulvar fistula,  
Aorto-d uodenal fistula,  
Aorto- oesophageal fistula,  
Appendiceal abscess,  
Appendicitis perforated,  
Chemical peritonitis,  
Colon fistula repair,  
Colonic abscess,  
Colonic fistula,  
Diverticular fistula,  
Diverticular perforation,  
Douglas' abscess,   
Duodenal fistula,  
Duodenal perforation,  
Duodenal ulcer perforation,  
Duodenal ulcer perforation,  
obstructive,  
Duodenal ulcer repair,  
Enterocolonic fistula,  
Enterocutaneous fistula,  
Enterovesical fistula,  
Gastric fistula,  
Gastric fistula repair,  
Gastric perforation,  
Gastric ulcer perforation,  
Gastric ulcer perforation,  
obstructive,  
Gastrointestinal anastomotic leak,  
Gastrointestinal fistula,  
Gastrointestinal fistula repair,  
Gastrointestinal perforation,  
Gastrointestinal ulcer perforation,  
Gastropleural fistula,   
Ileal fistula,  Ileal perforation,  Ileal ulcer perforation,  Intestinal fistula,  
Intestinal fistula repair,  
Intestinal perforation,  Intestinal ulcer perforation,  
Jejunal fistula,  Jejunal perforation,  Jejunal ulcer perforation ,  
Large intestinal ulcer perforation,  Large intestine perforation,  Neonatal intestinal perforation,  
Oesophageal fistula,  
Oesophageal fistula repair,  
Oesophageal perforation,  
Oesophageal rupture,  
Oesophageal ulcer perforation,  
Oesophagobronchial fi stula,  
Paraoesophageal abscess,   
Peptic ulcer perforation,  
Peptic ulcer perforation,  
obstructive,  
Perforated peptic ulcer oversewing,  
Perforated ulcer,  
Perineal abscess,  
Perirectal abscess,  
Peritoneal abscess,  
Peritonitis,  
Peritonitis bacterial,   
Procedural intestinal perforation,  
Rectal abscess,  
Rectal fistula repair,  
Rectal perforation,  
Rectoprostatic fistula,  
Rectourethral fistula,  
Retroperitoneal abscess,  
Small intestinal perforation,  Small intestinal ulcer perforation. 
  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 96 of 99 
 
 Appendix 5. Kaplan Meier Estimates and 95% CI from Brookmeyer and Crowley method 
 SAS Code example for KM estimates and 95% CI from a log -log transformation based on 
Brookmeyer -Crowley method  
Example SAS code for 95% CI calculated from a log -log transformation based on the method by 
Brookmeyer and Crowley, for median, 25th and 75th percentiles : 
*** KM Estimates - Quartiles ***; 
ods output quartiles=quartiles1; 
proc lifetest  
 data=ADTTE(where=(PARAMCD="OS")) 
 conftype=loglog; 
 time AVAL*CNSR(1); 
 strata TRTPN; 
run; 
 
AVAL is the time in months, CNSR is the censoring variable, TRT PN is the treatment group variable.  
The output dataset (quartiles1) contains by treatment group, the estimate for median (ESTIMATE, where 
PERCENT=50), 25% (ESTIMATE, where PERCENT=25), and 75% (ESTIMATE, where PERCENT=75), 
along with the corresponding 95% CI calculated from a log -log transformation (for each corresponding 
PERCENT =25, =50 and =75, the CI values are stored  in LowerLimit  and UpperLimit).  
 SAS Code example for KM estimates and 95% CI from a linear transformation based on 
Brookmeyer -Crowley method at selected landmarks  
Example SAS code for 95% CI calculated from a linear transformati on based on the method by Brookmeyer 
and Crowley at selected landmarks, for example, at 3, 6, 9, 12, and 18 months : 
*** KM Estimates - Timelist ***; 
proc lifetest  
 data=ADTTE(where=(PARAMCD="OS")) 
 conftype=linear method=km atrisk timelist=(3, 6, 9, 12, 18) 
reduceout outsurv=tlist; 
 time AVAL*CNSR(1); 
 strata TRTPN;  
run; 
 
AVAL is the time in months, CNSR is the censoring variable, TRTP N is the treatment group variable.  
The outsurv dataset (tlist) will provide  by treatment group , the estimate (SURVIVAL*100) at specified time 
points (variable TIMELIST)  and the corresponding 95% CIs (SDF_LCL*100, SDF_UCL*100).  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 97 of 99 
 
 Appendix 6. Stratified Log- Rank Test  
Example SAS code for Stratified Log- Rank Test, accounting for randomization schedule  stratification 
factors.  
*** Stratified Log rank test ***; 
ods output LogUniChisq= logunichisq1; 
proc lifetest  
 data=ADTTE(where=(PARAMCD="OS")) 
 method=km; 
 time AVAL*CNSR(1 ); 
strata STRAT1RN STRAT2RN STRAT3RN; 
test TRTPN; 
run; 
 
AVAL is the time in months, CNSR is the censoring variable, TRT PN is the treatment group variable, and 
STRAT1RN, STRAT2RN and STRAT3 RN are placeholder variables representing the randomization 
schedule  stratification factors.  
The output dataset ( logunichisq1 ) contains the p-value for the Log -Rank Test (ProbChiSq) comparing the 
treatment groups.  
 Multiplicity Adjustment for Log -Rank Tests for OS and PFS  
A fixed-sequence (hierarchical) testing procedure  is used to control the overall type I error rate at 0.05 .  If 
the resulting 2 -sided p- value from the analysis of primary endpoint OS is ≤ 0.05 , then, a superiority test of 
for PFS will be conducted at the two -sided significance  level of 0.05.  
If the resulting p -value from the analysis of primary endpoint OS is ≤ 0.05 then the adjusted p- values are 
the maximum value between the p- values produced for the OS and PFS procedures.  
data pvalue; 
   input p @@; 
   if (_n_ = 1 ) then 
      pseq = 0 ; 
   pseq = max(pseq, p); 
   retain pseq; 
   cards; 
0.021 0.043; 
run;  
The raw p -values used to calculate the adjusted p -value will be obtained from the SAS programming for 
OS and PFS, then, this sample program will be tailored in the production.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 98 of 99 
 
 Appendix 7. Stratified Cox Proportional Hazard Model  
Example SAS code for hazard ratio between the 2 treatment groups (fruquintinib vs placebo), and 
corresponding 95% CIs, calculated from a stratified Cox proportional hazard model (i.e. accounting for 
randomization schedule  stratification factors) in which t he treatment group is the only covariate in the model :  
*** Hazard ratio ***; 
ods output hazardratios=hazrat 1; 
proc phreg 
 data=ADTTE(where=(PARAMCD="OS")) 
alpha=0.05;  
 model AVAL*CNSR(1 )=TRTPN; 
strata STRAT1RN STRAT2RN STRAT3RN ; 
hazardratio TRTPN; 
run; 
 
AVAL is the time in months, CNSR is the censoring variable, TRT PN is the treatment group variable, and 
STRAT1RN, STRAT2RN and STRAT3 RN are placeholder variables representing the randomization 
schedule  stratification factors.  
The output dataset (h azrat1) contains the hazard ratio (HazardRatio) and the corresponding 95% CI 
(WaldLower, WaldUpper) . Confirm the order of TRT PN variables is coded so HR < 1 indicates a favorable 
clinical benefit from fruquintinib over the placebo group.  
 Appendix 8. Cochran- Mantel Ha enszel test stratified by randomization schedule  
stratification factors  
Example SAS code for p- value of comparing treatment groups based on a Cochran -Mantel Hanzel test 
stratified by the randomization schedule  stratification factors . 
 
 *** stratified Cochran- Mantel Haenszel (CMH) test ***;  
ods output CMH=cmh1; 
proc freq 
 data=ADEFF( where=(PARAMCD=" ORR")); 
table STRAT1RN*STRAT2RN*STRAT3RN *TRTPN*AVAL/cmh; 
run; 
 
TRTP N is the treatment group variable and STRAT1RN, STRAT2RN and STRAT3 RN are placeholder 
variables representing the randomization schedule  stratification factors.  
The output dataset (cmh1) contains the p -value ( Prob, corresponding to the Statistic=3, for General 
Association). If the number of objective   response s is not sufficient to utilize the CMH test,  a stratified exact 
CMH test will be performed instead.  
 Appendix 9. Adjusted proportion difference between treatment groups with 95% CI using 
the Wald method to account for randomization schedule  stratification factors 
Example SAS code for adjusted proportion difference between treatment groups with 95% CI using the 
Wald method to account for randomization schedule  stratification factors : 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted ; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.0 dated 25Mar2021 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 99 of 99 
 ods output CommonPdiff=pdiff1;  
proc freq data = ADEFF( where=(PARAMCD="ORR")); 
      tables STRAT1RN*STRAT2RN*STRAT3RN*TRTPN*AVAL/ riskdiff( column=2 
common cl=wald); 
run; 
 
Using ADEFF and variable AVAL, the outcome of interest is ORR (i.e. Objective response rate), TRTP N is 
the treatment group variable and STRAT1RN, STRAT2RN and STRAT3RN are placeholder variables 
representing the randomization schedule  stratification factors. The above example assumes the response 
is coded in column 2 (i.e. AVAL is coded as 0, 1, where 1 is response), and that fruquintinib is presented in 
row 1, and placeb o is presented in row 2.  The above code will be adjusted for correct presentation based 
on the actual coding in ADEFF if necessary.  
The output ( pdiff1) provides an adjusted proportion difference between treatment groups  (the variable 
Value, when Method="Mantel -Haenszel")  with a 95% CI  (the variables LowerCL, UpperCL, when 
Method="Mantel -Haenszel" ) using the Wald method to account for randomization schedule  stratification 
factors . 
 Appendix 10. REML -based MMRM  
Example SAS code for REML -based MMRM:  
 
proc mixed  
data=ADQS(where=(PARAMCD=" PHYSF" and ANL20FL="Y")) 
method=reml; 
class USUBJID TRTPN AVISITN STRAT1RN STRAT2RN STRAT3RN ; 
model CHG = BASE TRTPN AVISITN TRTPN*AVISITN STRAT1RN STRAT2RN 
STRAT3RN/ solution ddfm=kr;  
repeated AVISITN/ subject=U SUBJID type=UN; 
lsmeans TRTPN*AVISITN/ diff cl slice = AVISITN; 
run;   
CHG is the change from baseline in  score of the subscale, USUBJID is the subject identification variable,  
TRTP N is the tr eatment group variable, AVISIT N is a placeholder variable for visit, TRT PN*AVISITN is the 
treatment group -by-visit interaction, BASE is a placeholder variable for baseline value of scale, and 
STRAT1RN, STRAT2RN, and  STRAT3RN are placeholder variables representing the randomization 
schedule  stratification factors.  
Prior to performing th is analysis, the visits for each subject  are limited within the dataset up to the last cycle 
with at least 20 subjects in any of the treatment groups (i.e. all subsequen t cycles have less than 20 patients 
in each of the treatment groups).  If there is a convergence issue with the unstructured covariance model, 
Toeplitz, Autoregressive (1) (AR (1)) covariance structure is used, following this sequence until 
converg ence is achieved.  If the model still does not converge with AR (1) structure, no results are reported. 
When the covariance structure is not unstructured, the sandwich estimator for the variance -covariance 
matrix is derived, using the EMPIRICAL option in t he PROC M IXED statement in SAS.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 4 of 134 
 I conf rm that I have rev ewed th s document and agree w th the content.  
Approvals 
Syneos Health Approval  
 
    
 
Name, T t e  
Lead  B ostat st c an  / Support 
B ostat st c an   S gnature   Date (DD Mmm YYYY)  
 
    
 
Name, T t e   S gnature   Date (DD Mmm YYYY)  
Hutchison MediPharma Limited Approval  
 
    
 
 
Sponsor Contact   S gnature   Date (DD Mmm YYYY)  
 
    
 
 
Sponsor Contact   S gnature   Date (DD Mmm YYYY)  
     
 
   
  
 
Sponsor Contact   S gnature   Date (DD Mmm YYYY)  

Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 5 of 134 
 Table of Contents 
Revision History  ............................................................................................................................  2 
Approvals .................................................................................................................................... 4  
 Glossary of Abbreviations  .................................................................................................. 10 
 Purpose  ..............................................................................................................................  14 
 Study Objectives  ................................................................................................................ 16 
 Study Details/Design  .......................................................................................................... 18 
 Endpoints  ...........................................................................................................................  24 

Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 6 of 134 
 
 Analysis Populations  .......................................................................................................... 28 
 General Aspects for Statistical Analysis  ............................................................................ 30 
 Demographic, Other Baseline Characteristics and Medication  .......................................... 39 

Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 7 of 134 
 
 Efficacy  ..............................................................................................................................  47 
 Pharmacokinetics  ............................................................................................................... 60 

Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 8 of 134 
 
 Safety ................................................................................................................................ . 62 
 IDMC Review  ..................................................................................................................... 73 
 Changes from Analysis Planned in Protocol  ...................................................................... 74 
 Reference List  ....................................................................................................................  75 
 Programming Considerations  ............................................................................................  76 

Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 9 of 134 
 
 Quality Control  ...................................................................................................................  82 
 Appendix  ............................................................................................................................  83 
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 10 of 134 
 
 Glossary of Abbreviations 
Abbreviation Description  
AE Adverse event  
ADaM  Analysis Data Model  
ALP Alkaline phosphatase  
ALT Alanine aminotransferase 
ANCOVA Analysis of covariance  
aPTT Activated Partial thromboplastin time  
AST Aspartate aminotransferase 
ATC 2 Anatomical therapeutic class 2  
AR (1)  Autoregressive (1)  
BMI Body mass index  
BLQ Below the lower limit of quantification 
BRAF B-Raf proto -oncogene 
BSC Best supportive care  
CEA Carcino -embryonic antigen 
CI Confidence interval  
CMH Cochran -Mantel Ha enszel  
COVID -19 Coronavirus 2019  
ctDNA  Circulating tumor DNA  
CTMS Clinical trial management system  
CR Complete response  
CS Clinically  significant  
CSR Clinical study report  
CV Coefficient of variation  
CRO Clinical research organization  
CT Computed tomography  
CTCAE  Common Terminology Criteria for Adverse Event  
dMMR  Deficient mismatch repair  
DCR Disease control rate  
DoR Duration of response  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 11 of 134 
 Abbreviation Description  
eCRF  Electronic case report form  
ECHO  Echocardiogram  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group 
EDC Electronic data capture  
EGFR Epidermal growth factor receptor  
EORTC European Organization for Research and Treatment of Cancer  
EOT End of treatment 
ERT eResearchTechnology, Inc.  
HR Hazard ratio  
ICF Informed consent form  
IDMC  Independent data monitoring committee 
IND Investigational new drug 
INR International normalized ratio  
IRT Interactive response technology  
ITT Intent- to-Treat  
IWRS  Interactive web response system 
JSMC  Japanese safety monitoring committee  
LDH Lactate dehydrogenase  
LS Least -square  
mCRC  Metastatic colorectal cancer  
MedDRA  Medical Dictionary for Regulatory Activities  
MSI Microsatellite instability  
MSI-H Microsatellite instability -high 
MID Minimally important difference  
MMR  Mismatch repair  
MSS  Microsatellite stable  
MMRM Mixed model repeated measures  
MRI Magnetic resonance imaging  
MUGA  Multigated  acquisition  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 12 of 134 
 Abbreviation Description  
NA Not available 
NCS Not clinically significant  
NE Not evaluable  
ORR Objective response rate  
OS Overall survival  
pMMR  Proficient mismatch repair  
PD  Progressive disease  
PID Percentage intended dose  
PFS Progression -free survival  
PK Pharmacokinetic 
PO Per os (oral administration) 
PR Partial response 
PR PR Interval (ECG Parameter) 
PT Preferred term  
Q1 Lower quartile  
Q3 Upper quartile  
QoL Quality of life 
QD Quaque die (once daily)  
QTcB  QT correction Bazett formula  
QTcF  QT correction Fridericia formula  
QRS  A combination of the Q wave, R wave and S wave 
RAS  Rat sarcoma  
REML  Restricted maximum likelihood  
RD Relative dose  
RDI Relative dose intensity  
RECIST  Response Evaluation Criteria In Solid Tumors  
SAE  Serious adverse event  
SAP Statistical analysis plan 
SAS Statistical Analysis System 
SD Stable disease  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 13 of 134 
 Abbreviation Description  
StdDev  Standard deviation 
SDTM  Study Data Tabulation Model  
SE Standard error  
SI International System of Units 
SOC System organ class  
TLFs  Tables, listings and figures  
TSH Thyroid -stimulating hormone  
TTD Time to deterioration  
TEAE  Treatment -emergent adverse event  
ULN Upper limit of normal  
VAS Visual analogue scale  
VEGF Vascular Endothelial Growth Factor  
WHODD  World Health Organization Drug Dictionary  
 
  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 14 of 134 
 
 Purpose 
The purpose of this statistical analysis plan (SAP) for the study is to ensure that the data listings, summary 
tables and figures that are to be produced, and the statistical methodologies that are used, are complete and appropriate to allow valid conclusions regarding the study objectives.  The SAP adheres to the proper regulatory guidelines and most recent International Council for Harmonisation guidelines  (E3, E6, E9) . All 
decisions regarding the final analyses, as defined in this SAP document, have been made prior to locking the database; any deviations from these guidelines will be documented in the clinical study report (CSR).  
A separate SAP is to be developed for t he protocol Japanese Specific Addendum (Safety Lead -In for 
Japan).  
 Responsibilities  
Syneos Health is to perform the statistical analyses and are responsible for the production and quality control of all Study Data Tabulation Model (SDTM ) datasets, Analysi s Data Model ( ADaM ) datasets, and 
the tables, listings, and figures (TLFs) for efficacy  and safety, as well as tabulation of fruquintinib and M11 
concentrations from PK  (pharmacokinetic) plasma samples.  Details for analysis of circulating tumor DNA 
and pharmacogenomics will be prepared in a separate document. The SAP for population PK , 
Electrocardiogram (ECG ) (pharmacodynamics)  and QTc- PK analysis will be prepared separately by 
another contract research organization (CRO). 
 Timings of Analyses  
An independent data monitoring committee (IDMC) is to review descriptive summaries of accumulating safety and subject disposition every 6 months, or at a frequency recommended by the IDMC, as described in the IDMC Charter Final Version 1.0 dated 25 -Aug-2020.  An unblinded team from Syneos Health 
Biostatistics is to perform the analyses as described in Section 18, Content of Open and Closed Sessions of the IDMC Charter, in order to maintain the blinding of the study.  
 Interim Analyses  
One interim non-binding  futility analysis is to be performed once 1/3 of the total number of overall survival 
(OS) events (i.e., 160 OS events) have occurred.  This interim analysis is for futility only,  there are no plans 
to stop the study early for efficacy based on OS data at the interim analysis.  
The IDMC is to be instructed to recommend stopping the study for futility if the 1 -sided p -value from a 
stratified log -rank test is at least 0.772 (correspond ing to an observed HR of 1.133).  Otherwise, the study 
is to be continued with full enrollment.  
There is a 22.8%  chance of terminating the study for futility at the interim analysis if the true median OS in 
fruquintinib arm is 5 months, i.e., fruquintinib  is ineffective.  There is a 0.4%  chance of stopping for futility, 
declaring fruquintinib ineffective at the interim if the true median OS in fruquintinib arm is 6.8 months, i.e., fruquintinib is effective in the study population.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 15 of 134 
 
 Final Analysis  
If the stu dy does not stop based on the futility analysis, the final analysis for the CSR will be conducted 
when at least 480 OS events  have been observed . All study data collected up through the time of the final 
analysis will be summarized, unless otherwise specified. Unblinding will occur at the time of the final 
analysis.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 16 of 134 
 
 Study Objectives 
 Primary Objective  
• To evaluate the overall survival (OS) of fruquintinib plus best supportive care (BSC) compared to 
placebo plus BSC in subjects with refractory  metastatic colorectal cancer (mCRC).  
 Secondary Objective(s)  
• To evaluate progression -free survival (PFS) of fruquintinib plus BSC compared to placebo plus 
BSC. 
• To evaluate the objective response rate (ORR), disease control rate (DCR), and duration of response (DoR) . 
• To assess the safety and tolerability of fruquintinib plus BSC compared to placebo plus BSC . 
• To characterize the PK exposure of fruquintinib and metabolite M11 in subjects with refractory 
mCRC . 
• To evaluate the effect of fruquintinib on cardiac repolarization, as detected by changes in 
electrocardiogram (ECG) QTc intervals, and the potential relationship with fruquintinib and M11 plasma concentrations. 
• To explore the relationship between fruquintinib exposure and endpoints  for efficacy and safety . 
• To evaluate quality of life (QoL) as assessed by using European Organisation for Research and Treatment of Cancer (EORTC) QLQ -C30: cancer -specific; and EQ -5D-5L questionnaires. 
• To assess resource utilization (for example, hospital izations, concomitant medications) . 
 Exploratory Objective  
• To assess potential predictive biomarkers of response to fruquintinib . 
Details of the study objectives and correspondent endpoints is provided in Table 1. 
Table 1. Objectives and Corresponding Endpoints  
Tier Objectives  Endpoints  
Primary To evaluate the overall survival of  
fruquintinib plus BSC compared to placebo 
plus BSC in subjects with refractory mCRC  OS 
Secondary  To evaluate progression -free survival  of 
fruquintinib plus BSC compared to placebo 
plus BSC  PFS 
To evaluate the objective response rate, 
disease control rate, and duration of response  • ORR  
• DCR  
• DoR  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 17 of 134 
 Tier Objectives  Endpoints  
To assess the safety and tolerability of  
fruquintinib plus BSC compared to placebo 
plus BSC  Safety including treatment -emergent 
adverse events (TEAEs), serious 
adverse events (SAEs), deaths, ECG’s, and clinical laboratory abnormalities  
To characterize the PK profile of fruquintinib in 
subjects with refractory mCRC  Observed plasma concentrations, 
estimated population PK and exposure parameters of fruquintinib and M11  
To evaluate the effect of fruquintinib on  
cardiac repolarization, as detected by  
changes in electrocardiogram (ECG) QTc  
intervals, and the potential relationship with  
fruquintinib and M11 plasma concentrations  QTc inter val and plasma concentrations 
of fruquintinib and M11 at specified time 
points  
To evaluate the relationship between  
fruquintinib exposure and endpoints for  
efficacy and safety  Parameters describing exposure -
response with efficacy (e.g., OS) and 
safety (e.g., adverse events [ AEs]) 
endpoints 
To evaluate quality of life (QoL) as  
assessed by using QLQ- C30: cancer specific;  
and EQ -5D-5L questionnaires Changes in health status (QLQ -C30: 
cancer specific; and EQ -5D-5L) 
To assess resource utilization (for example, 
hospitalizations, medications)  Resource utilization including all 
concomitant medications, days in hospital  
Exploratory  To assess potential predictive biomarkers of  
response to fruquintinib  • Change from baseline in circulating 
tumor DNA (ctDNA) 
• Change from baseline in tumor markers (carcino -embryonic antigen 
[CEA]) • Pharmacogenomics  
 
  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 18 of 134 
 
 Study Details/Design 
 Brief Description  
The study is a global, randomized, double -blind, placebo- controlled, multicenter phase 3 clinical trial to 
compare the efficacy and safety of fruquintinib plus BSC versus placebo plus BSC in subjects with mCRC.  
Approximately 687 subjects are to be randomized in a 2:1 ratio to either the fruquintinib plus BSC treatment group or the placebo plu s BSC treatment group.  
Randomization is stratified by the following factors:  
• Prior therapy with trifluridine/tipiracil (TAS -102) versus regorafenib versus both trifluridine/tipiracil 
(TAS -102) and regorafenib . 
• RAS (rat sarcoma)  status (wild type versus mut ant). 
• Duration of metastatic disease (≤18 months versus >18 months) . 
Subjects are to receive study treatment, with each 4 -week cycle consisting of 3 weeks of daily oral study 
medication and 1 week of study treatment interruption (3 weeks on/1 week off).  T umor evaluation is 
performed by imaging (computed tomography [CT] or magnetic resonance imaging [MRI] scan) every 8 weeks until there is progressive disease (PD), death, new anti -cancer treatment, study treatment 
discontinuation or study completion,  whiche ver comes first.  Safety parameters include assessment of 
adverse events (AE), laboratory tests, vital signs, ECG, Echocardiogram (ECHO), physical examination, Eastern Cooperative Oncology Group (ECOG) performance status, EORTC QLQ -C30 and EQ- 5D-5L 
questionnaires.  Post -discontinuation anti -tumor treatment and survival follow -up after PD is also recorded.  
 Subject Selection 
The study is conducted at approximately 140 international study sites with a study population of subjects ≥18 years of age with histolog ically and/or cytologically documented metastatic colorectal adenocarcinoma 
who progressed on, or were intolerant to, all standard chemotherapies and relevant biologics and TAS -102 
and/or regorafenib.  
 Inclusion Criteria  
Refer to Section 5.3 Inclusion Crite ria of the study protocol.  
 Exclusion Criteria 
Refer to Section 5.4 Exclusion Criteria of the study protocol.  
 Statistical Hypothesis  
This study is designed to demonstrate superiority of fruquintinib plus BSC (fruquintinib arm) over placebo plus BSC (placebo arm) in prolonging OS for subjects with refractory mCRC. The study is designed to test 
the null hypothesis H0: λ=1.0 versus the alternative hypothesis Ha: λ < 1.0, where λ is the hazard ratio (treatment arm/placebo arm).
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 19 of 134 
 
 Determination of Sample Si ze 
With regards to the study, the total sample size and number of OS events required for efficacy assessment 
in the intent -to-treat population is calculated based on the following assumptions:  
• A one -sided significance level of 0.025;  
• Assuming an OS hazard ratio (HR) of 0.73 (fruquintinib arm/placebo arm), this sample size yields 
approximately 90% statistical power to detect superiority of the fruquintinib arm over placebo arm.  
If the true median OS for the placebo arm is 5 months, then the HR of 0.73 corre sponds to median 
OS of 6.8 months in the fruquintinib arm (median OS improvement of 1.8 months).   
• An enrollment rate of 30 subjects per month during the first 3 months and 50 subjects per month 
thereafter; 
• Yearly dropout rate of 10%;  
• Randomization ratio = 2:1 (fruquintinib arm/placebo arm); 
• Data maturity = 70%;  
• One interim futility analysis when 1/3 of the total number of OS events (i.e., 160 OS events) have occurred, the Lan- DeMets spending function is used in the calculation.  
Under t he premise of these assumptions, approximately 687 subjects are to be randomized to this study 
over approximately 15 months in this study.  OS is to be analyzed when 480 OS events have been observed, which is expected to occur in approximately 7 months after the end of enrollment.  EAST version 6.5 was utilized for the calculation.  
In clinical practice, TAS -102 is used more commonly than regorafenib.  To ensure that the subject 
population is representative of clinical practice, post -regorafenib (regorafenib  or both trifluridine/tipiracil 
(TAS -102) and regorafenib) subjects are to be capped at 344.  This ensures that at least 50% of the subjects 
are post -TAS.   
Subjects are considered in post -TAS-102 or post -regorafenib populations if they have received at le ast one 
dose of either agent, respectively, prior to entering the study.  Based on the similar mechanisms of action between regorafenib and fruquintinib, it is to be of clinical interest to evaluate the magnitude of benefit in each of the populations when compared to the intent -to-treat population.  
 Treatment Assignment and Blinding 
The study subject, investigators, and study site personnel are to remain blinded to all randomization assignments throughout the study.  The sponsor’s study director, study monitor, and any other sponsor and Syneos Health personnel who are in regular contact with the study site are to remain blinded to all subject randomization assignments, except sponsor pharmacovigilance personnel for the purpose of Investigational New Drug (IND ) safety reports.  Treatment is allocated using Interactive Web Response 
System (IWRS) randomization strategy and procedure defined in the IWRS manual.    
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 20 of 134 
 Unblinding can occur in emergency cases.  If unblinding is required for treatment of a subject for an  SAE, 
the investigator must first contact the sponsor’s medical monitor before unblinding, and then unblind the 
subject using the IWRS.  Once unblinded, the subject should discontinue the treatment but continue to be followed for safety and efficacy.  The investigator should record the event in the source document.  
The interim futility analysis maintains blinding at IDMC meetings during the Open Sessions following the procedures described in Section 18, Content of Open and Closed Sessions of the latest vers ion of the 
IDMC Charter.  
 Administration of Study Medication 
Fruquintinib (HMPL -013) capsule 5 mg is administered orally (PO) once daily (QD), 3 weeks on, 1 week off 
(4-week cycles).  Subjects are randomized into either fruquintinib in combination with BSC group (treatment 
group) or placebo in combination with BSC group (control group) in a 2:1 ratio ( Figure 1). 
If study treatment dose adjustment is required, the site must log into the IWRS, adj ust the dose, reassign 
the drug serial number, and dispense new study treatment dose (in 1 mg capsules) to the subject.  If the dose is adjusted a second time, i.e., from 4 mg QD to 3 mg QD, the site must log into the IWRS and record the second dose adjust ment.  On this occasion, it is not necessary to reassign a new drug serial number. 
If tumor evaluation shows PD during the previous cycle and new drug has been dispensed, the subject must return all unused study treatment on the 30 -day safety visit after end of treatment (EOT).  
• Treatment group: fruquintinib 5 mg PO, QD, plus BSC, 3 weeks on/ 1 week off, every 4 -week cycle.  
• Control group: Matching placebo 5 mg PO, QD plus BSC, 3 weeks on/ 1 week off, every 4 -week 
cycle.  
Subjects are allowed to have no more than 2 dose reductions: one reduction from 5 mg QD to 4 mg QD, and if not tolerated, then a second reduction from 4 mg QD to 3 mg QD.  Once a dose has been reduced, it cannot be re- escalated.  The dose reduction sequence by starting dose is shown in Table 2 below.   
Table 2.  Dose Modification Sequence by Starting Dose  
Dose Level 0*  
(Original dose)  5 mg QD 3 weeks on, 1 week off  fruquintinib of 5 mg, 1 capsule, or 1 capsule of the matching placebo  
Dose Level -1* 
(the 1st dose reduction)  4 mg QD 3 weeks on, 1 week off  fruquintinib of 1 mg, 4 capsules, or 4 
capsules of the matching placebo  
Dose Level -2* 
(the 2nd dose reduction)  3 mg QD 3 weeks on, 1 week off  fruquintinib of 1 mg, 3 capsules, or 3 
capsules of the matching placebo  
 
Reasons and guidelines for dose modifications are detailed in Section 7.5.6 of the protocol.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 21 of 134 
 
 Study Procedures and Flowchart  
The study contains the following procedures.  
• Screening Period: This period contains two visit windows of -28 to -1 days and -7 to -1.  
• Study Treatment Period: This period contains treatment cycles, with a visit window of +/ - 3 days for 
each scheduled visit starting at Cycle 2 day 1.  
o Cycle 1 includes cycle 1 day 1 and cycle 1 day 21 visits;  
o Cycle 2 includes cycle 2 day 1 and cycle 2 day 21 visits;  
o Cycle 3 includes cycle 3 day 1 and cycle 3 day 21 visits;  
o Cycle 4 and beyond include cycle 4 day 1, cycle 5 day 1, etc.   
• Follow- Up: This period contains the following.  
o Post treatment : 7 days after last dose with a visit window of +/ - 3 days,  
o Safety Follow- up: 30 days after EOT visit with a visit window of +/- 7 days, and 
o Survival Follow -up: 12 weeks from EOT visit with a visit window of +/- 14 days.  
o EOT: last non- missing assessment during the treatment period  (treatment period is from 
the date  of the first study drug administration until 37 days after last dose) 
The protocol activities include the following throughout the periods listed above.   
• Informed Consent . 
• Demographics . 
• Medical History, Disease History, and molecular characterization of R AS, B-Raf proto -oncogene 
(BRAF) , Microsatellite Instability (MSI)/ Mismatch Repair (MMR) status . 
• Prior and Concomitant Medication/Concomitant Procedure . 
• Comprehensive Physical Examination . 
• Limited Physical Examination . 
• ECOG . 
• Vital Signs. 
• Hematology . 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 22 of 134 
 • Blood Chemistry. 
• Blood amylase and lipase . 
• Coagulation . 
• Thyroid Function. 
• Urinalysis . 
• Serum Pregnancy Test . 
• Urine Pregnancy Test . 
• 12-lead ECG . 
• ECHO/ Multigated acquisition  (MUGA) . 
• Tumor Evaluation/Imaging . 
• Tumor Markers . 
• Circulating Tumor DNA, excluded from Japanese Specific Addendum .  
• PK Plasma Sampling. 
• Subject Randomization, excluded from Japanese Specific Addendum . 
• Drug/Dispense/Return . 
• Study Treatment . 
• Adverse Event . 
• Survival Follow -up. 
• EORTC  QLQ -C30 Questionnaire, excluded from Japanese Specific Addendum . 
• EQ-5D-5L Questionnaire, excluded from Japanese Specific Addendum . 
Details of study procedures can be found in the following tables within the protocols.  
• Table 1. Schedule of Events . 
• Table 2. Schedule of Events for Pharmacokinetic and Electrocardiogram Evaluations for the First 
Approximately 120 Subjects, and  
• Table 3.  Schedule of Events for Pharmacokinetic and Electrocardiogram Evaluations for Subjects 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 23 of 134 
 Enrolled After the First Approximately 120 .  
The study schematic is presented in Figure 1. 
Figure 1.  Study Design Schema  
 

Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 24 of 134 
 
 Endpoints   
 Primary Efficacy Endpoint  
The primary endpoint of the study is OS, defined as the time (months) from date of randomization to death 
from any cause. That is, OS is calculated as (date of death or last known alive – date of randomization + 
1)/30.4375.    Subjects without report of death at the time of analysis are censored at the date last known 
alive.   Subjects lacking data beyond the date of randomization have their survival ti me censored at the date 
of randomization.  OS will not be censored if a subject receives subsequent anticancer treatments after 
discontinuation of the study treatments . Date of last known alive defined in Section 7.2.4  and date of death 
is defined in Section 7.2.5  of the SAP.  
 Secondary Endpoints  
• Key secondary efficacy endpoint:  PFS.  
PFS is defined as the time (months) from randomization until the first radiographic documentation of objective progression as assessed by investigator using Response Evaluation Criteria In Solid Tumors 
(RECIST ) v1.1, or death from any cause. More sp ecifically, PFS will be determined using all the assessment 
data up until the last evaluable visit prior to or on the date of (i) disease progression as defined by RECIST Version 1.1 or death; or (ii) withdrawal of consent  or lost to follow -up; or (iii) re ceiving subsequent anti -
cancer therapy, whichever is earlier. Subjects without report of PD or death from any cause at the time of 
analysis are censored as described in Table 3 below.  
The PFS time will always be derived based on scan dates not tumor assessment dates. RECIST 
assessments/scans contributing towards a particular visit may be performed on different dates. The 
following rules are applied: 
1. Date of progression is determined based on the earliest of the dates of the component that triggered  
the progression.  
2. When censoring a subject for PFS, the subject is censored at the latest of the dates contributing to 
a particular overall visit assessment.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 26 of 134 
 Objective response rate (ORR) will be calculated using two different ways:  
§ Scenario #1: ORR will be calculated using a strict interpretation of RECIST Version 
1.1. Objective response will be derived as no/yes variable. Subject s with a BOR of 
confirmed CR or PR will be assigned ‘Yes’. Subject s not having a BOR of 
confirmed CR or PR will be assigned ‘No’. Hence, ORR is defined as the proportion of subjects with objective response being “Yes”.  
§ Scenario #2: ORR
UNCONF RMED  will be calculated using all responses regardles s of 
confirmation. Objective response will be derived as no/yes variable.  Subject s with 
a BOR of confirmed CR, confirmed PR, unconfirmed CR or unconfirmed PR will be assigned “Yes”.  All subjects with other BOR values will be assigned “No”.  
Hence, ORR
UNCONF RMED  is defined as the proportion of subjects with objective 
response being “Yes”.  
o DCR is defined as proportion of subjects achieving a best overall response of confirmed CR, PR, or SD  (for at least 7 weeks) per RECIST v1.1, as determined by the investigator.  
To be qualified for SD, the duration of SD should last for at least 7 weeks.  
o DoR is defined as the time (months) from the first occurrence of PR or CR  by RECIST 
Version 1.1, until the first date that progressive disease is documented by RECIST Vers ion 
1.1, or death, whichever comes first . Only those subjects with confirmed responses of CR 
or PR will be included in this analysis. Censoring will follow the rules outlined for PFS in 
Table 3 in this section . For those subjects who do not have censored DoR, it is calculated 
as (date of death or PD or last assessment – date of first occurrence of confirmed CR or 
PR + 1)/30.4375.  
• Changes in health status (QLQ -C30: cancer specific; and EQ -5D-5L). 
• Resource utilization including all concomitant medications, days in hospital . 
 Exploratory Endpoints  
• Change from baseline in circulating tumor DNA (ctDNA) , analysis plan to be included in a 
separate document . 
• Change from baseline in  tumor markers (carcino -embryonic antigen [CEA]) . 
• Pharmacogenomics ,  analysis plan to be included in a separate document . 
 Safety Endpoints  
• Safety including treatment -emergent adverse events (TEAEs), serious adverse events (SAEs), 
deaths, ECG’s, and clinical laboratory abnormalities . 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 27 of 134 
 
 Pharmacokinetic Endpoints  
• Observed plasma concentrations, estimated population PK and exposure parameters of 
fruquintinib and M11 . 
• QTc interval and plasma concentrations of fruquintinib and M11 at specified time points.  
 Pharmacodynamic Endpoints  
• Parameters describing exposure -response with efficacy (e.g., OS) and safety (e.g., AEs) 
endpoints. 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 28 of 134 
 
 Analysis Populations 
 Screened  Population  
The Screened population includes all subjects who signed informed consent form (ICF).   
 Intent- to-Treat Population  
The Intent -to-Treat (ITT) population includes all randomized subjects.  Subjects are analyzed by treatment 
group as randomized.  The ITT population is the primary population for evaluating all efficacy endpoints 
and subject characteristics.   
 Safety Population  
The Safety population includes all randomized subjects who received at least one dose of study treatment.  Subjects in this population are analyzed according to the treatment they actually received.  This population is used fo r all safety analyses.   
In the event that there are protocol deviations reported during the conduct of the study leading to a patient receiving mixed treatment (ie, receiving both placebo and fruquintinib), the actual treatment assigned for the patient will be the most frequently used treatment. For example, if a patient received 42 days of placebo 
and 21 days of fruquintinib during the treatment period, then the actual treatment for the patient will be 
PLACEBO. However, if the duration of treatment for placebo and fruquintinib tie, then the assig ned 
treatment at the time of randomization for the patient will be the actual treatment used for the patient in the summary. For example, a patient was randomized to fruquintinib, but received 21 days of placebo and 21 
days of fruquintinib during the treat ment period, then the actual treatment for the patient will be 
FRUQUINTINIB which is the assigned treatment at randomization.  
 Per Protocol (PP) Population  
The per -protocol (PP) analysis set will include only those subjects in ITT who received the treatment  to 
which they were randomized  to and have no major protocol deviations that preclude the assessment of 
efficacy and/or data integrity. Subjects who took the wrong treatment at any time during the study  will be 
excluded from the PP population. PP population is used for sensitivity analyses of OS and PFS, and may 
be used to analyze selected endpoints to test the robustness of results. The criteria for inclusion in the PP subset will be finalized and documented prior to unblinding of the study.  
 Pharmacokinet ic (PK) Population  
The PK population includes all subjects who receive at least one dose of study treatment and have at least one post -dose PK sample obtained and analyzed (i.e. valid result being available) .  The PK population is 
used for tabulation of fruquintinib and M11 concentrations from PK plasma samples . 
 Protocol Deviations  
Protocol deviations including deviations that are related to COVID -19 are recorded in the clinical trial 
management system (CTMS) as outlined in the latest version of the Protocol Deviation and Non -compliance 
Management Plan. During the course of the study , a list of key programmable PDs will be produced and 
reviewed periodically, these PDs will be reconciled into the CTMS. These programmable PDs  include but 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 29 of 134 
 not limited to the (i) programmable inclusion c riteria 1 -5, 7- 9, 12, exclusion criteria 1 -7, 13, 21, 26 ; (ii) 
randomized but failed to receive treatment; (iii) treated without randomization; (iv) other PDs that may affect 
efficacy evaluation.    All major and minor protocol deviations will be reviewed and confirmed during blind 
data review meeting prior to database lock. Out of all major protocol deviations identified, a subset of protocol deviations leading to exclusion of subjects from PP population will be determined.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 30 of 134 
 
 General Aspects for Statistical Analysis 
 General Methods  
• Summaries are presented for each treatment group and overall for subjects’ disposition, 
demographics and baseline characteristics, medical history, di sease history, prior medications, and 
concomitant medications tables.  Summaries are presented for each treatment group for other tables.  
• All data listings that contain an evaluation date contains a relative study day as defined in Section 
7.2.3. 
• For categorical variables, summary tabulations of the number and percent of subjects within each category of the parameter as seen on the  electronic case report form (eCRF ) are to be presented.  
Percen tage calculations are based on the number of subjects within treatment group and overall, 
unless otherwise specified.  Percentages are rounded to 1 decimal place, unless otherwise specified.  The category Missing is included in subject -level demographics a nd disease history 
tables when the count is greater than zero for missing subjects.  
• For continuous variables, the number of subjects, mean, standard deviation (StdDev), median, 
lower quartile ( Q1), upper quartile  (Q3), minimum, and maximum values are pres ented.  The 
precision of summary statistics, unless otherwise specified, is as follows:  
o Minimum, maximum: same decimal places as the raw data . 
o Mean, median, Q1, and Q3 : 1 more decimal place than the raw data . 
o Standard deviation, standard error:  2 decimal places more than the raw data.  
• For results from a mixed model repeated measures, least- square (LS) mean and LS mean 
difference are presented with one decimal place, and standard error (SE) of LS means and SE of 
LS mean difference are presented with two decimal places.   
• Comparison between treatment groups are calculated as fruquintinib plus BSC versus placebo plus 
BSC.  
• Two-sided 95% confidence intervals (CI) are provided and rounded to 2 decimal places , unless 
otherwise specified.  
• 2- sided p -values are presented with 3 decimal places.  
• Any rounding will be done after all calculations are made. 
 Key Definitions  
 First Dose Date 
First dose date is defined as the day of first dose of study treatment received on or after date of  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 31 of 134 
 randomization.  
 Last Dose Date  
Last dose date is defined as day of the last non- zero dose of study treatment. The last dose date is typically 
obtained from the study drug administration records. For the situation that the last non -zero dose record 
has a partial end date (i.e. only missing day) for a patient, the following algorithm will be implemented to 
impute the partial end date.  
1. Calculate the date that is 21 days after the start date of the record;  
2. Obtain the end date of the month for the month of partial end date;  
3. Get th e end of study date;  
4. Get the death date;  
5. The partial end date will be imputed to be the earliest among those dates from Item 1 to 4.  
For example, for a patient, the last non -zero dosing record has the start date being 19 Aug 2020, and the 
end date being partial as Sep 2020. With the end of study and death date being 13 Sep 2020, after 
implementing the algorithm above, the partial end date will be imputed to be 08 Sep 2020 which is the earliest date among (08 Sep 2020, 30 Sep 2020, and 13 Sep 2020).  
For su bjects ongoing for the treatment period at time of analysis prior to database lock, the last dose date 
is the date of the most recent study visit in the database for that subject.  
 Study Day  
The study day is determined relative to the date of first dose of study treatment, unless otherwise specified.  
The day of the first dose of study treatment is defined as study day 1.  The day prior to the first dose of study treatment is study day -1.  There is no study day 0.  
For events that occur before the first dose  of study treatment,  
study day = date of the event – first dose date;  
for events that occur on or after the first dose of study treatment,  
study day = date of the event – first dose date + 1.  
 Date of Last Known Alive  
The date of last known alive is defi ned as the last alive date of contact from the Survival Follow -up page on 
the eCRF.  For subjects ongoing at time of analysis, the date of last known alive is the date of the most recent study visit in the database for that subject.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 32 of 134 
 More specifically , the last known alive date will be derived for subjects not known to have died at the 
analysis cut -off date using the latest date (including complete and partial date with Month and Year 
information) among the following data:  
- All assessment dates (e.g.  laboratory, vital signs assessments, ECG, ECOG, performance status 
assessment, tumor assessment dates etc.).  
- Medication dates including study medication, concomitant medications, anticancer therapies 
administered after study treatment discontinuation. 
- Adverse events start and end date , and the date of adverse event becoming serious . 
- Date latest known alive collected during the survival follow -up. 
- Randomization date.   
 
After sorting properly for all those available dates, if the last  last known alive date is a partial date with 
Month and Year information, day will be imputed as 15, unless this is after the cut off date in which case the cut off date will be used as last alive date.  
 
 Date of Death  
Date of death is defined as the date of death from the Death Detail page on the eCRF.  Date of death is 
cross- checked with AEs where outcome is ‘Fatal’, if applicable.  In rare case, if year and month of death 
date are known but the day is unknown, day will be imputed as 15. For example, if a subject  is reported to 
die on Dec2017, the death date will be imputed as 15 Dec2017.  In the case of the imputed death date being 
after the end of study date  and the death date and end of study date being the same month, the death date 
will be assigned to be the  date of end of study.  
 Baseline and Change from Baseline  
For all change from baseline variables, t he baseline is defined as the last non- missing assessment prior to 
or on the day of randomization, and must be prior to the first administration of study treatment, including 
scheduled and unscheduled visits, unless otherwise specified.  Hence, change from baseline = post -
baseline value – baseline value.  
The baseline value for analyses of qualitative parameters (e.g., normal/abnormal) is defined as the last evaluation prior to or on the day of randomization, and must be prior to the first administration of study 
treatment. 
 Treatment -emergent Events  
An AE is considered a TEAE if the onset date is on or after the start of study treatment or if the onset date is missing, or if the AE has an onset date before the start of study treatment but worsened in severity after 
the study treatment until 37 days af ter the last dose of study treatment or a new treatment of anti -tumor 
therapy, whichever is earlier. After this period, treatment- related SAEs will also be considered as TEAEs. 
AEs with an unknown/not reported onset date will also be included. 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 33 of 134 
 
 Missing Data  
All available data of the subjects who withdraw from the study for any reason is analyzed.  Missing data is 
assumed to be missing at random.  Category ‘Missing’ is displayed for qualitative assessments, where applicable.  
For demographic and ba seline characteristics, each variable will be analyzed and/or summarized using the 
available data. Unless otherwise specified, subjects with missing data will be excluded only from analyses for which data are not available.  
There is no imputation of missin g data for the analysis purpose, unless otherwise stated.  
 Imputation of the Missing  Dates  
Imputation rules described in this section are applicable to partial dates of AEs, concomitant medications, 
anti-cancer therapy, primary diagnosis and metastatic dise ase diagnosis . However, imputation of missing 
AE and concomitant medication onset and stop dates will be used to determine the status of each AE and the prior/concomitant status of each medication, the imputed dates should not be shown in listings.  
Incomplete Start Date of AEs : 
- If the AE onset date is completely missing, the AE start date will be imputed as the reference start 
date (i.e. first dosing date) ; 
- If the AE onset date is partial missing, then  
§ If both the year and the month are av ailable and the year and the month are the corresponding 
year and month of the reference start date , then the AE start date will be imputed as the 
reference start date ;  
§ If both the year and the month are available and the year and the month are not equal to the corresponding year and month of the reference start date , then the AE start date will be imputed 
as the 1
st day of the month;  
§ If only the year is available and the  available year is the corresponding year of the reference start 
date, then the AE start date will be imputed as the reference start date ; 
§ If only the year is available, and the available year is not equal to the corresponding year of the reference start date, then the AE start date will be imputed as the January 1
st of the year . 
Incomplete Stop Date of AEs :  
AE end date will be imputed as below for the partial date only, the imputation rules only apply when the 
AE is not ongoing:  
- If both the year and the month are available, AE end date will be imputed as the last day of the 
month;  
- If only the year is available, AE end date will be imputed as the December 31st of the year.  
If the imputed AE end date is after the death date for subj ects is know to be dead at end of study or cut 
off date, the date of the death will be used for AE end date. If the imputed AE end date is after the last 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 34 of 134 
 known alive date for subjects alive at the end of study or cut off date, the date of last known alive date will 
be use for AE end date.  
For AE continuing at the cut -off date, the end date will not be imputed and instead will be reported as 
“ongoing”.  
Concomitant Medication/Procedure/Surgery with onset/end dates  
Concomitant Medication/Procedure/Surgery wi th onset/end dates that are partially/completely missing will 
be imputed as follows.  
(i) start date:  
- 1st day of the month will be used to impute the start date if only the day is missing . 
- January 1st will be used to impute  the start date if both the day and month are missing . 
- If the date is completely missing , then the day before the reference start date will be imputed as the 
start date.  
(ii) end date:  
- Last day of the month will be used to impute the end date if only the day is missing. 
- December 31st of the year will be used to impute the end date if both the day and month are missing . 
- If the date is completely missing, assign ‘continuing’ status to the end date . 
If the imputed end date is after the death date or last known  alive date, the date of the death or last known 
alive date will be imputed as the Concomitant medication/procedure/surgery  end date.  
Subsequent Anti -cancer Therapy Date  (collected during Survival Follow -Up) 
When a partial new anti -tumor therapy start date is reported, every effort will be made to identify the 
precedence relationship of starting date of new anti -tumor therapy relative to the reference end date (i.e. 
last dose date). Below rules will be used:  
- If the date is completely missing, new anti -tumor therapy date will be imputed as reference end date + 
1; 
- If only the day is missing, 15th day will be imputed as the new anti -tumor therapy date;  
- If both the day and the month are missing, then July 1st will be imputed as the new anti -tumor therapy . 
If the imputed start date is prior to the reference end date for subjects, the reference end date + 1 will be 
used as the imputed start date of the subsequent anti -cancer therapy.   
Primary Diagnosis Date and Metastatic Disease Diagnosis Date  
When a partial date of primary diagnosis for advanced colorectal cancer or a partial date of first 
metastatic disease diagnosis is reported, the below imputation rules will be used:  
- If the date is completely missing, no imputation will be conducted; 
- If only the day is missing, 15th day will be assigned;  
- If both the day and the month are missing, then July 1st will be assigned.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 35 of 134 
 
 Visit Windows  
It is expected that there will be a variation between subjects in the actual num ber of study days from the 
start of administration of study drug within each cycle  defined as Day 1  to the dates that the scheduled 
visits occurs. To handle this, for tables and figures where data are grouped by visit, assessments will be 
categorized using visit windows based on study days (relative to the Day 1 of each cycle). The visit -window 
mapping is described in Table 4. Visit-based summaries will be based on the windowed visits. All data, 
whether or not within the visit windows, will be presented in subjects listings.  
For windowed visits during the treatment cycles, if more than 1 vis it occurs during a visit window, the visit 
closest to the scheduled day will be assigned to the windowed visit. If two visits are equidistant from the scheduled day, the later visit will be assigned to the windowed visit. If there are multiple assessments on 
the same day, the worst case will be used.  For the treatment completion visit, the last assessment in the window will be included in the summary.  
For a subject  who prematurely discontinues the study, the premature visit will be slotted accordingly. The 
window for post treatment visit will be " last dose date of last cycle + 4 days to last dose date of last cycle + 
10 days" and the window for safety follow -up visit will be “Last dose date of last cycle + 11 days to last dose 
date of last cycle + 37 days”.
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 38 of 134 
 
 Pooling of Centers  
Data from all study centers is combined for analysis.   
 Outliers  
Data Management are to be notified of outliers, if identified during TLF reviews, for query.  Syneos Health 
Biostatistics and Programming do not change or remove outliers from the data.  
 Data Sources  
Randomization numbers, stratification factors, and treat ment assignments derived from IWRS are 
reconciled with the dummy randomization schedule prior to database lock and unblinding, and with the 
actual randomization schedule after database lock and unblinding.  
After the study is unblinded, fruquintinib and M11  concentrations from PK plasma samples are provided by 
Covance and mapped onto SDTM PC domain.  Syneos Health then transfers SDTM PC domain to Certara.  
Protocol deviations are recorded in the CTMS and provided as an Excel document.  Protocol deviations 
are to be reviewed prior to database lock.  
CRF data are extracted from Rave database.  
Laboratory data are provided by local labs.  
Imaging data are provided by  eResearchTechnology, Inc.  (ERT). 
Intera ctive Response Technology (IRT) data are provided by Endpoint.  
Quality of life data using EORTC QLQ- C30 and EQ -5D-5L questionnaires are collected via Electronic 
Clinical Outcome Assessment (eCOA) and provided by ERT.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 39 of 134 
 
 Demographic, Other Baseline Characteristics and Medication 
 Subject Disposition and Withdrawals  
The following summaries will be presented for all enrolled subjects to reflect the subject disposition:  
- Number of subjects who signed the informed consent .  
- Number of screen failures . 
- Reason for scre en failure . 
- Number of subjects who are randomized .  
- Number of subjects who do not receive study drug. 
- Number of subjects who received study drug.  
- Subject s still on treatment (i.e., missing end- of treatment information). 
- Reason for study drug discontinuation (for study drug) . 
- Number of subjects going into Survival follow -up if there are any assessments after the last dose 
date + 37 days.  
- Number and percentage of subjects still on study (i.e., missing end -of-study information). 
- Number and perce ntage of subjects who discontinue d the study. 
- Reason for study discontinuation . 
Since there is no designated CRF field to collect the reasons at the end of Study (EoS) page of the CRF, 
the following algorithm will be implemented to derive the reason for Eo S.  
1. If a patient died on the study, the reason for EoS will be “death.”  
2. If a patient did not die on the study,  
a. Check the Survival Follow -Up (SFU) page, extract the value (eg, Lost to Follow -up and 
Withdrawal of Consent) in the field of Survival Status from the last available SFU page, and it will 
be assigned as the EoS reason.  
b. When 2.a is not available, check the Visit Information page where SFU visit was not performed, 
extract the last available value in the field of reason not conducting the visit, and it will be assigned as the EoS reason  or “Missing” if the visit information is there but reason is missing before 
proceeding to the next step. 
c. When 2.a and 2.b are both not available, check th e End of Treatment (EoT), extract the reason of 
EoT, and it will be assigned as the EoS reason.  
A separate table will be presented  to show the subjects included in each analysis set and proper reasons 
for exclusion from an analysis set.   
A separate table will be presented for the ITT population to show the concordance of randomization 
schedule stratification factors and C RF collected factors of prior t herapy [i.e. Trifluridine/Tipiracil (TAS -102), 
Regorafenib, or Both Trifluridine/Tipiraci l (TAS -102) and Regorafenib] , duration of metastatic disease (≤ 18 
months, > 18 months) , and RAS status (Wild Type, Mutant) . The following summaries will be presented:  
- Number of subjects with all randomization schedule stratification factors concordant with CRF 
collected factors . 
- Number of subjects with at least one randomization schedule stratification factor discordant with 
CRF collected factors . 
o Number of subjects with discordance in prior therapy  [i.e. Trifluridine/Tipiracil  (TAS -102), 
Regorafenib, or Both Trifluridine/Tipiracil (TAS -102) and Regorafenib] , duration of 
metastatic disease, and RAS status . 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 40 of 134 
 Subject discontinuation status and analysis population are also listed. 
 Protocol Deviations  
Protocol deviations are summariz ed descriptively for subjects with at least 1 major protocol deviation and 
subjects with at least 1 minor protocol deviation for each treatment group and overall.  Each protocol 
deviation is also summarized descriptively by categories within major and mino r protocol deviations for 
each treatment group and overall for the ITT population.  A subject can have multiple major and/or minor 
deviations and counted once per major and/or minor deviation. COVID -19-related protocol deviations are 
summarized descriptively for each treatment group and overall for the ITT population.  
A listing of protocol deviations, including COVID -19-related protocol deviations, is provided.  
 Demographic and Baseline Characteristics  
The following parameters are summarized descriptively for each treatment group and overall for the ITT population.  
• Age (years)  at ICF date, Age Categories (< 65 years, ≥ 65 years) . 
• Sex (Female, Male); If female, Child Bearing Potential .  
• Race (American Ind ian or Alaskan Native, Asian, Black or African American, Native Hawaiian or 
Other Pacific Islander, White, Other, Multiple Races, Not Reported, Unknown) . A subject can have 
multiple races and is summarized in the  multiple race category.  
• Ethnicity (Hispani c or Latino, Not Hispanic or Latino, Not Reported, Unknown) .  
• Region (North America, Europe, and Asia ).  
• Baseline Height (cm ). 
• Baseline Weight (kg). 
• Baseline body mass index [ BMI] (kg/m
2): it is calculated as Weight at Baseline (kg)/ [Height at 
Baseline (m)]2. 
o BMI category: < 18.5, ≥ 18.5 and < 24, ≥ 24 kg/m2. 
• Baseline ECOG Performance Status: 0, 1. 
Age (years) at ICF date is calculated by site personnel as the number of years from date of birth up to date 
of informed consent.  For example,  
Date of Birth  Date of Informed Consent  Original Age  Age to be entered into IWRS  
01MAR1985 01JUL2020 35 years 4 months 35 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 41 of 134 
 01AUG1985 01JUL2020 34 years 11 months 34 
 
A separate tabl e presenting number and percentage of subjects by site and country will be produced  for 
the ITT population. Demographic data and baseline characteristics , randomization scheme and codes, informed consent data, 
and inclusion/exclusion criteria are listed by subject . 
 Disease History  
History of colorectal cancer of the ITT population is  summarized descriptively for each treatment group and 
overall for the following : 
• Time (months) since First Diagnosis of Colorectal Cancer: it is calculated as (date of randomization 
– date of f irst diagnosis of colorectal cancer)/30.4375 .   
• Stage of Colorectal Cancer at First Diagnosis (stage I, stage II, stage III, stage IV). 
• Primary Tumor Location at First Diagnosis . 
o Colon .  
§ Colon – Right (cecum, ascending colon, and hepatic flexure) . 
§ Colon – Left (splenic flexure, descending colon, transverse colon, sigmoid colon) . 
§ Colon – Right and Left . 
§ Colon – Unknown . 
o Rectum. 
o Colon and Rectum . 
§ Colon – Right (cecum, ascending colon, and hepatic flexure) . 
§ Colon – Left (splenic flexure, descending colon, transverse colon, sigmoid colon).  
§ Colon – Right and Left . 
§ Colon – Unknown . 
o Unknown . 
• Primary Site at First Diagnosis (Colon  Left, Colon  Right, Both Colon  Left and Right, Colon  
Unknown, Rectum Only, Unknown) . 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 42 of 134 
 • Duration of Metastatic Disease (months): it is calculated as (date of randomization – date of 
diagnosis of metastasis disease)/30.4375 . 
o Duration of Metastatic Disease Categories ( ≤ 18 months, > 18 months) . 
• Prior Oncology Treatments (Prior Anti- cancer Medication, Prior Anti -cancer Radiotherapy, Prior 
Anti-cancer Procedures). 
• RAS Status (Wild Type, Mutant) . 
• BRAF Status (Wild Type, V600 E Mutation, Other) . 
• Microsatellite/Mismatch Repair Status (Microsatellite stable [MSS ] and/or  proficient mismatch 
repair [ pMMR ], microsatellite instability -high [ MSI-H] and/or deficient mismatch repair [dMMR ]). 
• Prior Therapy with Trifluridine/Tipiracil (TAS -102) and/or Regorafenib (Trifluridine/Tipiracil (TAS -
102), Regorafenib, Both Trifluridine/Tipiracil (TAS -102) and Regorafenib). 
• Number of Prior Treatment Lines (≤ 3, > 3). 
• Number of Prior Treatment Lines for Metastatic Disease (≤ 3, > 3) . 
• Prior Treatment with Vascular Endothelial Growth Factor (VEGF) Inhibitors (Yes, No) . 
• Prior Treatment with Epidermal Growth Factor Receptor (EGFR) Inhibitors (Yes, No) . 
• Prior  Treatment  with EGFR/VEGF Inhibitors .  
o No anti -VEGF and no anti -EGFR. 
o Anti-VEGF, or anti -EGFR, or both. 
§ Anti-VEGF and no anti -EGFR. 
§ Anti-EGFR and no anti -VEGF. 
§ Both anti -VEGF and anti -EGFR. 
• Prior Treatment with Immune Checkpoint Inhibitors for MSI -H/dMMR  (Yes, No) . 
• Prior Treatment with BRAF Inhibitors for BRAF V600E Mutation (Yes, No) . 
• Liver Metastases at Baseline (Yes, No): obtained based on whether the liver organ was involved 
in the target and non -target lesion tumor scan assessment at the baseline . 
• Number of Metastatic Sites Other than Colon or Rectum ( Single, Multiple ): obtained based on the 
number of sites/organs was involved in the target and non -target lesion tumor scan assessment at 
the baseline. If only one is involved, that would be single; if m ore than one are involved, it will be 
multiple.  For this derivation, paired organs, such as lung, kidney, ovaries, and lymph nodes will be 
considered as one organ, irrespective of the number of parts they may be made up of  (i.e. tumors 
in the left lung and right lung will be counted as in one site) .  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 43 of 134 
 • Number of Metastatic Sites (Single, Multiple): obtained based on the number of sites/organs was 
involved in the target and non -target lesion tumor scan assessment at the baseline. If only o ne is 
involved, that would be single; if more than one are involved, it will be multiple.  For this derivation, 
paired organs, such as lung, kidney, ovaries, and lymph nodes will be considered as one organ, 
irrespective of the number of parts they may be ma de up of  (i.e. tumors in the left lung and right 
lung will be counted as in one site) .   
 Medical History  
The conditions/diseases from medical history are those conditions/diseases that stopped prior to the study entry.
 Medical history is coded using the Me dical Dictionary for Regulatory Activities (MedDRA) version 
25.0.  Medical history is summarized using discrete summary statistics for each MedDRA system organ 
class (SOC) and preferred term (PT) by treatment group and overall for the ITT population.  Subj ects with 
multiple medical histories in the same SOC or PT are counted only once for the respective SOC or PT.   
Summaries are ordered in alphabetical order of SOC and then, within an SOC, in decreasing frequencies 
by PT in overall column. If the frequenci es tie, an alphabetic order will be applied.   
A listing of medical history by subject is provided.   
 Prior and Concomitant Medication  
Prior and concomitant medications are classified by Anatomical Therapeutic Classification  (ATC) 
therapeutic subgroup (Level 2)  and PT using the World Health Organization Drug Dictionary (WHODD) 
version March2020 or later.  Medications with partial start or stop dates are imputed as described in Section 
7.3.1 prior to be determined whether the medication is prior or  concomitant medication. 
Medications taken prior to the first dose of study treatment are denoted “Prior”. Medications taken prior to the first dose of study treatment and continuing beyond the first dose of study treatment or those 
medications started on or after the first dose of study treatment but no later than 37 days after the last dose are denoted “Concomitant”.  Medication with start date/time being partially or compl etely missing will be 
assumed to be concomitant if it cannot be definitely shown that the medication did not occur during the treatment period. 
The use of prior and concomitant medications will be summarized using discrete summary statistics in each 
treatm ent group and overall for the ITT population.  If a subject took a specific medication multiple times or 
took multiple medications within a specific ATC or PT, the subject is counted only once for the respective ATC or PT.  
Summaries are ordered in alphabet ical order of ATC and then, within an ATC , in decreasing frequencies 
by PT in overall column. If the frequencies tie, an alphabetic order will be applied.  
A listing of prior medication and concomitant medication by subject is provided. 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 44 of 134 
 
 Concomitant Medical or Surgical Procedure  
Medical or surgical procedures that occurs after first dose date but no later than 37 days after the last dose 
are denoted “Concomitant”.  Concomitant medical or surgical procedures are classified using the MedDRA 
version 25.0.  
The use of concomitant medical or surgical procedures will be summarized using discrete summary 
statistics in each treatment group and overall for the ITT population.  If a subject took a specific medication  
or surgical procedures  multiple times or took multiple medications  or surgical procedures within a specific 
SOC or PT, the subject is counted only once for the respective SOC or PT.  
Summaries are ordered in alphabetical order of SOC and then, within an SOC , in decreasing frequ encies 
by PT in overall column. If the frequencies tie, an alphabetic order will be applied.  
A listing of concomitant medical or surgical procedures by subject is provided.  
 Prior Oncology Treatment  
Prior oncology treatments including prior anti -cancer medi ation, prior anti -cancer radiotherapy,  prior anti-
cancer procedure or surgery are summarized descriptively for each treatment group and overall for the ITT population.   
 Prior Anti -cancer Medication  
Summary of prior anti -cancer medication for the ITT population includes the following:  
• The number and percent of subjects with at least one prior anti -cancer medication . 
• The total number of prior anti-cancer medications. 
• The number of prior lines of therapy and its categories of 0, 1, 2, 3, >  3.  
Prior anti -cancer medications are classified using the WHODD version March 2022 . 
The use of prior anti -cancer medications will be summarized  by ATC and PT using discrete summary 
statistics, each treatment group and overall for the ITT population.  A subject with multiple prior medication 
entries in the same ATC (PT) is only counted once within a particular ATC (PT). Results are sorted by ATC 
followed by PT in decreasing order of frequency (by Total column). If the frequencies are tied, an alphabetic order is applied.  
 Prior Anti -cancer Radiotherapy  
Summary of prior anti -cancer radiotherapy  for the ITT population includes the following.  
• The number and percent of subjects with at least one prior anti -cancer radiotherapy . 
• The total number of prior anti -cancer radiotherapy. 
 Prior Anti -cancer Procedure or Surgery  
Summary of prior anti -cancer procedure or surgery  for the ITT population includes the following 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 45 of 134 
 • The number and percent of subjects with at least one prior anti -cancer procedure or surgery. 
• The total number of prior anti -cancer procedures or surgery.  
The number and percent of subjects for each purpose of prior anti- cancer procedure or surgery . A 
subject with multiple occurrences  of the same purpose will be co unted only once for the purpose, 
and a subject with multiple purposes will be counted once in each category of purpose.    
Prior anti -cancer procedure or surgery is coded (MedDRA) version 25.0. 
The number and percent of subjects with each procedure or surgery will be summarized using discrete 
summary statistics in each treatment group and overall for the ITT population by SOC and PT. If a subject  
had a procedure multiple times or had multiple pro cedures  within a specific SOC or PT, the subject is 
counted only once for the respective SOC or PT. Summaries are ordered in alphabetical order of SOC and 
then, within an SOC, in decreasing frequencies by PT in overall column. If the frequencies tie, an al phabetic 
order will be applied. 
 Extent of Exposure  
Exposure of study treatment is descriptively summarized for each treatment group as follows. Table 5 
details the parameters of study treatment exposure.  
Table 5. Extent of Exposure Parameters  
Parameter  Definition  
Duration of Exposure (days)  (Last dose date of study drug or death, whichever comes 
earlier) – first dose date of study drug + 8 or the date of death 
while on study, whichever comes first . 
Number of Days with Recorded 
Dose  Sum of days with recorded doses  
Number of Cycles Treatment 
Received  Subjects are considered to have started a cycle if they have 
received at least one dose of any study treatment.  
Number of Cycles Treatment 
Received Categories  1, 2, 3, 4, 5,  6 and > 6 
Cumulative Dose (mg)  Sum of doses administered in all cycles. The total dose 
administered in each cycle is defined as: the sum of (number of 5 mg capsules taken × 5 + number of 1 mg capsules taken)  
where number of capsules taken = total capsules dispensed – 
total capsules returned.  
Dose Intensity (mg/day)  Cumulative Dose (mg) / Duration of Exposure (day)  
Target dose intensity is 3.75 mg  
Relative dose intensity (RDI) (%)  100 * [Dose Intensity (mg/day) / (5 × 21/28 (mg/day))]   
RDI Categories  < 50%  
50 - < 70%  
70 - < 90%  
90 - < 110%  
 ≥ 110%.  
Relative Dose (RD) (%)  100 * [Cumulative dose (mg) / (5×21× number of cycles 
treatment received (mg)]  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 46 of 134 
 Parameter  Definition  
RD Categories  < 50%  
50 - < 70% 
70 - < 90%  
90 - < 110%  
 ≥ 110%.  
Percentage Intended Dose (PID) (%)  100 * [(number of days with any recorded doses) /duration of 
exposure ]  
Target PID is 75%. 
Number of days with any recorded doses  
The following s ummary for  dose adjustment will be summarized for each treatment group.  
o Study drug is administered orally on days 1 -21 of each 28 -day cycle. A cycle will be called 
cycle delay if the duration of the cycle is longer than 28 days. However, the last cycle will 
not be evaluated for cycle delay. Reason for delay is not collected. Hence, the total number 
of cycle delay will be calculated for each subject.  Number of subjects with any cycle delay, 
and the frequency of cycle delay (0, 1, 2, 3, 4, 5, 6, > 6) will be summarized.  
o Number of subjects with any dose modification (including both drug interruption and dose 
reduction);  
o Frequency of dose modification: 0, 1, 2, 3, 4, 5, 6, >  6. 
o Drug interrupted (number of subjects experienced drug interruption  and reasons for drug 
interruption ; frequency of drug interruptions: 0, 1, ≥ 2) . 
o Drug withdrawn  (number of subjects experienced drug withdrawn and reasons for drug 
withdrawn) . 
o Dose reduced  (Number of subjects with any dose reduction and reasons for dose 
reduction; and frequency of dose reduction: 0, 1, 2, ≥  3), also the dose reduction category 
below will be summarized .  
§ Reduction from 5mg to 4mg .  
§ Reduction from 4mg to 3mg .  
Study treatment accountability, study treatment administration are extent of exposu re are listed by subject 
and visit.  
 
  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 47 of 134 
 
 Efficacy 
Efficacy analyses are based on the ITT population.  All secondary endpoints based on radiological 
assessments of tumor burden are derived from investigator assessment using Response Evaluation 
Criteria In Solid Tumors (RECIST) version 1.1  (Eisenhauer et al  2009) . 
 Primary and Key Se condary Efficacy Endpoint and Analysis  
 Primary Efficacy Endpoint and Analysis 
The primary endpoint of the study is OS, defined in Section  5.1 of the SAP and calculated as (date of death 
or last known alive – date of randomization + 1)/30.4375. 
The Kaplan- Meier plots will be produced and the median, 25% and 75% percentile of time -to-event will be 
estimated using Kaplan- Meier method with their corresponding 95% CI which are calculated from a log -log 
transformation based on the method by Brookmeyer and Crowley (1982). Additionally, estimates will be provided for the survival probability along with their 95% CIs which are calculated using linear 
transformation
 based on the method by Brookmeyer and Crowley (1982)  at selected landmarks, for 
example, at 3, 6, 9, 12, and 18 months. Example Statistical Analysis System (SAS) code is provided in 
Appendix 6 . 
The two- sided p -value to test t he treatment effect will be calculated  using a stratified log- rank test 
accounting for randomization  schedule  stratification factors. Example SAS code is provided in Appendix 7 . 
The hazard ratio (HR) between the 2 treatment groups (fruquintinib vs placebo), together with its 95% CIs, 
will be calculated from a stratified Cox proportional hazard model (i.e. accounting for randomization  
schedule  stratification factors) in which the treatment group is the only covariate in the model. A HR < 1 
indicates a favorable clinical benefit f rom fruquintinib over the placebo group.  Example SAS code is 
provided in Appendix 8 . 
Duration of follow -up is defined as the time (months) from date of randomization to the last date known to 
be alive for subjects who have not yet been reported to have died by the time of the analysis. Subjects who were reported to have died by the time of  the analysis are censored at date of death. That is, duration of 
follow -up is calculated as (date of death or last known alive – date of randomization + 1)/30.4375. The 
duration of follow -up will be calculated using the Kaplan -Meier method.  
All OS data are provided in listings by subject.  
 Key Se condary Efficacy Endpoint and Analysis  
The key secondary efficacy endpoint is PFS. PFS is defined in Section 5.2  and calculated as (date of death 
or radiographic PD or last assessment – date of randomization + 1)/30.4375 . 
The number and percent of subjects who had progression -free events, the number and percent of 
subjects censored, and reasons for censoring are presented for each treatment group.  Reasons for 
censoring include the following.  
a. No baseline nor post -baseline assessment  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 48 of 134 
 b. No death nor PD  
c. Lost to follow -up without death or PD  
d. Withdrawal of consent without death or PD  
e. New anti -tumor therapy started prior to PD  
f. Death or PD occurred after two or more consecutive missed assessment  
The Kaplan- Meier plots will be produced and the median, 25% and 75% percentile of time -to-event will be 
estimated using Kaplan- Meier method with their corresponding 95% CI  which are calculated fro m a log -log 
transformation based on the method by Brookmeyer and Crowley (1982). Additionally, estimates will be 
provided for the survival probability along with their 95% CIs which are calculated using linear transformation based on the method by Brookmeyer and Crowley (1982) at selected landmarks, for 
example, at 3, 6, 9, 12, and 18 months.  
The two- sided p -value to test the treatment effect will be calculated using a stratified log -rank test 
accounting for randomization schedule stratification factors. The hazard ratio (HR) between the 2 treatment 
groups (fruquintinib vs placebo), together with its 95% CIs, will be calculated from a stratified Cox 
proportional hazard model  (i.e. accounting for randomization schedule stratification  factors)  in which the 
treatment group is the only covariate in the model. A HR < 1 indicates a favorable clinical benefit from fruquintinib over the placebo group.  
A Kaplan- Meier plot of the time to censoring, where the censoring indicator of the primary PFS analysis is 
reversed, will be presented.  
All PFS data is provided in listings by subject.  
 Multiplicity Adjustments  
The clinical trial evaluates the objectives defined in terms of the comparison of fruquintinib + BSC versus 
placebo + BSC on the primary  and key secondary efficacy endpoints in Section 9.1.1 and Section 9 .1.2. 
The multiplicity problem includes 2 hypotheses of no effect : 
• Hypothesis 𝐻!. Comparison of fruquintinib + BSC versus placebo + BSC for OS.  
• Hypothesis 𝐻". Comparison of fruquintinib + BSC versus placebo + BSC for PFS.  
The 2-sided p -values for the 2 comparisons will be used for the multiple testing procedure. Example SAS 
code in Appendix 7 . 
A fixed -sequence (hierarchical) testing procedure  is used t o control the overall type I error rate at 0.05 .  If 
the resulting 2 -sided p- value from the analysis of primary endpoint OS is ≤ 0.05, then, a superiority test of 
for PFS will be conducted at the two -sided significance level  of 0.05.  
 Sensitivity Analysis for OS and PFS  
The following sensitivity analyses for OS and PFS will be performed, in which the p -value will always be 
obtained from the stratified  log-rank test and the hazard ratio (HR) between the 2 treatment groups 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 49 of 134 
 (fruquintinib vs placebo), together with its 95% CIs will be calculated from the model  in Section 9.1.1  and 
Section  9.1.2 for OS and PFS, respectively, unless otherwise specified.  
- using ITT population, unstratified Cox proportional hazard model in which the randomization 
schedule stratification factors  and treatment group are included in the model as covariates ; 
- using ITT population, stratified analysis for both log -rank test and Cox proportional hazard model, 
but using the stratification factors collected on the case report form (CRF);  
- using ITT population, unstratified Cox proportional hazard model in which the stratification factors 
collected on the CRF and treatment group are included in the model as covariates;  
- using ITT population,  subjects with primary cause of death attributed to COVID -19 will be censored 
at one day before the death date (i.e. death date – 1).; and will follow the censoring rule defined in 
Table 3 for PFS  and will use the data prior to the date of death .  
- using PP population 
- using PP population, unstratified Cox proportional hazard model in which the randomization 
schedule stratification factors and treatment group are included in the model as covariates ;  
- using PP population, stratified analysis for both log- rank test and Cox proportional hazard model 
using the stratification factors collected on the CRF;  
- using ITT population, multivariate Cox’s proportion hazard model with treatment  and randomization 
schedule  stratification factors (i.e. prior therapy, RAS status, and duration of metastatic disease) 
included in the model as covariate and,  adjust for key prognostic factors using stepwise selection 
process with level of enter alpha= 0.15 and level of remove alpha= 0.15.  Key prognostic factors 
include a set of potential prognostics/predictive factors as described in Section 9.1.5. 
An additional sensitivity analyses for OS will be performed  
- using ITT population, based on the first exact 480 deaths and the additional  s ubjects who died  will 
be censored at one day before the death  date (i.e. death date – 1). 
- using ITT population,  subjects who take the subsequent anti -cancer therapy and are still alive will 
be censored at the date of initiating the subsequent anti -cancer therapy for OS.  
The following additional sensitivity analyses for PFS will be performed, and all those sensitivity analyses 
defines the PFS event in an alternative way.  
- For Rule 6 of Table 3, subjects who take  new anti -cancer therapy are considered as a progression, 
and the date of progression is on the date of initiating the new anti -cancer therapy. However, if the 
new anti -cancer therapy is initiated after  two or more consecutive missed/non -evaluable tumor 
assessments, the subjects will still be  censored at date of last radiological assessment before the 
missed assessments.  Then, the same analysis methods outlined in Section 9.1.2 will be conducted.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 50 of 134 
 - For Rule 7 of Table 3, ignore the missing tumor assessments, that is, subjects with PD or death 
after two or more consecutive missed/non- evaluable tumor assessments will be considered as PFS 
event, and the event date for PD or death will be obtained as usual. Then, the same analysis 
methods outlined in Section 9.1.2 will be conducted.  
 Examination of Subgroups 
Subgroup analyses will be conducted based on the unstratified Cox proportional hazard model in which the 
applicable randomization schedule stratification factors and treatment group are included in the model as covariates . It should be noted that the study was not designed to detect treatment differences with high  
statistical power within subgroups. For OS and PFS subgroup analysis, if a subgroup is too small, it may be pooled with others. If the number of events in a subgroup is not sufficient, analysis will not be performed. 
The following subgroups will be assess ed for OS and PFS:  
• Age: < 65 years, >= 65 years 
• Sex: Female, Male  
• Region: North America, Europe, Asia  
• Race: White, Asian, Black or African American, Other ( including American Indian or Alaska Native, 
Native Hawaiian or Other Pacific Islander, Other as recorded on the Demographics eCRF, and 
subjects with multiple races selected )  
• Baseline ECOG Performance Status: 0, 1 
• Prior Therapy with Trifluridine/Tipiracil (TAS -102) and/or Regorafenib : Trifluridine/Tipiracil (TAS -
102), Regorafenib, Both Trifluridine/T ipiracil (TAS -102) and Regorafenib . This is a stratification 
factor which will not be included in the model for subgroup analysis.  
• RAS Gene Status: Wild Type, Mutant . This is a stratification factor which will not be included in the 
model  for subgroup anal ysis.   
• BRAF Status: Wild Type, V600 E Mutation, Other  
• Microsatellite/Mismatch Repair Status: Microsatellite Stable (MSS) and/or proficient mismatch 
repair (pMMR), Microsatellite Instability -High (MSI -H) and/or deficient mismatch repair (dMMR)  
• Duration of metastatic disease (t ime from 1st Metastatic Diagnosis to Randomization) : ≤ 18 months, 
> 18 months . This is a stratification factor which will not be included in the model for subgroup 
analysis.  
• Number of Prior Chemotherapy Treatment Lines: ≤ 3, > 3  
• Number of Prior Chemotherapy Treatment Lines for Metastatic Disease: ≤ 3, > 3  
• Prior Treatment with Vascular Endothelial Growth Factor (VEGF) Inhibitors: Yes, No  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 51 of 134 
 • Prior Epidermal Growth Factor Receptor (EGFR) Inhibitors: Yes, No  
• Prior target treatment  
o No an ti-VEGF and no anti -EGFR 
o Anti-VEGF, or anti -EGFR, or both 
§ Anti-VEGF and no anti -EGFR 
§ Anti-EGFR and no anti -VEGF 
§ Both anti -VEGF and anti -EGFR 
• Prior Treatment with Immune Checkpoint Inhibitors for MSI -H/dMMR: Yes, No  
• Prior Treatment with BRAF Inhibitors for BRAF V600E Mutation: Yes, No 
• Primary Tumor Location at First Diagnosis:  
o Colon, Rectum, Colon and Rectum, Unknown  
• Primary Tumor Site at First Diagnosis:  
o Colon Left (Splenic flexure, descending colon, transverse colon, sigmoid colon and 
rectum), Colon Right (Cecum, ascending colon and hepatic flexure) , Colon Left and Right, 
Colon Unknown, Rectum Only, Unknown  
• Liver Metastases at Baseline: Yes, No  
• Number of Metastatic  Tumor Sites Other than Colon or Rectum: Single, Multiple  
• Number of Metastatic Tumor Sites: Single, Multiple  
The values of stratification factors used for subgroup analysis are actual values of strata collected through 
eCRF.  
 
All the sensitivity and the subgroup analysis for both OS and PFS will be considered exploratory and may 
only be supportive of the primary analysis of OS and PFS.  Forest plot will also be used to graphically show 
the results.  
 Secondary Efficacy Endpoints and Analyses  
Secondary effic acy endpoints include ORR, DCR, and DoR. 
 Objective Response Rate  and Disease Control Rate  
The 95% CIs of ORR and ORR UNCONF RMED are calculated using the Clopper -Pearson exact binomial method 
for each treatment group.  
The adjusted proportion difference and along with its 95% CI in ORR between treatment groups will  be  
calculated using the Wald  method to account for the randomization schedule  stratification factors , and p -
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 54 of 134 
 
 EORTC QLQ -C30 Questionnair e  
The EORTC QLQ -C30 questionnaire , composed of both multi -item scales and single -item measures, is a 
30-item cancer- specific instrument (Aaronson et al, 1993 ) which are grouped into 15 subscales as  detailed 
below .  
1. Global health status/QoL scale  
2. Five f unctional scales: Physical functioning, Role functioning, Emotional functioning, Cognitive 
functioning, Social functioning  
3. Three symptom scales: Fatigue, Nausea and vomiting, Pain  
4. Six s ingle items: Dyspnea, Insomnia, Appetite loss, Constipation, Diarrhea, Financial difficulties  
Each subscale/single item is scored in accordance to the EORTC QLQ -C30 Scoring Manual  (Aaronson et 
al, 1993) .  All scales and single -item measures range in score from 0 to 100 after linear transformation.  A 
technical summary of scoring can be found in Appendix 1 .  Higher score for the Global health status/QoL 
and functioning scales represent higher functioning (i.e. a better state).  However, the direction is opposite 
in symptom scales and single items. Higher scores on symptom and single -item scales represent higher 
levels of symptoms (i.e. a worse state).  
The number and percent of subjects who completed the questionnaires will be summarized by visit and 
each treatment group.   
9.2.5.1.  Analysis of Change from Baseline in 15 Subscales 
Change from baseline in the scores of each of the 15 subscales will be summarized by visit and each 
treatment group.   
Analysis of change from baseline in the scores of each of the 15 subscales will be performed by visit (i.e. 
cycle), using a restricted maximum likelihood (REML) -based mixed model repeated measures (MMRM) 
approach. The MMRM model will include treatment group, visit  (i.e. cycle), treatment group by visit 
interaction,  baseline value of scale, and randomization schedule  stratification factors as fixed effects.  An 
unstructured variance- covariance structure will be used to model within -subject errors.  The Kenward- Roger 
approximation will be used to estimate denominator degrees of freedom and adjust standard errors.  MMRM 
is based on the assumption of missing at random and the assumption that dropouts would behave similarly 
to othe r subjects in the same treatment group, and possibly with similar covariate values, had they not 
dropped out.  Example SAS code is provided in Appendix 10 . To ensure the proper amount of data utilized 
in the model for each visit, the following steps will be implemented  to identify data to be included in the 
model.  
(1) C alculate the number of subjects with non -missing asse ssments for each cycle . 
(2) Identify the last cycle with at least 20 subjects in any of the treatment groups  and no subsequent cycles 
having at least 20 subjects in any of the treatment groups.  
(3) A ssessments after the cycle ident ified in St ep 2 will not be included in the model.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 55 of 134 
 If there is a convergence issue with the unstructured covariance model, Toeplitz, Autoregressive (1) (AR 
(1)) covariance structure is used, following this sequence until convergence is achieved.  If the model still does not converge with AR (1) structure, no results are reported. When the covariance structure is not 
unstructured, the sandwich estimator for the variance- covariance matrix is derived, using the EMPIRICAL 
option in the PROC MIXED statement in SAS.  
The visit  windowing rules defined in Section 7.4 will be applied to identify the record for a cycle of eac h 
subject, and hence to be included in the analysis. The comparison are between fruquintinib plus BSC to 
placebo plus BSC at each scheduled post -baseline visit.  The tabulation of MMRM includes estimates of 
least- square (LS) means, standard errors (SE), and 2 -sided 95% CIs for each treatment group.  Estimates 
of the LS mean difference, SE of the difference, 2 -sided 95% CI of the difference between treatment groups, 
and p- value are also presented. As a sensitivity analysis, subjects who have more than one assessment in 
a cycle (i.e., a quality of life assessment at an unscheduled visit), the worst score for that cycle is used in 
the analysis of change from baseline in  the 15 subscales.  The above analysis is replicated using these 
substituted values.  
9.2.5.2.  Analysis of Minimally Important Difference and Time to Deterioration  
Depending on each scale and item, the minimally important difference (MID) cut -off for QoL improvemen t 
is defined as a change of at least 6.35 to 14.24 points from baseline, based on a recent validation study on 
subjects with mCRC (Musoro et al., 2020) and the study (Osoba  et al., 1998) cited in the EORTC -QLQ- 30 
Scoring Manual.  The MID cut -off for QoL deterioration, stable, and improvement and in each scale and 
item are listed in Table 8 based on change scores.  
Table 8. Summary of MID for EORTC QLQ- C30 Questionnaire  
 
Scale/item  Deterioration  Stable  Improvement  
Global health status/QoL  ≤-6.38 -6.38 < and < 8.43  ≥8.43 
Physical functioning  ≤-7.47 -7.47 < and < 7.81  ≥7.81 
Role functioning  ≤-10.66 -10.66 < and < 14.24 ≥14.24 
Emotional functioning*  ≤-10 -10 < and <10  ≥10 
Cognitive functioning*  ≤-10 -10 < and < 10  ≥10 
Social functioning ≤-6.18 -6.18 < and < 9.23  ≥9.23 
Fatigue ≥10.79 -7.38 < and < 10.79  ≤-7.38 
Nausea and vomiting  ≥7.75 -6.62 < and < 7.75 ≤-6.62 
Pain*  ≥10 -10 < and < 10  ≤-10 
Dyspnoea*  ≥10 -10 < and < 10  ≤-10 
Insomnia* ≥10 -10 < and < 10  ≤-10 
Appetite loss  ≥12.28 -9.78 < and < 12.28  ≤-9.78 
Diarrhea  ≥6.35 -7.96 < and 6.35 ≤-7.96 
Constipation  ≥12.75 -10* < and <12.75 ≤-10 
Financial difficulties*  ≥10 -10 < and < 10  ≤-10 
*The MID of these sca e/ tems were not reported n (Musoro et a ., 2020). Instead, the MID for these sca e/ tems were arb tra r y 
determ ned at 10 po nts, fo ow ng the study (Osoba et a ., 1998) c ted n EO RTC QLQ 30 Scor ng Manua . Osoba et a . reported “a 
tt e” change as a change of 5 10 po nts, and “moderate” change as 10 20 po nts.     
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 56 of 134 
 The number and percent of subjects achieving MID  for each scale (by categories defined in Table 8) are 
summarized by visit and treatment group.   
In addition, for each scale and single item, time to deterioration (TTD) is defined as the time (months) from 
randomization until the first change of at least -10.66 to 12.75 points (depending on each scale and item) 
from baseline (Table 8, “Deterioration” column value ), or death, whichever come s first.  Any subject who 
does not experience TTD at the time of analysis is censored at the date of the most recent study visit in the 
database for that subject.   
TTD is calculated as (date of the first reduction of at least -10.66 to 12.75 points from b aseline, death or 
most recent visit – date of randomization + 1)/30.4375. 
When no post -baseline assessments available, date of randomization will be used for this calculation.   
Kaplan -Meier estimates for TTD will be tabulated by treatment group, using 25th, 50th (median), and 75th 
percentiles with associated 2 -sided 95% CIs. In addition, the two -sided p- value will be obtained from the 
stratified Kaplan -Meier method to account for the stratification factors. The hazard  ratio (HR) between the 
two treatments (fruquintinib vs placebo), together with its 95% CIs will be calculated from a  stratified  (i.e. 
accounting for randomization schedule stratification factors) Cox hazard model  in which treatment and 
baseline value of scale will be included as fixed effects . 
Data of EORTC QLQ -C30 questionnaire and subscales are listed by subject and visit.  
9.2.5.3.  Handling Missing Data for EORTC QLQ -C30 Questionnair e 
The number of and percent subjects of missing data on each of the 15 subscales will be presented by visit 
and also for the overall trial.  Subjects who have died are included in this count.  
As a simple sensitivity analysis of the impact of intercurrent ev ents such as death and drop -out, an analysis 
of covariance ( ANCOVA) will be conducted using the change from baseline to the last available assessment 
for each subject  during the period  from the date of randomization to the 37 days after the date of last do se. 
The ANCOVA model, include baseline scale score, randomization schedule  stratification factors , treatment, 
and a baseline score and treatment interaction as fixed -effect variables.    
 EQ-5D-5L Questionnair e  
The EQ -5D is a generic preference- based measure that indirectly measures the utility for health that 
generates an index -based summary score based upon societal preference weights (Pickard et al 2007). The 
EQ-5D-5L consists of 5 items that cover 5 main dimensions including mobility, self -care, usual activities, 
pain/discomfort, and anxiety/depression, and a general visual analogue scale (VAS)  for health status. The 
range of VAS scoring is from 0 (the worst health imaginable ) to 100 (the best health imagi nable).   
Each of the 5 dimensions comprising the EQ -5D descriptive system is divided into 5 levels of perceived 
problems as follows.  
• Level 1: indicating no problem  
• Level 2: indicating slight problems  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 57 of 134 
 • Level 3: indicating moderate problems  
• Level 4: indicating severe problems  
• Level 5: indicating extreme problems  
The response levels collected from the EQ -5D-5L five dimensions  as a health profile are converted into an 
EQ-5D-5L index (utility) scores to represent subjects’ utility value.  The EQ-5D-5L index -based score is 
typically interpreted along a continuum where a  utility value of 1 represents perfect health, 0 represents a 
state equal to death and a negative value represents a state worse  than dead.    
The UK value set and scoring algorithm are used to derive the EQ-5D-5L index score for this analysis 
(Devlin et al., 2018).  The detailed scoring algorithm can be found in Appendix 2 .  
The number and percent of subjects who completed the questionnaires are summarized by visit for each 
treatment group.  
9.2.6.1.  Analysis of Change from Baseline in VAS and Index Scores 
Change from baseline in VAS and index scores are summarized by visit and for each treatment group. The 
MMRM analysis and the sensitivity analysis described in Section 9.2.5.1 can be similarly applied to the 
endpoints of  
- change from baseline in VAS with the bas eline VAS score as covariate;  
- change from baseline in EQ -5D-5L index score with the bas eline EQ -5D-5L index score as 
covariate  
To ensure the proper amount of data utilized in the model for each visit, the following steps will be implemented to identify data to be included in the model.  
(1) C alculate the number of subjects with non -missing assessments for each cycle . 
(2) Identify the last cycle with at least 20 subjects in any of the treatment groups and no subsequent cycles 
having at least 20 subjects in any of the treatment groups.  
(3) A ssessments after the cycle iden tified in S tep 2 will not be included in the model.  
9.2.6.2.  Analysis of Minimally Important Difference and Time to Deterioration  
The appropriate MID cut -off for VAS is defined as a reduction of at least 7 points from baseline, based on 
a study of 534 cancer subjects evaluated by UK -based scoring algorithm (Pickard et al, 2007).  
The appropriate MID cut -off for index score is defined as a reduction of at least 0.063 points from baseline, 
based on the study on the scoring algorithm from England (McClure et al., 2017).  McClure et al. reported 
the MID in the England population has a mean (standard deviation) of 0.063 (0.013), and a median of 0.064 (interquartile range: 0.055 to 0.073).  
The MID cut -off for VAS and index scores for QoL deterioration, stable, and improvement are listed in Table 
9.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 58 of 134 
 Table 9. Summary of MID for EQ -5D-5L Questionnaire  
Scale/item  Deterioration  Stable  Improvement  
VAS ≤-7 -7 < and < 7  ≥7 
Index Score  ≤-0.063 -0.063 < and <0.063  ≥0.063 
 
The number and percent of subjects achieving MID are summarized by visit for each treatment group.   
In addition, TTD of VAS is defined as the time (month) from randomization until the first reduction of at least 
7 points from baseline or death, whichever comes first. TTD of index score is defined as the time (month) from randomization until the first red uction of at least 0.063 points from baseline or death, whichever comes 
first.  
TTD for VAS is calculated as (date of the first reduction of at least 7 points from baseline, death or most 
recent visit – date of randomization + 1)/30.4375. 
TTD for EQ-5D-5L index score is calculated as (date of the first reduction of at least 0.063 points from 
baseline, death or most recent visit – date of randomization + 1)/30.4375. 
Subjects who does not experience TTD at the time of analysis are censored at the last visit.  Then, for the 
two time -to event endpoints 
- TTD for VAS  
- TTD for EQ -5D-5L index score  
When no post -baseline assessments are available, the date of randomization will be used for this 
calculation, that is, subjects will be censored at the date of randomization .  
The Kaplan -Meier method will be used to obtain the descriptive statistics of median, 25% and 75% 
percentiles along with their 95% CIs by treatment group.  In addition, the two- sided p -value will be obtained 
from the stratified Kaplan -Meier method to account for the randomization stratification factors. The hazard 
ratio (HR) between the two treatments (fruquintinib vs placebo), together with its 95% CIs will be calculated 
from a stratified (i.e. accounting for randomization schedule stratification factors)  Cox hazard model in which 
treatment and baseline value of scale will be included as fixed effects.  
Results from the descriptive system of 5 dimensions are summarized descriptively by visit for each treatment group.  A shift table from baseline for the levels within e ach of the 5 dimensions is provided by 
visit and treatment group.  
Data of EQ -5D-5L questionnaire are listed by subject and visit.  
9.2.6.3.  Handling Missing Data for EQ-5D-5L Questionnair e 
The number of and percent subjects of missing data on the VAS and index score are presented by visit and 
for the overall trial.  Subjects who have died are included in this count.  
The sensitivity ANCOVA analysis described in Section 9.2.5.3  will be similarly applied to the endpoints of  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 59 of 134 
 - change from baseline in VAS for each subject during the period from the date of randomization to 
the 37 days after the date of last dose with the bas eline VAS score as covariate;  
- change from baseline in EQ -5D-5L index score for each subject during the period from the date of 
randomization to the 37 days after the date of last dose with the bas eline EQ -5D-5L index score 
as covariate 
 Health Resource Utilization  
Data of hea th resource utilization including primary reason for visit, type of resource, duration of visit (days) 
which is calculated as stop date – start date +1 , number of visits, concomitant medication prescribed 
(Yes/No), and special transportation required are s ummarized descriptively for each treatment group. Eac h 
subject may have multiple health care visit s during the study period, and the non -missing value from eac h 
visit will be utilized in the analysis.  
In addition, in the analysis of primary reason for visit, type of resource, concomitant medication prescribed 
(Yes/No), and special transportation required ( Yes/No), only the unique response categories for a subject 
will be summarized. For example, a subje ct may have 10 health care visits, the response ca tegories from 
those 10 visits are just 8 times of “Adverse Event” and 2 times of “Management of mCRC”, hence, this subject will only be counted in those two categories instead of summarizing 10 times in the  aforementioned 
analysis.  
Data of heath resource utilization are listed by subject.  
 Exploratory Efficacy Endpoints  
 Circulating Tumor DNA  
The analysis of ctDNA will be documented separately, and is not covered in this SAP . 
 Tumor Marker  
Change from baseline in serum CEA will be summarized by visit and  for each treatment group.  
Data of CEA  is listed by subject and visit.   
 
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 60 of 134 
 
 Pharmacokinetics 
PK population is used for tabulation as specified in this section.   
 PK Sampling Schedule  
The PK sampling schedule for for the subset of approximately 120 subjects  with evaluable ECGs  is 
displayed in Table 2 in the study protocol.  Furthermore, the PK sampling schedule for for subjects not 
included in the approximately 120 subjects  with evaluable ECGs  in the subset in Table 2  is displayed in 
Table 3 in the protocol.  
 Data Handling  
 Handling of Missing Data  
Missing concentration data for all subjects who are administered schedul ed study treatments is considered 
as non -informative missing and is not imputed.  No concentration estimates are provided for missing sample 
values.  
 Handling of below the lower limit of quantification ( BLQ) Data  
For PK concentration summary, the following rules apply:  
• PK concentrations below the lower limit of quantification (BLQ) in pre -dose samples and in samples 
taken before the time of the first quantifiable value are set to zero;   
• The PK concentrations BLQ after quantifiable concentration are set to zero  
 Handling of the Difference between the Scheduled (nominal time) and the Actual Sampling 
Times (actual time)  
For all sampling times, the actual sampling times relative to dosing  are calculated as the difference 
between the actu al clock time of sampling and the actual clock time of dosing.  The actual post- dose 
sampling times relative to dosing expressed in hours and rounded off to two decimal digits are used . Actual 
predose time in sampling times will not be set to 0 . Scheduled sampling times are listed but will not be 
summarized.  If the actual time of sampling is missing, it is reported as NR (not recorded) in the listing, the 
nominal time is used  for summary statistics. 
 Listing and Presentation of Individual PK Data   
PK data are presented by subject, cycle and day (for instance, C1D1, C1D21, C2D1, etc.),  and time 
point.  
1. Concentration data for fruquintinib and M11 are presented to the same decimal place and in original 
units as reported by the b ioanalytical lab, e.g., ng/mL;   
2. Listing of PK sampling times including nominal and actual time elapsed from dose with the deviation from the nominal time. 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 61 of 134 
 
 Summary of PK Concentration Data  
The observed concentrations for fruquintinib and metabolite M11 are summarized descrip tively at each 
scheduled timepoint and dose level including . Summaries are presented by cycle and day (for instance, 
C1D1, C1D21, C2D1, etc.) and time point using descriptive statistics.   
• If the time deviation is greater than ± 20%, the PK concentration va lue is excluded from the 
summary descriptives.  
• Predose samples collected after C1D1, will be excluded from summary statistics if  the time 
deviation is greater than ± 20% from 24 hours of the last dose.  
PK plasma concentration data at each scheduled timepoint and dose level is presented using the following 
descriptive statistics.  
• n  
• arithmetic mean and StdDev  
• coefficient of variation ( CV)% 
• m edian 
• m inimum and maximum  
• geometric mean and geometric CV%  
• number and percent of subject with BLQ  
Geometric mean and geometric CV% will not be reportable in the summary statistics if there is a BLQ value at a timepoint. The conventions pre sented in Table 10  below are used for the presentation of the descriptive 
statistics of plasma concentrations.  
Table 1 0. PK Reporting Precision 
Variable  Summarized  with:  
Minimum, Maximum 3 significant  digits  or as needed based on actual  
measured  values   
Mean  (arithmetic and  geometric), Median  3 significant  digits 
StdDev  3 significant  digits 
CV%  and Geometric CV%  1 decimal  point  
 
  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 64 of 134 
 Category  Sub-category  
Leading to Death  
Treatment -emergent AESIs 
 CTCAE Grade ≥ 3  
Serious  
Treatment -related  
Treatment -related CTCAE Grade ≥3  
Leading to Dose Reduction 
Leading to Dose Interruption  
Leading to Treatment Discontinuation  
Treatment -related Leading to Dose Reduction  
Treatment -related Leading to Dose Interruption  
Treatment -related Leading to Treatment Discontinuation  
Leading to Death 
COVID -19-related TEAEs * CTCAE Grade ≥ 3  
Serious  
Treatment -related  
Leading to Dose Reduction 
Leading to Dose Interruption  
Leading to Treatment Discontinuation  
Treatment -related Leading to Dose Reduction  
Treatment -related Leading to Dose Interruption  
Treatment -related Leading to Treatment Discontinuation  
Leading to Death 
* COVID -19-related TEAEs will be characterized according to Table 19 Appendix 4  
A subject with two or more AEs in a category is counted only once for the subject count.  
 TEAEs by SOC and PT  
The number and percen t of subjects experiencing a TEAE within each of the categories and sub -categories 
listed in Table 12 are also summarized by SOC, PT, and highest CTCAE grade for each treatment group. 
A subject with two or more adverse events for each combination of SOC and PT is counted only once for 
the combination.   
The summary is sorted in descending order of frequency of SOC according to the sum of Fruquintinib + BSC and Placebo + BSC columns. Within SOC, sort by descending frequency of PT in according to the sum of Fruquintinib + BSC and Placebo + BSC columns.  
In addition, the number and percent of subjects are summ arized by PT and highest CTCAE grade and by 
PT and CTCAE grade >=3  for each treatment group.  
 Treatment -emergent Adverse Events of Special Interest  
Treatment -emergent AESI are also summarized by highest CTCAE grade for each treatment group and 
the subgrou ps listed below . 
Time  (days) to  onset of first treatment- emergent AESI are descriptively summarized for each AESI and 
treatment group. Time to first AESI is defined as time interval from date of first administration of study 
treatment to the earliest onset date among TEAEs within the same AESI categories. That is, if a subject  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 65 of 134 
 has multiple AEs occurrences under the same AESI category, the earliest AE onset date will be used as 
the first onset date to the AESI category.  
Adverse events of special interest (AESI) are summarized for the following subgroups. 
• Age: < 65 years, >= 65 years 
• Sex: Female, Male  
• Region: North America (including USA), Europe (including Austria, Belgium, France, Germany, Hungary, Italy, Spain, and United King dom); Asia (including Japan) 
• Race: White, Asian, Black or African American, Other  
• BMI (kg/m
2): < 18.5, >= 18.5 to < 24, >= 24  
• Prior Therapy: Trifluridine/Tipiracil (TAS -102), Regorafenib , Both Trifluridine/Tipiracil (TAS -102) 
and Regorafenib   
• RAS Status: Wild Type, Mutant  
• Duration of metastatic disease: <= 18 months, > 18 months  
• Liver Metastases at Baseline: Yes, No  
For AEs falling into the AESI category “ Hepatic function abnormal ”, a summary table will also be provided 
by SOC, PT, and highest CTCAE for subjects with the following liver function category at baseline. Each 
liver function category will be evaluated separately to identify the subjects meeting the criteria. A listing of 
hepatotoxicity AEs will also be produced for subjects who meet any of  the liver function category criteria at 
baseline (i.e. aspartate aminotransferase [ AST] or alanine aminotransferase [ ALT] >3x upper limit of normal 
[ULN] or total bilirubin >2xULN , or alkaline phosphatase [ALP]  <2xULN).  
• AST or ALT >3xULN  & ≤ 5xULN;  
• AST or ALT > 5xULN;  
• Total bilirubin  >2xULN;  
• AST or ALT > 3xULN and Total bilirubin  >2xULN;  
• AST or ALT >3xULN, Total bilirubin  >2xULN and ALP <2xULN  
 Subgroup analysis of AE 
Analysis by BMI category (<18.5, ≥18.5 and <24 and ≥24 ) will be performed for the following AE summary : 
 
• TEAE overview summary  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 66 of 134 
 • SAE summary 
• Summary of TEAE leading to drug discontinuation  
• Summary of TEAE with CTCAE grade ≥3.  
 Laboratory Evaluations  
Blood and urine samples for the determination of clinical chemistry, hematology, and urinalysis laboratory 
variables described in Table 13 will be measured.   
Clinical laboratory results w ill be graded according to CTCAE criteria, Version 5.0 .Any graded changes that 
occur following the initiation of study drug and represents at least a 1 -grade change from the baseline 
assessment is defined as treatment emergent. Any assessment,  for which CTCAE toxicity grades are not 
available, will not be included in any analyses for which toxicity grades are required. Grade 0 is assigned 
to all laboratory values except missing values and not already assigned another grade.  Missing values are  
considered missing.  
The non -protocol specified tests and urinalysis results will not be summarized; they will only be included in 
listings. Data recorded by the laboratory will be converted to the International System of Units (SI) and all presentations w ill use SI units. Quantitative laboratory measurements reported as “< X”, i.e. below the lower 
limit of quantification (LLQ), or “>  X”, i.e. above the upper limit of quantification (ULQ), will be converted 
to X for the purpose of quantitative summaries, but will be presented as recorded, i.e. as “< X” or “> X” in 
the listings. Quantitative data collected between after date of first dose administration and up to 37 days following the last dose of study medication will be used for analysis.  
Table 13. List of Laboratory Parameters  
Laboratory Category Parameters  
Hematology  Hemoglobin, Hematocrit, Red Blood Cell Count (RBC), Platelet Count, White Blood Cell Count (WBC), Absolute Neutrophil Count, Neutrophils %, Absolute Lymphocyte Count, Lymphocytes %,  Absolute Monocyte Count, Monocytes %, 
Absolute Eosinophil Count, Eosinophils %, Absolute Basophil Count, Basophils % 
Blood Chemistry Albumin, Blood urea nitrogen (BUN), Creatinine, Aspartate transaminase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Total 
Bilirubin, Lactate dehydrogenase (LDH), Uric acid, Sodium, Potassium, Chloride, Bicarbonate, Glucose, Calcium, Magnesium, Phosphorus, Total cholesterol, Triglycerides, Total Protein  
Blood Chemistry – 
Thyroid Function Free triiodothyronine (fT3), Serum free thyroxine (fT4), Thyroid- stimulating 
hormone (TSH)  
Urinalysis  pH, Glucose, Protein, White blood cell, Red blood cell 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 67 of 134 
 Laboratory Category Parameters  
Urinalysis Microscopy  Microscopic White Blood cell count, Microscopic Red Blood cell cou nt, Other  
Coagulation  Activated Partial thromboplastin time (aPTT), Prothrombin time, International 
normalized ratio (INR) 
 
All summaries of hematology, blood chemistry (including thyroid function), urinalysis and coagulation 
parameters are based on the results of SI units, where applicable.  Thyroid function parameters are 
analyzed under blood chemistry category.  
Summary tables for hematology, blood chemistry, coagulation, and urinalysis (pH only) laboratory variables include descriptive statistics for result values and change from baseline for all continuous variables by visit 
and treatment group.   
Toxicities for clinical labs will be characterized according to CTCAE, Version 5.0 (Table 20 of Appendix 5  
when possible), and the frequency and percentage of subjects with each CTCAE grade for each visit during 
the treatment period will be described. Moreover, any occurrence of grade 3 or grade 4 during the treatment period will be summarized, and shift in grade from baseline to the worst post -baseline value will be 
summarized.  
Summary tables and listings are also provided for treatment -emergent hepatotoxicity and subjects with or 
without liver metastasis by each treatment g roup. Hepatotoxicity is based on the pre- specified thresholds 
below:  
1. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3x upper limit of normal (ULN) and ≤ 5x ULN 
2. AST > 3,5,8,10, and 20x ULN, AST  > 5x ULN for more than 5 weeks  
3. ALT > 3,5,8,10, and 20x ULN, ALT > 5x ULN for more than 5 weeks  
4. AST and/or ALT > 3,5,8,10, and 20x ULN, >  5x ULN for more than 5 weeks  
5. Total bilirubin elevations > 1.5x, 2x ULN  
6. ALP >1.5×, 2 × ULN  
7. Potential Drug -Induced Liver Injury  (DILI): AST and/or ALT > 3x U LN and (total bilirubin > 1.5× , > 
2x ULN ) 
8. AST and/or ALT >3 × ULN and (TBL >2xULN or international normalized ratio [INR] >1.5)  
9. Hy's Law criteria: AST and/or ALT > 3x ULN and total bilirubin ≥ 2x ULN and ALP < 2x ULN  
An eDISH plot presenting peak total bilirubin and peak ALT values will also be produced.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 68 of 134 
 Qualitative assessments of urinalysis parameters are summarized for all subjects using the number of 
subjects with results of negative, trace, or positive.  
For the urinalysis parameters, if the test result is “ -“ or “negative”, the investigation interpretation for the lab 
test will be considered to be “normal”. The i nformation of converting urinalysis parameters (i.e. WBC, RBC, 
and protein) results  is provide d in Table 21 of  Appendix 5 . 
Summary of clinical significance (Abnormal not clinically significant [ NCS] and Abnormal clinically significant 
[CS]) is also provided by visit and treatment group. Shift from baseline to the worst post -baseline 
investigators’ assessment (i.e. normal, NCS, and CS for quantitative measurements and categorical measurements)  will be presented . 
All laboratory results (including hematology, blood chemistry ,
 blood chemistry – thyroid function, urinalysis, 
coagulation, hepatitis, amylase and lipase, and serum/urine pregnancy test data)  in SI units are presented 
in data listings.  Tests are listed in alphabetical order within their respective panels (hematolog y, blood 
chemistry, urinalysis, and coagulation).   
 Vital Signs  
Vital signs include systolic blood pressure, diastolic blood pressure, respiratory rate, body temperature, 
pulse rate, weight , body mass index (BMI) will be computed as weight (kg)/[height (m)]2.   
For vital signs, change from baseline to each post -baseline visit and timepoint will be calculated. The 
potentially clinically significant findings of vital signs will also be defined based on criteria defined in Table 
14.  
Vital signs are summarized with descriptive statistics for the observed values at each visit and change from baseline to post -baseline visits values by treatment group. The criteria of potentially clini cally significant 
findings are defined in Table 14. The frequency and percentage of subjects with any potentially clinically 
significant findings during the treatment period will be presented .  
Table 14.  Potentially Clinically Significant Criteria for Vital  Signs   
Variable  Criterion value   
SBP (mmHg)  Increase from baseline of  
˃ 0 - ≤ 20  
˃ 20 - ≤ 40  
˃ 40  
Decrease from baseline of  
˃ 0 - ≤ 20  
˃ 20 - ≤ 40  
˃ 40  
 
DBP (mmHg)  Increase from baseline of  
˃ 0 - ≤ 20  
˃ 20 - ≤ 40  
˃ 40  
Decrease from baseline of  
˃ 0 - ≤ 20  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 70 of 134 
 QTcF , QTcB   (msec) > 450  
 > 480  
 > 500 
 ≤ 300 
 Increase from baseline > 30  
 Increase from baseline > 60 
 > 450 and increase from baseline > 30  
 > 450 and increase from baseline > 60  
 > 480 and increase from baseline > 30  
 > 480 and increase from baseline > 60  
 > 500 and increase from baseline > 30  
 > 500 and increase from baseline > 60  
 
Single 12- lead ECG are collected in all subjects using standardized equipment  during cycles 1 to 3.  From 
cycle 4 onward, ECG is only performed as clinically indicated.   
For each ECG parameter, the observed values and change from baseline will be  summarized. The 12 -lead 
ECG interpretation by investigator are summarized at each visit descriptively, including the number and 
percent of subjects with normal, abnormal not clinically significant, and abnormal clinically significant results at baseline and each evaluation.  
The criteria of potentially clinically significant findings are defined in Table 15. The frequency and 
percentage of subjects with any potentially clinically significant findings during the treatment period will be 
presented. Shift table from baseline to worst post- baseline ECG results is provided.  
Single 12- lead ECG interpretations by in vestigator data are listed by subject and visit.  
 Echocardiogram  
ECHOs are performed at Screening, cycle 2 day 1, and on day 1, every 3 cycles thereafter.  Assessment parameters include left ventricular ejection fraction and overall interpretation of cardiac function.  MUGAs 
are permitted if ECHOs cannot be performed.   
Categorical summaries of overall interpretation and change from baseline of left ventricular ejection fraction 
of ECHO/MUGA results at each visit are summarized.  A shift from baseline to the worst post-baseline table 
for overall interpretation is also pr ovided.   
ECHO/MUGA data is listed by subject and visit.   
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 71 of 134 
 
 Physical Examination  
A comprehensive physical examination at Screening includes subject general appearance, eyes, ears, 
nose and throat, head and neck, respiratory, cardiovascular, abdomen (gastro intestinal), skin, genitourinary 
system, lymph nodes, musculoskeletal, neurological assessments.  
Limited physical examination at scheduled visits is a subset the comprehensive physical examination as deemed appropriate by the investigator.  
Results of physical examination are listed by subject and visit.  
 ECOG Performance Status  
ECOG performance status will be summarized descriptively using counts and percentages by visit for each 
treatment group.  A shift from baseline to worst post -baseline value table is also provided.   
ECOG performance status will be listed by subject and visit.  
 Other Safety Endpoints  
 Anti-cancer Medication during Survival Follow -up 
Anti-cancer medication  during survival follow -up are classified using the WHODD version March 2022 . 
The use of anti -cancer medication during survival follow -up will be summarized using  discrete summary 
statistics, each treatment group and overall for the safety population.  If a subject took a specific medication multiple times or took multiple medicatio ns within a specific ATC or PT, the subject is counted only once for 
the respective ATC or PT.  
Summaries are ordered in alphabetical order of ATC and then, within an ATC, in decreasing frequencies 
by PT in overall column. If the frequencies tie, an alphabe tic order will be applied. 
Data of anti-cancer medication  during survival follow -up are listed by subject.  
 Anti-cancer Procedure during Survival Follow -up 
The anti-cancer procedures during survival follow -up are coded using MedDRA version 25.0.  
The use of anti -cancer procedures during survival follow -up will be summarized using discrete summary 
statistics in each treatment group and overall for the safety population.  If a subject had a specific procedure 
multiple  times or had multiple procedures  within a specific SOC or PT, the subject is counted only once for 
the respective SOC or PT.  
Summaries are ordered in alphabetical order of SOC and then, within an SOC, in decreasing frequencies 
by PT in overall column. If the frequencies tie, an alphabetic order will be applied.  
Data of anti -cancer procedure during survival follow -up are listed by subject.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 72 of 134 
 
 Anti-cancer Radiotherapy during Survival Follow -up 
The number and percent of subjects with at least one anti -cancer radiotherapy  during survival follow -up are  
summarized for each treatment group.  
Data of anti -cancer radiot herapy during survival follow -up are listed by subject.  
 Deaths  
Primary cause of death and whether autopsy was performed will be summarized descriptively for each 
treatment group.  Similarly, the deaths happening during the treatment period, defined as the  period from 
the date of the first study drug administration until 37 days after last dose, will also be tabulated. Data of 
deaths are listed by subject.  On-treatment death will be flagged.  
 Impact of COVID -19 
The study is conducted during the COVID -19 pandemic, additional data is collected for evaluating the 
impact of COVID -19.  
To eliminate potential hazards to subjects and study staff due to the COVID -19 pandemic while ensuring 
subjects safety and maintaining  data integrity, subjects are allowed remote visits during the pandemic.  
The planned protocol deviation analyses are described in Section 8.2 ; planned sensitivity analyses for the 
PFS and OS are described in Section 9.1.4 , and the s ummary for COVID -19-related  TEAEs are included  
in Section 11.1.1 .  
 
Additional  summar ies related to the COVID -19 pandemic from the following aspects  will be produced  for 
ITT population:  
• Type of impact on s tudy visit  (missing entire visit; Interrupted and/or out of window in -person visit at 
site; remote visit (virtual or telephone); or other ) 
• Reason related to COVID -19 (subject diagnosed with COVID -19; quarantined due to COVID -19; site 
closed or access restricted due to COVID -19; site open but subject unwilling or unable to come to site 
due to COVID -19; or other)  
• Study drug discontinuation due to COVID -19 
The number of subjects impacted by COVID -19 during the study investigation period as well as at any 
time will be summarized by treatment group and overall.  The study investigation period is defined as the 
period from the date of randomization to the 37 days after the date of last study treatment administration.   
Supporting listings for the described anal yses above will be provided.   
 Interstitial Lung Disease 
Interstitial lung disease data collected, including chest x -ray results and oxygen saturation, are listed by 
subject.  
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 73 of 134 
 
 IDMC Review  
A subset of TLFs for the study final analysis will be used  for IDMC meetings.  The specific content of the 
TLFs submitted to the IDMC are determined by the IDMC members.  The results to be reviewed by  the 
IDMC will be primarily  based on the safety data.  Efficacy data is also provided for the purpose of the 
planned interim futility analysis after 1/3 of OS events has occurred.  
For open sessions, the tables are presented with column Total only and the listings contains no treatment 
header. For closed sessions, the tables are presented with columns Treatment A + BSC, Treatment B + BSC, and Total, and the listings contain treatment headers.  The unblinded statistici an to be involved in the 
closed sessions of the IDMC will share the actual treatment information for Treatment A an d Treatment B.  
The IDMC may request to be unblinded by treatment group or per -subject basis at any time.  The unblinded 
biostatistician provides the information to unmask.  These communications are maintained in the IDMC workspace and submitted to the Trial Master File at the end of the study.  
The study is to be terminated in the case of confirmed futility after evaluation of 1/3 of OS events (i.e., 160 
OS events) . 
At any time, the IDMC may request any other safety -related information deemed necessary to contribute 
to an appropriate review of safety.  
Further details of content for open and closed sessions are provided in Section 18, “Content of Open and Closed Sessions”, of the IDMC Charter in order to maintain the blinding of the study.
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 74 of 134 
 
 Changes from Analysis Planned in Protocol 
• Not applicable . 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 75 of 134 
 
 Reference List 
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman 
SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA,  Sullivan 
M, Takeda F. The European Organisation for Research and Treatment of Cancer A quality -of-life instrument 
for use in international clinical trials in oncology. Journal of the National Cancer Institute  1993; 85: 365- 376. 
Brookmeyer R., and Crowley J. (1982). A confidence interval for the median survival time. Biometrics, 29 -
41. 
Devlin et al., Valuing health -related quality of life: An EQ -5D-5L value set for England. Health Economics. 
2018;27:7– 22. https://doi.org/10.1002/hec.3564 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228 -247. 
European Organization for Research and Treatment of Cancer. EORTC QLQ -C30 Scoring Manual. 
https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf  
EuroQol Research Foundation. EQ- 5D-5L User Guide. Version 3.0; September 2019. 
https://euroqol.org/wp -content/uploads/2019/09/EQ -5D-5L-English -User -Guide_version -3.0-Sept-2019-
secured.pdf 
Kim, Y., & Won, S. (2013). Adjusted proportion difference and confidence interval in stratified randomized 
trials. PharmaSUG 2013. https://www.pharmasug.org/proceedings/2013/SP/PharmaSUG- 2013- SP04.pdf  
McClure et al., Instrument -Defined Estimates of the Minimall y Important Difference for EQ -5D-5L Index 
Scores. Value Health. 2017 Apr;20(4):644- 650. doi: 10.1016/j.jval.2016.11.015. Epub 2017 Jan 10. PMID: 
28408007.  
Musoro et al., Minimally important differences for interpreting European Organisation for Research an d 
Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in subjects with ovarian 
cancer,  Gynecologic Oncology,  10.1016/j.ygyno.2020.09.007,  (2020).  
Osoba et al., Interpreting the significance of changes in health -related quality -of-life scores. J Clin Oncol. 
1998 Jan;16(1):139- 44. doi: 10.1200/JCO.1998.16.1.139. PMID: 9440735.  
Pickard et al., Estimation of minimally important differences in EQ -5D utility and VAS scores in 
cancer.  Health Qual Life Outcomes.  2007;5:70. doi: 10.1186/1477- 7525-5- 70. 
Pickard AS, Wilke CT, Lin HW, Lloyd A. Health Utilities Using the EQ -5D in Studies of Cancer. 
PharmacoEconomics  2007;25:365– 84 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 76 of 134 
 
 Programming Considerations 
All TLFs and statistical analyses are generated using SAS for Windows, Release 9.4 (SAS Instit ute Inc., 
Cary, NC, USA). Computer -generated table, listing and figure outputs adhere to the following specifications.   
 General Considerations  
• One SAS program can create several outputs  
• Each output is stored in a separate file 
• Output files are delivered as follows 
o Two compiled pdf files (with bookmark and TOC) – one for tables and figures, and one for 
listings]; 
o Individual rtf file for the TLFs (this is only applicable to the final delivery, e.g. final interim 
analysis delivery, final database lock delivery for clinical study report);  
o For figures, include the individual .tiff file (this is only applicable to the f inal delivery, e.g. 
final IA delivery, final DBL delivery for CSR)  
• Numbering of TLFs follows ICH E3 guidance  
 Table, Listing, and Figure Format  
 General  
• All TLFs are produced in landscape format on American letter paper size.  
• All TLFs are produced using the  Courier New font, size 8 which is the smallest acceptable point size 
for the Regulatory Authorities.  
• The data displays for all TLFs have a minimum blank 1 -inch margin on all 4 sides.  
• Headers and footers for figures are in Courier New font, size 8 which is  the smallest acceptable point 
size for the Regulatory Authorities.  
• Legends are used for all figures with more than 1 variable, group, or item displayed.  
• Table and listings are in black and white (no color).  Figures are in colors, where applicable.  
• Only s tandard keyboard characters are used in the TLFs.  Special characters, such as non -printable 
control characters, printer- specific, or font- specific characters, are not used.  Hexadecimal -derived 
characters are used, where possible, if they are appropriate to help display math symbols (e.g., μ).  
Certain subscripts and superscripts (e.g., cm2, Cmax) are employed on a case -by-case basis.  
• Mixed case is used for all titles, footnotes, column headers, and programmer -supplied formats, as 
appropriate.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 77 of 134 
 
 Headers  
• TLFs are internally paginated in relation to the total length (i.e., the page number should appear 
sequentially as page n of N, where N is the total number of pages in the table).  
• The date output was generated should appear along with the program n ame as a footer on each 
page.  
15.2.2.1.  Headers for Study  
• All output should have the following header at the top of each page:  
Hutch son Med Pharma L m ted  
Protoco  No.: 2019 013GLOB1  Page X of Y 
    Data Cut off Date: DDMMMYYYY  
15.2.2.2.  Headers for Study – Interim Analysis  
• All output should have the following header at the top of each page:  
Hutch son Med Pharma L m ted  
Protoco  No.: 2019 013GLOB1  Inter m Ana ys s  
 Page X of Y 
Data Cut off Date: DDMMMYYYY  
15.2.2.3.  Headers for IDMC Meeting  
• All output should have the following header at the top of each page:  
Hutch son Med Pharma L m ted  
Protoco  No.: 2019 013GLOB1  IDMC Meet ng  
 Page X of Y 
   Data Cut off Date: DDMMMYYYY  
15.2.2.4.  Headers for Japan Safety Lead -in Cohort 
• All output should have the following header at the top of each page:  
Hutch son Med Pharma L m ted  
Protoco  No.: 2019 013GLOB1  Japan Safety Lead n Cohort  
 Page X of Y 
Data Cut off Date: DDMMMYYYY  
15.2.2.5.  Headers for Japan Safety Monitoring Committee  (JSMC) Meeting  
• All output should have the following header a t the top of each page:  
Hutch son Med Pharma L m ted  
Protoco  No.: 2019 013GLOB1  JSMC Meet ng 
 Page X of Y 
Data Cut off Date: DDMMMYYYY  
 Display Titles  
• Each TLF are identified by the designation and a numeral.  (i.e., Table 14.1.1).  A decimal system 
(x.y and x.y.z) are used to identify TLFs with related contents.  The title is centered.  The analysis 
set are identified on the line immediately following the title.  The title and table designation are single -
spaced.  A solid line spanning the mar gins separate the display titles from the column headers.  
There is 1 blank line between the last title and the solid line.  Parameters or Visits, if applicable, are 
between the last title and the solid line. 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 78 of 134 
 Table x.y.z 
First Line of Title 
Second Line of Title if Needed 
(Intent -to-Treat Population) 
 Column Headers  
• Column headings are displayed immediately below the solid line described above in initial upper -
case characters .  
• In the case of efficacy tables, the variable (or characteristic) column is on the far left followed by the 
treatment group columns.  P -values are presented under the ‘Fruquintinib + BSC’ column.  
• For numeric variables, include “unit” in column or row heading when appropriate.  
• Analysis set sizes are presented for each treatment group in the column heading as (N=xx) (or in the 
row headings, if applicable).  This is distinct from the ‘n’ used for the descriptive statistics representing the number of subjects in the analysis set.  
• The order of treatments in the tables and listings is ‘Plac ebo + BSC’ first then ‘Fruquintinib + BSC’, 
followed by a ‘Total’ column, where applicable.  
 Body of the Data Display  
15.2.5.1.  General Conventions  
Data in columns of a table or listing are formatted as follows:  
• Alphanumeric values are left -justified; 
• Whole numbers (e.g., counts) are right -justified; and 
• Numbers containing fractional portions are decimal aligned.  
15.2.5.2.  Table Conventions  
• Units are included where available  
• If the categories of a parameter are ordered, then all categories between the maximum and minimum 
category are presented in the table, even if n=0 for all treatment groups in a given category that is between the minimum and maximum level for that parameter.  For example, the frequency distribution for symptom severity would appear as: 
Severity  Rating  N 
severe 0 
moderate  8 
mild 3 
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 79 of 134 
 Where percentages are presented in these tables, zero percentages are presented and so counts of 0 are 
presented as 0 and not as 0 (0%).  
• If the categories are not ordered (e.g., Medical History, Reasons for Discontinuation from the Study, 
etc.), then only those categories for which there is at least 1 subject represented in 1 or more groups are included.  
• An Unknown or Missing category are added to each parameter for which information is not available for 1 or more subjects.   
• Unless otherwise specified, the estimated mean , median , Q1, and Q3  for a set of values are printed 
out to 1 more significant digit than the original values, and standard deviations are printed out to 2 more significant digits than the ori ginal values.  The minimum and maximum should report the same 
significant digits as the original values.  For example, for systolic blood pressure:  
N   XX 
Mean (StdDev)  XXX.X (X.XX)  
Median  XXX.X 
Min, Max  XXX, XXX 
Q1, Q3  XXX, XXX 
Missing  XXX  
• P-values are output in the format: “0.xxx”, where xxx is the value rounded to 3 decimal places.  Every 
p-value less than 0.001 is presented as <0.  If the p -value is returned as >0.999, then present as 
>0.999.  
• Percentage values are printed to one decimal p lace, in parentheses with no spaces, one space after 
the count (e.g., 7 (12.8), 13 (5.4)).  Unless otherwise noted, for all percentages, the number of subjects in the analysis set for the treatment group who have an observation is the denominator.  Percent ages after zero counts should not be displayed and percentages equating to 100% are 
presented as 100, without decimal places.   
• Tabular display of data for medical history, prior/concomitant medications, and all tabular displays of AE data are presented by the body system, treatment class, or SOC with the highest occurrence in 
the active treatment group in decreasing order, assuming all terms are coded.  Within the body system, drug class and SOC, medical history (by preferred term), drugs (by ATC 2 code), and AEs 
(by preferred term) are displayed in decreasing order.  If incidence for more than 1 term is identical, they should then be sorted alphabetically.   
• Missing descriptive statistics or p -values which cannot be estimated are reported as “ -”. 
• The percentage of subjects is normally calculated as a proportion of the number of subjects assessed in the relevant treatment group (or overall) for the analysis set presented.  However, careful consideration is required in many instances due to the complicated na ture of selecting the 
denominator, usually the appropriate number of subjects exposed.  Describe details of this in 
footnotes or programming notes.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 80 of 134 
 • For categorical summaries (number and percent of subjects) where a subject can be included in 
more than one category, describe in a footnote or programming note if the subject are included in 
the summary statistics for all relevant categories or just 1 category and the criteria for selecting the criteria.  
• Where a category with a subheading (such as system organ class) has to be split over more than 
one page, output the subheading followed by “(cont. )” at the top of each subsequent page.  The 
overall summary statistics for the subheading should only be output on the first relevant page.  
15.2.5.3.  Listing Conventions 
• Listings are sorted for presentation in order of treatment groups as above, subject number, visit/collection day, and visit/collection time.  
• Missing data are represented on subject listings as either a hyphen (“ -”) with a corresponding 
footnote (“- = unknown or n ot evaluated”), or as “N/A”, with the footnote “N/A = not applicable”, 
whichever is appropriate.  
• Dates are printed in SAS DATE9.format (“ddMMMyyyy”: 01JUL2000).  Missing portions of dates are represented on subject listings as dashes (--JUL2000).  Dates th at are missing because they are not 
applicable for the subject are output as “N/A”, unless otherwise specified. 
• All observed time values are to be presented using a 24 -hour clock HH:MM.  Time is reported if it 
was measured as part of the study.  
• Units are i ncluded where available  
15.2.5.4.  Figure Conventions 
• Unless otherwise specified, for all figures, study visits are displayed on the X -axis and endpoint (e.g., 
treatment mean change from baseline) values are displayed on the Y -axis. 
 Footnotes  
• A solid line spanning the margins separates the body of the data display from the footnotes.   
• All footnotes are left justified with single -line spacing immediately below the solid line underneath the 
data display.  Each footnote will end with a period “.”. 
• Footnotes should always begin with “Note:” if an informational footnote, or a, b, c, etc.  if a reference 
footnote.  Each new footnote should start on a new line, where possible.  
• Subject specific footnotes are avoided, where possible.  
• Footnotes are used sparingly and add value to the table, figure, or listing.  If more than six lines of footnotes are planned, then a cover page is strongly recommended to be used to display footnotes, and only those essential to comprehension of the data are repeated on each page.   
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 81 of 134 
 • The order of different types of footnotes need to follow the proper order as shown below  
1. Subject specific foo tnote, such as [a] , [b], *, 1, 2, 3, and etc.; 
2. General footnote starting with “Note: …”, also the text of the footnot es will be properly 
aligned at the place after the phrase “Note:” if the line of footnote will wrap to the next row.  
3. Abbreviation footnote. The abbreviation of the footnote will be ordered alphabetically, In 
addition, each word spelling the abbreviation wi ll use uppercase for the first letter unless it 
is the convention to use lowercase, e.g. “of”, “and”, etc. Each abbreviation will be separated by a “;”  
4. The last line of the footnote section is standard source line that indicates the name of the program used to produce the data display, date the program was run, and the listing source. For example,  
   
  Source: L st ng 16.2.x.x  
  Program: xxxx.sas      
Tab e Generat on: DDMMMYYYY HH:MM  
 
 
 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 82 of 134 
 
 Quality Control 
SAS programs are developed to produce output s such as analysis data sets, summary tables, data listings, 
figures or statistical analyses.  An overview of the development of programs is detailed in Syneos Health 
SOP Developing Statistical Programs (SOP Number: 3907).  
Syneos Health SOPs Developing Stati stical Programs (3907) and Conducting the Transfer of Biostatistical 
Deliverables (3908) describes the quality control procedures that are performed for all SAS programs and output.  Quality control is defined here as the operational techniques and activit ies undertaken to verify that 
the SAS programs produce the output by checking for their logic, efficiency and commenting and by review of the produced output.  
Syneos Health SOP Pharmacokinetic and Related Data Analyses  (3913.01) describes the procedure for 
the generation and reporting of PK and pharmacodynamics data.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 83 of 134 
 
 Appendix  
 Appendix 1. EORTC QLQ- C30 Scoring Algorithm  
The principle for scoring these scales is the same in all cases. The steps for scoring are:     1) Estimate 
the average of the items that contribute to the scale. (i.e. the raw score);  
    2) Use a linear transformation to standardize the raw score , so that scores range from 0 to 100.  
More specifically , if items 𝐼!,𝐼",…,𝐼# are included in a scale, the RawScore , RS, is the mean of the 
component items: 
𝑅𝑎𝑤𝑆𝑐𝑜𝑟𝑒 𝑅𝑆 (𝐼!+𝐼"+⋯+𝐼#)/𝑛 
Then apply the linear transformation to 0 -100 to obtain the desired score for the scale, i.e.  
- for Functional scales :  
𝑆𝑐𝑜𝑟𝑒 51(𝑅𝑆 1)
𝑟𝑎𝑛𝑔𝑒9×100 
- for Symptom scales/items  and Global health status/QoL : 
𝑆𝑐𝑜𝑟𝑒 	=(𝑅𝑆 1)
𝑟𝑎𝑛𝑔𝑒>×100 
where  Range  in the formula is the difference between the maximum possible value of RS and the minimum 
possible value. The QLQ -C30 has been designed so that all items in any scale take the same range of 
values. Therefore, the range of RS equals the range of  the item values. Most items are scored 1 to 4, giving 
range  = 3. The exceptions are the items contributing to the global health status / QoL, which are 7 -point 
questions with range  = 6. More detailed information about the items to be included in eac h scale is 
summarized in Table 16 below.  
To calculate the score for a scale following the aforementioned pri nciples, it is required to at least half of 
the items have been answered, oth erwise, the score will be set as missing. However, for single- item scale, 
set the score to missing if it is not answered. For example, role functioning and cognitive functioning each 
contain 2 items, and so these scales can be estimated whenever one of the ir constituent items is present; 
physical functioning contains 5 items, and so at least 3 need to have been completed.   
  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 84 of 134 
 Table 16. Scoring the EORTC QLQ- C30 version 3.0  
 Scale  Number of 
items  Item range  Version 3.0  
Item numbers  
Global health status / QoL      
Global health status/QoL (revised)  QL2 2 6 29, 30 
Functional scales      
Physical functioning (revised)  PF2 5 3 1 to 5 
Role functioning (revised)  RF2 2 3 6, 7 
Emotional functioning EF 4 3 21 to 24 
Cognitive functioning  CF 2 3 20, 25 
Social functioning SF 2 3 26, 27 
Symptom scales / items      
Fatigue FA 3 3 10, 12, 18 
Nausea and vomiting  NV 2 3 14, 15 
Pain PA 2 3 9, 19 
Dyspnoea  DY 1 3 8 
Insomnia  SL 1 3 11 
Appetite loss  AP 1 3 13 
Constipation  CO 1 3 16 
Diarrhoea  DI 1 3 17 
Financial difficulties  FI 1 3 28 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 85 of 134 
 
 Appendix 2. Scoring the EQ -5D-5L Descriptive System  
The EQ -5D-5L descriptive system can be scored as an example in Figure 2 below . There should be only 
one response for each dimension.  
Figure 2. Example of Scoring the EQ- 5D-5L Descriptive System  
 

Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 86 of 134 
 Then, the EQ -5D-5L index score is a weighted linear combination over 5 dimensions of health status.  The 
coefficient for the weighting for each level of domains are presented in Table 17. 
Table 17. EQ-5D-5L weighting coefficient scheme  from England for the response of ea ch 
dimension (Devlin et al., 2018)  
Score level of dimension Coefficient for each level of dimension  
Mobility   
Self-care Usual 
activities Pain/  
discomfort  Anxiety/  
depression 
Level 1: no problem  0 0 0 0 0 
Level 2: slight  0.027 0.023 0.023 0.029 0.036 
Level 3: moderate  0.035 0.037 0.029 0.039 0.048 
Level 4: severe 0.096 0.076 0.075 0.128 0.132 
Level 5: unable or extreme [a]  0.127 0.094 0.085 0.155 0.134 
[a] For dimen sions (Mobility, Self -care, and Usual activities), it takes value “Unable”. For dimensions 
(Pain/discomfort and Anxiety/depression), it takes value “Extreme”.  
The EQ -5D-5L index score is calculated using the equation  
EQ-5D-5L index score 12.159×∑coefficient 	value 	assigned 	to	the	response 	of	each 	dimention  
If any of the 5 dimension scores is missing, the index score will be set to missing.  
For example, for a value of health state 23245, the EQ-5D-5L index score is cal culated as  
EQ-5D-5L index score =1−2.159×
∑coefficient 	value 	assigned 	to	the	response 	of	each 	dimention =	1−2.159×
∑(0.027+0.037+0.023+0.128+0.134)=0.247	 
 
  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 88 of 134 
 Blood thyroid stimulating hormone abnormal  Protein bound iodine decreased Thyrotoxic cardiomyopathy  
Blood thyroid stimulating hormone decreased Protein bound iodine increased Thyrotoxic crisis  
Blood thyroid stimulating hormone increased  Radioactive iodine therapy  Thyrotoxic myopathy  
Butanol -extractable iodine decreased Radiotherapy to thyroid  Thyrotoxic periodic paralysis  
Butanol -extractable iodine increased Reverse tri -iodothyronine decreased  Thyroxin binding globulin abnormal  
Congenital hypothyroidism  Reverse tri -iodothyronine inc reased  Thyroxin binding globulin decreased  
Congenital thyroid disorder  Secondary hyperthyroidism  Thyroxin binding globulin increased  
Endocrine ophthalmopathy  Secondary hypothyroidism  Thyroxine abnormal  
Euthyroid sick syndrome  Silent thyroiditis  Thyroxine decreased  
Exophthalmos  Tertiary hypothyroidism  Thyroxine free abnormal  
Free thyroxine index abnormal  Thyreostatic therapy  Thyroxine free decreased  
Free thyroxine index decreased  Thyroglobulin absent  Thyroxine free increased  
Free thyroxine index increased  Thyroglobulin decreased  Thyroxine increased 
Gamma radiation therapy to thyroid Thyroglobulin increased Thyroxine therapy  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 89 of 134 
 Generalised resistance to thyroid hormone  Thyroglobulin present  Toxic goitre 
Goitre  Thyroid atrophy Toxic nodular goitre 
Hashimoto's encephalopathy  Thyroid autotransplantation  Transient hypothyroxinaemia of prematurity  
Hashitoxicosis  Thyroid dermatopathy  Tri-iodothyronine abnormal  
Hyperthyroidism Thyroid disorder  Tri-iodothyronine decreased  
Hypothyroidic goitre  Thyroid dysfunction in pregnancy  Tri-iodothyronine free abnormal  
Hypothyroidism Thyroid electron radiation therapy  Tri-iodothyronine free decreased  
Immune -mediated hyperthyroidism  Thyroid function test ab normal  Tri-iodothyronine free increased  
Immune -mediated hypothyroidism  Thyroid gland scan abnormal  Tri-iodothyronine free normal  
Immune -mediated thyroiditis  Thyroid hemiagenesis Tri-iodothyronine increased  
Inappropriate thyroid stimulating hormone 
secretion  Thyroid hormone replacement therapy  Tri-iodothyronine uptake abnormal  
Infectious thyroiditis Thyroid hormones decreased  Tri-iodothyronine uptake decreased  
Iodine uptake abnormal  Thyroid hormones increased  Tri-iodothyronine uptake increased  
Iodine uptake decreased  Thyroid operation Ultrasound thyroid abnormal  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 91 of 134 
 Aldosterone urine increased Ectopic renin secretion  Metanephrine urine increased  
Angiotensin converting enzyme increased  Endoc rine hypertension Neurogenic hypertension  
Angiotensin I increased  Epinephrine abnormal  Non-dipping 
Angiotensin II increased  Epinephrine increased Norepinephrine abnormal  
Angiotensin II receptor type 1 antibody 
positive Essential hypertension  Norepinephrine increased  
Blood aldosterone abnormal  Gestational hypertension  Normetanephrine urine increased  
Blood aldosterone increased  HELLP syndrome  Orthostatic hypertension  
Blood catecholamines abnormal  Hyperaldosteronism  Page kidney  
Blood catecholamines increased  Hypertension  Postoperative hypertension  
Blood pressure abnormal  Hypertension neonatal  Pre-eclampsia 
Blood pressure ambulatory abnormal  Hypertensive angiopathy  Prehypertension 
Blood pressure ambulatory increased Hypertensive cardiomegaly  Procedural hypertension  
Blood pressure diastolic abnormal  Hypertensive cardiomyopathy  Pseudoaldosteronism  
Blood pressure diastolic increased  Hypertensive cerebrovascular disease  Renal hypertension  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 92 of 134 
 Blood pressure fluctuation  Hypertensive crisis  Renal sympathetic nerve ablation  
Blood pressure inadequately controlled Hypertensive emergency  Renal vascular resistance increased  
Blood pressure increased  Hypertensive encephalopathy  Renin abnormal  
Blood pressure managem ent Hypertensive end -organ damage Renin increased  
Blood pressure orthostatic abnormal  Hypertensive heart disease  Renin -angiotensin system inhibition 
Blood pressure orthostatic increased  Hypertensive nephropathy  Renovascular hypertension  
Blood pressure systolic abnormal  Hypertensive urgency  Retinopathy hypertensive  
Blood pressure systolic increased  Labile blood pressure  Secondary aldosteronism  
Catecholamine crisis  Labile hypertension Secondary hypertension  
Catecholamines urine abnormal  Malignant hypertension  Superimposed pre- eclampsia 
Catecholamines urine increased  Malignant hypertensive heart disease  Supine hypertension  
Dialysis induced hypertension  Malignant renal hypertension  Systolic hypertension  
Diastolic hypertension Maternal hypertension affecting foetus  Tyramine reaction 
Diuretic therapy  Mean arterial pressure increased  Withdrawal hypertension  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 94 of 134 
 Anal fissure haemorrhage Haemorrhagic arteriovenous malformation  Post procedural haemorrhage 
Anal haemorrhage Haemorrhagic ascites  Post transfusion purpura  
Anal ulcer haemorrhage Haemorrhagic breast cyst  Postmenopausal haemorrhage 
Anastomotic haemorrhage Haemorrhagic cerebellar infarction  Postpartum haemorrhage 
Anastomotic ulcer haemorrhage Haemorrhagic cerebral infarction  Post-traumatic punctate intraepidermal 
haemorrhage  
Aneurysm ruptured Haemorrhagic cyst  Premature separation of placenta 
Angina bullosa haemorrhagica Haemorrhagic diathesis  Procedural haemorrhage 
Anorectal varices haemorrhage Haemorrhagic  disease of newborn Proctitis haemorrhagic 
Anticoagulant -related nephropathy  Haemorrhagic disorder  Prostatic haemorrhage 
Antiplatelet reversal therapy Haemorrhagic erosive gastritis  Pulmonary alveolar haemorrhage  
Aortic aneurysm rupture Haemorrhagic gastroenteritis  Pulmonary contusion  
Aortic dissection rupture Haemorrhagic hepatic cyst  Pulmonary haematoma 
Aortic intramural haematoma  Haemorrhagic infarction  Pulmonary haemorrhage 
Aortic perforation Haemorrhagic necrotic pancreatitis  Pulm onary haemorrhage neonatal  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 95 of 134 
 Aortic rupture Haemorrhagic occlusive retinal vasculitis  Puncture site bruise  
Aponeurosis contusion  Haemorrhagic ovarian cyst  Puncture site haematoma 
Application site bruise Haemorrhagic stroke  Puncture site haemorrhage  
Application site haematoma Haemorrhagic thyroid cyst  Purpura 
Application site haemorrhage Haemorrhagic transformation stroke  Purpura fulminans 
Application site purpura Haemorrhagic tumour necrosis  Purpura neonatal  
Arterial haemorrhage  Haemorrhagic urticaria  Purpura non- thrombocytopenic 
Arterial intramural haematoma  Haemorrhagic vasculitis  Purpura senile 
Arterial perforation  Haemorrhoidal haemorrhage  Putamen haemorrhage 
Arterial rupture  Haemostasis  Radiation associated haemorrhage  
Arteriovenous fistula site haematoma Haemothorax  Rectal haemorrhage  
Arteriovenous fistula site haemorrhage  Heavy menstrual bleeding  Rectal ulcer haemorrhage  
Arteriovenous graft site haematoma Henoch -Schonlein  purpura Renal artery perforation  
Arteriovenous graft site haemorrhage Hepatic haemangioma rupture  Renal cyst haemorrhage  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 96 of 134 
 Astringent therapy Hepatic haematoma  Renal haematoma  
Atrial rupture  Hepatic haemorrhage  Renal haemorrhage  
Auricular haematoma Hereditary haemorrhagic telangiectasia  Respiratory tract haemorrhage  
Basal ganglia haematoma Hyperfibrinolysis  Respiratory tract haemorrhage neonatal  
Basal ganglia haemorrhage Hypergammaglobulinaemic purpura of 
Waldenstrom  Retinal aneurysm rupt ure 
Basilar artery perforation  Hyphaema  Retinal haemorrhage  
Bladder tamponade Iliac artery perforation  Retinopathy haemorrhagic  
Bleeding varicose vein Iliac artery rupture  Retroperitoneal haematoma  
Blood blister  Iliac vein perforation  Retroperitoneal haemorrhage  
Blood loss anaemia Immune thrombocytopenia  Retroplacental haematoma  
Blood urine Implant site bruising  Ruptured cerebral aneurysm  
Blood urine present  Implant site haematoma  Scleral haematoma 
Bloody discharge  Implant site haemorrhage  Scleral haemorrhage 
Bloody peritoneal effluent  Incision site haematoma Scrotal haematocoele 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 97 of 134 
 Bone contusion  Incision site haemorrhage Scrotal haematoma 
Bone marrow haemorrhage  Increased tendency to bruise  Scrotal haemorrhage  
Brain contusion Induced abortion haemorrhage Shock haemorrhagic  
Brain stem haematoma Inferior vena cava perforation Skin haemorrhage 
Brain stem haemorrhage  Infusion site bruising Skin neoplasm bleeding 
Brain stem microhaemorrhage  Infusion site haematoma Skin ulcer haemorrhage 
Breast haematoma Infusion site haemorrhage Small intestinal haemorrhage  
Breast haemorrhage Injection site bruising  Small intestinal ulcer haemorrhage  
Broad ligament haematoma  Injection site haematoma  Soft tissue haemorrhage 
Bronchial haemorrhage Injection site haemorrhage  Spermatic cord haemorrhage 
Bronchial varices haemorrhage Instillation site bruise  Spinal cord haematoma 
Bullous haemorrhagic dermatosis Instillation site h aematoma  Spinal cord haemorrhage 
Bursal haematoma Instillation site haemorrhage  Spinal epidural haematoma  
Cardiac contusion  Intermenstrual bleeding  Spinal epidural haemorrhage  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 98 of 134 
 Carotid aneurysm rupture  Internal haemorrhage  Spinal subarachnoid haemorrhage 
Carotid artery perforation  Intestinal haematoma  Spinal subdural haematoma 
Catheter site bruise  Intestinal haemorrhage  Spinal subdural haemorrhage 
Catheter site haematoma  Intestinal varices haemorrhage Spleen contusion  
Catheter site haemorrhage  Intra-abdominal haematoma  Splenic artery perforation 
Central nervous system haemorrhage  Intra-abdominal haemorrhage  Splenic haematoma 
Cephalhaematoma  Intracerebral haematoma evacuation Splenic haemorrhage 
Cerebellar haematoma  Intracranial haematoma  Splenic varices haemorrhage 
Cerebellar haemorrhage  Intracranial tumour haemorrhage  Splinter haemorrhages 
Cerebellar microhaemorrhage  Intraocular haematoma  Spontaneous haematoma  
Cerebral aneurysm perforation  Intrapartum haemorrhage  Spontaneous haemorrhage  
Cerebral aneurysm ruptured syphilitic  Intratumoural haematoma  Stoma site haemorrhage 
Cerebral arteriovenous malformation 
haemorrhagic Intraventricular haemorrhage  Stomatitis haemorrhagic 
Cerebr al artery perforation  Intraventricular haemorrhage neonatal  Subarachnoid haematoma 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 99 of 134 
 Cerebral cyst haemorrhage  Iris haemorrhage  Subarachnoid haemorrhage 
Cerebral haematoma  Joint microhaemorrhage  Subarachnoid haemorrhage neonatal  
Cerebral haemorrhage  Jugular vein haemorrhage  Subcapsular hepatic haematoma 
Cerebral haemorrhage foetal  Kidney contusion  Subcapsular renal haematoma 
Cerebral haemorrhage neonatal  Lacrimal haemorrhage  Subcapsular splenic haematoma  
Cerebral microhaemorrhage  Large intestinal haemorrhage  Subchorionic haematoma 
Cervix haematoma uterine  Large intestinal ulcer haemorrhage  Subchorionic haemorrhage 
Cervix haemorrhage uterine  Laryngeal haematoma Subclavian artery perforation 
Chest wall haematoma Laryngeal haemorrhage  Subclavian vein perforation 
Choroidal haematoma  Lip haematoma  Subcutaneous haematoma  
Choroidal haemorrhage  Lip haemorrhage  Subdural haematoma 
Chronic gastrointestinal bleeding  Liver contusion Subdural haematoma evacuation 
Chronic pigmented purpura  Lower gastrointestinal haemorrhage  Subdural haemorrhage 
Ciliary body haemorrhage  Lower limb artery perforation  Subdural haemorrhage neonatal  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 100 of 134 
 Coital bleeding  Lymph node haemorrhage Subendocardial haemorrhage 
Colonic haematoma Mallory -Weiss syndrome  Subgaleal haematoma 
Conjunctival haemorrhage  Mediastinal haematoma  Subgaleal haemorrhage 
Contusion  Mediastinal haemorrhage  Subretinal haematoma 
Corneal bleeding  Medical device site bruise  Superior vena cava perforation  
Cullen's sign  Medical device site haematoma  Testicular haemorrhage 
Cystitis haemorrhagic  Medical device site haemorrhage  Thalamus haemorrhage 
Deep dissecting haematoma  Melaena  Third stage postpartum haemorrhage  
Diarrhoea haemorrhagic Melaena neonatal  Thoracic haemorrhage 
Disseminated intravascular coagulation  Meningorrhagia  Thrombocytopenic purpura  
Diverticulitis intestinal haemorrhagic  Menometrorrhagia  Thrombotic thrombocytopenic purpura  
Diverticulum intestinal haemorrhagic  Mesenteric haematoma  Thyroid haemorrhage 
Duodenal ulcer haemorrhage  Mesenteric haemorrhage  Tongue haematoma  
Duodenitis haemorrhagic  Mouth haemorrhage  Tongue haemorrhage  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 101 of 134 
 Ear haemorrhage Mucocutaneous haemorrhage  Tonsillar haemorrhage 
Ecchymosis  Mucosal haemorrhage  Tooth pulp haemorrhage  
Encephalitis haemorrhagic Muscle contusion  Tooth socket haemorrhage  
Enterocolitis haemorrhagic Muscle haemorrhage  Tracheal haemorrhage  
Epidural haemorrhage  Myocardial haemorrhage  Traumatic haematoma 
Epistaxis  Myocardial rupture  Traumatic haemorrhage 
Exsanguination  Naevus haemorrhage  Traumatic haemothorax  
Extra- axial haemorrhage  Nail bed bleeding  Traumatic intracranial haematoma 
Extradural haematoma Nasal septum haematoma  Traumatic intracranial haemorrhage 
Extradural haematoma evacuation Neonatal gastrointestinal haemorrhage  Tumour haemorrhage 
Extravasation blood  Nephritis haemorrhagic  Ulcer haemorrhage  
Eye contusion  Nipple exu date bloody Umbilical cord haemorrhage  
Eye haematoma  Occult blood positive  Umbilical haematoma  
Eye haemorrhage Ocular retrobulbar haemorrhage Umbilical haemorrhage  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 102 of 134 
 Eyelid bleeding Oesophageal haemorrhage  Upper gastrointestinal haemorrhage  
Eyelid contusion  Oesophageal intramural haematoma Ureteric haemorrhage  
Eyelid haematoma Oesophageal ulcer haemorrhage  Urethral haemorrhage  
Femoral artery perforation  Oesophageal varices haemorrhage  Urinary bladder haematoma  
Femoral vein perforation  Oesophagitis haemorrhagic  Urinary bladder haemorrhage  
Foetal -maternal haemorrhage  Omental haemorrhage  Urinary occult blood  
Fothergill sign positive Optic disc haemorrhage  Urinary occult blood positive  
Gallbladder haematoma Optic nerve sheath haemorrhage  Urogenital haemorrhage  
Gastric haemorrhage  Oral blood blister  Uterine haematoma  
Gastric occult blood positive  Oral contusion  Uterine haemorrhage  
Gastric ulcer haemorrhage  Oral mucosa haematoma  Vaccination site bruising 
Gastric ulcer haemorrhage, obstructive  Oral purpura  Vaccination site haematoma 
Gastric varices haemorrhage  Orbital haematoma Vaccination site haemorrhage 
Gastritis alcoholic haemorrhagic  Orbital haemorrhage Vaginal haematoma 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 103 of 134 
 Gastritis haemorrhagic  Osteorrhagia  Vaginal haemorrhage 
Gastroduodenal haemorrhage  Ovarian haematoma  Varicose vein ruptured 
Gastrointestinal anastomotic haemorrhage  Ovarian haemorrhage  Vascular access site bruising  
Gastrointestinal haemorrhage  Palpable purpura Vascular access site haematoma  
Gastrointestinal polyp haemorrhage  Pancreatic haemorrhage Vascular access site haemorrhage  
Gastrointestinal ulcer haemorrhage Pancreatic pseudocyst haemorrhage  Vascular access site rupture  
Gastrointestinal vascular malformation 
haemorrhagic Pancreatitis haemorrhagic Vascular anastomotic haemorrhage 
Genital contusion  Papillary muscle haemorrhage  Vascular graft haemorrhage 
Genital haemorrhage  Paranasal sinus haematoma Vascular pseudoaneurysm ruptured  
Gingival bleeding  Paranasal sinus haemorrhage Vascular purpura 
Graft haemorrhage  Parathyroid haemorrhage Vascular rupture 
Grey Turner's sign  Parotid gland haemorrhage  Vein rupture 
Haemangioma rupture  Pelvic haematoma Venous haemorrhage 
Haemarthrosis  Pelvic haematoma obstetric Venous perforation 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 104 of 134 
 Haematemesis  Pelvic haemorrhage Ventricle rupture 
Haematochezia  Penile contusion  Vertebral artery perforation  
Haematocoele  Penile haematoma Vessel puncture site bruise  
Haematoma  Penile haemorrhage Vessel puncture site haematoma  
Haematoma evacuation  Peptic ulcer haemorrhage Vessel puncture site haemorrhage 
Haematoma infection  Pericardial haemorrhage  Vitreous haematoma 
Haematoma muscle  Perineal haematoma Vitreous haemorrhage 
Haematosalpinx  Periorbital haematoma  Vulval haematoma 
Haematospermia  Periorbital haemorrhage  Vulval haematoma evacuation  
Haematotympanum  Periosteal haematoma Vulval haemorrhage 
Haematuria  Peripartum haemorrhage  Withdrawal bleed  
Haematuria traumatic  Peripheral artery aneurysm rupture  Wound haematoma  
Haemobilia  Peripheral artery haematoma  Wound haemorrhage  
Haemoperitoneum  Peripheral exudative haemorrhagic 
chorioretinopathy    
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 106 of 134 
 Anovulvar fistula  Gastrointestinal ulcer perforation Peptic ulcer perforation, obstructive 
Aortoenteric fistula Gastropleural fistula Peptic ulcer repair  
Aorto- oesophageal fistula Gastrosplenic fistula  Perforated ulcer  
Appendiceal abscess  Ileal perforation  Perineal abscess  
Appendicitis perforated Ileal ulcer perforation  Perirectal abscess  
Arterioenteric fistula  Incisional hernia perforation  Peritoneal abscess  
Atrio- oesophageal fistula Inguinal hernia perforation  Peritoneocutaneous fistula  
Chemical peritonitis  Intestinal fistula  Peritonitis 
Colon fistula repair  Intestinal fistula infection Peritonitis bacterial  
Colonic abscess  Intestinal fistula repair  Pneumoperitoneum  
Colonic fistula  Intestinal perforation  Pneumoretroperitoneum  
Colo-urethral fistula  Intestinal ulcer perforation  Procedural intestinal perforati on 
Diverticular fistula  Jejunal perforation  Rectal abscess  
Diverticular perforation  Jejunal ulcer perforation  Rectal fistula repair  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 108 of 134 
 Administration site thrombosis Eye infarction  Pulmonary artery therapeutic procedure  
Adrenal thrombosis Femoral artery embolism  Pulmonary artery thrombosis 
Amaurosis  Fluorescence angiogram abnormal  Pulmonary embolism  
Amaurosis fugax  Foetal cerebrovascular disorder Pulmonary endarterectomy 
Angiogram abnormal  Foetal vascular malperfusion  Pulmonary infarction 
Angiogram cerebral abnormal  Gastric infarction  Pulmonary microemboli  
Angiogram peripheral abnormal  Graft thrombosis  Pulmonary thrombosis 
Angioplasty  Haemorrhagic adrenal infarction  Pulmonary tumour thrombotic 
microangiopathy  
Antiphospholipid syndrome Haemorrhagic cerebral infarction  Pulmonary vein occlusion  
Aortic bypass  Haemorrhagic infarction  Pulmonary veno -occlusive disease  
Aortic embolus Haemorrhagic stroke  Pulmonary venous thrombosis  
Aortic surgery  Haemorrhagic  transformation stroke  Quadriparesis  
Aortic thrombosis Haemorrhoids thrombosed  Quadriplegia  
Aortogram abnormal  Hemiparesis  Renal artery angioplasty  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 109 of 134 
 Application site thrombosis Hemiplegia  Renal artery occlusion  
Arterectomy Heparin -induced thrombocytopenia  Renal artery thrombosis  
Arterectomy with graft replacement  Hepatic artery embolism  Renal embolism  
Arterial angioplasty Hepatic artery occlusion  Renal infarct  
Arterial bypass operation Hepatic artery thrombosis  Renal vascular thrombosis  
Arterial graft  Hepatic infarction  Renal vein embolism  
Arterial occlusive disease  Hepatic vascular thrombosis  Renal vein occlusion  
Arterial revascularisation Hepatic vein embolism  Renal vein thrombosis  
Arterial stent insertion  Hepatic vein occlusion  Renal -limited thrombotic microangiopathy  
Arterial therapeutic procedure  Hepatic vein thrombosis  Retinal artery embolism  
Arterial thrombosis Homans' sign positive  Retinal artery occlusion  
Arteriogram abnormal  Hypothenar hammer syndrome  Retinal artery thrombosis 
Arteriogram carotid abnormal  Iliac artery embolism  Retinal infarction  
Arteriotomy Iliac artery occlusion Retinal vascular thrombosis  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 110 of 134 
 Arteriovenous fistula occlusion  Iliac vein occlusion Retinal vein occlusion  
Arteriovenous fistula thrombosis Implant site thrombosis  Retinal vein thrombosis  
Arteriovenous graft thrombosis Incision site vessel occlusion  Revascularisation procedure  
Artificial blood vessel occlusion Infarction  Shunt occlusion  
Aseptic cavernous sinus thrombosis  Inferior vena cava syndrome  Shunt thrombosis  
Atherectomy  Inferior vena caval occlusion  SI QIII TIII pattern 
Atherosclerotic plaque rupture Infusion site thrombosis Silent myocardial infarction  
Atrial appendage closure Injection site thrombosis Spinal artery embolism  
Atrial appendage resection Inner ear infarction  Spinal artery thrombosis 
Atrial thrombosis Instillation site thrombosis  Spinal cord infarction 
Autoimmune heparin- induced 
thrombocytopenia  Internal capsule infarction  Spinal stroke  
Axillary vein thrombosis Intestinal infarction  Splenic artery thrombosis 
Basal ganglia infarction Intra-aortic balloon placement  Splenic embolism  
Basal ganglia stroke  Intracardiac mass Splenic infarction 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 111 of 134 
 Basilar artery occlusion Intracardiac thrombus  Splenic thrombosis 
Basilar artery thrombosis Intraoperative cerebral artery occlusion  Splenic vein occlusion  
Blindness transient  Ischaemic cerebral infarction Splenic vein thrombosis 
Bone infarction Ischaemic stroke Stoma site thrombosis 
Brachiocephalic artery occlusion  Jugular vein embolism  Stress cardiomyopathy  
Brachiocephalic vein occlusion  Jugular vein occlusion  Stroke in evolution 
Brachiocephalic vein thrombosis  Jugular vein thrombosis  Strokectomy  
Brain stem embolism  Lacunar infarction Subclavian artery embolism  
Brain stem infarction Lambl's excrescences  Subclavian artery occlusion  
Brain stem stroke Left atrial appendage closure implant Subclavian artery thrombosis  
Brain stem thrombosis Leriche syndrome Subclavian vein occlusion  
Budd -Chiari syndrome  Mahler sign  Subclavian vein thrombosis  
Capsular warning syndrome  May-Thurner syndrome Superficial vein thrombosis 
Cardiac ventricular thrombosis  Medical device site thrombosis  Superior sagittal sinus thrombosis 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 112 of 134 
 Carotid angioplasty  Mesenteric arterial occlusion  Superior vena cava occlusion  
Carotid arterial embolus  Mesenteric arteriosclerosis  Superior vena cava syndrome  
Carotid artery bypass  Mesenteric artery embolism  Surgical vascular shunt  
Carotid artery occlusion  Mesenteric artery stenosis  Testicular infarction 
Carotid artery stent insertion  Mesenteric artery stent insertion  Thalamic infarction  
Carotid artery thrombosis  Mesenteric artery  thrombosis  Thrombectomy  
Carotid endarterectomy  Mesenteric vascular insufficiency  Thromboangiitis obliterans 
Catheter directed thrombolysis  Mesenteric vascular occlusion  Thromboembolectomy 
Catheter site thrombosis  Mesenteric vein thrombosis  Thrombolysis  
Catheterisation venous  Mesenteric venous occlusion  Thrombophlebitis  
Cavernous sinus thrombosis  Microembolism  Thrombophlebitis migrans  
Central venous catheterisation  Monoparesis  Thrombophlebitis neonatal  
Cerebellar artery occlusion  Monoplegia  Thrombosed varicose vein 
Cerebellar artery thrombosis  Muscle infarction  Thrombosis  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 113 of 134 
 Cerebellar embolism  Myocardial infarction  Thrombosis corpora cavernosa  
Cerebellar infarction  Myocardial necrosis  Thrombosis in device 
Cerebral artery embolism  Obstetrical pulmonary embolism  Thrombosis mesenteric vessel  
Cerebral artery occlusion  Obstructive shock  Thrombosis prophylaxis  
Cerebral artery stent insertion  Ophthalmic artery occlusion  Thrombosis with thrombocytopenia syndrome  
Cerebral artery thrombosis  Ophthalmic artery thrombosis Thrombotic cerebral infarction 
Cerebral congestion  Ophthalmic vein thrombosis  Thrombotic microangiopathy 
Cerebral hypoperfusion  Optic nerve infarction  Thrombotic stroke 
Cerebral infarction  Ovarian vein thrombosis  Thrombotic thrombocytopenic purpura  
Cerebral infarction foetal  Paget -Schroetter syndrome  Thyroid infarction 
Cerebral ischaemia  Pancreatic infarction Transient ischaemic attack  
Cerebral microembolism  Papillary muscle infarction  Transverse sinus thrombosis 
Cerebral microinfarction  Paradoxical embolism  Truncus coeliacus thrombosis 
Cerebral septic infarct  Paraneoplastic thrombosis Tumour embolism  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 114 of 134 
 Cerebral thrombosis  Paraparesis  Tumour thrombectomy 
Cerebral vascular occlusion Paraplegia Tumour thrombosis 
Cerebral venous sinus thrombosis  Paresis  Ultrasonic angiogram abnormal  
Cerebral venous thrombosis  Pelvic venous thrombosis  Ultrasound Doppler abnormal  
Cerebrospinal thrombotic tamponade  Penile artery occlusion  Umbilical cord occlusion  
Cerebrovascular accident  Penile vein thrombosis Umbilical cord thrombosis  
Cerebrovascular accident prophylaxis  Percutaneous coronary intervention  Vaccination site thrombosis  
Cerebrovascular disorder  Peripheral arterial occlusive disease Vascular access site thrombosis  
Cerebrovascular insufficiency  Peripheral arterial reocclusion  Vascular device occlusion  
Cerebrovascular operation  Peripheral artery angioplasty  Vascular graft  
Cerebrovascular stenosis  Peripheral artery bypass Vascular graft occlusion  
Choroidal infarction  Peripheral artery occlusion Vascular graft thrombosis 
Coeliac artery occlusion  Peripheral artery stent insertion  Vascular operation 
Collateral circulation  Peripheral artery surgery  Vascular pseudoaneurysm thrombosis  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 115 of 134 
 Compression garment application  Peripheral artery thrombosis  Vascular stent insertion  
Coronary angioplasty  Peripheral embolism  Vascular stent occlusion  
Coronary arterial stent insertion  Peripheral endarterectomy  Vascular stent thrombosis  
Coronary artery bypass  Peripheral revascularisation Vasodilation procedure 
Coronary artery embolism  Peripheral vein occlusion Vena cava embolism  
Coronary artery occlusion  Peripheral vein thrombus extension Vena cava filter insertion 
Coronary artery reocclusion  Phlebectomy  Vena cava filter removal  
Coronary artery surgery  Pituitary infarction Vena cava thrombosis  
Coronary artery thrombosis  Placental infarction Venogram abnormal  
Coronary bypass thrombosis  Pneumatic compression therapy Venoocclusive disease  
Coronary endarterectomy  Popliteal artery entrapment syndrome  Venoocclusive liver disease  
Coronary revascularisation  Portal shunt procedure Venous angioplasty  
Coronary vascular graft occlusion  Portal vein cavernous transformation Venous occlusion  
Deep vein thrombosis  Portal vein embolism  Venous operation  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 116 of 134 
 Deep vein thrombosis postoperative  Portal vein occlusion  Venous recanalisation  
Device embolisation  Portal vein thrombosis  Venous repair  
Device occlusion  Portosplenomesenteric venous thrombosis Venous stent insertion 
Device related thrombosis  Post procedural myocardial infarction Venous thrombosis  
Diplegia  Post procedural pulmonary embolism  Venous thrombosis in pregnancy 
Directional Doppler flow tests abnormal  Post procedural stroke Venous thrombosis limb 
Disseminated intravascular coagulation  Post thrombotic syndrome  Venous thrombosis neonatal  
Disseminated intravascular coagulation in 
newborn Postinfarction angina Vertebral artery occlusion 
Embolia cutis medicamentosa Postoperative thrombosis  Vertebral artery thrombosis  
Embolic cerebellar infarction  Postpartum thrombosis Vessel puncture site occlusion  
Embolic cerebral infarction  Postpartum venous thrombosis  Vessel puncture site thrombosis  
Embolic pneumonia Precerebral artery embolism  Visceral venous thrombosis  
Embolic stroke  Precerebral artery occlusion Visual acuity reduced transiently  
Embolism  Precerebral artery thrombosis  Visual midline shift syndrome  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 118 of 134 
 Acute on chronic liver failure Hepaplastin decreased  Ischaemic hepatitis 
Acute yellow liver atrophy Hepatectomy  Jaundice  
Alanine aminotransferase abnormal  Hepatic adenoma  Jaundice cholestatic  
Alanine aminotransferase increased Hepatic angiosarcoma  Jaundice hepatocellular  
Allergic hepatitis Hepatic artery flow decreased  Kayser -Fleischer ring  
Alloimmune hepatitis  Hepatic atrophy  Liver carcinoma ruptured  
Ammonia abnormal  Hepatic calcification Liver dialysis 
Ammonia increased Hepatic cancer  Liver disorder  
Anti factor X activity abnormal  Hepatic cancer metastatic  Liver function test abnormal  
Anti factor X activity decreased  Hepatic cancer recurrent  Liver function test decreased  
Anti factor X activity increased Hepatic cancer stage I  Liver function test increased 
Antithrombin III decreased Hepatic cancer stage II  Liver induration  
Ascites  Hepatic cancer stage III  Liver injury 
Aspartate aminotransferase abnormal  Hepatic cancer stage IV  Liver operation  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 119 of 134 
 Aspartate aminotransferase increased Hepatic cirrhosis  Liver palpable  
AST/ALT ratio abnormal  Hepatic cyst  Liver scan abnormal  
Asterixis  Hepatic cyst ruptured  Liver tenderness 
Autoimmune hepatitis Hepatic cytolysis  Liver transplant  
Bacterascites  Hepatic encephalopathy  Lupoid hepatic cirrhosis 
Benign hepatic neoplasm  Hepatic encephalopathy prophylaxis  Lupus hepatitis 
Benign hepatobiliary neoplasm  Hepatic enzyme abnormal  Magnetic resonance imaging hepatobiliary 
abnormal  
Bile output abnormal  Hepatic enzyme decreased  Magnetic resonance proton density fat 
fraction measurement  
Bile output decreased  Hepatic enzyme increased  Mitochondrial aspartate aminotransferase 
increased  
Biliary ascites Hepatic failure  Mixed hepatocellular cholangiocarcinoma  
Biliary cirrhosis Hepatic fibrosis  Mixed liver injury  
Biliary fibrosis Hepatic function abnormal  Molar ratio of total branched -chain amino acid 
to tyrosine  
Bilirubin conjugated abnormal  Hepatic haemangioma rupture  Nodular regenerative hyperplasia  
Bilirubin conjugated increased Hepatic hamartoma  Nonalcoholic fatty liver disease  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 120 of 134 
 Bilirubin excretion disorder  Hepatic hydrothorax  Non-alcoholic steatohepatitis 
Bilirubin urine present  Hepatic hypertrophy  Non-cirrhotic portal hypertension  
Biopsy liver abnormal  Hepatic hypoperfusion  Ocular icterus  
Blood bilirubin abnormal  Hepatic infiltration eosinophilic  Oedema due to hepatic disease  
Blood bilirubin increased  Hepatic lesion  Oesophageal varices haemorrhage  
Blood bilirubin unconjugated increased Hepatic lipoma  Parenteral nutrition associated liver disease  
Blood fibrinogen abnormal  Hepatic mass  Perihepatic discomfort  
Blood fibrinogen decreased Hepatic necrosis  Peripancreatic varices 
Blood thrombin abnormal  Hepatic neoplasm  Portal fibrosis 
Blood thrombin decreased Hepatic neuroendocrine tumour  Portal hypertension 
Blood thromboplastin abnormal  Hepatic pain  Portal hypertensive colopathy  
Blood thromboplastin decreased Hepatic sequestration  Portal hypertensive enteropathy  
Bromosulphthalein test abnormal  Hepatic steato -fibrosis  Portal hypertensive gastropathy  
Cardiohepatic syndrome  Hepatic steatosis  Portal vein cavernous transformation  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 121 of 134 
 Child -Pugh -Turcotte score abnormal  Hepatic vascular resistance increased  Portal vein dilatation  
Child -Pugh -Turcotte score increased  Hepatic venous pressure gradient abnormal  Portopulmonary hypertension 
Cholaemia  Hepatic venous pressure gradient increased Primary biliary cholangitis  
Cholangiosarcoma  Hepatitis  Protein C decreased 
Cholestasis  Hepatitis acute  Protein S abnormal  
Cholestatic liver injury  Hepatitis cholestatic  Protein S decreased  
Cholestatic pruritus  Hepatitis chronic active  Prothrombin level abnormal  
Chronic graft versus host disease in liver  Hepatitis chronic persistent  Prothrombin level decreased 
Chronic hepatic failure  Hepatitis fulminant  Prothrombin time abnormal  
Chronic hepatitis  Hepatitis tox ic Prothrombin time prolonged  
Coagulation factor decreased  Hepatobiliary cancer  Prothrombin time ratio abnormal 
Coagulation factor IX level abnormal  Hepatobiliary cancer in situ  Prothrombin time ratio increased  
Coagulation factor IX level decreased  Hepatobiliary cyst  Radiation hepatitis  
Coagulation factor V level abnormal  Hepatobiliary disease  Regenerative siderotic hepatic nodule  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 122 of 134 
 Coagulation factor V level decreased  Hepatobiliary neoplasm  Renal and liver transplant  
Coagulation factor VII level abnormal  Hepatobiliary scan abnormal  Retrograde portal vein flow  
Coagulation factor VII level decreased  Hepatoblastoma  Reye's syndrome  
Coagulation factor X level abnormal  Hepatoblastoma recurrent  Reynold's syndrome  
Coagulation factor X level decreased  Hepatocellular carcinoma  Splenic varices  
Coma hepatic  Hepatocellular foamy cell syndrome  Splenic varices haemorrhage 
Computerised tomogram liver abnormal  Hepatocellular injury  Spontaneous bacterial peritonitis 
Conges tive hepatopathy Hepatomegaly  Steatohepatitis 
Cryptogenic cirrhosis  Hepatopulmonary syndrome  Steatohepatitis 
Diabetic hepatopathy  Hepatorenal failure  Subacute hepatic failure 
Drug -induced liver injury Hepatorenal syndrome  Sugiura procedure 
Duodenal varices  Hepatosplenomegaly  Thrombin time abnormal  
Flood syndrome Hepatotoxicity  Thrombin time prolonged 
Focal nodular hyperplasia  Hyperammonaemia  Total bile acids increased  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 124 of 134 
 Cardiac failure  Chronic right ventricular failure  Obstructive shock  
Cardiac failure acute  Congestive hepa topathy  Pulmonary oedema 
Cardiac failure chronic  Cor pulmonale  Pulmonary oedema neonatal  
Cardiac failure congestive  Cor pulmonale acute  Radiation associated cardiac failure  
Cardiac failure high output  Cor pulmonale chronic  Right ventricular ejection fraction decreased 
Cardiogenic shock  Ejection fraction decreased  Right ventricular failure  
    Ventricular failure  
 
  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 125 of 134 
 
 Appendix 4. COVID related AE  
Table 19. MedDRA (Version 25.0) Preferred Term List for COVID -19 Related AE  
 
  Asymptomatic COVID -19 Occupational exposure to SARS -CoV-2 
Breakthrough COVID -19 Post-acute COVID -19 syndrome 
Congenital COVID -19 SARS- CoV-2 antibody test positive 
Coronavirus infection  SARS- CoV-2 carrier  
Coronavirus pneumonia  SARS- CoV-2 RNA decreased  
Coronavirus test positive  SARS- CoV-2 RNA fluctuation  
COVID -19 SARS- CoV-2 RNA increased 
COVID -19 immunisation  SARS- CoV-2 sepsis 
COVID -19 pneumonia SARS- CoV-2 test false negative 
COVID -19 prophylaxis SARS- CoV-2 test positive 
COVID -19 treatment SARS- CoV-2 viraemia  
Exposure to SARS- CoV-2 Suspected COVID- 19 
Multisystem inflammatory syndrome  Thrombosis with thrombocytopenia syndrome  
Multisystem inflammatory syndrome in adults  Vaccine derived SARS- CoV-2 infection 
Multisystem inflammatory syndrome in children   
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 130 of 134 
 
 Appendix 6. Kaplan Meier Estimates and 95% CI from Brookmeyer and Crowley method 
 SAS Code example for KM estimates and 95% CI from a log -log transformation based on 
Brookmeyer -Crowley method  
Example SAS code for 95% CI calculated from a log -log transformation based on the method by 
Brookmeyer and Crowley, for median, 25th and 75th percentiles: 
*** KM Estimates - Quartiles  ***; 
ods output quartiles=quartiles1;  
proc  lifetest   
 data= ADTTE( where=(PARAMCD= "OS")) 
 conftype =loglog;  
 time AVAL*CNSR(1); 
 strata  TRTPN; 
run; 
 
AVAL is the time in months, CNSR is the censoring variable, TRT PN is the treatment group variable.  
The output dataset (quartiles1) contains by treatment group, the estimate for median (ESTIMATE, where 
PERCENT=50), 25% (ESTIMATE, where PERCENT=25), and 75% (ESTIMATE, where PERCENT=75), 
along with the corresponding 95% CI calculated from a log -log transformation (for each corresponding 
PERCENT =25, =50 and =75, the CI values are stored  in LowerLimit and UpperLimit).  
 SAS Code example for KM estimates and 95% CI from a linear transformation based on 
Brookmeyer -Crowley method at selected landmarks  
Example SAS code for 95% CI calculated from a linear transformation based on the method by Brookmeyer and Crowley at selected landmarks, for example, at 3, 6, 9, 12, and 18 months: 
*** KM Estimates - Timelist ***;  
proc  lifetest   
 data= ADTTE( where=(PARAMCD= "OS")) 
 conftype =linear method =km atrisk timelist=( 3, 6, 9, 12, 18 ) reduceout o utsurv= tlist; 
 time AVAL*CNSR(1); 
 strata  TRTPN;  
run; 
 
AVAL is the time in months, CNSR is the censoring variable, TRTPN is the treatment group variable.  
The outsurv dataset (tlist) will provide  by treatment group,  the estimate (SURVIVAL*100) at specified time 
points (variable TIMELIST) and the corresponding 95% CIs (SDF_LCL*100, SDF_UCL*100).  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 131 of 134 
 
 Appendix 7. Stratified Log- Rank Test  
Example SAS code for Stratified Log- Rank Test, accounting for randomization schedule stratification 
factors.  
*** Stratified Log rank test ***; 
ods output LogUniChisq =logunichisq1 ; 
proc  lifetest   
 data= ADTTE( where=(PARAMCD= "OS")) 
 method =km;  
 time AVAL*CNSR( 1); 
strata  STRAT1RN  STRAT2RN  STRAT3RN; 
test TRTPN; 
run; 
 
AVAL is the time in months, CNSR is the censoring variable, TRT PN is the treatment group variable, and 
STRAT1RN, STRAT2RN and  STRAT3 RN are placeholder variables representing the randomization 
schedule stratification factors.  
The output dataset ( logunichisq1 ) contains the p -value for the Log-Rank Test (ProbChiSq) comparing the 
treatment groups.  
 Multiplicity Adjustment for Log -Rank Tests for OS and PFS  
A fixed -sequence (hierarchical) testing procedure  is used to control the overall type I error rate at 0.05.  If 
the resulting 2 -sided p- value from the analysis of primary endpoint OS is ≤ 0.05, then, a superiority test of 
for PFS will be conducted at the two- sided significance level of 0.05.  
The multiplicity  adjusted p- value for OS is its raw p -value, and the adjusted p -values for PFS is the 
maximum value between the p -values produced for the OS and PFS.   
data pvalue;  
   input  p @@;  
   if (_n_ = 1) then 
      pseq = 0 ; 
   pseq = max(pseq, p); 
   retain pseq; 
   cards; 
0.021 0.043  
run; 
The raw p -values used to calculate the adjusted p -value will be obtained from the SAS programming for 
OS and PFS, then, this sample program will be tailored in the production.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 132 of 134 
 
 Appendix 8. Stratified Cox Proportional Hazard Model  
Example SAS code for hazard ratio between the 2 treatment groups (fruquintinib vs placebo), and 
corresponding 95% CIs, calculated from a stratified Cox proportional hazard model (i.e. accounting for 
randomization schedule stratification factors) in which the treatment group is the only covariate in the model:   
*** Hazard ratio ***;  
ods output hazardratios=hazrat1; 
proc  phreg 
 data= ADTTE( where=(PARAMCD= "OS")) 
alpha= 0.05;  
 model  AVAL*CNSR( 1)=TRTPN; 
strata  STRAT1RN STRAT2RN STRAT3RN ; 
hazardratio TRTPN; 
run; 
 
AVAL is the time in months, CNSR is the censoring variable, TRT PN is the treatment group variable, and 
STRAT1RN, STRAT2RN and STRAT3RN are placeholder variables representing the randomization 
schedule  stratification factors.  
The output dataset (h azrat1) contains the hazard ratio (HazardRatio) and the corresponding 95% CI 
(WaldLower, WaldUpper) . Confirm the order of TRT PN variables is coded so HR < 1 indicates a favorable 
clinical benefit from fruquintinib over the placebo group.  
 Appendix 9. Cochran- Mant el Ha enszel test stratified by randomization schedule  
stratification factors  
Example SAS code for p- value of comparing treatment groups based on a Cochran -Mantel Hanzel test 
stratified by the randomization schedule  stratification factors. 
 
 *** stratified Cochran- Mantel Haenszel (CMH) test ***;  
ods output CMH=cmh1;  
proc  freq 
 data=AD EFF( where=(PARAMCD= "ORR" )); 
table STRAT1RN*STRAT2RN*STRAT3RN *TRTPN* AVAL/cmh; 
run; 
 
TRTPN is the treatment group variable and STRAT1RN, STRAT2RN and STRAT3RN are placeholder 
variables representing the randomization schedule stratification factors.  
The output dataset (cmh1) contains the p -value (Prob, corresponding to the Statistic=3, for General 
Association). If the number of ob jective   responses is not sufficient to utilize the CMH test, a stratified exact 
CMH test will be performed instead.  
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 133 of 134 
 
 Appendix 10. Adjusted proportion difference between treatment groups with 95% CI using 
the Wald method to account for randomization schedule  stratification factors 
Example SAS code for adjusted proportion difference between treatment groups with 95% CI using the 
Wald method to account for randomization schedule stratification factors: 
ods output CommonPdiff=pdiff1;  
proc  freq data = ADEFF( where=(PARAMCD= "ORR")); 
      tables STRAT1RN*STRAT2RN*STRAT3RN*TRTPN*AVAL/ riskdiff( column= 2 common 
cl=wald); 
run; 
 
Using ADEFF and variable AVAL, the outcome of interest is ORR (i.e.  Objective response rate), TRTPN is 
the treatment group variable and STRAT1RN, STRAT2RN and STRAT3RN are placeholder variables 
representing the randomization schedule stratification factors. The above example assumes the response 
is coded in column 2 (i.e. AVAL is coded as 0, 1, where 1 is response), and that fruquintinib is presented in 
row 1, and placebo is presented in row 2.  The above code will be adjusted for correct presentation based 
on the actual coding in ADEFF if necessary.  
The output (pdiff1)  provides an adjusted proportion difference between treatment groups (the variable 
Value, when Method="Mantel -Haenszel") with a 95% CI (the variables LowerCL, UpperCL, when 
Method="Mantel -Haenszel" ) using  the Wald method to account for randomization schedu le stratification 
factors.  
 Appendix 11. REML -based MMRM  
Example SAS code for REML- based MMRM:  
 
proc  mixed   
data=ADQS(where=(PARAMCD= "PHYSF" and ANL20FL="Y")) 
method =reml;  
class USUBJID TRTPN AVISITN STRAT1RN STRAT2RN STRAT3RN ; 
model  CHG  = BASE TRTPN AVISITN TRTPN* AVISITN STRAT1RN STRAT2RN 
STRAT3RN /solution ddfm =kr;  
repeated  AVISITN/ subject =USUBJID type=UN; 
lsmeans  TRTPN*AVISITN/ diff cl slice = AVISITN; 
run;  
 
CHG is the change from baseline in score of the subscale,  USUBJID is the subject identification variable,  
TRTP N is the treatment group variable, AVISIT N is a placeholder variable for visit, TRT PN*AVISITN is the 
treatment group -by-visit interaction, BASE is a placeholder variable for baseline value of scale, and 
STRAT1RN, STRAT2RN, and STRAT3RN  are placeholder variables representing the randomization 
schedule stratification factors.  
Prior to performing th is analysis, the visits for each subject  are limited within the dataset up to the last cycle 
with at least 20 subjects in any of the treatment groups (i.e. all subsequent cycles have less than 20 patients 
in each of the treatment groups).  If there is a convergence issue with the unstructured covariance model, 
Statistical Analysis Plan  for Interventional Studies  
Sponsor: Hutch son Med Pharma L m ted; Protoco  No.: 2019 013 GLOB1  
 
 
 
Th s document s conf dent a .  
SAP Text Vers on: 1.4 dated 21Ju2022 
Contro ed Document ID: 3903A.0 2, Effect ve Date 31 Aug 2020 
F ng requ rements: TMF Page 134 of 134 
 Toeplitz, Autoregressive (1) (AR (1)) covarian ce structure is used, following this sequence until 
convergence is achieved.  If the model still does not converge with AR (1) structure, no results are reported. 
When the covariance structure is not unstructured, the sandwich estimator for the variance -covariance 
matrix is derived, using the EMPIRICAL option in the PROC MIXED statement in SAS.  
Statistical Analy sis Plan Summa ry of Changes  
 
Version # Date 
(DD-Mmm-YYYY) Revision Summary 
1.0 25-Mar-2021 Original Draft 
1.1 15-Nov-2021 Update to address sponsor comments on draft delivery 
Stable document signed for IA. 
1.2 25-Mar-2022 Update to address sponsor comments on v1.0 and v1.1. 
Some listed below: 
• Change in visit windows 
• Clarifications on Exposure duration calculation 
• Summary of MID for EORTC QLQ-C30 Questionnaire 
• Table updated 
• Update on TTD calculation for questionnaires 
1.3 09-Jun-2022 Update to address sponsor comments on v1.2.: 
Some listed below: 
• Censoring Rules for PFS Table updated 
• Non COVID population removed 
• Change in Exposure duration calculation 
• Change in sensitivity and subgroup analyses for OS and 
• PFS 
• Change in AESI definition 
• AESI Categories and Preferred Term Table updated 
• MedDRA (Version 25.0) Preferred Term List for COVID-19  
• Related AE Table added 
• PK updates and Change in partial know alive date 
• imputation rules 
1.4 21-Jul-2022 • Section 6.4 and 6.6 about the protocol deviation (just 
language changes) 
• Table 4 about the visit window 
• Section 11.2 some hepatic evaluation criteria added 
• Table 14.3.4.1.5 to reflect the hepatic criteria changes in the SAP 
• Listing 16.2.3.3 updates the title; adding a new Listing 16.2.3.4 by site. 
• Section 7.2.2 last dose date definition 
• Section 6.5 PK population additional detail 
• Table 12 additional raw with Treatment-related CTCAE Grade ≥3 
 